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The role of ischaemia-reperfusion injury and mitochondrial dysfunction in organ 
transplantation 
Ischaemia and subsequent reperfusion is inherent to solid organ transplantation and contributes to tissue 
damage, organ dysfunction, and worse recipient outcome. Demand for organs for transplantation in the 
UK has led to the increasing use of ‘less-than-ideal’ deceased organs that are less tolerant of ischaemia or 
have been exposed to greater ischaemic insults. Furthermore, outcomes from clinical transplantation 
suggest that increasing ischaemia-reperfusion (IR) injury influences not only short-term outcomes but 
also longer-term outcomes by increasing the rate of chronic organ rejection. Mitochondria are recognised 
as being integral to IR injury generating a burst of reactive oxygen species that initiates downstream 
tissue damage. There is emerging evidence that this process is driven by a specific metabolic pathway 
rather than by a series of random damaging events. A better understanding of this pathophysiology and 
the mechanisms underpinning IR injury will increase the opportunity for the development of rational 
therapeutic approaches. 
In this work, I have characterised ischaemic metabolism during warm and cold organ storage in murine, 
porcine and human myocardial tissue. I have demonstrated succinate accumulation to be a conserved 
signature of ischaemia across species and have demonstrated the ability to moderate metabolic 
pathways in the mouse heart during organ storage using metabolic inhibitors. In order to investigate the 
effects of the metabolic changes during ischaemia on reperfusion I developed a novel, small animal 
model of solid organ transplantation incorporating a warm ischaemic insult. I then used this model to 
examine the therapeutic efficacy of ameliorating succinate accumulation during ischaemia to reduce 
organ dysfunction upon reperfusion. Finally, I explored the impact of reperfusion injury on chronic 
rejection in a previously well characterised model of organ rejection. 
 
 












Thank you to my supervisors, Dr Kourosh Saeb-Parsy and Professor Michael Murphy. I feel very privileged 
to have had the opportunity to work within your outstanding laboratories. Your support, guidance and 
positivity has been invaluable and inspiring. You have introduced me to new opportunities and 
encouraged me to develop a passion for science that I hope to continue to explore in the years ahead.  
To the numerous collaborators with whom I have worked during the last few years, thank you so much 
for your time and expertise. None of this would have been possible without you. Thank you to everyone 
in the Department of Surgery and the Mitochondrial Biology Unit for all your help, patience, insightful 
discussions, companionship, and most importantly friendship. It has been instrumental in helping me 
navigate this journey. I look forward with interest to hearing about your successes in the coming years. 
Thank you to the staff at Central Biomedical Services past and present who provided excellent technical 
assistance, support and friendship during the time I spent in their department and thank you to the 
Medical Research Council for their generous financial support of my studies. 










Table of Contents 
Declaration .................................................................................................................................................... 2 
Summary ........................................................................................................................................................ 3 
Acknowledgements ....................................................................................................................................... 4 
CHAPTER 1: INTRODUCTION ......................................................................................................................... 18 
1.1 HISTORY OF ORGAN TRANSPLANTATION ............................................................................................................... 19 
1.1.1 Immunosuppression ............................................................................................................................ 19 
1.1.2 Organ procurement ............................................................................................................................ 19 
1.1.3 Organ preservation ............................................................................................................................. 20 
1.1.4 Hypothermic machine perfusion ......................................................................................................... 21 
1.1.5 Normothermic perfusion ..................................................................................................................... 21 
1.2 CURRENT TRENDS IN SOLID ORGAN TRANSPLANTATION ........................................................................................... 23 
1.2.1 Heart transplantation ......................................................................................................................... 23 
1.2.2 Lung transplantation .......................................................................................................................... 23 
1.2.3 Kidney transplantation ....................................................................................................................... 23 
1.2.4 Liver transplantation .......................................................................................................................... 23 
1.2.5 Pancreas transplantation ................................................................................................................... 23 
1.2.6 Summary ............................................................................................................................................. 24 
1.2.7 Standard criteria donors and expanded criteria donors ..................................................................... 24 
1.3 TYPES OF ISCHAEMIA DURING ORGAN TRANSPLANTATION ........................................................................................ 25 
1.3.1 Primary warm ischaemia (Asystolic phase) ........................................................................................ 25 
1.3.2 Functional warm ischaemia ................................................................................................................ 25 
1.3.3 Cold ischaemia .................................................................................................................................... 25 
1.3.4 Secondary warm ischaemia ................................................................................................................ 25 
1.4 OVERVIEW OF AEROBIC METABOLISM .................................................................................................................. 26 
1.5 CARDIAC METABOLISM ..................................................................................................................................... 27 
1.5.1 Fatty acid oxidation ............................................................................................................................ 27 
1.5.2 Glucose utilisation .............................................................................................................................. 27 
1.5.3 Citric acid cycle (CAC) .......................................................................................................................... 28 
1.5.4 Mitochondria and Oxidative Phosphorylation .................................................................................... 28 
1.6 ISCHAEMIA .................................................................................................................................................... 30 
1.6.1 Cardiac ischaemic metabolism ........................................................................................................... 30 
1.6.2 Cardioplegia and effects on cardiac metabolism ................................................................................ 31 
1.7 REPERFUSION INJURY ....................................................................................................................................... 32 
1.7.1 Reactive oxygen species ...................................................................................................................... 32 








1.7.3 NADPH oxidase ................................................................................................................................... 33 
1.7.4 Cellular xanthine oxidase .................................................................................................................... 34 
1.8 MITOCHONDRIA AND THE IMMUNE RESPONSE ...................................................................................................... 35 
1.8.1 Sterile Inflammation and the innate immune response ...................................................................... 35 
1.8.2 Mitochondria and innate immune response ....................................................................................... 35 
1.8.3 Mitochondrial ROS (mtROS) ............................................................................................................... 35 
1.8.4 Mitochondrial DNA (mtDNA) .............................................................................................................. 36 
1.8.5 Mitochondrial regulation of the innate immune response ................................................................. 36 
1.8.6 The adaptive immune response .......................................................................................................... 36 
1.8.7 Mitochondria and the adaptive immune response ............................................................................. 37 
1.9 CLINICAL MANIFESTATIONS OF REPERFUSION INJURY IN ORGAN TRANSPLANTATION ...................................................... 38 
1.9.1 Clinical impact of ischaemia on short and long-term outcomes ......................................................... 38 
1.9.2 Outcomes in heart transplantation .................................................................................................... 38 
1.9.3 Outcomes in liver transplantation ...................................................................................................... 39 
1.9.4 Outcomes in kidney transplantation ................................................................................................... 39 
1.9.5 Clinical outcomes of DCD compared to DBD ....................................................................................... 39 
1.10 ALLOGRAFT REJECTION IN TRANSPLANTATION ..................................................................................................... 41 
1.10.1 Hyperacute rejection ........................................................................................................................ 41 
1.10.2 Acute rejection .................................................................................................................................. 41 
1.10.3 Chronic rejection ............................................................................................................................... 42 
1.10.4 Impact of chronic rejection ............................................................................................................... 43 
1.11 PROTECTIVE STRATEGIES FOR TREATING IR INJURY ............................................................................................... 44 
1.11.1 Targeting mitochondria .................................................................................................................... 44 
1.11.2 Limiting oxidative stress and mitochondrial ROS .............................................................................. 44 
1.11.3 Reducing tubular death .................................................................................................................... 44 
1.11.4 Mitochondrial dynamics ................................................................................................................... 45 
1.11.5 Mitochondrial Immunomodulation .................................................................................................. 45 
1.11.6 Improving short and long-term outcomes ........................................................................................ 45 
1.12 TRANSLATION OF TRANSPLANTATION RESEARCH AND RATIONALE FOR PROJECT .......................................................... 46 
1.13 AIMS OF THIS WORK ...................................................................................................................................... 47 
CHAPTER 2: METHODS ................................................................................................................................. 49 
2.1 CHEMICALS AND SOLVENTS ............................................................................................................................... 50 
2.2 ANIMAL WORK ............................................................................................................................................... 51 
2.2.1 Mouse strains and animal husbandry ................................................................................................. 51 
2.2.2 Porcine strain and animal husbandry ................................................................................................. 51 
2.2.3 Human tissue ...................................................................................................................................... 51 








2.3.1 Metabolite accumulation in organ storage ........................................................................................ 52 
2.3.2 Heart temperature measurements ..................................................................................................... 52 
2.3.3 Administration of cardioplegia ........................................................................................................... 53 
2.4 PORCINE EXPERIMENTS .................................................................................................................................... 54 
2.5 HUMAN EXPERIMENTS ..................................................................................................................................... 55 
2.6 TISSUE EXTRACTION AND ANALYSIS ..................................................................................................................... 57 
2.6.1 Liquid chromatography coupled to mass spectrometry (LC-MS) ........................................................ 57 
2.6.2 ATP/ADP ratio ..................................................................................................................................... 57 
2.6.3 Glycogen assay ................................................................................................................................... 58 
2.7 HETEROTOPIC HEART TRANSPLANT MODELS OF IR INJURY ........................................................................................ 59 
2.7.1 Murine heterotopic heart transplantation ......................................................................................... 59 
2.7.2 Donor operation ................................................................................................................................. 59 
2.7.3 Recipient operation ............................................................................................................................. 60 
2.7.4 Prolonged Cold Ischaemia .................................................................................................................. 61 
2.7.5 Prolonged Warm Ischaemia ............................................................................................................... 61 
2.7.6 Metabolic inhibitors ............................................................................................................................ 62 
2.7.7 Administration of small molecule inhibitors as infusion ..................................................................... 62 
2.7.8 Administration of small molecule inhibitors with cardioplegia .......................................................... 63 
2.8 OUTCOME MARKERS OF IR INJURY ...................................................................................................................... 64 
2.8.1 Troponin-I ........................................................................................................................................... 64 
2.8.2 Tissue mitochondrial DNA amplification ............................................................................................. 64 
2.8.3 Gel Electrophoresis ............................................................................................................................. 66 
2.8.4 DNA Quantification ............................................................................................................................. 66 
2.9 OUTCOME MARKERS OF CHRONIC REJECTION ........................................................................................................ 67 
2.9.1 Collection of blood .............................................................................................................................. 67 
2.9.2 Quantification of anti-MHC class I antibody (H-Kd) by ELISA .............................................................. 67 
2.9.3 Quantification of autoantibody level by HEp-2 indirect immunofluorescence ................................... 67 
2.9.4 Rejection kinetics ................................................................................................................................ 69 
2.9.5 Chronic allograft vasculopathy ........................................................................................................... 69 
2.9.6 Statistics analysis ................................................................................................................................ 70 
2.9.7 Collaborative experiments .................................................................................................................. 70 
CHAPTER 3: THE METABOLIC PROFILE OF CARDIAC TISSUE DURING WARM AND COLD ISCHAEMIA .............. 71 
3.1 THE METABOLIC PROFILE OF CARDIAC TISSUE DURING WARM AND COLD ISCHAEMIA ...................................................... 72 
3.1.1 Introduction ........................................................................................................................................ 72 
3.1.2 Temperature changes during organ storage ...................................................................................... 72 
3.2 CHANGES IN ENERGY STORES ............................................................................................................................. 75 








3.3 CHANGES IN METABOLITES DURING WARM ISCHAEMIA AND COLD ISCHAEMIA .............................................................. 81 
3.4 GLYCOLYTIC INTERMEDIATES ............................................................................................................................. 86 
3.4.1 Glycolytic substrate utilisation during ischaemia ............................................................................... 86 
3.4.2 Pyruvate metabolism in warm and cold ischaemia ............................................................................ 87 
3.4.3 GAPDH constrains glycolysis during warm but not cold ischaemia .................................................... 92 
3.4.4 Summary of glycolytic metabolites during ischaemia ........................................................................ 93 
3.5 GENERATION OF NAD+ DURING ISCHAEMIA .......................................................................................................... 94 
3.6 PENTOSE PHOSPHATE PATHWAY ......................................................................................................................... 95 
3.7 CITRIC ACID CYCLE INTERMEDIATES ..................................................................................................................... 97 
3.8 CARDIAC CONTRACTION AND ISCHAEMIC METABOLISM ......................................................................................... 102 
3.8.1 Cardiac contraction and succinate accumulation in mouse hearts .................................................. 102 
3.8.2 Contractility and energy stores ......................................................................................................... 102 
3.8.3 Contractility and metabolite abundance .......................................................................................... 103 
3.9 TEMPERATURE AND CAC INTERMEDIATE ACCUMULATION ..................................................................................... 106 
3.10 UREA CYCLE INTERMEDIATES ......................................................................................................................... 112 
3.11 FREE FATTY ACIDS AND ACYL CARNITINES .......................................................................................................... 114 
3.12 AMINO ACID METABOLISM IN ISCHAEMIA ......................................................................................................... 116 
3.13 DISCUSSION ............................................................................................................................................... 120 
CHAPTER 4: EXPLORING THE SOURCE OF SUCCINATE ACCUMULATION DURING ISCHAEMIA ...................... 124 
4.1 EXPLORING THE SOURCE OF SUCCINATE ACCUMULATION DURING ISCHAEMIA ............................................................ 125 
4.1.1 Introduction ...................................................................................................................................... 125 
4.2 AMINOOXYACETATE (AOA) ............................................................................................................................ 126 
4.3 DIMETHYL MALONATE (DMM) ....................................................................................................................... 129 
4.4 DIMETHYL MALONATE AND AMINOOXYACETATE .................................................................................................. 133 
4.5 HADACIDIN .................................................................................................................................................. 134 
4.6 THENOYLTRIFLUOROACETONE (TTFA) AND DIAZOXIDE (DZX) ............................................................................... 137 
4.7 ROTENONE .................................................................................................................................................. 139 
4.8 DISCUSSION ................................................................................................................................................. 140 
4.8.1 Efficacy of metabolic inhibitors in organ storage ............................................................................. 140 
4.8.2 Activity of PNC during ischaemia ...................................................................................................... 141 
4.8.3 Summary ........................................................................................................................................... 142 
CHAPTER 5: MODERATING IR INJURY IN A MODEL OF SOLID ORGAN TRANSPLANTATION .......................... 143 
5.1 MODERATING IR INJURY IN A MODEL OF SOLID ORGAN TRANSPLANTATION ............................................................... 144 
5.1.1 Introduction ...................................................................................................................................... 144 
5.1.2 Developing a novel and reproducible model of IR injury in organ transplantation .......................... 144 
5.1.3 Additional primary warm ischaemia following retrieval with cardioplegia ...................................... 147 








5.2 THERAPEUTIC EFFICACY OF AGENTS IN AMELIORATING IR INJURY IN ORGAN TRANSPLANTATION ..................................... 149 
5.2.1 Modifying succinate accumulation and exacerbating IR injury in the mouse heart during organ 
transplantation .......................................................................................................................................... 152 
5.3 DISCUSSION ................................................................................................................................................. 155 
CHAPTER 6: EXAMINING THE ROLE OF IR INJURY IN A MODEL OF CHRONIC REJECTION .............................. 157 
6.1 THE ROLE OF ISCHAEMIA REPERFUSION INJURY IN CHRONIC ALLOGRAFT VASCULOPATHY .............................................. 158 
6.1.1 Introduction ...................................................................................................................................... 158 
6.2 PROLONGED COLD ISCHAEMIA AND CHRONIC REJECTION OF THE ALLOGRAFT ............................................................. 159 
6.3 FLUSHING OF THE DONOR HEART AND CHRONIC REJECTION OF THE ALLOGRAFT .......................................................... 162 
6.4 WARM ISCHAEMIA AND CHRONIC REJECTION OF THE ALLOGRAFT ............................................................................ 164 
6.5 INCREASED IR INJURY AND ITS IMPACT ON CHRONIC REJECTION .............................................................................. 166 
6.6 DISCUSSION ................................................................................................................................................. 168 
CHAPTER 7: DISCUSSION ............................................................................................................................ 171 
7.1 GENERAL DISCUSSION .................................................................................................................................... 172 
7.1.1 Metabolic profile of ischaemia ......................................................................................................... 172 
7.1.2 Examining IR injury in vivo in organ transplantation ........................................................................ 175 
7.1.3 Examining IR injury and chronic organ rejection .............................................................................. 176 
7.2 FUTURE DIRECTIONS ...................................................................................................................................... 178 
CHAPTER 8: REFERENCES ............................................................................................................................ 180 
CHAPTER 9: APPENDIX ............................................................................................................................... 188 
Appendix 1: Mouse LC-MS data ................................................................................................................. 189 
Appendix 2: Pig LC-MS data ....................................................................................................................... 212 










Table of Figures 
Figure 1: Mitochondria and oxidative phosphorylation. ............................................................................. 29 
Figure 2: Human donor characteristics. ....................................................................................................... 56 
Figure 3: Human epithelial cell line (HEp-2) standard dilution curve. ......................................................... 68 
Figure 4: Representative immunofluorescence photomicrographs of hyperimmune serum at increasing 
dilutions. ...................................................................................................................................................... 69 
Figure 5: Representative section of a coronary vessel with evidence of vasculopathy. .............................. 70 
Figure 6 (a - c): Temperature profile of the myocardial apex during cold storage and retrieval in murine 
heart transplantation. .................................................................................................................................. 74 
Figure 7 (a – c): ATP/ADP ratio and tissue AMP concentrations in the mouse heart during warm and cold 
ischaemia. .................................................................................................................................................... 76 
Figure 8: Changes in tissue concentrations of (a) ATP, and (b) ADP during warm (red) and cold (blue) 
ischaemia in the mouse heart measured by LC-MS. .................................................................................... 77 
Figure 9: ATP and ADP concentrations during warm and cold ischaemia in the mouse, pig and human 
heart. ........................................................................................................................................................... 78 
Figure 10 (a – d): ATP/ADP ratio and tissue AMP concentration in the pig and human heart during warm 
(red) and cold (blue) ischaemia. .................................................................................................................. 80 
Figure 11: Extended analysis of metabolic changes in the mouse, pig and human during warm and cold 
ischaemia. .................................................................................................................................................... 82 
Figure 12: Volcano plots of metabolites analysed by LC/MS. ...................................................................... 84 
Figure 13: Glycogen stores in the mouse heart during warm and cold ischaemia. ..................................... 86 
Figure 14: The metabolic profile of glycolytic intermediates during warm (red) and cold (blue) ischaemia 
in the mouse heart. ...................................................................................................................................... 89 
Figure 15 (a and b): Metabolic profile of lactate and glucose during cold organ storage extended to 12 
hours. ........................................................................................................................................................... 90 
Figure 16: Pyruvate metabolism during warm (red line) and cold (blue line) ischaemia in the mouse heart.
 ..................................................................................................................................................................... 91 
Figure 17: Changes in lactate/pyruvate ratio and NADH/NAD+ ratio during warm (red line) and cold (blue 








Figure 18: The metabolic profile of pentose phosphate pathway intermediates during warm and cold 
storage in the mouse heart. ......................................................................................................................... 96 
Figure 19: Metabolic profile of CAC intermediates during warm (red line) and cold (blue line) organ 
storage in the mouse heart. ......................................................................................................................... 98 
Figure 20: Relative change in the CAC intermediates in mouse, pig and human hearts tissue during warm 
(red line) and cold (blue line) organ storage. ............................................................................................... 99 
Figure 21 (a and b): Succinate accumulation and the succinate/fumarate ratio during warm (red line) and 
cold storage (blue line) in the mouse, pig and human heart. .................................................................... 100 
Figure 22: Comparative absolute tissue succinate concentrations during warm and cold organ storage in 
the mouse, pig and human. ....................................................................................................................... 101 
Figure 23: ATP/ADP ratio in mouse hearts from donors treated with (grey line) and without (black line) 
cardioplegia and stored for variable periods of warm ischaemia. ............................................................. 102 
Figure 24: Baseline normoxic metabolite abundance in mouse hearts following treatment with and 
without St Thomas’ cardioplegia. .............................................................................................................. 104 
Figure 25 (a and b): Effect of contractility on succinate and fumarate accumulation during warm and cold 
ischaemia in the mouse heart. ................................................................................................................... 105 
Figure 26 (a – c): Succinate and fumarate tissue concentrations after 12 minutes of ischaemia in mouse 
hearts stored at different temperatures. .................................................................................................. 106 
Figure 27: Succinate accumulation in the mouse heart after 12 minutes of organ storage at varying 
temperatures. ............................................................................................................................................ 107 
Figure 28: Tissue abundance of CAC metabolites in mouse hearts stored at variable temperatures for 12 
minutes. ..................................................................................................................................................... 108 
Figure 29: Relationship between glycolysis and temperature in mouse hearts stored for 12 minutes of 
ischaemia. .................................................................................................................................................. 109 
Figure 30: The accumulation of glycolytic intermediates after 12 minutes of ischaemic metabolism with 
varying temperatures of organ storage in the mouse heart. ..................................................................... 110 
Figure 31: Assessment of tissue NADH/NAD+ after 12 minutes of ischaemia in mouse hearts stored at 
difference temperatures. ........................................................................................................................... 111 
Figure 32: Accumulation of urea cycle intermediates during warm and cold ischaemia in the mouse heart.
 ................................................................................................................................................................... 113 








Figure 34: Amino acid and glutamate metabolism during warm and cold ischaemia in the mouse heart.
 ................................................................................................................................................................... 117 
Figure 35: Relative change in tissue alanine during warm and cold storage in the mouse heart. ............. 118 
Figure 36: Amino acid tissue concentrations during warm and cold storage in the mouse heart. ........... 119 
Figure 37: Effect of metabolic inhibitors on MAS intermediates during ischaemia in the mouse heart. .. 127 
Figure 38: Effect of metabolic inhibitors on transamination in the mouse heart. ..................................... 128 
Figure 39 (a – c): DMM undergoes rapid hydrolysis in vivo. ...................................................................... 130 
Figure 40: The effect of metabolic inhibitors on CAC metabolite accumulation during warm ischaemia. 131 
Figure 41: Relative change of CAC metabolites compared to baseline normoxic tissue following the 
administration of cardioplegia and various metabolic inhibitors or cardioplegia alone. .......................... 132 
Figure 42: Effect of hadacidin administration on ischaemic metabolism in the mouse heart .................. 135 
Figure 43 (a and b): The efficacy of hadacidin administration by bolus injection and the impact on PNC 
intermediate metabolites during warm ischaemia. ................................................................................... 136 
Figure 44: TTFA solubility and delivery to the heart following IVC bolus injection with cardioplegia. ...... 138 
Figure 45: Effect of 6 minutes of warm ischaemia on IR injury following heterotopic heart transplantation 
in the mouse. ............................................................................................................................................. 145 
Figure 46: Effect of 12 minutes of warm ischaemia on IR injury following heterotopic heart 
transplantation in the mouse. ................................................................................................................... 146 
Figure 47: Effect of cardioplegia and 12 minutes of warm ischaemia on reperfusion injury in the 
heterotopic heart transplant. .................................................................................................................... 148 
Figure 48: DMM ameliorates IR injury in a mouse heart transplant model. ............................................. 150 
Figure 49: The effect of DMM infusion on tissue malonate and succinate concentrations. ..................... 151 
Figure 50: DMM administered as a bolus did not significantly ameliorate IR injury in a mouse heart 
transplant model. ...................................................................................................................................... 152 
Figure 51: DMS delivery following IV bolus with cardioplegia and the associated metabolomic effect. .. 153 
Figure 52: DMS, AMS (in 5% w/v DMSO) or 5% DMSO administered to donor hearts prior to ischaemia did 
not significantly exacerbate reperfusion injury in a mouse heart transplant model. ................................ 153 
Figure 53 (a – c): Chronic rejection of the bm12.Kd.IE cardiac allograft following transplantation into a 








Figure 54 (a - c): Chronic rejection of the bm12.Kd.IE cardiac allograft prepared without flushing of the 
allograft during retrieval and transplanted into a C57BL/6 recipient after standard or prolonged cold 
static storage. ............................................................................................................................................ 162 
Figure 55 (a – d): Chronic rejection of the bm12.Kd.IE cardiac allograft prepared without flushing of the 
allograft during retrieval and transplanted into a C57BL/6 recipient following a standard retrieval or with 
an additional 6 minutes of warm ischaemia. ............................................................................................. 164 
Figure 56 (a - d): Chronic rejection of the bm12.Kd.IE cardiac allograft following either no additional warm 









All abbreviations and standard units, unless listed, are as described in the “Instructions to Authors” of the 
Biochemical journal (http://biochemj.org) 
 
Dp proton motive force 
ADSS adenylosuccinate synthetase 
AMPK AMP-activated protein kinases 
ANA antinuclear antibody 
ANOVA analysis of variance 
AOA 2-(aminooxy)acetic acid hemichloride 
APC antigen presentation cell 
AST aspartate aminotransferase 
AUC area under the curve 
BNP brain natriuretic peptide 
CAC citric acid cycle 
cAMP cyclic adenosine monophosphate 
CAV chronic allograft vasculopathy 
CD cluster of differentiation 
cGAS cyclic GMP-AMP synthase 
CIT cold ischaemia time 
CoA Co-Enzyme A 
CoQ Co-Enzyme Q 
CPB cardiopulmonary bypass 
DAMP damage-associated molecular patterns 
DBD donation after brainstem death 
DC dendritic cell 
DCD donation after circulatory death 
DD deceased donor (cadaveric donors) 
DGF delayed graft function 
DIC dicarboxylate carrier 
DMM dimethyl malonate 
DMS dimethyl succinate 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
DZX diazoxide 
ECD extended criteria donor 
ECMO extracorporeal membrane oxygenation 
ELISA enzyme linked immunosorbent assay 
ETC electron transport chain 
ETF electron transfer flavoprotein 
EVG elastin van Gieson 
Fc fragment crystallizable region 
GABA γ-aminobutyric acid 
GAPDH glyceraldehyde-3-phopshate dehydrogenase 
GLUT facilitated diffusion glucose transporter 
H&E haematoxylin and eosin 
HAD hadacidin 
HEp-2 human epithelial type 2 
HIF-1α hypoxia inducible factor 1a 
HMGB1 high mobility group box 1 
HLA human leukocyte antigen 








HPLC high pressure liquid chromatography 
HSP72 heat shock protein 72 
IL interleukin 
IMP inosinic acid 
IR ischaemia-reperfusion 
IRF interferon regulatory factors 
ISG interferon stimulated genes 
IVC Inferior vena cava 
LC-MS liquid chromatography – mass spectrometry 
LN2 liquid nitrogen 
MAS malate / aspartate shuttle 
MAVS mitochondrial antiviral signaling 
MDA5 melanoma differentiation antigen 5 
MHC major histocompatibility complex 
MOMP outer mitochondrial membrane 
mtDNA mitochondrial DNA 
mtROS mitochondrial reactive oxygen species 
NF-kB nuclear factor k-light chain enhancer of activated B cells 
NK natural killer 
NMP normothermic machine perfusion 
NOX NADPH oxidase 
O•- superoxide 
ONOO- peroxynitrite 
OPA1 optic atrophy type 1 
PAMP pathogen-associated molecular pattern 
PBS phosphate buffered saline 
PCR polymerise chain reaction 
PDH pyruvate dehydrogenase 
PFK-1 phosphofructokinase-1 
PGF primary graft failure 
PNC purine nucleotide cycle 
PNF primary non-function 
PPP pentose phosphate pathway 
PRR pattern recognition receptors 
Q-site ubiquinone binding 
RET reverse electron transport 
RIG-I retinoic acid-inducible gene-1 
ROS reactive oxygen species 
ROT rotenone 
SCD standard criteria donor 
SDH succinate dehydrogenase 
SOD superoxide dismutases 
Soltran© hyperosmolar citrate 
STING stimulator of interferon genes 
SVC superior vena cava 
TCA tricarboxylic acid  
TE Tris EDTA 
Th17 T helper 17 
TLR toll-like receptor 
TNF tumour necrosis factor 
Treg regulatory T-cell 
TTFA thenoyltrifluoroacetone 
UW University of Wisconsin solution (ViaSpanÒ) 








XO xanthine oxidase 
XOR xanthine oxidoreductase 
 
  
Publications and Prizes 
 
Publications 
Martin JL, Gruszczyk AV, Beach TE, Murphy MP, Saeb-Parsy K. 
Mitochondrial mechanisms and therapeutics in ischaemia reperfusion injury. 
Pediatr Nephrol. 2018 Jun 2. PMID: 29860579 
 
Bundgaard A, James AM, Gruszczyk AV, Martin J, Murphy MP, Fago A. 
Metabolic adaptions during extreme anoxia in the turtle heart and their implications for 
ischaemia-reperfusion injury. 
Sci Rep. 2019 Feb 26; 9(1): 2850. PMID 30808950 
 
Prizes 
Medawar Medal, British Transplantation Society (2018) 



















1.1 History of organ transplantation 
Significant progress over the last century within the field of organ transplantation has led to it becoming a 
routine part of clinical practice. Nevertheless, to become the everyday success that it is today, organ 
transplantation has had to overcome a number of fundamental challenges. These include, developing the 
technical aspects in anastomosing blood vessels, adequately preserving the organs during transfer from 
donor to recipient, and preventing rejection of the transplanted organ by the recipient’s immune system 
(1, 2). As clinicians continue to increase the number of lives that can be improved or saved by 
transplantation and the supply of organs suitable for transplantation dramatically outstrips demand, 
some of these fundamental problems continue to challenge in the 21st century. 
1.1.1 Immunosuppression  
There are occasional anecdotal reports and small cases series from attempts at solid organ 
transplantation dating back to the early part of the 20th century but these were largely unsuccessful with 
the transplanted organs either demonstrating primary non-function (PNF) or being rapidly rejected within 
a matter of hours. The modern era of organ transplantation began in 1954 when Joseph Murray 
successfully transplanted the kidney of one identical twin to another in Boston (1, 3). The transplanted 
kidney functioned well, and the recipient brother lived for another eight years. The success of this 
operation lay in the elimination of the risk of immunological rejection. Although successful, this was not 
an approach that would enable organ transplantation to be introduced to widespread clinical practice. 
Immunological rejection remained the principal hurdle in the progress of solid organ transplantation until 
the discovery of chemical immunosuppression, initially with azathioprine and prednisolone, and then then 
with the introduction of ciclosporin in the mid-1970s. The introduction of these drugs had an immediate 
effect on outcome and paved the way for widespread transplantation of deceased donor organs (3).  
1.1.2 Organ procurement 
With the introduction of effective immunosuppression and the associated improvement in outcome, the 
widespread use of deceased donor organs became a reality. This led to a period of renewed interest in 
improving organ preservation. Organ procurement is inherently associated with some degree of 
ischaemic damage, although the extent of this ischaemic injury is greatly dependent on the duration and 
the temperature of the organ when it is exposed to ischaemia. Warm ischaemia is particularly detrimental 
to the viability of an organ, something quickly realized during early attempts at transplantation where 
organs fared far better if cooled. 
The concept of brainstem death has had a great impact on organ transplantation. The concept originated 
in France where the term coma dépassé was coined in 1959 by Mollaret and Goulon. A Belgian surgeon, 
Guy Alexandre, was the first to adopt this to perform the first organ transplant from a brain dead donor in 
1963 (4). Prior to this, death in organ donors was declared by cardiopulmonary criteria. In 1968, the 







therefore, patients deemed to be in a state of irreversible coma could be regarded as dead (5). Codes of 
Practice were introduced in the UK to provide legal and ethical guidance for brain stem death criteria in 
the late 1970s by the Conference of Medical Royal Colleges in 1979 (5-7). Heart beating donors, later 
termed donation after brainstem death (DBD) formed the mainstay of organ donors in the UK and 
internationally for the next two decades. In DBD, the donor continues to receive cardiorespiratory 
support following the declaration of death by brainstem criteria until the time of donation. At this time, 
the circulation is stopped by cross clamping the aorta and ice cold preservation solution is flushed 
through the distal aorta whilst blood is simultaneously drained from the vena cava (1). This technique of 
in situ perfusion, in addition to topical cooling, attempts to minimise ‘primary’ warm ischaemia during 
DBD organ retrieval. 
The persistent shortage of donors has more recently however, led clinicians to re-examine other potential 
sources of organs including donors whose death is declared following circulatory arrest (donation after 
circulatory death; DCD). In the UK, a 5-minute standoff period of observation is required before death can 
be certified and the organ procurement process commenced. This period of observation varies 
internationally. The donor is then transferred to the operating theatre, a rapid laparotomy performed 
with cannulation of the distal aorta, and ice cold perfusion and topical cooling commenced (1). DCD can 
be classified according to the Maastricht classification. This was first developed in 1995 and has since 
been revised and expanded from the original four categories (8). The great majority of DCDs in the UK are 
Maastricht III in which patients die following the planned withdrawal of life-sustaining therapies (9).  
In the UK today, deceased donors (DD) account for approximately two thirds of all donors with both DBD 
and DCD organs used in most areas of solid organ transplantation including kidney, liver, pancreas, lung 
and heart transplantation (10).  
1.1.3  Organ preservation 
Since the early era of organ transplantation researchers have explored a variety of techniques to better 
preserve organs, ranging from topical cooling (11, 12), to perfusion with both cellular and acellular cooled 
preservation solutions (11), continuous ex situ hypothermic, sub-normothermic or normothermic 
machine perfusion techniques and in situ regional perfusion in the donor. Preservation solutions have also 
formed the focus of much transplant research and undergone numerous refinements over the years.  
Early practice adopted techniques reported by Belzer et al (13) who demonstrated good outcomes using 
hypothermic machine perfusion and oxygenated cryoprecipitate plasma (14). This was in the era before 
brainstem death criteria were widely accepted and therefore, kidneys were often retrieved from donors 
who had died by cardiopulmonary criteria and had suffered considerable warm ischaemic injury (14). 
Collins et al (15) demonstrated that kidneys could be preserved for prolonged periods by simple cold 
storage using a simple solution composed principally of glucose, potassium and phosphate (15). The high 
concentration of potassium reflected intracellular concentrations and aimed to preserved ion gradients by 







perfusion in organ donation after DBD became common practice and better organ perfusion and cooling 
was achieved. Cold static storage had the added benefit of not requiring a cumbersome perfusion 
machine, making organ transport easier, and forms the mainstay of organ preservation today (16).  
A number of preservation solutions have been developed. Whilst they have a diverse composition, they 
retain key constituents that include; an osmotic agent that provides an extracellular oncotic force, a 
buffer to counter intracellular acidosis, and electrolytes to maintain ion gradients. The two principal 
approaches to ionic composition in preservation solutions is either to mimic intracellular or extracellular 
environments (17). In the 1980s, preservation solutions developed at the University of Wisconsin 
(ViaSpanÒ) were demonstrated to extend preservation times in a range of organs in animal models (18-
21). This has resulted in the widespread adoption of UW into clinical practice today. With the use of DCD 
and more ‘less-than-ideal’ donors, there has been renewed interest in other strategies to improve organ 
preservation. These include, hypothermic machine prefusion, normothermic or sub-normothermic 
machine perfusion. 
1.1.4 Hypothermic machine perfusion 
Following Belzer’s early experience, there has been renewed interest in hypothermic machine perfusion 
in both liver and kidney transplantation with particular focus in the use of DCD and marginal donors. It is 
hypothesized that hypothermic machine perfusion improves preservation by flushing small capillaries and 
waste metabolites from the organs (1). 
1.1.5 Normothermic perfusion 
Two of the early pioneers of organ preservation were Charles Lindbergh and Carrel who performed a 
series of studies into isolated organ perfusion in the 1920s and 30s. Using a perfusion circuit they had 
developed, they were able to maintain organs in normothermic conditions for a number of days. These 
early concepts have been re-explored in the UK in recent years following the increased use of DCD organs. 
There are a number of approaches to normothermic perfusion that continue to be explored. These can be 
grouped into in situ and ex situ approaches. In situ normothermic perfusion involves the rapid cannulation 
of the donor circulation following death and the use of cardiopulmonary bypass (CPB) and extracorporeal 
membrane oxygenation (ECMO) technology and an in-line pump to recover venous blood to perfuse 
organs in situ. After a period of normothermic perfusion the organs can then be retrieved and preserved 
using any of the techniques used following DBD retrieval. Both abdominal and cardiothoracic organs can 
be perfused using this approach. If abdominal organs are being retrieved without cardiothoracic organs, 
abdominal regional perfusion is performed by either placing large-bore canulae peripherally in the 
femoral vasculature and then limiting reperfusion to abdominal organs with the use of an aortic balloon 
clamp, or by open cannulation of the abdominal aorta and inferior vena cava (IVC) and clamping the 
thoracic aorta. Cardiothoracic organs have also been retrieved following in situ normothermic perfusion. 
In this situation, open cannulation following median sternotomy is performed and the patient is placed on 







Another approach is to retrieve organs immediately and then perfuse the organs ex situ using similar 
technology. In this setting organs can be assessed and reconditioned. There is evidence to suggest that in 
some circumstances normothermic machine perfusion (NMP) can itself recondition organs against some 
of the deleterious effects of reperfusion injury. Increasingly it is also being explored as a potentially 
platform for the delivery of therapeutic agents (24). 
Normothermic perfusion involves delivering adequate oxygen and nutrients to maintain cellular integrity 
and vascular processes during perfusion. Normothermic perfusion is more complex than cold static 
storage or hypothermic machine perfusion but potential advantages include; minimizing cold ischaemic 
injury, the ability to make an assessment of the organ prior to transplantation, and organ reconditioning 







1.2 Current trends in solid organ transplantation 
In 2016-2017, 3710 DD transplants and 1043 living donor transplants performed in the UK. The total 
number of patients on the transplant waiting list peaked in 2009-10 and having started to decrease, now 
appears to have stabilised to approximately 6400 patients. Despite this, compared to 2015-2016, there 
was a 4% increase in overall deceased organ donation. DBD donors accounted for the majority of this, 
increasing by 6% on the previous year whilst DCD donation increased by 1% (10). 
1.2.1 Heart transplantation 
The heart transplant waiting list has plateaued to the current level of approximately 250 patients a year. 
Whilst the waiting list is not increasing, in 2016-2017 there were only 198 transplants performed and 25% 
of patients on the urgent waiting list were removed or died by one year and only 18% of non-urgent 
recipients received transplants. A DCD heart transplant programme was introduced in 2015-2016. 14 (7%) 
DCD heart transplants were performed in 2016-2017 (10). 
1.2.2 Lung transplantation 
Between October 2014 and September 2017, 539 lung transplants were performed in the UK. There has 
been a slight increase in the number of lung transplants performed in 2016-2017 after a slight decrease in 
2015-2016. Approximately 20% of lung transplants are performed with organs from DCD (10).  
1.2.3 Kidney transplantation 
The kidney transplant waiting list continues to decline year-on-year from its peak in 2009. This represents 
a decline of approximately 25% from 2009 levels. Deceased donor kidney transplants performed in the UK 
in 2016-2017 increased by 3% compared to 2015-2016 with the number of both DBD and DCD donors 
increasing from the previous year. Living donor kidney transplants fell by 2% to 937 in 2016-2017 (10). 
Median cold ischaemia time has decreased in both DBD and DCD over the last 10 years from a median of 
17 (DBD) and 16 hours (DCD) in 2007/2008 to 14 (DBD) and 13 hours (DCD) respectively (10).  
1.2.4 Liver transplantation 
Over the last decade, the number of patients on the liver transplant waiting list has gradually increased. 
This is in contrast to the last couple of years where the waiting list has decreased. The waiting list in 2016-
2017 decreased by 8% from 2015-2016. The number of liver transplants from deceased donors increased 
by 8% with transplants from DBD donors increasing by 10% and transplants from DCD donors increasing 
by 1% (10). 
1.2.5 Pancreas transplantation 
The number of patients on the pancreas waiting list in 2016-2017 fell by 1% from the previous year. There 
was also a 1% decrease in the number of pancreas transplants performed in 2016-2017 despite an 








In summary, the number of patients on transplant waiting lists in the UK are either remaining constant or 
decreasing however, the number of transplants that are being performed continues to increase. Despite 
this, demand continues to outstrip supply with people continuing to die on the waiting list. In 2016-2017, 
457 people died on the waiting list. A further 875 patients were removed from the waiting list. The 
majority of these were removed due to deteriorating health and ineligibility for transplantation and would 
likely have died soon after their removal from the waiting list (10). Whilst the overall number of donors 
have increased over the last decade, the donor demographic has changed substantially. Deceased donors 
have become older, more obese and less likely to have died following trauma. Furthermore, there has 
been a large increase in the use of donation after circulatory death (DCD) organs. These changes all have 
the potential to negatively impact the quality of transplanted organs and consequently recipient 
outcomes (10).  
1.2.7 Standard criteria donors and expanded criteria donors 
Standard Criteria Donors (SCD) and Expanded Criteria Donors (ECD) are additional sub-classifications of 
deceased donors that are used to inform clinicians and patients about potential outcomes and can aid 
organ allocation. It is derived from factors associated with graft loss and defines ECD as those >60 years, 
or ≥ 50 years with at least two of the following risk factors; a terminal serum creatinine > 1.5 mg/dL, a 







1.3 Types of ischaemia during organ transplantation 
The transplantation process introduces a range of potential ischaemic insults to the transplanted organ. 
These are discussed below; 
1.3.1 Primary warm ischaemia (Asystolic phase) 
An organ is exposed to primary warm ischaemia during the asystolic phase which is defined as the time 
from circulatory arrest to the start of an organ perfusion procedure. This is most commonly the start of 
cold perfusion with preservation solution but also includes the commencement of regional in situ 
perfusion or machine perfusion (8). 
1.3.2 Functional warm ischaemia 
Following the withdrawal of life sustaining treatment in DCD there is a variable period of haemodynamic 
instability until circulatory arrest. This period is defined as the agonal phase (27). A prolonged agonal 
phase with a long period of haemodynamic instability potentially increases warm ischaemic injury and 
negatively impacts organ outcome. Counter to this, a prolonged agonal phase with a short period of 
haemodynamic instability immediately before asystole can be associated with minimal warm ischaemic 
injury (2, 28, 29). The term functional warm ischaemia attempts to better define the onset of warm 
ischaemic injury from the commencement of haemodynamic instability and organ hypoperfusion during 
the withdrawal phase. A number of haemodynamic parameters have been proposed including; mean 
arterial pressure ≤ 50 mmHg, systolic blood pressure ≤ 50 mmHg, peripheral oxygen saturations ≤ 60% 
(29). In the UK, the onset of functional warm ischaemia is arbitrarily defined as a systolic blood pressure 
of ≤ 50 mmHg (26). 
1.3.3 Cold ischaemia 
This is the period form the commencement of cooling with cold preservation solution to when the organ  
is removed from cold storage prior to implantation. During this period, additional techniques may be used 
in an attempt to better preserve organs including hypothermic machine preservation.  
1.3.4 Secondary warm ischaemia 
Secondary warm ischaemia is the period from removal of the organ from cold storage to reperfusion in 
the recipient. This period is defined by the implantation of the organ into the recipient. During this period, 
the organ is exposed to gradual re-warming and there is emerging evidence to suggest that prolonging 







1.4 Overview of aerobic metabolism 
The eukaryotic cell is thought to have originated following an endosymbiotic event 2.5 billion years ago. It 
is theorised that an alpha-proteobacteria that used oxygen to convert organic molecules into energy was 
phagocytosed by an archaebacterium and the mutually beneficial arrangement of a safe, nutrient rich 
environment for the alphaproteobacteria and a ready source of energy for the arachaebacterium gave 
rise to the eukaryotic cell (31, 32). In evolutionary terms, anaerobic metabolism is a more primitive form 
of metabolism. Whilst sufficient to support simple single cell life, glycolysis alone is unable to support the 
increased energy requirements of more complex life. Aerobic organisms have evolved to live in oxygen 
rich environments but are nevertheless, frequently exposed to brief periods of ischaemia whereupon they 
look to their more primitive metabolism to sustain them.  
The tolerance of organs to periods of warm and cold ischaemia differs between organs and to some 
extent reflects subtle differences in metabolic requirements and metabolism. The human heart is a highly 
metabolically active organ and is the one of the least tolerant grafts to ischaemia during organ 
transplantation. UK registry data suggests that recipient outcome is worse if cold ischaemic time (CIT) in 








1.5 Cardiac metabolism 
The daily energy requirements of the heart are the greatest of any organ in the human body. The complex 
machinery that converts chemical energy into the mechanical myofibril contraction required to beat 
100,000 times a day consists of three main components; substrate utilisation, oxidative phosphorylation, 
and ATP transfer and utilisation. In order to meet these high energy demands there is a degree of 
metabolic flexibility and a variety of energy substrates can be utilised to generate ATP if required (34). 
Nevertheless, under normal physiological conditions, 90-95% of ATP production is generated by 
mitochondrial oxidative phosphorylation with fatty acid ß-oxidation accounting for 60-80% of this ATP 
production and the remainder largely accounted by carbohydrate oxidation. The principal function of 
both pathways under aerobic conditions is to transfer protons and electrons via the reduced forms of 
flavin adenine dinucleotide (FADH2) and nicotinaminde adenine dinucleotide (NADH) to mitochondria to 
drive oxidative phosphorylation (35).  
1.5.1 Fatty acid oxidation 
Fatty acids must undergo esterification in the cytosol prior to further metabolism. This is an ATP-
dependent process generating a fatty acyl-CoA moiety. These acyl-CoA molecules are bound to specific 
proteins and can be used in a variety of cellular processes including, phospholipid synthesis, signal 
transduction of pathways or ß-oxidation. The inner mitochondrial membrane is impermeable to acyl-CoA 
and therefore, mitochondrial uptake relies on a complex of proteins using carnitine as a shuttle. Once 
inside the mitochondria, ß-oxidation results in the sequential two-carbon shortening of the fatty acyl-CoA 
liberating acetyl-CoA which then enters the citric acid cycle (CAC) whilst also generating NADH and FADH2 
in the process. Glycolysis converts glucose to pyruvate. In the heart the majority of this then undergoes 
pyruvate decarboxylation by pyruvate dehydrogenase (PDH) to acetyl-CoA that then enters the CAC (35). 
1.5.2 Glucose utilisation 
Glycolysis is the biochemical process that converts glucose to pyruvate. In the process, two moles of ATP 
are generated for each mole of glucose. Under aerobic conditions, this relatively meagre energy return is 
dwarfed by the energy generated by the subsequent oxidation through the CAC and mitochondrial 
oxidative phosphorylation (35, 36). 
Glycolysis is regulated at several key steps in the pathway with the principal ones being; glucose uptake 
and the reactions controlled by phosphofructokinase-1 (PFK-1) and glyceraldehyde-3-phopshate 
dehydrogenase (GAPDH) (36). 
Glucose uptake into cells is restricted to specific transporters. There are two uptake mechanisms that are 
known to exist in animals, Na+-dependent co-transport and facilitated diffusion glucose transporters 
(GLUT). Na+-dependent co-transport does not occur in myocardium and therefore, myocardial glucose 
uptake is determined by GLUT. There are six recognised isoforms of the GLUT family of which GLUT-4 is 







into myocardium preventing efflux. The rate of glucose phosphorylation in the cytosol by hexokinase is 
usually faster than glucose transport and therefore under physiological conditions, glucose uptake into 
myocardium forms the first regulatory step in glycolysis (37).  
The next regulatory step is the conversion of fructose-6-phosphate to fructose 1,6-bisphosphate by PFK-1. 
This process requires ATP and is the first irreversible step that commits glucose to glycolysis. ATP, citrate 
and protons are all negative effectors of PFK-1 that provide allosteric inhibition (37). 
GAPDH is another regulatory step in glycolysis. The oxidation and phosphorylation of glyceraldehyde-3-
phosphate is linked to the reduction of NAD+ to NADH. To ensure flux through GAPDH is not restricted, 
NADH must be re-oxidised to NAD+. In the presence of oxygen, NADH is oxidised by the malate/aspartate 
shuttle (MAS) and the mitochondrial electron transport chain (ETC). Under anaerobic conditions, NADH is 
reduced by lactate dehydrogenase (see below) (35, 36)  
1.5.3 Citric acid cycle (CAC) 
The CAC, or tricarboxylic (TCA) cycle, or Krebs cycle, is a series of chemical reactions that occur in the 
matrix of mitochondria of aerobic organisms to release energy by the oxidation of carbohydrates, fats and 
proteins. In the process, the cycle generates ATP and NADH which can be fed into oxidative 
phosphorylation. 
1.5.4 Mitochondria and Oxidative Phosphorylation 
Mitochondria generate ATP through oxidative phosphorylation. Oxidative phosphorylation is the final step 
in the aerobic metabolism. This process is performed by a series of large, multi-subunit complexes that 
are embedded in the inner mitochondrial membrane. These complexes channel electrons generated by 
the CAC and fatty acid ß-oxidation, along the ETC, down an electron gradient via a series of redox 
reactions to the final electron acceptor, oxygen. Complex I passes electrons produced by the oxidation of 
NADH to NAD+ and FADH2 to FADH to the CoEnzyme Q (CoQ) pool. Electrons can also be passed to CoQ 
following the oxidation of succinate at complex II. Similarly, electrons from ß-oxidation of fatty acids can 
also be transferred directly to the CoQ pool via the electron transfer flavoprotein (ETF). Electrons in the 
CoQ pool are transferred via complex III to cytochrome c and then from cytochrome c to complex IV 
where they are used to reduce oxygen to water. The energy released as the electrons are transferred 
from complex I, III and IV are used to pump protons across the inner mitochondrial membrane into the 
cytosol. This generates an electrochemical gradient across the inner mitochondrial membrane. It is this 
proton motive force (Dp) that then drives the phosphorylation of ADP to ATP at ATP synthase (complex V) 








Figure 1: Mitochondria and oxidative phosphorylation. 
Electrons generated by the CAC and fatty acid ß-oxidation are channelled along a series of multi-
subunit complexes down an electron gradient to the final electron acceptor, oxygen. As a 
consequence, protons are pumped across the inner mitochondrial membrane into the cytosol 
generating an electrochemical gradient. This proton motive force (Dp) drives the phosphorylation of 


































1.6.1 Cardiac ischaemic metabolism 
Whenever the arterial supply cannot deliver enough oxygen to meet the metabolic demands of a cell, 
tissue or organ, it becomes ischaemic. For the majority of organisms that have evolved to exist in oxygen 
rich environments, ischaemia can only be tolerated transiently and without prompt revascularisation and 
restoration of blood flow cell death is inevitable. 
With the cessation of myocardial blood flow, there is a rapid decrease in tissue oxygen. Studies from 
animal models have demonstrated that myocardial oxygen tension drops to approximately 75% of 
baseline values within 8-10 seconds following the onset of ischaemia and exhaustion of tissue oxygen is 
complete within 30 seconds (41). When oxygen is not available oxidative phosphorylation ceases. 
Anaerobic metabolism, through glycolysis, is the only available source of energy. This is a more primitive 
form of energy production but during an episode of ischaemia it can generate limited but sufficient 
energy to sustain cellular function transiently until revascularisation; however, it is the metabolic changes 
that occur during anaerobic metabolism that can prime cells and paradoxically lead to reperfusion injury 
and cellular death on re-oxygenation. 
In the first few minutes following the onset of ischaemia there is a paradoxical increase in the rate of 
glycolysis. This is due to a transient upregulation of key regulatory steps. There is an initial increase in 
substrate utilisation through an increase in glycogenolysis stimulated in part by ischaemia-induced local 
catecholamine release and an associated increase in cyclic adenosine monophosphate (cAMP), and also 
by the reduction in the phosphorylase b inhibition due to a decrease in tissue ATP concentration. The 
increase in the rate of glycolysis is also the result of increased substrate utilisation through PFK-1 
upregulation. Activation of PFK-1 is the result of increased concentrations of the positive effectors, ADP 
and adenosine monophosphate (AMP), and removal of the inhibition by the negative effector ATP (42). 
Despite the upregulation of glycolysis during early ischaemia, it is still insufficient to meet energy 
demands.  
After a few minutes of ischaemia, there is a marked reduction in the rate of ATP production and this 
corresponds to a cessation in contraction. The reduction in ATP generation is likely the result of 
subsequent inhibition of PFK-1 and GAPDH by the increasing NADH and protons associated with the 
absence of oxidation and lactate production (42).  
Glycolysis cannot continue indefinitely. Studies in animal models were conflicting in identifying the causal 
mechanisms for the eventual failure of glycolysis (42). Exhaustion of glycolytic substrate or cofactors, or 
the inhibition or denaturation of glycolytic enzymes have been proposed as potential mechanisms (36, 
43). In the absence of coronary flow, lactate and protons accumulate and it is generally understood that 
this is the causal mechanism that results in the inhibition of glycolysis and ATP production with resultant 







1.6.2 Cardioplegia and effects on cardiac metabolism 
The early era of open-heart surgery in the 1950s was performed with brief periods of circulatory arrest 
under whole-body hypothermia that was used to provide protection against hypoxic injury, in particular 
to the brain. Subsequent development of cardiopulmonary bypass circumvented the hypoxic injury to the 
brain and other organs, but the extended periods of myocardial ischaemia required to treat more 
complex cardiac pathologies were increasingly problematic. ‘Stone heart’ was a previously well-
recognised phenomenon in which irreversible ischaemic contracture occurred as a result of exhaustion of 
ATP. Cardiac surgeons at the time experimented with solutions of high potassium citrate to induce a 
chemical arrest but the practice was abandoned in the UK for 20 years after it was found to cause focal 
myocardial necrosis. In the mid-1970’s renewed interest in cardioplegic solutions led to the development 
of St Thomas’ Hospital cardioplegic solution by the biochemist, David Hearse and the cardiac surgeon, 
Mark Braimbridge (44). This solution was based on an extracellular ionic composition. A moderately 
elevated potassium chloride concentration was used instead of potassium citrate to induce arrest as it 
was believed that the previous accounts of focal myocardial necrosis resulted from the high citrate 
concentrations. This cardioplegic solution was first used surgically in 1975 and quickly became the 
predominant cardioprotective technique used throughout the world (44).  
Hyperkalaemic solutions induce a diastolic flaccid arrest by making the resting membrane potential of the 
myocyte more positive or depolarized compared to normal. This resting potential is more positive than 
the threshold potential for the voltage dependent Na+ channel which therefore remain inactivated. This 
prevents repolarisation, hence the term, ‘depolarised’ arrest. The cessation of cardiac contraction is 









1.7 Reperfusion injury 
Reperfusion injury is the pathological exacerbation of tissue injury that occurs on re-oxygenation of an 
organ that has previously been subjected to a period of restricted or interrupted blood flow (46). The 
concept of reperfusion injury was first suggested in the 1960s by Jennings et al (47). They observed the 
structural and electrophysiological changes that occurred on coronary reperfusion of canine myocardium, 
noting that reperfusion actually hastened necrosis (47, 48). Subsequent work by Hearse et al (49) 
demonstrating that intracellular enzymes were released predominantly during reperfusion and not during 
ischaemia supported this observation. Furthermore, they demonstrated that oxygen was essential for the 
observed cellular injury and did not occur on anoxic reperfusion (50). This counterintuitive observation 
that restoration of blood flow and re-oxygenation exacerbates tissue injury is termed, “reperfusion injury” 
and is recognized as a major contributor to a wide range of pathological entities including; acute coronary 
syndrome, acute kidney injury, stroke, intestinal ischaemia, multi-organ failure, hypovolaemic shock 
following trauma and graft dysfunction following solid organ transplantation (46). 
It is now known that upon reperfusion, the restoration of oxygen to ischaemic tissues results in the 
formation of reactive oxygen species (ROS) and that it is ROS that are the effectors of the subsequent 
tissue injury. ROS are reactive molecules that contain oxygen. They were directly implicated as the central 
mediators of IR injury using electron spin resonance and spin trapping in the 1980s (50). These studies 
demonstrated a marginal increase in ROS during ischaemia. ROS remained unchanged during hypoxic 
reperfusion but rapidly spiked, with a peak at about 20 seconds when the tissues were reperfused with 
oxygen. The central role of ROS in IR injury was confirmed by studies that demonstrated similar 
pathophysiological changes to those seen at reperfusion with exogenously administered ROS (50). 
1.7.1 Reactive oxygen species  
Since ROS were identified as the effectors of reperfusion injury research has focused on the precise 
source and the mechanism through which they’re generated. There are a number of biologically 
important ROS that include, superoxide (O•-), hydrogen peroxide (H2O2), nitric oxide (NO•), peroxynitrite 
(ONOO-), hypochlorus acid (HClO), and the hydroxyl radical (HO•)(51).  The O•- is the predominant ROS 
generated during ischaemia-reperfusion (IR). Physiological O•-  formation occurs at low levels, 
predominantly as a result of electron leakage within the ETC. During IR there is a burst of O•- formation. 
There are multiple potential sources of ROS that include, mitochondria, the xanthine oxidase pathway and 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity. Whilst all sources of ROS 
contribute, it has been estimated that mitochondria account for the great majority (up to 90%) of the 
overall oxidative burden (52). 
1.7.2 Mitochondria 
Mitochondria are frequently referred to as the powerhouses of the cell since their primary function is the 







oxidative phosphorylation and ROS production is a by-product of this process. Mitochondria are 
important sources of ROS both during physiological and pathophysiological conditions. The principal 
sources of ROS production are complex I and III. ROS are generated when redox-active prosthetic groups 
found within these complexes are exposed to oxygen. Antioxidant enzymes are defense mechanisms 
found both in the mitochondrial matrix and cytoplasm. These superoxide dismutases (SOD) contain 
copper or manganese metal centers that dismutate O•- to H2O2 that can then be further deactivated by 
catalase to water and oxygen, or by glutathione peroxidases to glutathione disulfide and water (38, 39). 
Until recently, mitochondrial ROS generation during IR injury was thought to be a non-specific 
consequence of the rapid re-oxygenation of a dysfunctional respiratory chain. It has recently been 
hypothesized that O•- generation during IR injury is, in fact, the product of a specific metabolic process, 
namely, reverse electron transport (RET) through complex I driven by succinate accumulation during 
ischaemia (53).  
Liquid chromatography – mass spectrometry (LC-MS) analysis of mammalian tissues during ischaemia, 
demonstrated succinate to be the only CAC metabolite to accumulate in all tissues assessed in the mouse. 
Under physiological conditions, succinate is generated through a variety of processes including, the 
oxidation of carbons from glucose, fatty acids, glutamate and the γ-aminobutyric acid (GABA) shunt. 
During ischaemia however, mitochondria best preserve the electrochemical gradient to enable continued 
ATP production by reversing the action of succinate dehydrogenase (SDH) to generate succinate from 
fumarate. The fumarate required for this process is thought to be produced by two pathways, the MAS, 
and the AMP-dependent activation of the purine nucleotide cycle (PNC) (53). At reperfusion, with the 
reintroduction of oxygen, the conventional direction of the respiratory chain can resume. The 
accumulated succinate can be oxidized back to fumarate with complex II donating electrons to CoQ in the 
standard manner. The sudden generation of electrons through complex II by the oxidation of the 
accumulated succinate, overwhelms complex III and IV which are running at full capacity. This generates a 
high Dp. The high Dp may be further exaggerated by the degradation of adenine nucleotides during 
ischaemia. This limits the availability of ADP for ATP generation by ATP synthase that would normally 
decrease Dp in the process. In the presence of the high Dp and highly reduced CoQ pool, the 
bioenergetically favored method to disperse the excess electrons is through RET at complex I which in the 
process generates O•- (53, 54). 
1.7.3 NADPH oxidase 
The first member of the NADPH oxidase (NOX) family of transmembrane enzymes was identified in 
phagocytes. Other members of this family of ROS producing enzymes have since been identified in almost 
all tissues. They all transport electrons across biological membranes to enable the reduction of oxygen to 
O•- (55, 56).  
The early studies confirming the proximal role of O•- in reperfusion injury also suggested a role for 







production. However, when translated to whole animal studies, this ROS production was shown to remain 
elevated for over 3 hours. The ‘respiratory burst’, which is a result of neutrophil infiltration, is an 
important source of ROS, although whether it has causative or effector role in the pathogenesis of IR 
injury is uncertain (55, 56). 
1.7.4 Cellular xanthine oxidase 
The xanthine oxidoreductase (XOR) describes two inter-convertible yet functionally distinct enzymes, 
xanthine dehydrogenase (XD) and xanthine oxidase (XO) (57). XOR is involved in purine metabolism, 
catalyzing the conversion of hypoxanthine to xanthine and subsequently uric acid. XD is present in vivo 
and catalyzes the oxidation of hypoxanthine to xanthine by coupling the reaction to the reduction of NAD+ 
to NADH. Under certain physiologic and pathophysiologic conditions XD undergoes a post-transcriptional 
change to XO. XO is unable to couple the oxidation of hypoxanthine to the reduction of NAD+ instead 
requiring oxygen, which is reduced in the process producing O•-. XOR is found in a variety of tissues 
including, liver intestine, spleen, kidney and skeletal muscle. In addition, it has been shown to be present 
in high concentrations on the luminal surface of the microvasculature endothelium of organs including 
the heart (57). 
The XOR system has long been implicated in ROS generation during IR injury. Ischaemia results in 
modification of XD by proteolytic cleavage to XO. At reperfusion the irreversibly modified XO then 
generates ROS (50). Unfortunately, the initial positive results in animal studies investigating the role of 
ROS scavenging with antioxidants or inhibitors of XOR such as allopurinol have not been translated to the 







1.8 Mitochondria and the immune response 
The immune system comprises two complementary and close connected defense mechanisms that enact 
a response to threatening stimuli. These are the innate and adaptive immune responses. The innate 
immune response provides the first line of defense generating a non-specific immediate response to 
invading microorganisms, tissue injury or malignancy. This is an antigen independent response and is not 
associated with the development of immunological memory. In evolutionary terms, the adaptive immune 
response is more modern. It is an antigen dependent response that enables the host to develop 
immunological memory, enabling a heightened immune response if the host encounters the respective 
pathogen at a later time. mtROS is an upstream effector of the exaggerated tissue injury that occurs 
during IR injury. The burst of mtROS has the potential to not only impact acute function through 
potentiation of an innate immune response but also longer-term function through effects on the adaptive 
immune response. 
1.8.1 Sterile Inflammation and the innate immune response 
The ROS generated on reperfusion combined with cellular oxidative damage, mitochondrial dysfunction 
and ischaemic tissue injury initiate an inflammatory response with activation of the innate immune 
system. This ‘sterile inflammation’ occurs in the absence of any microorganisms but there are many 
phenotypical parallels between this, sterile inflammation, and the immune response directed against 
pathogens.  
The innate immune response is characterized by the recruitment of neutrophils, macrophages, the 
production of pro-inflammatory cytokines, fibroblast proliferation and aberrant collagen accumulation 
and fibrosis. Microorganisms are recognized through conserved structural moieties found in 
microorganisms that are collectively known as pathogen-associated molecular patterns (PAMPs). These 
are recognized by germline encoded pattern recognition receptors (PRR) of which five classes are 
recognized.  
In sterile inflammation, these PRRs are activated by endogenous molecules in the absence of microbial 
infection. These ligands are termed damage-associated molecular patterns (DAMPs) and when sensed by 
PRRs initiate an immune response with the production of pro-inflammatory cytokines (58, 59). 
1.8.2 Mitochondria and innate immune response 
Mitochondria have been shown to be a direct source of DAMPs directly initiating an innate immune 
response through a number of pathways. Mitochondrial DAMPs include mitochondrial ROS (mtROS) and 
mitochondrial DNA (mtDNA). 
1.8.3 Mitochondrial ROS (mtROS) 
mtROS are generated during periods of cellular stress and have been shown to have direct roles as 







protein is a key protein in a signaling pathway, activating nuclear factor k-light chain enhancer of 
activated B cells (NF-kB) and interferon regulatory factors (IRFs) to induce type-I interferons (60). MAVS is 
localized to the mitochondria and in addition to activation in response to viral replication through 
(retinoic acid-inducible gene-1) RIG-I and melanoma differentiation antigen 5 (MDA-5) (60), has been 
shown to be activated by mtROS independent of RNA (32). mtROS have also been shown to have a role in 
the activation of the NLRP3 inflammasome (32, 61).  
1.8.4 Mitochondrial DNA (mtDNA) 
The bacterial origins of mitochondria are retained in their DNA. mtDNA is located in close proximity to the 
respiratory chain and is a circular loop containing 37 genes (62). Like bacterial DNA, mtDNA contains CpG 
DNA repeats that when liberated into the cytosol or extracellular space by cellular stress or necrosis, can 
be recognised by the Toll-like receptors (TLRs) and act as a damage associated molecular pattern (DAMP) 
(63, 64). mtDNA has been shown to activate TLR9 (63), the NLRP3 inflammasome (65), and the STING 
pathway (66). TLR9 activation leads to activation of the NF-kB signaling pathway with associated 
induction of proinflammatory genes including those encoding tumour necrosis factor (TNF) (63). 
Activation of the NLRP3 inflammasome activates caspase-1 which results in the maturation and secretion 
of IL-1ß and IL-18 (64). Finally, activation of the cytosolic DNA sensor, cGAS, activates the STING pathway 
culminating in the upregulation of interferon stimulated genes (ISGs) and potentiates type I interferon 
responses (66). mtDNA is therefore capable of activating an innate immune response through a number 
of central signaling pathways. Although the innate immune response is not sufficient to itself reject the 
allograft, this inflammatory milieu may modify the adaptive immune response, upregulating an insidious 
immune response and thereby potentiating chronic rejection (58). 
1.8.5 Mitochondrial regulation of the innate immune response 
In addition to the potentiation of an innate immune response directly through the release of these 
DAMPs described above, in certain settings CAC intermediates such as succinate have been shown to 
modify the innate immune response by stabilizing hypoxia inducible factor 1a (HIF-1α). This also results in 
an increase in cytokine production thus providing a separate mechanism through which mitochondria can 
up regulate the innate immune response at the time of transplantation (58). Finally, mitochondria may 
also have indirect effects in mediating the innate immune response through additional cellular oxidative 
damage and the release of other DAMPs.  
 
1.8.6 The adaptive immune response 
There is emerging evidence that IR injury has the potential to modulate the adaptive immune response 
through a number of pathways. High mobility group box 1 (HMGB1) and heat shock protein 72 (HSP72) 
are both DAMPs. HMGB1 is released following cellular injury and HSP72 is expressed following oxidative 







upregulation in expression of MHC class II, costimulatory molecules and cytokine secretion. Mature DCs 
can then activate naïve T-cells in secondary lymphoid tissue generating an adaptive alloimmune response.   
The cytokines released by the activated innate immune system recruit leukocytes to the inflamed organ, 
activate the complement cascade facilitating antigen presentation, modify the activation status and 
permeability of the endothelial cells, upregulate antigen presentation, and stimulate migration of antigen 
presentation cells (APCs) both into and out of the transplanted organ. These events are all intimately 
involved in the upregulation of the adaptive immune response (59). 
1.8.7 Mitochondria and the adaptive immune response 
mtROS have also been shown to be intimately involved in the adaptive immune response. T-cell activation 
results in a rapid increase in mtROS production that is critical for CD4+ T-cell activation in vitro and in vivo 
though CD3 initiated Ca2+ signalling; without mtROS, CD4+ T-cells do not express IL-2 (67). Furthermore, 
mtROS have also been shown to have a role in the fate determination of activated B cells by promoting 
class switch recombination (68). Together, these observations support a central role for mtROS in the 
activation and regulation of the adaptive immune response(32). 
In addition to direct activation through mtROS, mitochondria are increasingly recognised as a having 
central role in orchestrating the adaptive immune response. The ancient ancestry of mitochondria 
underpins the intricate relationship they are increasingly recognised to play in other core metabolic and 
cellular processes outside of energy synthesis (32, 39). The mammalian immune response requires an 
intricately coordinated balance of cell activation and inhibition of signaling pathways across a range of cell 
types. These signaling pathways have traditionally been thought of as linear phosphorylation-based 
cascades initiated at the cell surface and conveyed to the nucleus. More recent evidence suggests that 
cellular metabolism not only provides the energy to fuel this process, but also independently moderates 
these signaling pathways(58). T-cell subsets have dramatically different metabolic profiles that are 
necessary for T-cell differentiation. Increased glycolytic metabolism has been observed in Th17 cells due 
to an increase in HIF-1. Inhibiting the effector target of HIF-1 in Th17 cells suppresses Th17 cells and 
increases Treg formation in vitro and in vivo models. Similarly, B-cells have also been observed to undergo 
major transitions in their metabolic requirements during maturation(58). The impact of reperfusion injury 







1.9 Clinical manifestations of reperfusion injury in organ 
transplantation 
The characterisation of reperfusion injury as a distinct pathological entity and its associated clinical 
manifestations is confounded by the inherent close association with direct ischaemic injury. There is 
extensive research supporting the concept that reperfusion injury causes additional myocardial injury, 
perhaps best evidenced by interventions that can be initiated at the end of ischaemia and still reduce 
infarct size(69). In organ transplantation, whilst organ injury frequently occurs during the process of 
transplanting an organ, the precise individual contributions of irreversible ischaemia, and subsequent 
reperfusion to the overall organ injury are very difficult to isolate and are yet to be definitively defined. 
Nevertheless, clinical manifestations of IR injury are frequently associated with IR injury in transplantation 
and include; delayed graft function (DGF) in kidney transplantation, aspartate aminotransferase (AST) rise 
and the post-reperfusion syndrome in liver transplantation, graft pancreatitis in pancreas transplantation 
and myocardial dysfunction in heart transplantation.  
1.9.1 Clinical impact of ischaemia on short and long-term 
outcomes 
Evidence from in vitro and in vivo models has identified multiple pathways through which IR injury can 
impact both short and long-term outcomes in organ transplantation. Data from clinical studies further 
supports the impact of IR injury on acute organ dysfunction or graft failure, as well as potentially 
moderating chronic rejection and long-term outcomes.  
1.9.2 Outcomes in heart transplantation  
Hearts tolerate periods of ischaemia very poorly. The catastrophic complication of irreversible ischaemic 
injury and primary graft function was all too common to the early pioneers of heart transplantation. 
Nevertheless, as outcomes quickly improved, the demand for hearts quickly outstripped supply. Clinicians 
sought ways of expanding the donor pool and one potential source was organs with prolonged ischaemic 
times (>4 hours). Whilst some studies from single centres have suggested there is no association between 
ischaemic times and primary graft failure (PGF) (70, 71), the general consensus, supported by recent UK 
and international data, is that the length of ischaemic time is a strong predictor of PGF and that the risk of 
PGF increases for ischaemic times beyond 3 hours (33, 72). Whether graft ischaemia impacts mid and 
long-term outcome in cardiac transplantation is less well defined. Registry data identified ischaemic time 
as an independent risk factor for 1, 5 and 15-year patient mortality and multivariate analysis 
demonstrated ischaemic time is likely to be a risk factor for the development of chronic allograft 
vasculopathy (CAV) at 5 years (73). These findings were at odds with large, single centre cohort studies 
demonstrating no difference in overall survival with prolonged graft ischaemia(70, 71). In another study, 
prolonged graft ischaemia was weakly associated with greater incidence of transplant coronary artery 







ischaemia: In a subgroup of donors >50 years of age, prolonged graft ischaemia was associated with 
significantly worse short and long-term outcomes(70, 71). 
1.9.3 Outcomes in liver transplantation 
Increased cold ischaemia is associated with worse short and long-term outcomes following liver 
transplantation(75-77). A number of clinical trials have been undertaken in liver transplantation adopting 
a range of pharmacological strategies to minimise IR injury with limited success(78).  
1.9.4 Outcomes in kidney transplantation 
The relationship between cold ischaemia time and outcomes in kidneys from DBD has proved difficult to 
define and there are conflicting results from registry studies (79). Some authors have suggested that there 
are threshold values below which CIT has no impact on outcome, whilst others have suggested that it 
should be considered as a continuous risk factor (79). 
Prolonged CIT (>24 hours) has been shown to be a risk factor for PNF, DGF, and increased incidence of 
acute rejection episodes (80-85). Data from the UK registry demonstrate that increasing cold ischaemic 
time up to 21 hours is not associated with worse short-term outcomes. However, beyond this the risk of 
transplant failure was increased by 4% for each additional hour of cold ischaemia(82).  
The impact of cold ischaemia on longer-term outcomes is less certain, with studies producing conflicting 
results. Some studies have shown that prolonged cold ischaemia is associated with worse long-term 
outcomes (79-81, 83, 86-91), although others have failed to identify any difference in longer-term graft 
survival (82, 85, 92, 93). There are a number of explanations for the disparity between these studies. The 
multifactorial aetiology of chronic graft loss, differences in study design and the variation in regional and 
national retrieval practice, donor types, ischaemic times, immunosuppression and long term follow up, all 
introduce the potential for considerable bias. A recent analysis of data from the modern era of 
immunosuppression suggested that prolonged cold ischaemia was detrimental to mid-term outcomes. 
Moreover, there was also a proportional relationship between CIT and mid-term outcomes with every 
hour of cold ischaemia increasing the risk of graft failure (79). Recent data from the UK transplant registry 
also suggests ischaemia may impact long-term graft function. In a study by Summers et al organs from 
deceased donors that were exposed to a more severe ischaemic insult had a worse 5 year survival (9). 
1.9.5 Clinical outcomes of DCD compared to DBD 
DCD is an invaluable source of organs for transplantation, but concern surrounds the additional period of 
primary warm ischaemia that can be detrimental to immediate and long-term organ outcome. Kidney and 
liver transplants comprise the majority of DCD transplanted organs and therefore, the impact of DCD on 
organ outcome outside single centre experience in other organs is limited. 
In kidney transplantation, the general consensus, is that DCD negatively impacts immediate graft function 







outcomes. UK registry data demonstrates no difference in the 3-year, risk adjusted, graft or patient 
survival following DCD and DBD (26, 91). Animal models (94) and clinical data have shown that DCD 
kidneys tolerate subsequent prolonged cold ischaemia worse than DBD kidneys with a higher incidence of 
PNF, DGF and long-term survival (9, 95-97). 
In liver transplantation, DCD organs are also associated with increase in surgical complications including 
PNF (98, 99). Furthermore, in some series this has been shown to translate into a worse longer-term 
outcome when compared to DBD organs (98, 100, 101). In contrast, some single centre experience and 
registry data have demonstrated similar short and long-term outcomes in selected cohorts (98, 102). The 
additional primary warm ischaemia associated with DCD, rather than simply compounding reperfusion 
injury as observed in some organs, manifests in liver transplantation as a different spectrum of 
complications with an increased incidence of ischaemic cholangiopathy. This is characterised by the 
presence of non-anastomotic biliary strictures in the donor biliary tree that occur in the absence of 
hepatic artery thrombosis or stenosis. The increased ischaemic cholangiopathy translates into a worse 
longer-term outcome and an increased rate of re-transplantation in recipients of organs following DCD in 
liver transplantation (100, 103).  
In summary, clinical evidence suggests that DCD are an invaluable source of potential organs and, with 
appropriate donor and recipient selection outcomes, comparable to DBD organs can be achieved. 
Nevertheless, the additional period of warm ischaemia introduces an insult the precise mechanisms for 







1.10 Allograft rejection in transplantation 
The immune response generated following the transplantation of an organ can be both an innate and an 
adaptive response. Non-specific injury elicits an innate immune response and whilst this is only rarely able 
to itself reject a graft it is integral in initiating and amplifying the adaptive immune response that results 
in rejection of the allograft (59).  
Various classifications are used to describe the adaptive immune response that can produce rejection of 
an allograft. These can be based on pathophysiological changes, severity, response to treatment, 
presence or absence of organ dysfunction and immunologic mechanisms. Categorized simply according to 
the time course of rejection, rejection can be divided into hyperacute, acute or chronic (104, 105).  
1.10.1 Hyperacute rejection 
Hyperacute rejection is now relatively rare in solid organ transplantation due to improvements in pre-
operative cross matching and a reduction in HLA panel reactive antibodies in potential recipients. 
Hyperacute rejection is the result of pre-formed recipient antibodies that bind donor endothelial antigens 
(ABO, HLA). In kidney transplantation, it causes diffuse haemorrhagic cortical necrosis and vascular 
thrombosis. Within a few minutes of reperfusion the transplanted organ turns a mottled blue and fails to 
produce urine. The organ usually has to be explanted (106, 107). 
1.10.2 Acute rejection 
Acute rejection typically occurs within the first 3 months following transplantation and may be cell or 
antibody mediated.  Cell mediated rejection is driven by T-lymphocytes. Solid organ transplantation 
produces a unique immunological situation in which recipient T cell recognition of foreign antigen can 
occur through three distinct pathways. Recipient T cells can recognize the intact MHC on the surface of 
donor APC such as DC. This is termed direct allorecognition. An alternative process of antigen 
presentation is indirect allorecognition. This involves the internalisation and processing of the donor 
alloantigen, which is then re-presented by APCs on self MHC. More recently, a further mechanism for 
alloantigen presentation has been described. In this semidirect pathway, donor MHC is internalized and is 
represented intact on the recipient APC surface (59, 108). 
Direct pathway allorecognition plays a dominant role in initiating an adaptive immune response in clinical 
transplantation but its effects are short lived as donor APCs are rapidly cleared by the recipient NK cells 
due to a lack of recipient MHC class I. The indirect pathway, however, can potentially provide a long-lived 
immune response as donor antigen will be available for internalization, processing and representation by 
recipient APCs for as long as the graft remains in situ. Whilst there is undoubtedly some crossover 
between these two pathways in clinical practice, direct allorecognition is thought to dominate during the 
early stages of transplantation with indirect allorecognition becoming the dominant pathway at later 







Humoral or antibody mediated rejection accounts clinically for approximately 10% of acute rejection 
episodes (107). There are a variety of antigenic targets against which antibodies can be generated, 
including MHC molecules, minor histocompatibility complex molecules, endothelial cells, blood group 
antigens and autoantigens (59, 109). Antibody-mediated graft damage is primarily the result of 
complement fixation, although direct activation of natural killer cells and macrophages by binding of the 
antibody Fc region to cell surface receptors expressed on these cells may also contribute to graft damage 
through antibody-dependent cellular cytotoxicity (59). 
There have been significant improvements in the overall management of acute rejection with 1 year 
survival of organs now over 90% (107). 
1.10.3 Chronic rejection 
The array of terminology used to describe the insidious decline in function of a transplanted organ reflects 
the complexity of the pathophysiological processes that undermine it.  
Chronic graft dysfunction is a functional definition that does not differentiate the underlying 
pathophysiological process whereas chronic rejection is used to imply an ongoing immunological 
response. Histologically, the decline in graft function is characterized by a progressive replacement 
fibrosis of the graft parenchyma. While there may be a degree of heterogeneity in the predominant 
pathological process responsible for this, the most common of these is chronic allograft vasculopathy 
(CAV), which is universal to all transplanted vascularised organs (104, 110). 
Allograft vasculopathy is a progressive, concentric intimal hyperplasia that results in luminal narrowing 
along the entire length of transplanted arterial vasculature (as opposed to atherosclerosis which produces 
lipid-rich, discrete, eccentric plaques in epicardial vessels). Histopathologically, the plaques are lipid-poor 
and composed of smooth muscle cells and extra-cellular matrix. The loss of luminal diameter is 
predominantly due to intimal hyperplasia, although there may also be a degree of adventitial scarring that 
results in a restrictive component to the luminal stenosis. Vascular remodeling occurs, to some degree, in 
all transplanted grafts, although clinically significant chronic vasculopathy only occurs in a small subset of 
patients. Graft failure is associated with a progressive parenchymal replacement fibrosis of allograft 
thought to be a result of progressive parenchymal ischaemia (104, 110, 111). 
Allograft vasculopathy does not occur in syngeneic grafts in experimental models and is not seen past the 
suture line or atrial remnant in human recipients. This provides strong evidence that the process is driven 
by an alloimmune response (104, 110, 111). 
Although the alloimmune response underlies the pathogenesis of chronic allograft vasculopathy, ongoing 
allogeneic stimulation is not necessarily required (112-115). This poses the question as to whether an 
initial activation of an alloimmune response can upregulate the secondary response sufficient for 







The aetiology of chronic rejection in kidney allografts is less certain and parenchymal fibrosis is 
occasionally seen without significant vasculopathy (chronic parenchymal cell rejection). Nonetheless, 
allograft vasculopathy is still commonly seen in failing renal allografts (112). 
1.10.4 Impact of chronic rejection 
Chronic graft dysfunction remains a major clinical challenge in transplantation and currently occurs in 
approximately 3-5% of transplanted grafts per year. This has remained largely unchanged despite 
considerable progress in other areas of transplantation. In addition to the direct consequences and 
increased mortality associated with losing a graft for the individual patient, chronic graft loss has a direct 
impact on the fundamental problem of organ shortage (116). 
Chronic graft dysfunction is a complex multifactorial process with an aetiology that likely involves some or 
all of: the alloimmune response, ischaemia reperfusion injury, toxicity from immunosuppressive agents, 








1.11 Protective strategies for treating IR injury 
There are multiple opportunities during the transplant process that are theoretically amenable to 
therapeutic intervention in ameliorating ischaemia and or reperfusion. The use of agents prior to the 
confirmation of death with the implicit purpose of improving donor organ outcome is controversial. In the 
UK, the use of interventions that are not of direct benefit to the donor are prohibited pre-mortem.  
There is a potential window in DBD during which agents could be administered to the donor prior to the 
onset of ischaemia. However, DCD organs comprise a significant proportion of all organs transplanted in 
the UK today and with the increased incidence of IR injury associated with these organs it would be 
preferable to target interventions during the stages of organ storage and reperfusion. 
Pharmacological therapies have been used experimentally to target all aspects of IR injury; pre-ischaemia, 
during organ storage, and on reperfusion.  
1.11.1 Targeting mitochondria 
Ameliorating IR injury has previously been explored and the use of the antioxidant scavenger superoxide 
dismutase demonstrated some efficacy in improving outcomes in kidney transplantation (117). The 
increasing recognition of the fundamental role of mitochondria in mediating IR injury has increased 
interest in developing strategies to target the mitochondrial mechanisms that underpin IR injury (39, 118). 
Therapeutic strategies targeting mitochondria can be grouped into a number of areas including; limiting 
oxidative stress and mitochondrial ROS generation, reducing tubular cell death through necrosis and 
apoptosis, moderating mitochondrial dynamics and mitochondrial immunomodulation (118).  
1.11.2 Limiting oxidative stress and mitochondrial ROS 
The fundamental role of oxidative stress in IR injury has been extensively reported and has provided a 
strong rationale for the use of antioxidants in this setting. Paradoxically, however, the translation of these 
therapies to clinical practice has been disappointing. This can be interpreted in one of two ways. Either 
ROS do not have a role in the pathophysiology of these diseases, or the antioxidants are not adequately 
delivered to the appropriate region of the cell or at an appropriate time during reperfusion to prevent the 
cellular damage. Dimethyl malonate (DMM) is a competitive inhibitor of succinate dehydrogenase.  As 
discussed above, reversal in the conventional direction of this enzyme during ischaemia results in the 
generation of succinate from fumarate. DMM competitively inhibits this process and has been shown in 
vivo to ameliorate succinate accumulation and subsequent IR injury in a variety of animal models (53) and 
is an appealing therapeutic approach in organ transplantation (118). 
1.11.3 Reducing tubular death 
Mitochondria are central to necrosis and apoptosis. Apoptosis is initiated by two major but 
interconnected pathways; mitochondria and death receptors. Increased permeability of the outer 







proteins leading to the formation of the apoptosome. This activates caspase-activation pathways resulting 
in apoptosis. Therapies designed to target this pathway have demonstrated early promise in other areas 
of IR injury and are currently in phase II human clinical trials (118-120). 
1.11.4 Mitochondrial dynamics 
Mitochondria are not solitary, isolated entities but exist as complex interconnected networks that are in 
constant flux through fusion, fission and the selective removal of individual units by autophagy, a process 
termed mitophagy. Altered mitochondrial dynamics may contribute to changes in cellular injury and 
repair following IR injury. A variety of proteins have been identified as regulators of mitochondrial fusion 
and fission including the pro-fusion proteins, mitofusin 1 and 2, OPA1, and the pro-fission protein 
dynamin-related protein 1. Pharmacological inhibition or unpregulation of these processes has been 
shown to have protective effects in models of IR injury, though these findings are yet to be translated to 
clinical trials (121-124). 
1.11.5  Mitochondrial Immunomodulation 
Mitochondria are increasingly recognized as being central to the activation and regulation of both the 
innate and adaptive immune response as discussed above. These emerging pathways may be amenable 
to pharmacological intervention in the future. The conversion of M1 inflammatory macrophages to M2 
anti-inflammatory cells has been shown to be facilitated by both metformin and rotenone. This switch is 
thought to be initiated through actions on complex I by reducing RET and the generation of ROS. 
Furthermore, inhibition of SDH using DMM has also been shown to limit a pro-inflammatory response and 
boost anti-inflammatory responses whilst the metabolite itaconate has also been shown to inhibit SDH 
and has anti-inflammatory actions (32, 125-127).  
1.11.6 Improving short and long-term outcomes 
Evidence from animal models supports the role of reperfusion injury in a variety of diseases including 
organ transplantation. The translation of therapies from animal models to clinical transplantation has 







1.12 Translation of transplantation research and rationale for 
project 
Early research in transplantation identified and developed methods to preserve organs and these have 
proved largely successful allowing the widespread introduction of transplantation programmes. IR injury 
is inherent to organ transplantation. However, with the current need to continue to expand the donor 
pool to meet demand, the organs that are being transplanted today are increasingly exposed to more 
significant ischaemic insults and are less tolerant of ischaemia. The recognition of specific metabolic 
pathways that underpin IR injury may help to explain the paradoxically poor translation of findings from 
previous small animal models to clinical practice and provides a new opportunity for therapeutic 
intervention. The demonstration of conserved metabolic pathways across species is, however, 
fundamental if therapeutic efficacy is to be realized in clinical practice. Registry data and case series 
support the association of increased IR injury and a worse short-term graft and recipient outcome 
providing a rationale for the development of therapies to mitigate IR injury and improve short term 
outcomes. 
In addition to the association with a worse short-term outcome, data from registries and case series also 
supports a role for IR injury mediating longer term outcomes in transplantation. Mechanistically, 
connecting a distinct, acute event such as IR injury and the insidious process of chronic rejection at the 
outset may seem contrived. However, the emergence of immunometabolism and the integral role of 
mitochondria in this process provides a potential link between these two events and supports the 
development of models that would enable further work and the development of therapeutic strategies 







1.13 Aims of this work 
The success of organ transplantation has led to it becoming a routine part of clinical practice. 
Nevertheless, demand for organs in the UK continues to outstrip supply and people continue to die on the 
waiting list. The persistent demand for organs has driven an expansion of the donor pool and the use of 
organs from DCD donors and other ‘less than ideal’ organs are fundamental to increasing the number of 
organs for transplantation. DCD organs provide a vital source of organs in the UK but have been exposed 
to an additional period of warm ischaemia that can impact outcomes. In addition, less-than-ideal organs 
(from extended criteria or marginal donors) may be less tolerant of additional warm and prolonged cold 
ischaemia than organs from SCD. The worse outcomes associated with periods of warm ischaemia and the 
relative intolerance of ischaemia that may be associated with ‘less-than-ideal’ organs are potentially 
routed in the pathological exacerbation of tissue injury that occurs on re-oxygenation that is termed 
reperfusion injury. Mitochondria are increasingly recognised as initiators of this process generating a 
burst of ROS upon reperfusion that drives downstream pathways and organ dysfunction. Therapies that 
ameliorate IR injury could therefore both improve outcome and further expand the donor pool. In 
addition to impacting short term outcome, increasing IR injury may also worsen chronic rejection and 
long-term outcomes. Understanding the biochemical pathophysiology is paramount to the development 
of rational therapeutic strategies to treat IR injury and improve outcomes. 
 
This thesis sought to address the following hypotheses:  
Mitochondrial dysfunction contributes to IR injury during organ transplantation and these mechanisms 
are amenable to therapeutic intervention.  
Mitochondrial dysfunction and the subsequent tissue injury associated with IR injury impacts both 
short- and long-term allograft outcomes.  
 
The overall objective of this thesis was therefore, to examine the mechanism of IR injury in organ 
transplantation and the relationship between IR injury and early and late organ dysfunction. Specifically, 
this work:  
1. Investigated the metabolic profile of myocardial tissue during organ storage in mice, pigs and humans 
and identified key metabolic pathways, including the accumulation of succinate, and demonstrated 
whether these were conserved across species.  
2. Explored the metabolic pathways identified through metabolic profiling and demonstrated efficacy in 







3. Examined the efficacy of small molecule inhibitors in modifying reperfusion in vivo in a small animal 
model of solid organ transplantation. 
4. Examined whether increasing IR injury was associated with an increase in chronic rejection in a 



















2.1 Chemicals and solvents  
All chemicals were of analytical grade and obtained from Sigma Aldrich (UK) unless otherwise stated. 
Solvents used for the preparation of samples for LC-MS were of high pressure liquid chromatography 
(HPLC) grade (Thermo Fisher Scientific).  
Soltran© (hyperosmolar citrate): K+ 80 mM, Na+ 84 mM, Mg2+ 41 mM, citrate 54 mM, sulphate 41 mM, 
mannitol 33.8g/l, pH 7.1 
University of Wisconsin (UW) solution (Viaspan®, Cold Storage Solution, Bridge to Life Ltd, USA): 
hydroxyethyl starch 50 g/l, lactobionic acid 105 mM, KH2PO4 25 mM, MgSO 5 mM, raffinose 30 mM, 
adenosine 5 mM, allopurinol 1 mM, glutathione 3 mM, KOH 100 mM, pH 7.4 
St Thomas’ cardioplegia (Cardioplegic Solution, Harefield Hospital Formulation, Terumo BCT Ltd, UK): Na+ 








2.2 Animal work 
2.2.1 Mouse strains and animal husbandry 
C57BL/6 mice were purchased from Charles River Laboratories (Margate, UK). All animal experiments 
were approved by the UK Home Office under the Animals (Scientific Procedures) Act 1986. Mouse 
experiments were covered by project license PPL 80/2638.   
Bm12.Kd.IE mice were previously created in-house from crosses using Bm12 mice (B6(C)-H2-
Ab1bm12/KhEgJ (H-2bm12)(128) purchased from Jackson Laboratories (Bar Harbor, ME), B6.Kd mice 
(C57BL/6-Tg(Kd)RPb that additionally express the H-2Kd gene) gifted by Dr R.P. Bucy (University of 
Alabama, Birmingham, AL)(129) and ABOIE mice (C57BL/6 mice that lack the expression of I-Ab, but 
express the I-Ea gene and express I-E on the surface of their APCs) gifted by Prof C. Benoist (Joslin 
Diabetes Centre, Boston, MA)(130). Initially bm12 were crossed with B6.Kd and the offspring that 
expressed I-Abm12 and H-2Kd but not I-Ab were selected using PCR. These, bm12.Kd animals were then 
crossed with ABOIE animals and the female off-spring expressing I-Abm12, A-E and H-2Kd (bm12.Kd.IE) on 
PCR were selected(131).  
All mice were maintained in specific-pathogen-free animal facilities with ad libitum access to food and 
water.  
2.2.2 Porcine strain and animal husbandry  
Large white male (Landrace) pigs (45-55 kg) were supplied by Envigo (Huntingdon, UK) and were 
acclimatised for a minimum of 7 days prior to experiments, with ad libitum access to food and water. All 
animal experiments were approved by the UK Home Office under the Animals (Scientific Procedures) Act 
1986. Pig experiments were performed under project license WRS0001 (Envigo Reference).   
2.2.3 Human tissue 
Heart biopsies were taken from deceased human organ donors aged 36-69 (Figure 2). Ethical approval for 
the studies was obtained from NRES Committee East of England – Cambridge South (REC Reference 








2.3 Murine experiments 
2.3.1 Metabolite accumulation in organ storage 
Metabolite accumulation during organ storage was measured in whole murine hearts exposed to variable 
periods of warm or cold ischaemia and compared to baseline normoxic hearts.  
The donor animals were anaesthetised with isoflurane (Abbott Laboratories, US) and oxygen at 2 l/min. 
The animals’ rectal temperature was measured continuously using a rectal thermometer and maintained 
at 37°C ± 1°C using a relayed variable heat mat (Kent Scientific). Heparin 100 µl heparin (100 IU in 100 μl 
0.9% w/v sodium chloride Leo Pharma A/S, Ballerup, Denmark) was administered via Inferior Vena Cava 
(IVC) injection 1 minute prior to exsanguination by division of the IVC and aorta.  
To measure metabolite concentrations in the heart under baseline normoxic conditions, as close as 
possible to those in vivo, the still-beating heart of anesthetised mice were rapidly frozen using Wollenberg 
clamps (manufactured by Josh Firman, LMB Workshop, UK) at liquid nitrogen (LN2) temperature. This 
process from division of the great vessels to clamp freezing was performed in < 5 seconds. The frozen 
myocardium was then scraped from the clamps and transferred to a pre-cooled (on dry ice) safe-lock 
Eppendorf and stored at –80°C until further analysis. 
To measure metabolite accumulation in cold ischaemia (CI), hearts were placed directly in 10 ml UW 
solution (Viaspan®, Cold Storage Solution, Bridge to Life Ltd, USA) pre-cooled on wet ice (1-2°C). The 
retrieval of the heart by division of the great vessels in all experiments was performed in < 20 seconds. 
Under these conditions, the cardiac beat would stop within 5 contractions (< 5 seconds). To expose the 
hearts to warm ischaemia, the excised heart was left in the abdomen of the animal, with the abdominal 
wound closed and the animal maintained at 37°C on a heat mat. Under these conditions the hearts 
continued to contract intermittently for up to 90 seconds.  
At the end of the period of warm or cold ischaemia, hearts were clamp frozen using Wollenberg clamps as 
described above. The clamped samples were promptly transferred to a pre-cooled (on dry ice) safe-lock 
Eppendorf and stored at –80°C until further analysis. 
2.3.2 Heart temperature measurements 
Myocardial temperature during the retrieval process was measured using a thermocouple (model: 
EasyLog EL-USB-TC-LCD, Lascar Electronics, UK). The donor animals were anaesthetised with isoflurane 
(Abbott Laboratories, US) and oxygen at 2 l/min. The animals’ rectal temperature was measured 
continuously using a rectal thermometer and maintained at 37°C ± 1°C by a relayed variable heat mat 
(Kent Scientific). A laparotomy was performed and St Thomas’ cardioplegic solution (Cardioplegic 
Solution, Harefield Hospital Formulation, Terumo BCT Ltd, UK) was administered systemically to the donor 
animal by IVC injection resulting in complete cessation of cardiac contraction. The heart was exposed, and 







Tokyo, Japan). The heart was retrieved by either division of the great vessels (< 20 seconds) or using a 
standard retrieval technique described to enable heterotopic heart transplantation (approximately 8 
minutes ± 30 seconds) described below (2.7). The hearts were then transferred into 10 ml UW (Viaspan®, 
Cold Storage Solution, Bridge to Life Ltd, USA) kept on wet ice (1-2°C). Temperature measurements were 
recorded every 5 seconds. 
2.3.3 Administration of cardioplegia  
Following division of the great vessels the normothermic mouse hearts continued to beat in isolation for 
up to 90 seconds. Immersion of a beating mouse heart in UW (Viaspan®, Cold Storage Solution, Bridge to 
Life Ltd, USA) solution kept on wet ice (1-2°C) produced rapid arrest of cardiac contraction. In order to 
ensure myocardial contraction was comparable under conditions of cold and warm ischaemia, systemic 
administration of cardioplegia (Cardioplegic Solution, Harefield Hospital Formulation, Terumo BCT Ltd, 
UK) via a central vein was used to produce rapid cessation of cardiac contraction (< 5 seconds). After 
administration of heparin (100 IU in 100 μl 0.9% w/v sodium chloride Leo Pharma A/S, Ballerup, Denmark) 
500 μl of St Thomas’ cardioplegia was administered by IVC injection using a 1 ml syringe attached to a 31-
gauge needle. The apex beat was used to confirm cessation of cardiac contraction (less than 5 seconds). 
To minimise passive diffusion of the cardioplegia out of the heart and prevent spontaneous return of 
cardiac contraction, the abdominal aorta and IVC were not divided. The heart was retrieved by either 
division of the great vessels (< 20 seconds) and then stored in CI or WI as described above or using a 
standard retrieval technique described to enable heterotopic heart transplantation (approximately 8 
minutes ± 30 seconds) described below. Spontaneous return of cardiac contraction was not observed 







2.4 Porcine experiments 
Pigs were sedated and received narcotic analgesia (ketamine 10 mg/kg, midazolam 0.1 mg/kg, 
medetomidine 0.02 mg/kg). General anaesthesia was induced using intravenous propofol (10 mg/ml) and 
remifentanil (6 μg/ml) through a peripheral vein. Animals were intubated and ventilated with intermittent 
positive pressure ventilation. Heart rate, blood pressure and O2 saturation was monitored throughout the 
procedure. The pigs were exsanguinated and, at the time of exsanguination, the thoracic cavity was 
accessed through the diaphragm and the apex of the heart (~ 20 - 30 g) was amputated with a scalpel. A 
full thickness tissue sample (~ 100 mg) was immediately clamped frozen using Wollenberger clamps at 
LN2 temperature, taking < 10 seconds from cessation of aortic pulse to freezing. The remaining tissue was 
divided in half, one half transferred to cold storage solution and then further cut into smaller pieces (~ 
100 mg) which were then stored in UW (Viaspan®, Cold Storage Solution, Bridge to Life Ltd, USA) storage 
solution at ~ 2˚C. The other half of the heart tissue was also cut into sections (~ 100 mg) which were 
stored in a humidified atmosphere at 37˚C by suspension above saline in sealed Eppendorf tubes 
maintained using a heat block (Thermo Fisher Scientific, UK).  At various times the tissues were then 







2.5 Human experiments 
Deceased human organ donors, undergoing donation after brainstem death (DBD) abdominal multi-organ 
procurement, but for whom cardiothoracic organs had been declined for transplantation were identified 
(Figure 2). Appropriate consent for research was obtained from the donor families. A thoracotomy was 
performed as a routine part of the abdominal organ retrieval procedure, thus allowing a sample (~ 20-30 
g) of myocardium from the apex of the still-beating heart to be removed at the same time as 
exsanguination of the donor as part of the organ procurement procedure. The heart tissue was frozen in 
Wollenberg clamps, taking < 5 seconds to go from the beating oxygenated heart to frozen sample. After 
this base line sample, further samples (~ 100 mg) were removed, maintained at either 37˚C or 2˚C as 










Figure 2: Human donor characteristics. 
   












































































































































































































































































































































































































































































2.6 Tissue extraction and analysis 
2.6.1 Liquid chromatography coupled to mass spectrometry (LC-
MS) 
Frozen tissue samples, obtained from murine, porcine and human experiments outlined above, were 
weighed into Precellys tubes prefilled with ceramic beads (Stretton Scientific Ltd., Derbyshire, UK), and an 
exact volume of extraction solution (30% acetonitrile, 50% methanol and 20% water) was added to obtain 
40 mg specimen per ml of extraction solution. Samples were lysed using a Precellys®24 tissue 
homogeniser (Bertin Corp, Rockville, MD 20850, USA. 5500 rpm 15 seconds x 2) and then centrifuged 
(16,162 x g for 10 min at 4°C ). The supernatant was transferred to glass vials (Microsolv Technology 
Corp., Leland, NC 28451, USA) and stored at -80°C until LC-MS analysis. 
LC-MS analyses were performed on a Q Exactive Orbitrap (Thermo Scientific) mass spectrometer coupled 
to an Ultimate 3000 RSLC system (Dionex). The liquid chromatography system was fitted with either a 
Sequant ZIC-HILIC column (150 mm × 4.6 mm) or a ZIC-pHILIC column (150 mm × 2.1 mm) and respective 
guard columns (20 mm × 2.1 mm) (all Merck Millipore, Germany). The metabolites were eluted with 
previously described gradients (132). The mass spectrometer was operated in full MS and polarity 
switching mode. Samples were randomised in order to avoid bias due to machine drift and processed 
blindly. The acquired spectra were analysed using Xcalibur Quan Browser and XCalibur Quan Browser 
software (Thermo Scientific) by referencing to an internal library of compounds. Absolute quantification 
of selected metabolites was performed by interpolation of the corresponding standard curve obtained 
from serial dilutions of commercially available standards (Sigma Aldrich) run with the same batch of 
samples. When calculating relative change in metabolites with undetectable ion counts, half the lowest 
detectable ion count for that metabolite was used. LC-MS was analysis performed by Dr Ana S.H. Costa. 
2.6.2 ATP/ADP ratio 
ATP and ADP concentrations were measured using a Luciferase based assay (133).  Frozen tissue samples 
were homogenised in ice-cold perchloric acid extractant (3% v/v HClO4, 2 mM Na2EDTA, 0.5% Triton X-
100). The supernatant was diluted to a concentration of 1 mg frozen tissue/ml. Samples, ATP and ADP 
standards (400 µl) were pH neutralized using a potassium hydroxide solution (2 M KOH, 2 mM Na2EDTA, 
50 mM MOPS), vortexed until formation of a white precipitate (KClO4), then centrifuged (17, 000 X g for 
1 min at 4°C). For ADP measurements, 250 µl neutralised sample supernatant was mixed with 250 µl ATP 
sulfurylase assay buffer (20 mM Na2MoO4, 5 mM GMP, 0.2 U ATP sulfurylase (New England Biolabs), in 
Tris-HCl buffer (100 mM Tris-HCl, 10 mM MgCl2 (pH 8.0) to 250 µl), incubated for 30 min at 30°C with 
shaking (500 rpm), heated at 100°C for 5 min and then cooled on ice. Standards (100 µl), samples for ATP 
measurement (100 µl) or samples for ADP measurement (200 µl) (in duplicate) were added to 400 µl Tris-
acetate (TA) buffer (100 mM Tris, 2 mM Na2EDTA, 50 mM MgCl2, pH 7.75 with glacial acetic acid) in 







P1506)) were added to one set of samples for ADP measurement and incubated for 30 min at 25oC in the 
dark to convert ADP to ATP. The other duplicate tube (without addition of pyruvate kinase solution) 
served as an ATP ‘blank’ value. The samples were then all assayed for ATP content in a Berthold 
AutoLumat Plus luminometer by addition of 100 µl Luciferase/Luciferin Solution (7.5 mM DTT, 0.4 mg/ml 
BSA, 1.92 µg luciferase/ml (SIGMA #L9506), 120 µM D-luciferin (SIGMA # L9504), made in TA buffer (25% 
v/v glycerol)), delivered via auto injection, protected from light. Bioluminescence of the ATP- dependent 
luciferase activity was measured 3 x for 1 min post injection and the data quantified against standard 
curves. The luciferase based assay was performed by Ms A Gruszczyk.  
2.6.3 Glycogen assay 
Animals were anaesthetised and donor hearts rapidly excised using the technique described above 
(2.3.1). The apex of the mouse heart was immediately transected (~ 10 mg) and clamp frozen to provide a 
baseline, normoxic control. The heart was then returned to warm or cold storage. Intermittently the heart 
was removed at variable times (6, 12, 30, 60 or 240 minutes) from storage and further myocardial axial 
sections (~ 10 mg) were excised and clamp frozen. After each sample was excised the heart was returned 
to organ storage and the process repeated to enable up to 4 separate time points to be taken. Tissue 
glycogen was measured using a standard assay and relative change in tissue glycogen compared against 
baseline normoxic values (134). The glycogen assay was performed by Ms F Allen (MRC Mitochondiral 







2.7 Heterotopic heart transplant models of IR injury  
2.7.1 Murine heterotopic heart transplantation 
The murine heterotopic heart transplant model is a vascularised solid organ transplant model. It was 
originally described by Corry et al(135) and the operations used in this work were performed using 
modifications of this original technique. The basic procedure is described below with subsequent 
variations on this technique described in detail later.  
Operations were performed using an operating microscope (M651, Leica, UK) at 6 x to 40 x magnification. 
The total operative time for the combined donor and recipient procedures was approximately 50 minutes 
with an operative mortality of less than 5%.  
2.7.2 Donor operation 
Donor animals were anaesthetised with isoflurane (Abbott Laboratories, US) and oxygen at 2 l/min and 
the skin at the operative site shaved. Animals were then transferred from the anaesthetic room to the 
operation table and positioned in a supine position and secured using adhesive tape (Duraporeä, 3Mä, 
UK). The animals’ rectal temperature was measured continuously using a rectal thermometer and 
maintained at 37°C ± 1°C using a relayed variable heat mat (Kent Scientific, UK). The depth of anaesthesia 
was adjusted as necessary to ensure complete absence of a response to a surgical stimulus. 
A midline laparotomy incision was performed and 100 IU heparin (Leo Pharma A/S, Ballerup, Denmark) in 
100 μl 0.9% w/v sodium chloride was administered via central vein injection using a 1 ml syringe attached 
to a 31-gauge needle. Animals were exsanguinated by division of the IVC and aorta. In experiments 
requiring cardioplegia administration, 500 µl cardioplegia (Cardioplegic Solution, Harefield Hospital 
Formulation, Terumo BCT Ltd, UK) was administered via the IVC using a 1 ml syringe attached to a 31-
gauge needle. Cessation of cardiac contraction was observed before progression to thoracotomy but IVC 
and aorta were not transected to prevent passive diffusion of the cardioplegic solution and associated 
return of spontaneous contraction.  
The thoracic cavity was entered by dividing the diaphragm and adequate exposure achieved by dividing 
the ribs laterally up to the thoracic inlet and retracting the anterior rib cage cranially. The IVC or caudal 
caval vein, left SVC or cranial caval vein and right SVC or cranial caval vein were ligated with silk ties(136). 
The fat and connective tissue was dissected between the aorta and pulmonary artery prior to division of 
the ascending aorta at the level of the innominate artery. If the heart were to be flushed (chapter 6), the 
innominate, right carotid and right brachiocephalic artery were ligated and divided. The descending aorta 
was then divided. The left and right pulmonary arteries were divided adjacent to their bifurcation and the 
connecting vessel wall divided to create a single opening. During dissection and ligation of vessels the 
heart was topically cooled intermittently with 0.9% w/v sodium chloride kept on ice. If the donor heart 
was flushed, 500 µl Soltran® (Baxter Healthcare) was injected via a fine bore (0.28 x 0.165 mm) polyethene 







retrograde fashion into the descending aorta resulting in antegrade coronary perfusion. Adequate 
antegrade coronary flushing was confirmed visually by extrusion of blood from the pulmonary artery. 
Following ligation of the pulmonary artery blood remaining in the ventricles was manually expressed. The 
pulmonary veins were ligated en masse and the heart excised and stored in UW (Viaspan®, Cold Storage 
Solution, Bridge to Life Ltd, USA) until implantation.  
2.7.3 Recipient operation  
The donor heart was transplanted heterotopically into the abdomen of the recipient animal using a 
modified microsurgical techniques previously described by Lui et al (137). The recipient mouse was 
weighed before being anaesthetised with isoflurane (Abbott Laboratories, US) and oxygen at 2 l/min. The 
skin at the operative site was shaved and prepped with HibiScrubÒ (chlorhexidine gluconate 4% w/v, 
Mölnlycke Health Care, UK). Analgesia was administered by subcutaneous injection of 100 µl Temgesic 
(Indivior, UK) diluted in 500 µl 0.9% w/v sodium chloride to the nape of the animal. The animal was 
transferred to the operating table, secured in a supine position using adhesive tape (Duraporeä, 3Mä, 
UK) and the animal’s rectal temperature was measured continuously using a rectal thermometer and 
maintained at 37°C ± 1°C using a relayed variable heat mat (Kent Scientific, UK). A midline laparotomy was 
performed and adequate exposure achieved using an abdominal self-retaining retractor. The urinary 
bladder was emptied by gentle pressure using sterile cotton buds. The small bowel and colon were 
reflected superiorly and a small strip of connective tissue divided to facilitate this manoeuvre. The 
abdominal viscera were retracted and covered with moistened sterile gauze to provide adequate 
exposure to the abdominal aorta and IVC and adequate moisture maintained throughout the procedure 
by periodic topical irrigation.  
The connective tissue overlying the abdominal aorta and IVC was divided by a combination of sharp and 
blunt dissection. The posterior lumbar vessels were identified and ligated using 7-0 silk ties.  
Non-crushing vascular clamps were applied to the vessels distal to the renal vessels and proximal to their 
bifurcation. The IVC was emptied via a venotomy created with a 31-gauge needle. An arteriotomy was 
then made in the aorta and this was extended using micro-surgical scissors to match the diameter of the 
donor aorta. The lumen was flushed with 0.9% w/v sodium chloride to remove any remaining blood and 
clots.  
The donor heart was then retrieved from cold storage and placed into the right side of the recipient’s 
abdomen with the remnant ascending aorta adjacent to the arteriotomy. A small piece of gauze 
moistened with cold (1-2°C) 0.9% w/v sodium chloride was placed over the heart to minimise warming 
and periodic topical application of (1-2°C) 0.9% w/v sodium chloride was applied to the donor heart 
during the procedure.  Cranial and caudal stay sutures were placed between the donor and recipient 
vessels using 10-0 nylon Bearä surgical suture on a round bodied 4 mm (3/8) needle (Bear Medic Corp., 







constructed from the caudal stay suture. After completing one side of the anastomosis, the heart was 
turned to the animal’s left side to enable access and completion of the anastomosis.  
The venotomy on the IVC was then extended in a cranial direction. The pulmonary artery was 
anastomosed in a similar fashion using 10-0 nylon Bearä surgical suture. Over tightening of sutures was 
minimised to ensure there was no constriction of the anastomosis. Cut pieces of SurgicelÒ (Ethicon, 
Johnson and Johnson, US) were applied around the anastomosis. The distal clamp was removed followed 
by the proximal clamp. Satisfactory perfusion was indicated by a bright red heart displaying strong 
rhythmic contractions and warmed topical 0.9% w/v sodium chloride was applied to the heart to expedite 
this process. The abdominal fascia and skin were closed in two layers with continuous 5-0 vicrylä 
(Ethicon, Johnson and Johnson, UK).  
Following reperfusion and closure of the midline wound 500 µl of 0.9% sterile saline was injected 
subcutaneously.  
Animals were recovered in an incubator at 28°C overnight on soft, dry bedding with food and water. 
Animals that developed post-operative hind limb paralysis were killed immediately. The next day animals 
were returned to standard cages with standard rodent diets and kept for up to 100 days.  
2.7.4 Prolonged Cold Ischaemia 
In order to develop a model of vascularised solid organ transplant IR injury it was necessary to modify the 
original procedure of Correy et al(135) to introduce an ischaemic insult. A model of mild and severe IR 
injury had previously been established and validated by Dr Kourosh Saeb-Parsy (Department of Surgery, 
Cambridge) and Dr Anna Dare (Mitochondrial Biology Unit, Cambridge)(138). This model introduced a 
period of prolonged cold ischaemia as the ischaemic insult. The “mild” IR injury group was performed 
using the standard technique and the heart was implanted and reperfused as quickly as is technically 
feasible. To introduce a more severe ischaemic insult the period in which the donor heart was stored in 
cold storage solution was extended from 30 minutes (as for the standard operation) to 4 hours. Previous 
work by Dr Kourosh Saeb-Parsy had demonstrated 4 hours to be the maximum tolerated period of 
ischaemia (personal communication) that was reliably associated with a return of spontaneous 
contraction upon reperfusion. 
 
2.7.5 Prolonged Warm Ischaemia 
Data from LC-MS of donor tissue following variable periods of warm and cold ischaemia demonstrated 
more profound metabolic changes during warm ischaemia. This provided a rationale for the development 
of a solid organ reperfusion model that introduced a warm ischaemic insult to the period of ischaemia.  
The donor animal was anaesthetised and prepared using the standard technique described above and 







administration of heparin the animal was exsanguinated by division of the IVC and aorta. Hearts were 
then either immediately retrieved with no additional warm ischaemia or left for 6 or 12 minutes prior to 
performing the standard retrieval operation. Spontaneous return of contraction was observed with hearts 
following both 6 and 12 minutes however, there was no significant difference in the 24-hour recipient 
serum troponin between recipients of hearts control hearts (no additional warm ischaemia) or those 
exposed to warm ischaemia (Figure 3.1). 
To reduce variability in ischaemic injury, cardioplegia was administered to the donor heart at the time of 
retrieval. Using this technique it was necessary to proceed immediately to the retrieval operation to avoid 
passive diffusion of cardioplegia and a return of spontaneous contraction. During the retrieval operation, 
topical ice cold (2°C) saline was periodically applied to the heart. An additional period of warm ischemia 
was introduced by transferring the prepared donor heart to the abdominal compartment of the carcass 
maintained at 37°C with a heat mat for the duration of the additional warm ischaemia. After the period of 
warm ischaemia the heart was transferred to cold static storage as above. 
2.7.6 Metabolic inhibitors 
The effect of metabolic inhibitors on ischaemic metabolism was examined using two approaches. 
Metabolic inhibitors were either administered to the donor 10 minutes prior to retrieval as an infusion 
administered via a central vein or at the precise time of retrieval in cardioplegia (Cardioplegic Solution, 
Harefield Hospital Formulation, Terumo BCT Ltd, UK). The metabolic inhibitors used in these experiments 
are listed below; 
Dimethyl malonate (DMM) (Sigma-Aldrich, UK) 
Dimethyl succinate (DMS) (Sigma-Aldrich, UK) 
Diazoxide (DZX) (Sigma-Aldrich, UK) 
Hadacidin (HAD) (ACC Corporation, US) 
2-(aminooxy)acetic acid hemichloride (AOA) (FluoroChem, UK) 
Thenoyltrifluoroacetone (TTFA) (Sigma-Aldrich, UK) 
Rotenone (ROT) (Sigma-Aldrich, UK) 
2.7.7 Administration of small molecule inhibitors as infusion 
Agents were administered as an infusion over 10 minutes via a central vein by microinfusion pump (Kd 
Scientific, Holliston, MA, USA) via a fine bore (0.28 x 0.165 mm) polyethene tube (Portex tubing, Smith 
Medical International Ltd, UK). Control animals were infused with 0.9% w/v sodium chloride by 
microinfusion pump (Kd Scientific, Holliston, MA, USA). On completion of the infusion, 100 µl heparin (Leo 
Pharma A/S, Ballerup, Denmark) was administered via central vein injection. Mice were divided into 2 







2.7.8 Administration of small molecule inhibitors with cardioplegia 
Donor animals were prepped and draped as previously described and a midline laparotomy performed. 
100 µl heparin (Leo Pharma A/S, Ballerup, Denmark) was administered via central vein injection. 
Metabolic inhibitors were administered in 500 µl of cardioplegic solution (Cardioplegic Solution, Harefield 
Hospital Formulation, Terumo BCT Ltd, UK) via a central vein. Retrieval proceeded immediately upon 
administration of cardioplegic solution. Mice were divided into 2 groups; metabolic inhibitor (DMM, DMS, 
AOA, DZX, HAD, TTFA, or ROT) or control (cardioplegia alone). Metabolic inhibitors were infused in a 500 
µl bolus via the abdominal inferior vena cava in cardioplegic solution (Cardioplegic Solution, Harefield 
Hospital Formulation, Terumo BCT Ltd, UK) in the following doses; AOA; 20 µM, 200 µM, 2 mM, 20 mM, 
and 50 mM, DMM; 12 µM, 48 µM, 97 µM, 302 µM and 757 µM (concentrations of DMM were based on 
the equivalent total volume of DMM that would have been administered during a 40 minute infusion at 
the following rates; 1 mgKg-1min-1, 4 mgKg-1min-1, 8 mgKg-1min-1, 25 mgKg-1min-1, 62.5mgKg1min-1), DMS; 
87.6 µM (the DMS concentration was based on the equivalent total volume of DMS that would have been 
administered during a 40 minute infusion of DMS at 8 mgKg-1min-1), HAD; 20 µM, 200 µM, 2 mM, 20 mM, 
and 50 mM, DZX; 100 µM and 1 mM, TTFA; 10 10uM, 100 µM, 1 mM, and 10 mM, and ROT; 6 µM and 60 
µM. TTFA and rotenone were dissolved in 5% w/v DMSO in cardioplegia (Cardioplegic Solution, Harefield 







2.8 Outcome markers of IR injury 
To assess the tissue metabolomic profile on reperfusion of the graft, heart grafts were transplanted 
heterotopically into a syngeneic (C57BL/6) recipient using the technique described above (2.7.3). The 
recipient was recovered and the graft subsequently removed under terminal anaesthesia at 24 hours. At 
the time of harvest the animal was anaesthetised with isoflurane, a midline laparotomy performed. The 
heart was examined and the beat of the graft scored, a venous blood sample was taken from the IVC, and 
the heart was then excised by division of the anastomosed great vessels. The atria were removed and 
discarded. Axial sectioning of the remaining ventricular tissue was performed and specimens snap frozen 
in liquid nitrogen.  
2.8.1 Troponin-I 
Non-heparinised IVC blood samples were taken immediately prior to graft harvest. Samples were left for 
30 minutes at room temperature to ensure adequate clot propagation, centrifuged (2000 x g for 10 
minutes) and serum apportioned into aliquots and stored at -80°C. Serum was analysed for troponin-I and 
a panel of pro-inflammatory cytokines.  
Troponin-I was measured using a mouse cardiac troponin-I ELISA (KT-470, Kamiya Biomedical Company, 
Seatlle, WA, USA) by the Core Biomedical Analysis Laboratory, Addenbrooke’s Hospital, Cambridge.   
The panel of inflammatory cytokines included IL-1ß, IL-6, IL-g and was measured using a 10-plex 
electrochemical luminescence immunoassay for mouse cytokines (MesoScale Discovery) by the Core 
Biomedical Analysis Laboratory, Addenbrooke’s Hospital, Cambridge.  
2.8.2 Tissue mitochondrial DNA amplification 
Mitochondrial DNA damage blocks progression of amplification of DNA polymerase during PCR and this 
enables the quantification of mitochondrial DNA damage using the technique described by Santos et al 
2006 (107). This assumes that mitochondrial oxidative damage occurs at random and therefore, 
amplification of a long target (~ 10kb) will be interrupted with increasing oxidative damage as compared 
to a control short target (~ 120b). 
Tissues were snap frozen and stored at -80°C prior to DNA extraction. DNA was isolated from tissues using 
the Qiagen DNeasy Blood and Tissue kit (Qiagen, UK). Briefly, approximately 20 mg tissue (heart apex) 
was transferred to an Eppendorf. The tissue was lysed with tissue lysis buffer (ATL) and 20 μl  proteinase 
K, at 70°C in a shaking water bath until the tissue had been completely lysed. 200 μl proprietary buffer 
(AL) and 210 μl ethanol (96-100%) were added and the sample centrifuged (16 160 x g). Two washing 
steps (500 μl AW1 and AW2) were performed prior to elution. The eluted DNA was then quantified using 
the PicoGreen assay. 
Primers were previously designed by Logan et al. for mice based on the sequence from Santos et al(107) 







The forward and reverse sequences for the short and long targets are detailed below:  
 Tm° (°C) GC% Sequence 
Forward primer 71.3 54.1 GCCAGCCTGACCCATAGCCATAAT 
Long target reverse 
primer 
67.0 44 GAGAGATTTTATGGGTGTAATGCGG 
Short target reverse 
primer 
68.8 54.5 GCCGGCTGCGTATTCTACGTTA 
 
Each sample was amplified in duplicate. Each PCR reaction was 50 μl consisting of; 5 μl DNA sample (3 
ng/μl, total DNA template [15 ng]) or standard, 35 μl mastermix (5 μl 10 X LA PCR Buffer II (without Mg2+), 
0.5 μl bovine serum albumin (10 mg/ml), 2 μl 25 mM MgCl2, 1 μl dNTP Mixture (2.5 mM each dNTP), 2 μl 
forward primer [20 pmol], 2 μl reverse primer [20 pmol], 22.5 μl nuclease free water) and 10 μl Taq 
polymerase (1 U) in NFW. 
The PCR conditions were chosen so that amplification occurred in a linear fashion with the amount of PCR 
product amplified from a 5 ng sample of undamaged control DNA was 50% (range 40-60%) that of a 10ng 
sample when quantified using the PicoGreen assay. To determine this, PCR was performed with increasing 
cycles of annealing and extension until a reaction that met the above criteria identified. For each 
experimental specimen a blank control (nuclease free water), 50% dilution of a control sample and a 
control sample reaction were performed. The PCR was started using a manual hot start with the 




Hot Start 70°C 3 minutes  
Denaturation 94°C 30 seconds 
15 cycles Annealing 64°C 45 seconds 
Elongation 72°C 45 seconds 
Final elongation 72°C 10 minutes  
 
 
Long target  
Hot Start 70°C  3 minutes  
Denaturation 94°C 30 seconds 
20 Cycles Annealing and 
elongation 
64°C 12 minutes  








2.8.3 Gel Electrophoresis 
To confirm the products amplified by PCR were the long and short targets gel, electrophoresis was 
performed. 10 μl of the amplified DNA samples were suspended in 2 μl loading buffer (6x stock: 0.25% 
(w/v) bromophenol blue, 0.25% (w/v) xylene cyanol FF, 30% (w/v) glycerol in H2O) were loaded on to a 
0.8% (w/v) agarose gel in 1% TBE buffer supplemented with 1 μl GelRed™. Two separate ladders were run 
with the gel. A 1 Kb ladder (Invitrogen) and λDA/HindIII digest (500 ng, New England Biolabs). The 
samples were separated by running the gel in TBE buffer for approximately 45 minutes at 100 V. The gel 
was visualised on a UV transilluminator and photographed with Genesnap software. 
2.8.4 DNA Quantification 
Quantification of the purified genome and the PCR products was performed using PicoGreen fluorimetric 
analysis. The samples were analysed in triplicate using the Quant-iT™PicoGreen®dsDNA Assay Kit 
(Invitrogen, ThermoFisher Scientific). DNA was quantified against a standard curve run with each plate. 







2.9 Outcome markers of chronic rejection 
2.9.1 Collection of blood 
Animals were warmed at 37°C to dilate tail veins. Tail vein blood samples were taken (20 – 30 μl) from 
animals. Samples were stored at 4°C to encourage clot formation. After centrifugation (16 162 x g for 7 
min) serum was aspirated and aliquoted. Complement was inactivated by heating at 56°C for 30 min. 
Samples were stored at -20°C until they were analysed.  
2.9.2 Quantification of anti-MHC class I antibody (H-Kd) by ELISA 
Serum samples were collected weekly from recipient animals. An ELISA was used to quantify the 
production of anti-H-2Kd antibody. 96 well plates were coated with recombinant conformational H-2Kd 
(generated in-house(139)) at 5 μg/ml in Na2CO3-NaHCO3 buffer (pH 9.6) and incubated overnight at 4°C. 
Non-specific binding was blocked with 200 μl/well Marvel (Premier International Foods, UK) dried 
skimmed milk powder (1 %) in PBS for 2 hours at 37°C. After washing (6 x 0.05% Tween in PBS), 50 μl 1:9 
dilutions (in Marvel/PBS) of samples were added to wells of the top row. Triplicate serial  dilutions (1/n)  
were performed down the plate. The plate was incubated for 1 h. After washing (Tween/PBS) 50 μl/well 
of biotinylated Rabbit F(ab’)2 anti-mouse IgG (STAR11B, AbD Serotec, Oxford, UK) at 1 μg/ml in Marvel 
was added to all wells and the plate incubated for 1 h at 37°C. After washing (Tween/PBS) 50 μl of 
ExtrAvidin peroxidase conjugate (Sigma, Poole, UK) at 1 μg/ml in Marvel/PBS was added and incubated at 
room temperature for 1 h. Plates were washed (Tween/PBS) and TMB microwell peroxidase substrate 
(Kirkegaard & Perry Laboratories, Gaithersburg, MD, USA) was added. The colour change was observed 
for 5 min before the reaction was stopped with 50 μl 0.2M H2SO4 and the absorbance at 450 nm 
measured using a FLUOstar OPTIMA plate reader (BMG Labtech, Aylesbury, UK). For each sample, the 
area under the curve of an absorbance versus dilution curve was calculated. On each plate a serial dilution 
positive (pooled hyperimmune serum from C57BL/6 recipients of BALB/c cardiac allograft collected at 5 
weeks post-transplant) and negative (pooled serum from a naïve C57BL/6 mouse) control was run. The 
AUC of each experimental sample was expressed as a percentage of the AUC of the positive control 
(pooled hyperimmune) serum(140). 
2.9.3 Quantification of autoantibody level by HEp-2 indirect 
immunofluorescence 
The relative antinuclear antibody (ANA) was quantified using a commercially available human epithelial 
type 2 (HEp-2) indirect immunofluorescence kit (NOVA LiteÒ, Inova Diagnostics, Inc. San Diego, CA 92131, 
US). This technique was developed for detecting autoimmune responses in human patients but murine 
autoantibody has also been shown to bind the target nuclear antigens and has been previously validated 
for the detection of autoantibody production in transplant models of chronic rejection(131, 141, 142). 
Serum samples were diluted 1 in 40 with dilute PBS and incubated for 30 minutes on slides coated with 







IgG (STAR70; AbD Serotec, Oxford, UK) by fluorescence microscopy. The intensity of staining of 3 random 
photomicrographs was measured by morphometric analysis using MetaMorph software (Molecular 
Devices, Downington, PA, USA). Monospecific positive and negative controls were used according to the 
manufactures instructions to ensure all reagents and procedures performed appropriately. Serial two-fold 
dilutions (1 in 10 to 1 in 2560) of pooled hyperimmune serum from TCRKO mice injected IV with 5 x 106 
purified bm12 CD4 T cells was used to generate a standard curve (Figure 3). This has previously been 
demonstrated to generate an ANA response(142). Serial dilutions were assigned arbitrary values of 1000 
autoantibody units for the 1 in 10 dilution, 500 units for the 1 in 20 dilution etc. The presence of 
autoantibody in samples was then interpolated using the relative fluorescence intensity compared to a 
rectangular hyperbola calculated using the standard control values (Figure 3).  
 
Figure 3: Human epithelial cell line (HEp-2) standard dilution curve. 
The relative fluorescence intensity of serial two-fold dilutions of pooled hyperimmune serum (1 
in 10 to 1 in 2560) from TCRKO mice injected i.v. with 5 x 106 purified bm12 CD4 T cells was 
measured by morphometric analysis to generate a standard curve that was used to interpolate 
relative fluorescence of samples.  
 






















Figure 4: Representative immunofluorescence photomicrographs of hyperimmune serum at 
increasing dilutions. 
Control serum samples at increasing dilutions (1 in 2560 to 1 in 10) were diluted 1 in 40 with 
dilute PBS and incubated for 30 minutes on slides coated with HEp-2 cell line. Bound 
autoantibody was detected with fluorescein labelled conjugated goat anti-mouse IgG (STAR70; 
AbD Serotec, Oxford, UK) by fluorescence microscopy. 
2.9.4 Rejection kinetics  
Rejection of the grafts was assessed by abdominal palpation. Rejection was defined as the complete 
cessation of a palpable contraction. 
2.9.5 Chronic allograft vasculopathy 
Donor hearts were stored in 10% formalin in PBS. Paraffin embedded slides were prepared and stained 
with haematoxylin and eosin (H&E) or elastin van Gieson (EVG) by the Department of Pathology, 
Papworth Hospital, Cambridge, UK. 
Chronic allograft vasculopathy was assessed using CellR digital imaging software. Luminal stenosis was 
calculated in elastin positive vessels in each section. The measured cross-sectional area of the lumen was 
subtracted from the cross-sectional area of the internal elastic lamina. This area was then measured as a 
percentage of the internal elastic lamina cross-sectional area giving a percentage luminal stenosis (%) 
(Figure 5).  
Antibody	
dilution
1	in	2560 1	in	1280 1 in	640 1	in	320 1	in	160 1	in	80 1	in	40 1	in	20 1	in	10
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Figure 5: Representative section of a coronary vessel with evidence of vasculopathy. 
Donor hearts were formalin fixed, paraffin embedded and slides prepared and stained with 
elastin van Gieson (EVG). The cross-sectional area of arteries and luminal stenosis was estimated 
from the cross-sectional area of the lumen and internal elastic lamina using CellR digital imaging 
software. External elastic lamina (dashed arrow); internal elastic lamina (solid arrow); lumen 
(dashed line).  
 
2.9.6 Statistics analysis 
All data in figures are presented as mean values ± SEM nless otherwise stated. Statistical analysis was 
performed between two groups using Student’s t-test and between multiple groups by one-way analysis 
of variance (ANOVA) or two-way ANOVA with Bonferroni’s multiple comparison testing. A p value of less 
than 0.05 was considered significant. 
To calculate relative concentrations of metabolites that were not detected in all time points by mass 
spectrometry, half the minimal detectable ion intensity (AU) was used. 
 
2.9.7 Collaborative experiments 
A number of experiments were performed in collaboration with other experimenters. Dr Ana S.H. Costa. 
(MRC Hutchinson/MRC Research Centre, UK) was responsible for LC-MS analysis of tissues and generated 
the heat maps. The luciferase-based assay was performed by Ms A Gruszczyk (MRC Mitochondrial Biology 
Unit, UK). The glycogen assay was performed by Ms F Allen (MRC Mitochondrial Biology Unit, UK). Dr Alan 
Robinson (MRC Mitochondrial Biology Unit, UK) assisted in the analysis of metabolomic data and 
generated the volcano plots presented. 
 





Chapter 3:   The metabolic profile of cardiac tissue during 
warm and cold ischaemia 
 
 





3.1 The metabolic profile of cardiac tissue during warm and cold 
ischaemia 
3.1.1 Introduction 
Hypothermia has long been recognised to have therapeutic potential in a range of clinical scenarios and 
has formed the mainstay of organ preservation for the great majority of the modern era of organ 
transplantation (143). During a transplant procedure, the transplanted organ is subjected to ischaemic 
conditions across a range of temperatures for varying periods of time. The potential permutations of 
warm and cold ischaemia to which an organ is subjected has increased with the greater use of DCD organs 
and renewed interest in hypothermic and normothermic machine perfusion techniques. 
The general principle commonly assumed to account for these observed protective effects is stipulated by 
the Arrhenius equation, the foundation for which lies in the Van’t Hoff equation. A generalisation of these 
formulae is that most enzymatic reactions have a Q10 temperature coefficient of approximately 2 and 
therefore, for every 10°C increase in temperature, the metabolic rate doubles. This is also true in the 
reverse and therefore there is a halving in the metabolic rate with every 10°C decrease in temperature 
(143, 144). Anecdotal observations would suggest that the mechanism of hypothermic protection may, 
however, be more complex and could vary between tissue types(143). 
3.1.2 Temperature changes during organ storage 
To examine the metabolic changes that occur in vivo, mouse, pig and human models of organ storage 
were developed to measure the changes in a range of metabolites using an untargeted mass 
spectrometry approach. The mouse model was based on the modified retrieval procedure used for the 
heterotopic heart transplantation model reported by Dare et al  (138) and used to investigate IR injury in 
organ transplantation. To characterise the metabolic profile of mouse hearts during warm and cold 
ischaemia a simplified model was first devised. In this model, the heart was rapidly excised by division of 
the great vessels and placed in warm or cold ischaemic conditions for variable periods. Cold ischaemia 
was induced by placing the heart in UW cooled on ice. Using this technique, hearts were rapidly cooled to 
10 °C within 12 seconds of immersion, reaching 3°C after 1 minute and 2°C after 2 minutes (Figure 6(a)). 
Warm ischaemic conditions were designed to replicate the clinical environment of DCD donation and 
therefore, the excised hearts were placed in the abdominal compartment of the carcass of the animal 
whose core rectal temperature was maintained at 37°C. After the period of ischaemia had elapsed the 
heart was rapidly frozen using Wollenberg clamps and the metabolic profile analysed by untargeted LC-
MS. Comparative analyses of the changes in myocardial tissue were also performed using pig and human 
hearts. In these models, the apex of the heart was rapidly divided. Full thickness sections of myocardium 
were then placed in warm or cold storage and the changes in metabolites compared to a baseline, 
normoxic control sample from the same heart. 
 





During the retrieval process for mouse heterotopic heart transplantation, the animal was exsanguinated 
by division of the IVC or caudal caval vein and aorta and rendered hypoxic by division of the diaphragm 
and subsequent clamshell thoracotomy. The necessary ligation and division of various great vessels in 
preparation for subsequent implantation took approximately 7 - 8 minutes. During this period, the heart 
was intermittently topically cooled with ice cold saline. Topical cooling of the heart results in brief periods 
of cooling to approximately 12°C and subsequent rewarming to 24°C (Figure 6 (b)). The cooling resulted in 
marked bradycardia or intermittent brief periods of asystole and rewarming was associated with 










Figure 6 (a - c): Temperature profile of the myocardial apex during cold storage and retrieval in murine 
heart transplantation. 
The temperature of the apex was measured using a thermocouple placed into the myocardium. (A) 
Hearts were either rapidly excised and placed in cold storage or (B) retrieved using a technique with 
the necessary surgical preparation of the great vessels required for heterotopic heart transplantation. 
During this process topical saline was applied at the start of the retrieval process and then at regular 
intervals thereafter (arrows). (C) demonstrates the murine cardiac anatomy and the great vessels that 
were ligated (red) and divided (dashed red line) in preparation for transplantation; 1. ligation and 
division of the IVC or caudal caval vein and left superior vena cava (SVC) or left cranial caval vein (CCV), 
2. ligation and division of the right SVC (right CCV), 3. preparation and division of the ascending aorta, 
















































3.2 Changes in energy stores  
Changes in tissue energy stores are recognised as important determinants of cell integrity and viability 
and previous work into the mechanism of hypothermic organ protection has focused on the ATP/ADP 
ratio as this determines the driving force for reactions (146). Two techniques were used to analyse the 
changes in myocardial ATP and ADP concentration in the mouse heart tissue in this model; Ms A 
Gruszczyk (Department of Surgery and MRC Mitochondrial Biology Unit) used a luciferase-based assay, 
and Dr Ana S.H. Costa (Hutchinson/MRC Research Centre) used LC-MS. The luciferase-based assay has 
been well validated and estimates absolute tissue concentrations of ADP and ATP which can then be used 
to estimate relative change compared to the normoxic baseline tissues if required. We have less 
experience measuring ATP with LC-MS. Estimates of tissue concentrations could be inferred from ion 
counts that could then be used to calculate relative change compared to normoxic baseline tissues. There 
was concern that there would be degradation of phosphate groups during analysis however, the 
luciferase-based analysis enabled validation of the LC-MS ATP and ADP data.  There was a more rapid 
decrease in the ATP/ADP ratio in warm ischaemia than in cold ischaemia consistent with the hypothesis 
that cold storage provides organ protection, at least in part, through preservation of the ATP/ADP ratio 
(Figure 7). Mammalian cytosolic ATP/ADP ratio estimates in the literature range from 1 to > 100. The wide 
range is likely due to the inherent problems in measuring tissue concentrations of these nucleotides in 
vivo. Changes in tissue metabolite concentrations were calculated as relative change to normoxic control 
hearts using LC-MS. The luciferase-based assay provided an estimate of the absolute tissue 
concentrations of ATP and ADP.  
 






Figure 7 (a – c): ATP/ADP ratio and tissue AMP concentrations in the mouse heart during warm and 
cold ischaemia. 
 (a) ATP/ADP ratio in the mouse heart during warm (red) and cold (blue) ischaemia measured by LC-
MS. Mouse hearts were rapidly excised and exposed to either warm (red line) or cold (blue line) 
ischaemia (n = 4-5). Tissue abundance of ATP and ADP was analysed by LC/MS and used to calculate 
the relative change of each nucleotide in tissue abundance compared to normoxic control hearts (n = 
11). The ATP/ADP ratio was calculated from the derived relative change for each heart. 
(b) AMP concentration in the mouse heart during warm and cold ischaemia measured by LC-MS. 
Relative tissue concentrations of AMP estimated by LC-MS (n = 4-5) during warm (red line) and cold 
(blue line) ischaemia and compared to normoxic control hearts (n = 11) 
(c) ATP/ADP ratio in the mouse heart during warm and cold ischaemia measured by luciferase-based 
assay. Absolute tissue concentrations of ATP and ADP (nmol) were calculated using the luciferase-
based assay for each heart (n = 4-13) and used to generate a mean ATP/ADP ratio of mouse heart 
tissue during warm and cold ischaemia.    
 
  





















































There was a rapid decrease in the ATP/ADP ratio within 6 minutes of ischaemia that was more 
pronounced during warm ischaemia compared to cold ischemia. This trend was observed using both 
techniques. There was a discrepancy between the two techniques with detectable tissue ATP and ADP 
concentrations declining more rapidly when calculated using LC/MS. When calculated using LC-MS, this 
translated to detectable ATP/ADP ratios that rapidly approached zero during warm ischaemia when 
compared to normoxic baseline control tissue. The ATP ion count was detected in tissue during cold 
storage, however, which translated into an ATP/ADP ratio that remained at approximately 20% of 
normoxic control tissue after the initial rapid decline. The changes in nucleotides that contributed to the 
differences in the ATP/ADP ratio determined by LC-MS differed in warm and cold ischaemia. The relative 
tissue ATP was better preserved during cold ischaemia, remaining at approximately 80% of baseline until 
30 minutes compared to warm ischaemia where relative ATP rapidly approached zero. ADP relative tissue 
concentrations increased more rapidly and remained better preserved in cold ischaemia compared to 
warm ischaemia. In warm ischaemia, ADP concentrations increased less rapidly when compared to the 
baseline, normoxic controls and achieved lower peak concentrations at 12 minutes. Relative tissue 
concentrations then decreased to near undetectable levels at 30 minutes (Figure 8).  
 
Figure 8: Changes in tissue concentrations of (a) ATP, and (b) ADP during warm (red) and cold (blue) 
ischaemia in the mouse heart measured by LC-MS. 
Mouse hearts were rapidly excised and exposed to either warm or cold ischaemia (n = 4-5). Tissue 
abundance of ATP and ADP was analysed by LC/MS and used to calculate the relative change of each 
nucleotide in tissue abundance compared to normoxic control hearts (n = 11). 
 
These findings from the LC-MS analysis were in contrast to the changes demonstrated by the luciferase-
based assay. Here the ATP/ADP ratio was largely determined by ATP tissue concentrations which 
decreased more rapidly during warm as compared to cold ischaemia with ADP concentrations remaining 
constant (Figure 7 (c)). In addition to the rapid decrease in the ATP/ADP ratio, the overall consumption of 
nucleotides was faster during warm ischaemia when compared to cold ischaemia as indicated by the sum 
of ATP and ADP (Figure 9(a)). Although the relative changes in ATP/ADP ratio and AMP were largely 
conserved across species, it was interesting to observe the marked differences in the baseline levels of ATP and 
ADP between the mouse, and the pig and human myocardium (Figure 9 (c)(i) – (vi)). This may reflect differences 
in the experimental technique, however accurate understanding of baseline energy stores across species is 


























surprisingly sparse within the literature. It will be important to examine these apparent discrepancies in more 
detail in future studies. Understanding these differences will be paramount in translating findings from animal 
models to clinical trials and the conserved absolute concentrations of ATP and ADP between the pig and human 
tissue would support the need for validation of findings from small animal models in such large animal models. 
 
 
Figure 9: ATP and ADP concentrations during warm and cold ischaemia in the mouse, pig and human 
heart. 
Mouse hearts were rapidly excised and exposed to either warm or cold ischaemia (n = 3-4). For the pig 
(n = 5) and human (n = 4) assays, the apex was excised from normoxic hearts and rapidly divided into 
multiple full thickness sections and exposed to either warm (red line) or cold (blue line) ischaemia (n = 
5). The ATP and ADP concentrations were calculated using a luciferase-based assay and are presented 
in columns for the mouse, pig and human. The total nucleotides (SATP + ADP) (a(i )- (iii)), the ATP/ADP 
ratio (b (i) – (iii)), and the absolute tissue concentrations of both ATP (solid line) and ADP (dashed line) 
for warm (red line) and cold (blue line) (c (i)- (vi)) are presented for mouse, pig and human. 
 
AMP-activated protein kinases (AMPK) play a crucial role in regulating cellular ATP during periods 
increased demand such as hypoxia. During periods of ATP depletion, adenylate kinase is activated 
converting two molecules of ADP to ATP and AMP (147, 148). In these experiments, tissue AMP 
concentrations increase rapidly until 6 minutes in both warm and cold ischaemia relative to normoxic 















































































































































































































control hearts. After this time, the relative tissue concentrations then diverge as AMP levels during cold 
ischaemia plateau, whereas AMP concentrations in warm ischaemia continue to rise until 30 minutes of 
warm ischaemia (Figure 7). The findings in this analysis are consistent with these previous studies that 
propose activation of adenylate kinase as a cardioprotective mechanism to maintain cellular ATP during 
periods hypoxia (148).  
The changes in nucleotides were also analysed in pig and human heart tissue. The ATP/ADP ratio was 
calculated using the luciferase-based assay and tissue AMP relative abundance was calculated using LC-
MS. Similar relative changes to those in the mouse were observed in pig and human heart tissue during 
warm and cold ischaemia (Figure 10).  
  
 







Figure 10 (a – d): ATP/ADP ratio and tissue AMP concentration in the pig and human heart during warm 
(red) and cold (blue) ischaemia. 
(a) The apex was from excised from normoxic pig hearts and rapidly divided into multiple full thickness 
sections and exposed to either warm (red line) or cold (blue line) ischaemia (n = 5). The ATP/ADP ratio 
was calculated using a luciferase-based assay. (b) Tissue abundance of AMP was analysed in the same 
samples by LC/MS and the relative change in tissue abundance compared to the normoxic control 
tissue for each pig heart (n = 5). 
The same method was used to process human hearts (n = 4). (c) The ATP/ADP ratio was calculated 
using a luciferase-based assay. (d) Tissue abundance of AMP was analysed in the same samples by 
LC/MS and the relative change in tissue abundance compared to the normoxic control tissue for each 
human heart (n = 4). 
 
3.2.1 Summary of changes in energy stores 
Warm ischaemia is associated with a more rapid decrease in the nucleotides ATP and ADP than during 
cold ischaemia. This was paralleled by an accumulation of AMP and a more rapid loss of the ATP/ADP 
ratio during warm ischaemia compared to cold ischaemia and is consistent with the protective effect of 
cold storage during organ ischaemia. These changes were observed in myocardium from mice, pigs and 
humans.  






























































3.3 Changes in metabolites during warm ischaemia and cold 
ischaemia 
LC-MS-based metabolomic analysis of tissue allows the simultaneous measurement of a range of 
metabolites. Subsequent LC-MS analyses reported in the following chapters were all performed with Dr 
Ana S.H. Costa (Hutchinson/MRC Research Centre). Myocardial tissue of mouse, pig and human hearts 
was exposed to varying periods of warm and cold ischaemia. In total 54 metabolites were analysed in all 
samples in mouse, pig and human myocardial tissue. These data are presented as heat maps generated 
with these data by Dr Ana S.H. Costa (Hutchinson/MRC Research Centre) (Figure 11). Qualitatively, it was 
observed that similar metabolic changes were present in mouse, pig and human heart tissue during warm 
and cold ischaemia.   
  
 







Figure 11: Extended analysis of metabolic changes in the mouse, pig and human during warm and cold 
ischaemia. 
Heat maps showing the relative change in metabolite abundance of 107 different metabolites during 
warm ischaemia (WI) and cold ischaemia (CI) in mouse (n = 4-11), pig (n = 5) and human (n = 4) heart 
tissue. The data are from 3-6 independent biological replicates and relative change was compared to 
normoxic controls (Ct). Colour corresponds to relative change compared to normoxic control heart 
tissue. Blue labelled metabolites are less abundant, orange-red labelled metabolites are more 
abundant. Heat maps were constructed by Dr Ana SH Costa. 
 
To facilitate a quantitative comparison of the metabolites that significantly changed between warm and 
cold ischaemia, I determined the fold change for each metabolite between warm and cold ischaemia at 
various times. Using the adjusted p value and the fold change, volcano plots were constructed with Dr A 
Robinson (MRC Mitochondrial Biology Unit) (Figure 12). Using this analysis, metabolites that changed in 
the same way between warm and cold ischaemia in all three species were identified and have been 
 





annotated in red. Metabolites that changed in the same way in two of the species have been annotated in 
green. An extended metabolic analysis was performed for the mouse heart tissue. This MS analysis was 
performed using a second column and increased the total number of metabolites analysed to 107. The 
metabolites that were shown to differ significantly between warm and cold ischaemia in the additional 
analysis performed in the mouse heart have been annotated in blue.   
  
 







Figure 12: Volcano plots of metabolites analysed by LC/MS.  
Volcano plots of the analysed metabolites that demonstrated significant fold change in warm 
iscahemia compared to cold ischaemia after 30 minutes of organ storage in the (a) mouse (n = 5 - 6), 
(b) pig (n = 5) and (c) human (n = 4). Volcano plots were constructed by plotting the -log10 of the 
adjusted p-value against the log2  of the fold-change in metabolite abundance between 30 mins WI and 
30 mins CI. Fold-changes and p-values were calculated using the Limma package with R.  Isovaleryl 
carnitine, isovalcarn; ribulose-5-phosphate, rib5p; proprionylcarnitine, propcarn; S-adenosyl 
homocysteine, S-adhomocys; acetyl carnitine, acetylcarn; succinyl adenosine;, succaden; 3-
hydroxybutyrate, 3HB; pyroglutamic acid, pyroglu; glutathione disulphide, GSSG. Those metabolites 
that changed in the same way in all three species are annotated in red, metabolites that changed in 
the same way in two of the species have been annotated in green and the additional metabolites that 
changed in the expanded analysis performed in mouse heart tissue are annoted in blue. 
 
 





The analyses in (Figure 11 and Figure 12) highlighted metabolites that should be further analysed. A more 
detailed analysis of individual metabolites with respect to different metabolic pathways was also 
considered. The time course of detected metabolites in glycolysis, the citric acid cycle, the pentose 
phosphate pathway, the urea cycle, free fatty acids, selected acyl carnitines, and amino acids are 
discussed below.   
 





3.4 Glycolytic intermediates 
The heart is a highly metabolically active organ. In regional ischaemia models of myocardial ischaemia 
there is a rapid decrease in myocardial oxygen concentrations following the cessation of coronary flow. 
Tissue oxygen decreases to 75% baseline values within seconds 8-10 seconds and to 10% of baseline 
values at 11-52 seconds (41, 149). With exhaustion of myocardial oxygen, fatty acid oxidation and 
oxidative phosphorylation will cease and the only source of energy available to the myocardium will come 
from anaerobic metabolism. Glycogen stores fuel glycolysis during anaerobic metabolism. Glycogen stores 
in the mouse heart were analysed using a glycogen assay. Glycogen was depleted more rapidly in warm 
compared to cold ischaemia. After an initial rapid depletion in glycogen stores during warm ischaemia, 
tissue glycogen levels plateaued. In contrast, during cold ischaemia the glycogen stores continued to 
decrease until they were completely exhausted (Figure 13).  
 
Figure 13: Glycogen stores in the mouse heart during warm and cold ischaemia. 
Mouse hearts were rapidly retrieved and the apex excised. This apical section was then rapidly clamp 
frozen to provide a baseline normoxic control glycogen concentration. Sequential axial sections were 
taken after variable periods of warm (red line) or cold (blue line) storage and tissue concentrations of 
glycogen were calculated relative to the control sample (n = 3). The glycogen assay was performed by 
Ms F Allen (MRC Mitochondrial Biology Unit). 
 
 
3.4.1 Glycolytic substrate utilisation during ischaemia 
To further analyse glycolysis during ischaemia, comparative changes in glycolytic intermediates were 
analysed by LC-MS in the mouse heart. Consistent with the findings from glycogen assays, glucose 
consumption demonstrated different trends during warm and cold organ storage. During cold organ 
storage, there was a more gradual decrease in myocardial glucose compared to warm ischaemia (Figure 
14). This was in contrast to the metabolic profile of glucose 6-phosphate and fructose 6-phosphate which 
demonstrated no difference between warm and cold ischaemia up to 12 minutes. After the early period 
of ischaemia, both glucose 6-phosphate and fructose 6-phosphate demonstrated similar trends with a 
divergence in the myocardial concentrations observed when hearts were stored in warm or cold 
ischaemic conditions. The product of PFK-1 phosphorylation, fructose 1,6 bisphosphonate, was very 























poorly detected in this analysis in all heart specimens including the control hearts despite discernible 
changes in tissue concentrations of metabolites up and downstream of it. 
Tissue concentrations of glyceraldehyde-3-phosphate remained approximately at baseline tissue 
concentrations in hearts stored under cold ischaemic conditions to 30 minutes of ischaemia and then 
decreased to a fraction of baseline concentrations by 240 minutes of cold ischaemia. In contrast to hearts 
stored in cold ischaemia, hearts stored in warm ischaemia demonstrated a slight increase in 
glyceraldehyde 3-phosphate tissue concentrations above baseline concentrations during early time points 
until 12 minutes. Beyond 30 minutes, tissue concentrations then appeared to decline. However, the 
decrease in tissue concentration were less exaggerated in warm ischaemia compared to hearts stored in 
cold ischaemia. The glycolytic intermediates downstream of glyceraldehyde-3-phosphate, 3-
phosphoglycerate and phosphoenolpyruvate were detected in only 20% of control hearts. This step in 
glycolysis generates ATP and therefore proceeds rapidly during ischaemia and would account for the 
limited detection even in control hearts. During cold ischaemia, there was a greater rate of detection of 3-
phosphoglycerate and phosphoenolpyruvate but these intermediates were still not detected in all 
samples. These data support existing evidence that glycolysis continues throughout cold organ storage at 
a slower rate compared to hearts maintained at normothermia and that glycolytic failure may be the 
result of inhibition of GAPDH. (Figure 14). 
Pyruvate is the end product of glycolysis. There are a number of potential pathways through which is it 
metabolised (Figure 16). During anaerobic respiration, reduction to lactate is the predominant pathway 
and can be used to assess flux through anaerobic glycolysis. Glycolytic flux in mouse hearts during organ 
storage was examined at prolonged periods of cold ischaemia. These periods of cold storage were outside 
the limits of viability for transplantation (Dr K Saeb-Parsy, personal communication). Lactate appeared to 
plateau during cold ischaemia and did not achieve peak tissue concentrations greater than those 
observed during warm ischaemia. Glucose tissue concentrations decreased to 10% of baseline tissue 
concentrations by 4 hours and then remained at this level even after extended periods of cold organ 
storage remaining at approximately 14% of baseline tissue concentrations. Tissue lactate increased to 
approximately 5 times baseline tissue concentrations demonstrating a reciprocal relationship with 
glucose. The peak tissue concentrations of lactate achieved during cold storage were lower than those 
during warm ischaemia (Figure 15). This supports the observations from glycogen assays that glycolysis is 
not inhibited by a lack of substrate during cold ischaemia. 
3.4.2 Pyruvate metabolism in warm and cold ischaemia 
Pyruvate tissue concentrations demonstrated a rapid decrease to approximately 20% of baseline tissue 
concentrations within 6 minutes of warm or cold storage and there was no significant difference in the 
profiles between warm or cold storage (Figure 14).  Pyruvate can be metabolised by a number of 
pathways (Figure 16) that include; reduction to lactate, transamination to alanine, carboxylation to 
oxaloacetate or conversion to acetyl-CoA following transfer across the mitochondrial inner membrane. 
 





During warm ischaemia, there was an increase in tissue alanine above baseline concentrations that 
plateaued after 12 minutes. This was not observed during cold organ storage where tissue concentrations 
remained unchanged from baseline. Although oxaloacetate was not detected by LC-MS, the products of 
oxaloacetate metabolism, malate and aspartate, were detected. Aspartate demonstrated a slight initial 
increase above baseline concentrations during cold storage and then remained constant. This was in 
contrast to warm ischaemia where tissue concentrations were observed to have a reciprocal relationship 
to alanine tissue concentrations initially declining to 50% of baseline concentrations, and then plateauing 
during continued warm ischaemia. Contrasting trends during warm and cold ischaemia were also 
observed in malate tissue concentrations. Malate was better preserved by cold storage compared to 
warm ischaemia where tissue concentrations rapidly decreased and were 25% of baseline tissue 
abundance by 12 minutes and 10% by 30 minutes of warm ischaemia (Figure 16).  
Ischaemia makes oxidative decarboxylation of pyruvate to acetyl CoA and subsequent carboxylation to 
oxaloacetate unfavourable. Reduction of pyruvate to lactate generates NAD+ and is employed during 
anaerobic metabolism to maintain the NADH/NAD+ ratio but cannot continue indefinitely as the lactate 
cannot be metabolised further and the associated cellular acidosis is toxic to the cell. 
An alternative pathway involves the transamination of pyruvate and glutamate to alanine and a-
ketoglutarate (Figure 16). Alanine also demonstrates rapid accumulation during the first 12 minutes of 
warm ischaemia. This is not observed during cold ischaemia where relative tissue concentrations remain 
at normoxic baseline levels. After 12 minutes of warm ischaemia however, relative tissue concentrations 
plateau. This coincides with the plateau seen in lactate and would be in keeping with flux through this 
pathway during anaerobic metabolism with transamination of the rapidly accumulating pyruvate and 










Figure 14: The metabolic profile of glycolytic intermediates during warm (red) and cold (blue) 
ischaemia in the mouse heart. 
Mouse hearts were rapidly excised and exposed to either warm (red line) or cold (blue line) ischaemia 
(n = 4-5). Tissue abundance of glycolytic intermediates was analysed by LC-MS and used to calculate 
relative change in tissue abundance compared to normoxic control hearts (n = 11). When metabolites 
were not detected a value of half the minimum recorded ion count from that dataset was used to 
enable calculations of relative change (*metabolites with at least one sample demonstrating 


































































































































































































Figure 15 (a and b): Metabolic profile of lactate and glucose during cold organ storage extended to 12 
hours. 
Mouse hearts were rapidly excised and exposed to cold (blue line) ischaemia (n = 4-5) for variable 
lengths of time up to 720 minutes and compared to hearts exposed to warm ischaemia (red line) up to 
30 minutes (n = 5). Tissue abundance of lactate (A) and glucose (B) was analysed by LC-MS and 
compared to normoxic baseline control hearts (n = 6-11). 
 































Figure 16: Pyruvate metabolism during warm (red line) and cold (blue line) ischaemia in the mouse 
heart. 
Mouse hearts were rapidly excised and exposed to either warm (red line) or cold (blue line) ischaemia 
(n = 4-5). Tissue abundance of metabolic intermediates was analysed by LC-MS and used to calculate 
























































































3.4.3 GAPDH constrains glycolysis during warm but not cold 
ischaemia 
The divergence observed between warm and cold organ storage in glucose and lactate tissue 
concentrations was not replicated in all other glycolytic intermediates. This supports the presence of key 
regulatory steps controlling glycolysis. Key regulatory steps previously identified include those catalysed 
by PFK-1 and GAPDH. A reduction in flux through any particular reaction can be implied by the 
accumulation of upstream intermediates however, an increase in flux will not be observed in this analysis 
unless substrate is limited. The cellular conditions required to increase flux through PFK-1 such as the 
depletion in ATP were demonstrated however, direct evidence with conclusive changes in up and 
downstream intermediates of PFK-1 were not identified.  
One key regulatory step in glycolysis is the metabolism of glyceraldehyde-3-phosphate by GAPDH. GAPDH 
is inhibited by an elevated NADH/NAD+ ratio. The lactate/pyruvate ratio reflects the tissue NADH/NAD+ 
ratio. During warm ischaemia there was a more rapid increase in both the lactate/pyruvate ratio and the 
NADH/NAD+ ratio compared to cold ischaemia (Figure 17). The lactate/pyruvate ratio is also observed to 
peak at 12 minutes whereas during cold ischaemia it continues to rise until 240 minutes. These data are 
consistent with a rapid increase in glycolysis that initially sustains ATP production during warm ischaemia 
but then ceases as the elevated NADH/NAD+ ratio inhibits GAPDH. In contrast, during cold ischaemia 
glycogenolysis and glycolysis continue until tissue stores have been exhausted. This supports the 
hypothesis that during cold ischaemia, the NADH/NAD+ ratio is never high enough to inhibit glycolysis. 
  
 







Figure 17: Changes in lactate/pyruvate ratio and NADH/NAD+ ratio during warm (red line) and cold 
(blue line) organ storage in the mouse heart. 
Mouse hearts were rapidly excised and exposed to either warm (red line) or cold (blue line) ischaemia 
(n = 4-5). Tissue abundance of glycolytic intermediates was analysed by LC-MS and used to calculate 
relative change in tissue abundance compared to normoxic control hearts (n = 11). When metabolites 
were not detected a value of half the minimum recorded ion count from that dataset was used to 
enable calculations of relative change. Pyruvate was not detected in both warm and cold stored 
hearts. NADH was not detected in 2 control hearts. 
 
3.4.4 Summary of glycolytic metabolites during ischaemia 
The rapid onset of anaerobic metabolism from the commencement of organ storage was confirmed by 
the immediate increase in tissue concentrations of lactate observed in these experiments. Furthermore, 
consistent with the proportional decline in metabolic rate with decreasing temperature, this data 
supports a slowing of anaerobic respiration in hearts subjected to cold storage evidenced by the 
reciprocal relationship between glucose and lactate tissue concentrations over periods of organ storage 
consistent with organ viability. Whilst anaerobic metabolism cannot continue indefinitely, the exact 
reason for the failure of glycolysis has been previously debated, with exhaustion of substrates and 
inhibition of key regulatory pathways both proposed as potential causes (36, 150). The data presented in 
this thesis would not support the exhaustion of glucose as the principal mechanism of myocardial 
glycolytic failure during warm ischaemia since glycogen stores persist after lactate concentrations have 
plateaued. In contrast, during cold ischaemia, glycogen stores are depleted to lower tissue concentrations 
than those observed during warm ischaemia. Lactate accumulation also mirrors these findings, supporting 
cessation of glycolysis due to an exhaustion of glycogen stores.  







































3.5 Generation of NAD+ during ischaemia 
Energy in the form of ATP is generated by glycolysis in the steps that occur downstream of GAPDH. 
Generating NAD+ becomes vitally important for the continued generation of ATP during anaerobic 
respiration. The principal pathway for this involves the reduction of pyruvate to lactate by lactate 
dehydrogenase, although alternative pathways may have a role in the regeneration of NAD+ during 
ischaemia. Alanine has previously been observed to increase during ischaemia, demonstrating a 
stoichiometric relationship with aspartate (151). A similar relationship was observed in these 
experiments. During warm ischaemia there was an increase in alanine during the early period of warm 
ischaemia until 12 minutes before tissue concentrations plateaued. This was reciprocated in aspartate 
tissue concentrations. In contrast, during cold organ storage tissue concentrations of both remained 
largely unchanged from baseline. The generation of malate from oxaloacetate by malate dehydrogenase 
has been proposed to take place during ischaemia (54) and generates NAD+. The transamination of 
aspartate to oxaloacetate provides the substrate for this process but it also necessitates a source of a-
ketoglutarate. Tissue concentrations of a-ketoglutarate are shown in these data to be rapidly exhausted. 
The anaplerotic transamination of glutamate and pyruvate to alanine and a-ketoglutarate would 
therefore provide an additional source of a-ketoglutarate to enable a brief period of additional NAD+ 
generation. This would result in no net change in tissue a-ketoglutarate or glutamate as was observed in 
these data and would be consistent with the reciprocal changes in alanine and aspartate observed (Figure 
16). Interestingly, the changes in alanine were not observed during cold organ storage where preserved 
glycolytic flux was observed. 
 





3.6 Pentose phosphate pathway 
The pentose phosphate pathway (PPP) runs parallel to glycolysis in the cytosol (Figure 18). It is primarily 
catabolic, generating nicotinamide adenine dinucleotide phosphate (NADPH) and ribulose-5-phosphate. It 
consists of an irreversible oxidative stage that results in the production of ribulose-5-phosphate from 
glucose-6-phosphate via a series of sequential steps that in the process generate NADPH. The NADPH 
serves a number of functions in the cell that include; de novo fatty acid synthesis, regulation of oxidative 
stress and cholesterol biosynthesis. The second reversible non-oxidative phase generates ribulose-5-
phosphate which serves as a precursor for nucleotide synthesis. In myocardial tissue, however, the PPP is 
thought to have a very limited metabolic role since, the rate limiting step of the irreversible oxidative 
phase, glucose-6-phosphate dehydrogenase along with other PPP enzymes, has very low expression and 
activity in myocardium (152). 
PPP metabolites were only detected in the additional LC-MS analysis performed on mouse hearts. There 
was no measurable ribulose-5-phosphate in the control (normoxic) hearts. Ribulose-5-phosphate was 
detected at increasing concentrations with prolonged durations of ischaemia. The accumulation of 
ribulose 5-phosphate was markedly greater in hearts stored in warm ischaemia compared to hearts 
stored in cold ischaemia and continued to increase for up to 30 minutes during warm ischaemia. Tissue 
concentrations were observed to be 20-fold higher following 6 minutes of warm ischaemia compared to 
cold ischaemia (Figure 18). The increase in ribulose-5-phosphate during ischaemia has previously been 
reported in rat hearts. Inhibition of the oxidative stage of the PPP by the NADPH inhibitor 
diphenyleneiodonium, was shown in this model to decrease IR injury (153). Changes in flux through the 
PPP has been reported in other pathophysiological processes such as heart failure (152) however, the 
significance of the changes in the PPP observed in this data during organ storage are uncertain. 
  
 






Figure 18: The metabolic profile of pentose phosphate pathway intermediates during warm and cold 
storage in the mouse heart. 
Mouse hearts were rapidly excised and exposed to either warm (red line) or cold (blue line) ischaemia 
(n=4-5). Tissue abundance of pentose phosphate pathway intermediates was analysed by LC-MS. 













































































































3.7 Citric acid cycle intermediates 
At the onset of ischaemia, with rapidly dwindling ATP and increasing concentrations of NADH, the 
conventional CAC cycling that occurs in aerobic conditions ceases. In this study, mouse hearts exposed to 
warm and cold ischaemia demonstrated different CAC metabolic profiles. During warm ischaemia, there 
was a rapid decline in all measured CAC intermediates, except succinate, which demonstrated a reciprocal 
increase in myocardial tissue concentrations reaching a peak tissue concentration 12-fold above baseline 
normoxic tissue concentrations by 30 minutes of warm ischaemia. After this rapid increase, tissue 
succinate levels plateaued. In contrast, during cold ischaemia there was a more gradual, constant increase 
in tissue succinate concentrations. These failed to achieve the same peak concentrations observed during 
warm ischaemia. Succinate accumulation during cold ischaemic was also observed to continue beyond 
viable cold ischaemic times1.  A linear increase in tissue succinate was observed when hearts were stored 
in cold storage for 8 and 12 hours (Figure 19). Similar changes in succinate accumulation were also 
observed in pig and human myocardial tissue (Figure 20 and Figure 21). These relative increases in tissue 
succinate abundance were highly conserved demonstrating similar absolute, quantified tissue succinate 
concentrations during warm and cold ischaemia (Figure 22).  
In mouse hearts, fumarate, malate and citrate decreased more rapidly for the first 12 minutes of warm 
ischaemia. In contrast, during cold ischaemia relative tissue abundance remained near baseline. At 
increasing durations of warm and cold ischaemia beyond 12 minutes, more gradual decline in these 
metabolites was observed. By 30 minutes of warm ischaemia, tissue concentrations had fallen to less than 
20% of baseline tissue levels (Figure 19). 
a-ketoglutarate tissue concentrations fell to approximately 5% of baseline normoxic concentrations 
within 6 minutes ischaemia, demonstrating similar profiles during both warm and cold ischaemia. The 
oxidative decarboxylation of isocitrate to a-ketoglutarate is an irreversible step in the TCA cycle and 
highly regulated. A rapid decline in tissue a-ketoglutarate concentrations was observed in mouse hearts 
stored in both warm and cold ischaemia and the disparity in cellular concentrations of this CAC metabolite 
compared to the other CAC intermediates in this study is an interesting observation (Figure 19). Rapid 
termination and reversal of the CAC could partially explain the process, however the discordance in the 
trends between warm and cold ischaemia observed in the downstream metabolites is not in keeping with 
this and would suggest flux through an additional catabolic pathway. Oxidative deamination to glutamate 
is usually unfavourable due to the low physiological NADH/NAD+ ratio but may occur in some 
                                                             
1The viability of a donor organ was assessed by the ability of the heterotopically transplanted heart to 
spontaneously return to ventricular contraction upon reperfusion. This was achieved regularly following 12 
minutes of warm ischaemia (in addition to the ischaemic injury sustained during the retrieval procedure) or 
following 240 minutes of cold ischaemia (personal observation). 
 





circumstances (154, 155). The high NADH/NAD+ ratio in ischaemia might favour this process and could 
explain the rapid decline in a-ketoglutarate. 
 
Figure 19: Metabolic profile of CAC intermediates during warm (red line) and cold (blue line) organ 
storage in the mouse heart.  
Mouse hearts were rapidly excised and exposed to either warm (red) or cold (blue) ischaemia (n = 4-5). 
Tissue abundance was analysed by LC-MS and relative change compared to normoxic baseline control 
hearts (n = 5-11) calculated. 
 
CAC intermediates were also examined in pig and human heart tissue (Figure 20). As discussed above, 
these data demonstrated similar trends in succinate accumulation in warm and cold ischaemia. The 
accumulation of the other CAC intermediates malate and fumarate however, demonstrated contrasting 
changes during warm ischaemia (Figure 20). In pig and human myocardium, malate and fumarate 
demonstrated similar trends to succinate during warm ischaemia with a rapid increase in tissue 
concentrations compared to the normoxic control that plateaued after 12 minutes of ischaemia. In 
contrast, tissue fumarate and malate remained at a similar concentration to normoxic baseline 
concentrations throughout cold organ storage. Tissue malate concentrations were only detected in one 















































































Figure 20: Relative change in the CAC intermediates in mouse, pig and human hearts tissue during 
warm (red line) and cold (blue line) organ storage. 
Relative change in the CAC intermediates (a) succinate, (b) fumarate, and (c) malate in mouse, pig and 
human hearts tissue during warm (red line) and cold (blue line) organ storage.  
Mouse (n = 5 -11), pig (n = 5) and human (n = 4) heart tissue was retrieved and exposed to variable 
periods of warm (red) or cold (blue) ischaemia. Tissue abundance was analysed by LC-MS and 
compared to normoxic baseline control tissue (mouse (n = 11), pig (n = 5), human (n = 4)). The 
succinate/fumarate ratio was calculated from absolute tissue concentrations of metabolites. Absolute 
quantification was performed by interpolation of the corresponding standard curve obtained from 
serial dilutions of commercially available standards that were run with the same batch of samples. 
*Tissue malate was only detected in one human donor heart.  
 
 



























































































































Figure 21 (a and b): Succinate accumulation and the succinate/fumarate ratio during warm (red line) 
and cold storage (blue line) in the mouse, pig and human heart. 
Mouse (n = 3-5), pig (n = 5) and human (n = 3 - 4) heart tissue was retrieved and exposed to variable 
periods of warm (red) or cold (blue) ischaemia. Tissue succinate abundance was analysed by LC-MS and 
compared to normoxic baseline control tissue (mouse (n = 15), pig (n = 5), human (n = 3-4)). The 
succinate/fumarate ratio was calculated from absolute tissue concentrations of metabolites. Absolute 
quantification was performed by interpolation of the corresponding standard curve obtained from 
serial dilutions of commercially available standards that were run with the same batch of samples.   
 
It has been hypothesised that upon reperfusion, rapid oxidation of accumulated succinate is responsible 
for the generation of mtROS through RET at complex I (53). RET in this process is dependent on a reversal 
of flux through NADH/NAD+ that can only occur in the presence of a sufficient succinate/fumarate ratio 
with the amount of mtROS proportional to the total pool of succinate (53, 54). Despite the differences in 
fumarate accumulation during warm ischaemia between species, the trend in the succinate/fumarate 
ratio is largely determined by tissue succinate concentrations. Warm ischaemia resulted in a more rapid 
and greater peak succinate/fumarate ratio compared to cold ischaemia. This trend was more pronounced 
in mouse hearts compared to the pig and human hearts. In the mouse heart, warm ischaemia resulted in 
a linear rise in the succinate/fumarate ratio to > 100:1 within 12 minutes, peaking at 30 minutes. Cold 
ischaemia abrogated this rise with succinate/fumarate ratios 3:1 at 12 minutes and reaching 25:1 at 240 
minutes of cold ischaemia (Figure 21). The succinate/fumarate ratio was also examined in tissue stored in 
cold ischaemia times beyond the limit of organ viability. Despite the continued increase in tissue succinate 
observed in these hearts a similar increase in tissue the succinate/fumarate ratio was not observed as 
tissue fumarate concentrations were not decreased to the same extent as observed during warm 
ischaemia (Figure 21). 



































































































Figure 22: Comparative absolute tissue succinate concentrations during warm and cold organ storage 
in the mouse, pig and human. 
Mouse (n = 3-5), pig (n = 5) and human (n = 3 - 4) heart tissue was retrieved and exposed to variable 
periods of warm (red) or cold (blue) ischaemia. Tissue abundance was analysed by LC-MS and 
compared to normoxic baseline control tissue (mouse (n = 15), pig (n = 5), human (n = 3-4)). Absolute 
quantification was performed by interpolation of the corresponding standard curve obtained from 
serial dilutions of commercially available standards that were run with the same batch of samples. 
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3.8 Cardiac contraction and ischaemic metabolism 
3.8.1 Cardiac contraction and succinate accumulation in mouse 
hearts 
The principal ATP-utilising process in myocardium is contraction. Contraction can be altered by a variety 
of conditions. It has previously been shown that there is a rapid loss of contractile activity in localised 
hypoxia, as occurs during coronary artery occlusion. Severe hypothermia is cardioplegic and the high 
potassium concentrations of the preservation solution used in these experiments also had a cardioplegic 
like effect. In this model, hearts subjected to cold ischaemia rapidly ceased to beat within 5 contractions 
(< 5 seconds) following immersion in UW. However, hearts stored under warm ischaemic conditions 
continued to contract for approximately 90 seconds.  To investigate whether the difference in contractility 
between the hearts stored in warm and cold storage might have contributed to the different metabolic 
profiles, St Thomas’ cardioplegia was administered to donor animals prior to warm organ storage. St 
Thomas’ cardioplegia is a crystalloid solution based on the extracellular ionic composition. The high 
potassium concentration induces rapid diastolic arrest (< 5 seconds) following intravenous injection 
through a central vein. 
3.8.2 Contractility and energy stores 
Complete cessation of contraction using cardioplegia did not decrease the ATP/ADP ratio in hearts stored 
in warm ischaemia compared to hearts stored in cold storage. These findings support the hypothesis that 
the observed changes in the ATP/ADP ratio between hearts stored in warm and cold ischaemia were not 
the result of changes in contractility. 
 
Figure 23: ATP/ADP ratio in mouse hearts from donors treated with (grey line) and without (black line) 
cardioplegia and stored for variable periods of warm ischaemia. 
Donor animals (n = 3) were treated with or without 500 µL St Thomas’ cardioplegia before hearts were 
rapidly excised and stored for variable periods of warm ischaemia. There was no difference in the 
ATP/ADP ratio measured by luciferase-based assay. 
 























3.8.3 Contractility and metabolite abundance 
The administration of St Thomas’ cardioplegia had no effect on baseline tissue succinate concentrations. 
There was a reduction in tissue fumarate concentration immediately following administration of 
cardioplegia with differences in the baseline tissue concentrations. These changes occurred very rapidly 
and were not observed in any other detected metabolite (Figure 24).  
Succinate accumulation during warm ischaemia was not significantly moderated by the administration of 
cardioplegia (F (4, 48) = 2.43, p = 0.06, 2-way ANOVA), although the relative peak succinate tissue 
concentration after 30 minutes of warm ischaemia was reduced (11.6 vs 13.7 p = 0.03, n = 3 - 5) when 
hearts were treated with cardioplegia (Figure 25). The rapid rise in succinate accumulation observed 
during warm ischaemia persisted with and without cardioplegia administration. In hearts treated with 
cardioplegia succinate accumulation was significantly greater following warm ischaemia compared to 
succinate accumulation during cold ischaemia (F (4, 49) = 15.73, p < 0.0001, 2-way ANOVA). Baseline 
tissue fumarate concentrations in hearts treated with cardioplegia were lower than those observed when 
hearts were not treated with cardioplegia (15.2 vs 3.2 ± 3.3, p = 0.029, n = 3, one-way ANOVA with 
Tukey’s multiple comparisons test) (Figure 26). Tissue fumarate concentrations in hearts treated with 
cardioplegia then remained constant. This profile was not significantly different to hearts not treated with 
cardioplegia and stored in warm ischaemia (F (4, 48) = 1.83, p = 0.13, 2-way ANOVA). In these hearts the 
initial fumarate concentration was greater but then rapidly decreased to tissue concentrations similar to 
those in hearts treated with cardioplegia within 12 minutes of warm ischaemia (Figure 25 (b)). Tissue 
concentrations of fumarate remained constant during more prolonged periods of warm ischaemia in both 
hearts treated with or without cardioplegia. These findings suggest that there was significant 
accumulation of succinate during warm ischaemia irrespective of the direct effects of temperature on 
myocardial contraction. These findings have implications for the application of therapeutic agents in the 
amelioration of IR injury and application of organ cooling strategies in the prevention of IR injury.  
 







Figure 24: Baseline normoxic metabolite abundance in mouse hearts following treatment with and 
without St Thomas’ cardioplegia. 
Donor animals (n = 3) were treated with or without 500 µL St Thomas’ cardioplegia. Hearts were 
rapidly excised and snap frozen within 20 seconds of the onset of ischaemia. Tissue abundance was 
measured by LC-MS. Absolute quantification was performed by interpolation of the corresponding 
standard curve obtained from serial dilutions of commercially available standards that were run with 
the same batch of samples. There was significant decrease in fumarate concentration following the 
administration of cardioplegia (15.2 vs 3.2 ± 3.3, p = 0.029, n = 3). There was no difference in the 
abundance of other detected metabolites. One-way ANOVA with Tukey’s multiple comparisons test (* 
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Figure 25 (a and b): Effect of contractility on succinate and fumarate accumulation during warm and 
cold ischaemia in the mouse heart. 
Mouse hearts (n = 3 - 8) were treated with (dashed red line) or without (red line) St Thomas’ 
cardioplegia prior to rapid retrieval and exposed to variable periods of warm (dashed red and red line) 
or cold ischaemia. (a) Succinate and (b) fumarate abundance was measured by LC-MS and relative 
change in metabolite abundance was compared to baseline control hearts (n = 17) that were not 
treated with cardioplegia. 
 


































3.9 Temperature and CAC intermediate accumulation 
It is generally assumed that a large proportion of the protective effects of hypothermia are the result of 
changes in the rate of metabolism, as governed by the relatively similar Q10 that most biological enzymes 
exhibit. To investigate whether the difference in succinate accumulation observed between warm and 
cold ischaemia was a linear phenomenon, tissue succinate and fumarate concentrations were measured 
after 12 minutes of ischaemia (Figure 26). 
 
Figure 26 (a – c): Succinate and fumarate tissue concentrations after 12 minutes of ischaemia in mouse 
hearts stored at different temperatures. 
St Thomas’ cardioplegia was administered to donor animals. Hearts (n = 4) were rapidly excised and 
stored for 12 minutes in UW at different temperatures (4, 16, 28, and 32°C). Tissue abundance of 
succinate (a) and fumarate (b) was measured using LC-MS. Relative change in metabolite abundance 
was compared to baseline control hearts (n = 9) that were not treated with cardioplegia. Data were 
compared to hearts treated with St Thomas’ cardioplegia and stored in the carcass of the animal 
maintained at 37°C with the use of a heat mat. To calculate succinate/fumarate ratio absolute 
quantification of succinate and fumarate was performed by interpolation of the corresponding 
standard curve obtained from serial dilutions of commercially available standards that were run with 
the same batch of samples. The mean succinate/fumarate ratio was then calculated from each heart 
(c).  
 
Succinate accumulated in a linear fashion with increasing temperature during 12 minutes of organ storage 
(R2 = 0.95) (Figure 26(a)). In addition, the accumulation of succinate occurred rapidly in the mouse heart 
with significant increases in tissue succinate observed after 12 minutes of organ storage at temperatures 
as low as 16°C. It was only when hearts were stored at 4°C that succinate tissue concentrations remained 
at normoxic baseline tissue concentrations after 12 minutes of organ storage (Figure 27). At temperatures 




















































in the range 16°C – 37°C, fumarate also demonstrated a linear trend. There was a significant depletion 
below baseline in tissue fumarate when mouse hearts were stored for 12 minutes in cold storage at 4°C 
(Figure 26(b)). This was in contrast to previous data when hearts were not treated with cardioplegia 
where there was no initial decrease in tissue fumarate compared to normoxic, baseline hearts at 12 
minutes of cold storage (Figure 19).   
 
Figure 27: Succinate accumulation in the mouse heart after 12 minutes of organ storage at varying 
temperatures. 
St Thomas’ cardioplegia was administered to donor animals. Hearts (n = 4) were rapidly excised and 
stored for 12 minutes in UW at different temperatures (4, 16, 28, and 32°C). Tissue abundance of 
metabolites was measured using LC-MS. Relative change in metabolite abundance was compared to 
baseline control hearts (n = 9) that were not treated with cardioplegia.  
One-way ANOVA with Tukey’s multiple comparisons test (**** p < 0.0001) 
 
Succinate tissue concentrations did not change as a result of cardioplegia administration (Figure 24). The 
differences in fumarate did not translate to changes in the succinate/fumarate ratio which demonstrated 
a linear relationship with temperature when hearts stored for 12 minutes ischaemia (R2 = 0.89) (Figure 
26(c)). The other detected CAC metabolites malate and citrate also demonstrated reciprocal linear 
relationships with temperature when hearts were stored for 12 minutes (malate, R2 = 0.86; citrate, R2 = 
0.86)There was a weaker correlation between a-ketoglutarate and temperature during 12 minutes of 
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Figure 28: Tissue abundance of CAC metabolites in mouse hearts stored at variable temperatures for 
12 minutes. 
St Thomas’ cardioplegia was administered to donor animals. Hearts (n = 4) were rapidly excised and 
stored for 12 minutes in UW at different temperatures (4, 16, 28, and 32°C). Tissue abundance of 
metabolites was measured using LC-MS. Relative change in metabolite abundance was compared to 
baseline control hearts (n = 9) that were not treated with cardioplegia. Data were compared to hearts 
treated with St Thomas’ cardioplegia and stored in the carcass of the animal maintained at 37°C with 
the use of a heat mat. 
 
The impact of increasing the temperature of organ storage on the flux through glycolysis was also 
examined. Lactate accumulation increased in a linear fashion with temperature and there was a reciprocal 
relationship with glucose suggesting there was increased flux through glycolysis with increasing 
temperature during 12 minutes of organ storage (Figure 29 (a) and (b)). This linear relationship was 
observed in the other glycolytic intermediates that were detected (Figure 30) across the temperature 
range of 4 to 32°C (glucose; R2 = 0.91, glucose 6-phopshate; R2 = 0.89, fructose 6-phopshate; R2 = 0.89, 
glyceraldehyde 3-phosphate; R2 = 0.46, lactate; R2 = 0.99). Relative tissue lactate after 12 minutes of 
ischaemia at 37°C was observed to rapidly decrease to 4-fold that of baseline, normoxic tissue 
concentrations. The hearts stored at 37°C were analysed by LC-MS at a discrete time to the remaining 
dataset. A 10-fold peak lactate tissue concentration was not previously achieved in hearts not 
administered cardioplegia and 12 minutes of warm ischaemia was only shown in other analyses to reach 












































































these data reflects a pathophysiological process or an error in analysis though the linear relationship 
observed between other glycolytic intermediates and temperature was also abolished when these data 
were analysed together. The difference in techniques used to maintain the temperature of organ storage 
could explain the differences in this analysis however, a similar disparity was not observed in other 
metabolites.  
 
Figure 29: Relationship between glycolysis and temperature in mouse hearts stored for 12 minutes of 
ischaemia. 
St Thomas’ cardioplegia was administered to donor animals. Hearts (n = 4) were rapidly excised and 
stored for 12 minutes in UW at different temperatures (4, 16, 28, and 32°C). Tissue abundance of 
metabolites was measured using LC-MS. Relative change in metabolite abundance was compared to 
baseline control hearts (n = 9) that were not treated with cardioplegia. 
 




























Figure 30: The accumulation of glycolytic intermediates after 12 minutes of ischaemic metabolism with 
varying temperatures of organ storage in the mouse heart. 
St Thomas’ cardioplegia was administered to donor animals. Hearts (n = 4) were rapidly excised and 
stored for 12 minutes in UW at different temperatures (4, 16, 28, and 32°C). Tissue abundance of 
metabolites was measured using LC-MS. Relative change in metabolite abundance was compared to 



















































































































Figure 31: Assessment of tissue NADH/NAD+ after 12 minutes of ischaemia in mouse hearts stored at 
difference temperatures. 
St Thomas’ cardioplegia was administered to donor animals. Hearts (n = 4) were rapidly excised and 
stored for 12 minutes in UW at different temperatures (4, 16, 28, and 32°C). Tissue abundance of 
metabolites was measured using LC-MS. Relative change in metabolite abundance was compared to 
baseline control hearts (n = 9) that were not treated with cardioplegia. Baseline, normoxic 
lactate/pyruvate ratio and NADH/NAD+ ratio is indicated by dotted line. 
 
The failure of energy stores during anaerobic metabolism was demonstrated in hearts not treated with 
cardioplegia to coincide with elevations in the NADH/NAD+ ratio and the inhibitory effects this may have 
on GAPDH (Figure 17(a) and (b)). The lactate/pyruvate ratio reflects the tissue NADH/NAD+ ratio. There 
was discordance in the trends of these ratios when analysed in these data. The lactate/pyruvate ratio 
after 12 minutes of ischaemia demonstrated a weak linear trend (R2 = 0.40) with increasing temperature 
of organ storage however there was no apparent trend in the NADH/NAD+ ratio in these data (Figure 31(a) 
and (b)). 
In summary, organ cooling significantly ameliorated the accumulation of succinate during ischaemia and 
demonstrated a linear relationship with temperature even after only short durations of organ storage. In 
addition, temperature had a linear relationship with the succinate/fumarate ratio. These findings highlight 
the need for very effective organ cooling during the early period of ischaemia if mtROS mediated IR injury 
is to be prevented by organ storage.  










































3.10 Urea cycle intermediates 
The urea cycle converts toxic ammonia into urea. Ammonia is derived primarily from the metabolism of 
amino acids but has also been shown during ischaemia to be the product of deamination of the purine 
nucleoside, adenosine (156). Although most tissues can synthesise urea, the greatest amount is produced 
in the liver. The first step occurs in the mitochondria generating citrulline from ornithine and carbamoyl 
phosphate. Citrulline is then transported into the cytoplasm by a specific transporter where the remaining 
three reactions occur. The urea cycle and CAC are connected by the aspartate-arginosuccinate shunt and 
in certain situations the urea cycle can replenish the CAC cycle with fumarate (32). 
During warm ischaemia, ornithine tissue concentrations remained near baseline levels up to 30 minutes 
but there was a significant difference in the effect of cold ischaemia compared to warm ischaemia on 
tissue abundance (F(1, 51) = 16.1. p = 0.0002, two-way ANOVA). Myocardial tissue concentrations of 
ornithine decreased to < 60% of baseline concentrations at 6 minutes of cold ischaemia and then 
remained at this level. There was no significant difference between myocardial concentrations of 
citrulline stored in warm or cold ischaemic conditions. Significant differences in tissue concentrations of 
the urea cycle intermediate, arginine, was observed between hearts stored in warm and cold ischaemia (F 
(1, 51) = 20.9 p < 0.0001, two-way ANOVA). Cold organ storage maintained tissue concentrations of 
arginine at baseline tissue concentrations. In contrast, warm ischaemia produced a rapid rise in arginine 
from 6 to 12 minutes of warm ischaemia. After this time tissue concentrations of arginine remained 
stable. There were significant differences in relative tissue abundance of aspartate (F (1, 51) = 38.3, p < 
0.0001, two-way ANOVA) and fumarate (F (1, 51) = 61.3, p < 0.0001, two-way ANOVA) between warm and 
cold organ storage (Figure 32). 
 






Figure 32: Accumulation of urea cycle intermediates during warm and cold ischaemia in the mouse 
heart. 
Mouse hearts were rapidly excised and exposed to either warm (red) or cold (blue) ischaemia (n = 4-5) 
for variable periods of time before being clamp frozen. Tissue abundance was analysed by LC-MS and 


















































































3.11 Free fatty acids and acyl carnitines 
Fatty acid oxidation represents a major substrate for energy metabolism in myocardium and is estimated 
to account for 60-90% of total oxygen consumption under aerobic conditions (157). Beta-oxidation is, 
however, highly sensitive to tissue hypoxia and under global ischaemic conditions is rapidly terminated. 
Inhibition of beta-oxidation is consistent with increasing cytosolic concentrations of long chain acyl-CoA 
and decreasing acetyl-CoA levels. The increase in long chain acyl-CoA might be expected to increase 
cytosolic long chain acylcarnitines.  
There was a more rapid increase in the short odd chain carnitines isovalerylcarnitine (F (1, 51) = 82.4, p < 
0.0001, two-way ANOVA) and propionylcarnitine (F (1, 51) = 103.1, p < 0.0001, two-way ANOVA) with 
warm ischaemia that was not observed with cold ischaemia. This likely represents an increase in amino 
acid catabolism during warm ischaemia. Butrylcarnitine can also be derived from amino acid metabolism 
and followed a similar trend to propionylcarnitine and isovalerylcarntine. The long chain carnitines, 
myristoylcarnitine (F (1, 51) = 21.5, p < 0.001, two-way ANOVA), stearoylcarnitine (F (1, 51) = 7.4, p < 
0.0001, two-way ANOVA), and palmitoylcarnitine (F(1, 51) = 81.0, p < 0.0001, two-way ANOVA) 
demonstrated a different profile with minimal change compared to baseline concentrations both during 
warm or cold ischaemia during early time points to 30 minutes. There was a late rise in these long chain 
carnitines in the tissues maintained under cold storage that was accompanied by a minor rise in 
acetylcarnitine. This was not observed in warm ischaemic myocardium, which at prolonged storage 
demonstrated an exhaustion of all tissue carnitines (Figure 33). 
 
 






Figure 33: Accumulation of carnitines in the mouse heart during warm and cold ischaemia. 
Mouse hearts were rapidly excised and exposed to either warm (red) or cold (blue) ischaemia (n = 4-5) 
for variable periods of time before being clamp frozen. Tissue abundance was analysed by LC-MS and 
relative change compared to baseline, normoxic control hearts (n = 11) calculated. 
 


























































































































3.12 Amino acid metabolism in ischaemia 
Under conditions unfavourable for oxidation such as ischaemia, the heart switches to alternative 
metabolic substrates in order to meet its energy requirements. Amino acids offer potential advantages to 
ischaemic myocardial metabolism as they can undergo non-oxidative metabolism and contribute little to 
cellular acidification (158). For this reason, there is increasing interest in the use of amino acids as 
cardioprotective substrates during ischaemia. The metabolic changes of some amino acids have already 
been discussed in relation to other metabolic pathways. The changes in a number of other key 
metabolites are discussed below. Transamination of glutamate was discussed in relation to the metabolic 
profile of α-ketoglutarate. There were no significant differences between the tissue concentrations of 
glutamate or glutamine in hearts stored in warm or cold ischaemia and tissue concentrations remained 
near baseline tissue concentrations. This profile would not support flux during myocardial ischaemia in 
this pathway (Figure 34). 
  
 






Figure 34: Amino acid and glutamate metabolism during warm and cold ischaemia in the mouse heart. 
Mouse hearts were rapidly excised and exposed to either warm (red) or cold (blue) ischaemia (n = 4-5) 
for variable periods of time before being clamp frozen. Tissue abundance was analysed by LC-MS and 
relative change compared to baseline, normoxic control hearts (n = 11) calculated. 
 
Alanine is produced and released by the heart in both physiological and pathophysiological conditions. It 
is thought to be produced by the transamination of pyruvate and has been shown to occur both in 
aerobic and anaerobic cells, where the availability of the substrate, pyruvate, is the rate limiting step. 
Alanine has been shown to increase in the hypoxic tissues of diving mammals and during myocardial 
ischaemia (158).  
In this data, alanine concentrations in hearts stored in cold ischaemia remained at baseline tissue 
concentrations but there was a significant difference in the tissue concentrations during warm ischaemia 
with a rapid rise during early ischaemia until 12 minutes whereupon tissue concentrations remained 
constant (F (1, 51) = 57.0, p < 0.0001, two-way ANOVA) (Figure 16 and Figure 36 (b)). These changes in 







































































































Figure 35: Relative change in tissue alanine during warm and cold storage in the mouse heart. 
(a) mouse (n = 5-11), (b) pig (n = 5) and (c) human (n = 4) hearts during warm (red line) and cold (blue 
line) storage.  
Mouse (n = 4 - 11), pig (n = 5) and human (n = 4) heart tissue was retrieved and exposed to variable 
periods of warm (red) or cold (blue) ischaemia. Tissue abundance was analysed by LC/MS and 
compared to normoxic baseline control tissue (mouse (n = 11), pig (n = 5), human (n = 4)). 
 
Asparagine can be converted to aspartate which can then be transaminated generating the CAC 
oxaloacetate (158). Asparagine levels remained near baseline until 30 minutes of ischaemia. Thereafter, 
there was a divergence in tissue concentrations between warm and cold ischaemia. This translated to a 
significant difference in asparagine abundance between hearts during warm and cold storage (F (1, 51) = 
11.8, p = 0.0012, two-way ANOVA). There was also a significant difference in tissue aspartate 
concentrations between warm and cold ischaemia (F (1, 51) = 38.3, p < 0.0001, two-way ANOVA).  (Figure 
36 (a)). 
  




































 Mouse Pig Human
A B C
 







Figure 36: Amino acid tissue concentrations during warm and cold storage in the mouse heart.  
Mouse hearts were rapidly excised and exposed to either warm (red) or cold (blue) ischaemia (n = 4-5) 
for variable periods of time before being clamp frozen. Tissue abundance was analysed by LC-MS and 
relative change compared to baseline, normoxic control hearts (n = 11) calculated.  
 
In summary, different metabolic profiles between warm and cold ischaemia were identified in certain 
amino acids, in particular, alanine. The concentrations of other amino acids by contrast were quiescent, 
remaining at baseline tissue concentrations. Whilst constant flux through these pathways could account 
for such findings, the absence of dynamic changes could be interpreted as a cessation of flux during 
ischaemia in this model.  
















































Research over the course of the last half century has generated great insights into myocardial metabolism 
during both normoxia and ischaemia. In view of the great burden that ischaemic heart disease places on 
Western healthcare, this research has primarily centred around the pursuit to develop cardioprotective 
strategies and to improve outcomes following myocardial infarcts. In translating our understanding of 
myocardial ischaemic metabolism to the transplant arena, it is important that the models adequately 
replicates the clinical setting to ensure accurate extrapolation of data.  
There are considerable difficulties exposing cells to periods of hypoxia in vitro and findings from studies in 
cardiomyocytes are often difficult to interpret. A number of ex vivo models of myocardial ischaemia have 
been used to expose myocardium to differing degrees of hypoxia or anoxia in a variety of flow states. 
There are a number of advantages to using isolated perfused organs to investigate myocardial 
metabolism. In these models, the heart can be exposed to hypoxia or anoxia in the presence of continued 
normal coronary perfusion, reduced coronary perfusion or a ‘low-flow’ state, or in the presence of no 
coronary flow. Myocardium may also be rendered locally ischaemic by ligation of a coronary artery or 
globally ischaemic through cessation of coronary perfusion or continued perfusion with anoxic perfusates. 
In vivo localised myocardial ischaemia models, such as the left anterior descending (LAD) coronary artery 
occlusion model, are also routinely used in the study of myocardial ischaemia. However, it is apparent 
that any conclusions drawn from a study or translated to another clinical scenario must take into account 
the true nature of the ischaemic environment to which the model exposes myocardium. For example, 
there is evidence that coronary occlusion does not completely stop perfusion in myocardial models of 
regional ischaemia. In animal models, collateral circulation has been shown to maintain flow at 10-20% of 
baseline flow in the infarct zone (150). This has the potential to significantly impact the ischaemic 
metabolic environment.  
In studying the ischaemic changes that occur during organ storage in the context of organ transplantation 
I aimed to develop a model that would replicate the clinical scenario of global, no flow ischaemia in a 
whole organ. Furthermore, upon characterising ischaemic metabolism, I wanted to be able to extrapolate 
any findings to a reperfusion model in a vascularised solid organ transplant. The murine heterotopic heart 
transplant model was established at my institution and had previously been used to investigate IR injury. I 
therefore designed the model used in these experiments around the donor procedure. Cold storage organ 
preservation was replicated by immersing the heart in cold UW which was shown to rapidly cool 
myocardium. Hearts were exposed to warm ischaemia by leaving the heart in the carcass of the donor 
animal maintained at a constant temperature by use of a heat mat. It could be argued that the warm and 
cold environments to which the hearts were exposed were different and a more appropriate design 
would have placed the hearts in identical environments with only changes made to temperature. I elected 
against this approach on the grounds that; (1) this model better replicated the clinically relevant scenario 
 





of primary warm ischaemia in DCD, and (2) previous investigators had used similar techniques and 
therefore, this enabled better comparison of findings (159). 
The descriptive nature of the data generated by this analysis presents challenges for drawing definitive 
conclusions about the ischaemic metabolism of myocardial tissue during warm and cold ischaemia. 
Nonetheless, this approach provides a wealth of information that can be used to guide the more detailed 
examination of individual pathways. Previous studies have examined ischaemic metabolism but this 
approach examined a wide range of metabolites using an untargeted mass spectrometry approach that 
included analysis of nucleotides, thereby also enabling estimates of ATP/ADP and NADH/NAD+ ratios to be 
made. There are inherent difficulties in measuring nucleotides accurately in vivo and therefore, cautious 
interpretation of the data is necessary. Furthermore, it is important to recognise that the measurement of 
intermediates reflect whole tissue changes. Using these techniques, for example, I was unable to 
differentiate between cytosolic or mitochondrial concentrations of these metabolites nor whether NADH 
or NAD+ were free or protein bound (160). 
I have made a number of assumptions in analysing the LC/MS spectrums of most of the metabolites. 
Importantly, I have assumed that there is a linear relationship between ion count and tissue 
concentration. The calculation of ratios such as ATP/ADP and NADH/NAD+ ratios also assume that these 
nucleotides were detected at the same frequencies and that there wasn’t degradation of these 
metabolites during analysis. One approach to addressing this issue was to quantify the ion count against 
standard curves of the metabolite. Tissue concentrations of some metabolites such as succinate and 
fumarate were quantified confirming a linear relationship between ion count and tissue concentrations of 
these metabolites at the concentrations observed in these tissues however, this could not be performed 
for all metabolites. An alternative method of analysing tissue concentrations of ATP and ADP were used 
and the results of this corroborated the findings of the LC-MS analysis for these nucleotides.  
In addition to biological variability, the extraction and analysis of samples was a potential source of 
variability. The duration across which experiments were performed was minimised and extractions and 
analyses performed in single batches. Furthermore, baseline controls were used to normalise datasets 
against, if required. 
These results are consistent with a rapid cessation of aerobic respiration at the onset of ischaemia in this 
model. Flux through glycolysis differed in warm and cold ischaemia. During warm ischaemia, there was 
evidence of inhibition of glycolysis despite there being detectable stores of tissue glycogen. This inhibition 
of glycolysis coincided with an elevation in tissue NADH/NAD+. These data support GAPDH inhibition, due 
to a high NADH/NAD+ ratio, as the cause for the cessation of anaerobic respiration during warm 
ischaemia. During cold ischaemia flux through glycolysis continued at a lower rate with more moderate 
tissue NADH/NAD+ increases. As a result, cessation of glycolysis during cold ischaemia coincided with 
exhaustion of tissue glycogen stores.  
 





In addition to the changes in glycolysis with warm and cold ischaemia I have also demonstrated diverse 
changes in succinate accumulation between warm and cold ischaemia. In warm ischaemia, succinate 
accumulated rapidly reaching a maximal succinate tissue concentration by 12 minutes. During organ 
storage in cold ischaemia, there was a small, early rise until 30 minutes. Thereafter, more prolonged 
duration of cold storage was associated with a persistent linear increase in succinate accumulation that 
continued until 12 hours. It is interesting that this rise continued in hearts that were beyond the limit of 
organ viability. These changes at the extreme durations of cold ischaemia were not observed in 
myocardial sections of human or porcine heart. In these experiments, further accumulation of succinate 
ceased.  
There was also a marked difference in the succinate/fumarate ratio with warm ischaemia demonstrating a 
rapid increase in this ratio, not observed with cold ischaemia. The succinate/fumarate ratio is proposed as 
the driving force behind RET and therefore these findings would suggest a possible mechanism for the 
detrimental impact of warm ischaemia. The difference in succinate accumulation with prolonged duration 
of cold ischaemia points towards a possible role for the intact heart in mediating continued succinate 
accumulation with prolonged cold storage. 
Finally, succinate accumulation during ischaemia was observed to be highly conserved across species 
including humans. This increases the potential for the translation of novel therapeutic agents designed to 
ameliorate IR injury from animal models into clinical practice. 
In contrast to succinate accumulation, there was discordance across species with regards to the 
accumulation of the other CAC intermediates malate and fumarate. During warm ischaemia, malate and 
fumarate demonstrated different trends with a rapid decrease observed in the mouse and rapid increases 
observed in the pig and human hearts.  
There is conflicting data within the literature relating to the metabolic profile of hearts during ischaemia. 
In contrast to the data from this analysis and other publications (53, 54, 161), data from a recent study 
examining myocardial interstitial, left ventricular metabolite concentrations measured using a 
microdialysis catheter in isolated, perfused rat hearts with global, no flow ischaemia demonstrated rapid 
accumulation of all CAC cycle metabolites during ischaemia within 30 minutes (162). The metabolic 
changes reported in this analysis are similar to those observed in the pig and human data reported here.  
The C57BL/6J mouse used in these experiments is known to have a mutation in Nnt that has roles in 
metabolism. NNT is a key protein in the inner mitochondrial membrane and has been shown to impair 
mitochondrial function (163). Nevertheless, these studies were focused on mitochondrial function within 
the context of impaired glucose tolerance and diabetes and not within the context of IR injury however, 
this impaired mitochondrial function is a possible limitation of this work. Examining the metabolic 
changes during ischaemia in mouse strains with wild type Nnt could be considered in the first instance in 
order to address this concern. 
 





Another explanation could be that these discrepancies reflect subtle differences in experimental models. 
Ex vivo models have a normoxic stabilisation period during which the heart is frequently perfused with 
glucose as the only substrate (162). Under physiological conditions, fatty acid oxidation provides the 
majority of substrate for ATP synthesis however, under a variety of conditions including heart failure, 
metabolic switching has been observed (34). The impact of metabolic switching on subsequent ischaemic 
episodes following changes in substrate utilisation is not known. In these data, the pig and human heart 
model used myocardial sections rather than whole hearts. The myocardial sections demonstrate only 
brief fibrillation as opposed to the whole mouse heart which continues to beat for up to 90 seconds 
following the onset of warm ischaemia. The impact of this is uncertain and contrasting effects on the 
direction of CAC cycling would not be impossible. Nevertheless, when mouse hearts were treated with 
cardioplegia, fumarate was observed to decrease, as opposed to the increase observed in pig and human 
cardiac sections. This would therefore, not support myocardial contraction as the source of the observed 
discrepancy in these CAC intermediates.  
Succinate accumulation during ischaemia has been suggested to be the result of a reversal in the direction 
of succinate dehydrogenase and CAC cycling. This occurs in the presence of a highly reduced CoQ pool 
(54). Succinate accumulation during ischaemia was a conserved finding across species and it might 
therefore be expected that the changes in other CAC metabolites would also be similar. The different 
profiles in malate and fumarate could be interpreted as a different cycling of the CAC however, fumarate 
and malate both have cytosolic and mitochondrial pools and therefore the measured intermediate 
concentrations might not reflect mitochondrial concentrations. There are also other pathways that 
generate fumarate and malate such as the urea cycle and the malate-aspartate shunt that could be 
responsible for the differences observed.  
This analysis highlights metabolites that appear to have similar profiles and provides a foundation for 
future work to elucidate the sources of key metabolites such as succinate and identify the active 
pathways during ischaemia and potentially provide novel targets for future therapies.   
 





Chapter 4:  Exploring the source of succinate accumulation 
during ischaemia 
 





4.1 Exploring the source of succinate accumulation during 
ischaemia 
4.1.1 Introduction  
In the previous chapter, metabolomic profiling of mouse hearts during warm and cold ischaemia 
demonstrated a rapid accumulation of succinate during warm ischaemia, with a corresponding increase in 
the succinate/fumarate ratio, that was abrogated by cold organ storage.  
Recent studies by our group has theorised the mechanism for this rapid accumulation of succinate during 
ischaemia to involve the reduction of fumarate at complex II (53, 54). This work demonstrated that the 
major carbon sources for CAC intermediates during normoxia, fatty acid ß-oxidation, glucose, the GABA 
shunt, and glutamate, did not contribute to the accumulation of succinate during ischaemia. Rather, two 
potential sources of fumarate were identified as possible candidates: the malate-aspartate shuttle 
(MAS)and AMP-dependent activation of the purine nucleotide cycle (PNC) (53). 
Elucidating the mechanism of succinate accumulation is central to the development of future therapeutic 
agents. To further explore the source of succinate proposed from the work using an ex vivo model (53), I 
examined a number of potential pathways were using a variety of metabolic inhibitors in this model of 
ischaemia during organ retrieval. Metabolic inhibitors were administered in cardioplegic solution 
administered to the anaesthetised donor animals. Hearts were then stored under warm ischaemic 
conditions prior to clamp freezing and metabolite accumulation was compared to untreated control 
hearts that received only cardioplegia prior to warm ischaemia. LC-MS analysis was performed by Dr Ana 
S.H. Costa (Hutchinson/MRC Research Centre). 
 





4.2 Aminooxyacetate (AOA) 
AOA is competitive inhibitor of transaminases such as aspartate aminotransferase which catalyses the 
transamination of aspartate to oxaloacetate (162, 164, 165). AOA would be hypothesised to inhibit 
succinate accumulation during ischaemia by limiting the potential fumarate reservoir available for 
reduction in mitochondria. When AOA was administered at the onset of ischaemia, there was a significant 
decrease in succinate tissue concentrations after 12 minutes of warm ischaemia compared to the 
untreated control (one-way ANOVA and Bonferroni multiple comparison testing, p = 0.001) (Figure 37). 
This was also associated with trends towards a decrease in fumarate and for an increase in tissue 
aspartate, but the differences were not statistically significant (p= 0.05 and p = 0.08 respectively, one-way 
ANOVA and Bonferroni multiple comparison testing). 
The amelioration of succinate accumulation together with a trend towards an increase in tissue aspartate 
concentrations would support the theory that the MAS is active in ischaemia and that inhibition of 
aminotransferases blocks this pathway. It is hypothesised that the cytosolic malate generated in the 
presence of the high NADH/NAD+ ratio is exchanged for mitochondrial succinate by the dicarboxylate 
carrier (DIC). In the mitochondria matrix, it can then be converted to fumarate by mitochondrial fumarate 
hydratase before being reduced to succinate (54). The inhibition of aspartate transaminase is consistent 
with the observed more rapid decline in concentrations of malate and fumarate since the upstream 
substrate to this process, oxaloacetate, can no longer be generated. 
Interestingly, these findings are at odds with the recent findings from Jespersen et al who reported an 
increase in myocardial interstitial fumarate and malate concentrations during ischaemia, in an ex vivo, 
global ischaemia model in the rat heart (162).  
AOA is a non-specific competitive inhibitor of transaminases. This was consistent with a significant 
decrease in tissue concentrations of alanine in hearts treated with AOA (Figure 38). The accumulation of 
alanine during ischaemia is well recognised (151). Conceivably, this non-glycolytic, anaplerotic reaction 
could complement the transamination of aspartate to oxaloacetate by regenerating the a-ketoglutarate 
required. The decreased tissue concentrations of alanine with inhibition of alanine transaminase suggests 
that there is flux through this pathway and a potential role in the accumulation of succinate. 
  
 






Figure 37: Effect of metabolic inhibitors on MAS intermediates during ischaemia in the mouse heart. 
Donor animals (n = 4) received various metabolic inhibitors (2 mM aminooxyacetate (AOA), 3.2 mg 
dimethyl malonate (DMM), 1 mM diazoxide (DZX), 2 mM hadacidin (HAD), 1 mM 
thenoyltrifluoroacetone (TTFA) in 5% DMSO, or 60 µM rotenone (ROT) in 5% DMSO) as bolus injections 
in St Thomas’ cardioplegia via a central vein immediately prior to rapid excision and storage in warm 
ischaemic conditions (12 minutes). Relative metabolite abundance was compared to control hearts 
that were treated with cardioplegia alone and stored in warm ischaemic conditions for 12 minutes (n = 
8). One-way ANOVA with Bonferroni multiple comparisons testing. * P < 0.05, ** P < 0.01, *** P < 














































































































Figure 38: Effect of metabolic inhibitors on transamination in the mouse heart. 
Donor animals (n = 4) received various metabolic inhibitors (2 mM aminooxyacetate (AOA), 3.2 mg 
dimethyl malonate (DMM), 1 mM diazoxide (DZX), 2 mM hadacidin (HAD), 1 mM 
thenoyltrifluoroacetone (TTFA) in 5% DMSO, or 60 µM rotenone (ROT) in 5% DMSO) as bolus injections 
in St Thomas’ cardioplegia via a central vein immediately prior to rapid excision and storage in warm 
ischaemic conditions (12 minutes). Relative metabolite abundance was compared to control hearts 
that were treated with cardioplegia alone and stored in warm ischaemic conditions for 12 minutes (n = 
8). One-way ANOVA with Bonferroni multiple comparisons testing. * P < 0.05, ** P < 0.01, *** P < 













































































































4.3 Dimethyl malonate (DMM) 
Dimethyl malonate is hydrolysed in vivo to produce the competitive inhibitor of complex II, malonate. 
DMM has previously been shown to ameliorate succinate accumulation during ischaemia (53, 161). 
Preliminary dose-response studies demonstrated rapid hydrolysis of DMM in vivo with no detectable 
DMM identified after 12 minutes of warm ischaemia following administration of up to 20 mg of DMM 
(Figure 39(a)). This was further supported by an associated increase in malonate abundance (Figure 
39(b)). In addition, there was an associated significant amelioration of succinate accumulation (one-way 
ANOVA and Bonferroni multiple comparison testing, p = 0.002). There were no significant changes in 
other detected MAS (Figure 37) or CAC (Figure 40) intermediates after 12 minutes of warm ischaemia. 
Similar changes in CAC intermediates were demonstrated between baseline normoxic controls and hearts 
exposed to 12 minutes of warm ischaemia (Figure 41).  
These data support the theory that complex II is responsible for the increase in succinate accumulation 
observed during ischaemia in the mouse heart. Furthermore, I have demonstrated that delivery of DMM 
at the onset of ischaemia is sufficient to achieve elevated tissue concentrations and effective inhibition of 
complex II in this model and will investigate this further in Chapter 5. 
  
 







Figure 39 (a – c): DMM undergoes rapid hydrolysis in vivo. 
A 500 μL inferior vena cava (IVC) bolus injection of St Thomas’ cardioplegia was administered to 
anaesthetised donor animals with varying concentrations of DMM (12 µM (0.8 mg), 48 µM (3.2 mg), 97 
µM (6.4 mg), 300 µM (20 mg), 757 µM (50 mg) (n = 1 - 4) or another metabolic inhibitor (2 mM 
aminooxyacetate (AOA) or 2 mM hadacidin (HAD) (n = 4)). Following the administration of metabolic 
inhibitor or cardioplegia alone, hearts were stored for 12 minutes of warm ischaemia prior to clamp 
freezing. Tissue DMM abundance and malonate was quantified by LC-MS and compared to control 
hearts that were treated with cardioplegia alone and stored in warm ischaemic conditions for 12 
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Figure 40: The effect of metabolic inhibitors on CAC metabolite accumulation during warm ischaemia. 
Donor animals (n = 4) received various metabolic inhibitors (2 mM aminooxyacetate (AOA), 3.2 mg 
dimethyl malonate (DMM), 1 mM diazoxide (DZX), 2 mM hadacidin (HAD), 1 mM 
thenoyltrifluoroacetone (TTFA) in 5% DMSO, or 60 µM rotenone (ROT) in 5% DMSO) as bolus injections 
in St Thomas’ cardioplegia via a central vein immediately prior to rapid excision and storage in warm 
ischaemic conditions (12 minutes). Relative metabolite abundance was compared to control hearts that 
were treated with cardioplegia alone and stored in warm ischaemic conditions for 12 minutes (n = 8). 
Significant changes by one-way ANOVA with Bonferroni multiple comparison testing * P < 0.05, ** P < 





















































































Figure 41: Relative change of CAC metabolites compared to baseline normoxic tissue following the 
administration of cardioplegia and various metabolic inhibitors or cardioplegia alone.  
Donor animals (n = 4) received various metabolic inhibitors (2 mM aminooxyacetate (AOA), 3.2 mg 
dimethyl malonate (DMM), 2 mM Hadacidin) as bolus injections in St Thomas’ cardioplegia via a central 
vein immediately prior to rapid excision and storage in warm ischaemic conditions (12 minutes). 
Relative metabolite abundance was compared to control hearts that were rapidly excised and 
immediately snap frozen (n = 5). Significant changes by one-way ANOVA with Bonferroni multiple 
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4.4 Dimethyl malonate and aminooxyacetate 
The data above demonstrate that DMM and AOA moderated ischaemic metabolism in this model, 
ameliorating the accumulation of succinate when administered in isolation. This was associated with 
complementary changes in other related metabolites. I next examined the impact of administration of the 
two compounds together on succinate accumulation and other metabolic intermediates.  
Interestingly, there was an additive effect on tissue fumarate when both DMM and AOA were 
administered concurrently. When administered alone, DMM and AOA significantly reduced tissue 
succinate compared to controls but there was no significant decrease in tissue fumarate. When 
administered together the significant reduction in tissue succinate was associated with a significant 
decrease in tissue fumarate. There were no other significant changes in other measured metabolites 
when compared to controls (Figure 37).  
  
 






Another proposed source of fumarate during ischaemia was the PNC (53). The net result of the PNC is to 
convert aspartate and GTP into fumarate and AMP. This is catalysed by adenylosuccinate synthetase 
(ADSS) and adenylosuccinate lyase. Hadacidin is a specific competitive inhibitor of ADSS (166).  
In this study, there was no significant change in the tissue succinate or fumarate concentration when 
donor hearts were treated with hadacidin. Furthermore, there was no significant change in the tissue 
abundance of the PNC intermediates, AMP, IMP nor adenosine which have also previously been used as 
surrogates of PNC activity (Figure 37 and Figure 42) (167).  
These findings are at odds with Wu et al who demonstrated evidence of inhibition of the PNC by 
hadacidin during ischaemia in ex vivo perfused hearts (167) and would refute the notion that the PNC is a 
source of fumarate for reduction to succinate at complex II by mitochondria. These data do not, however, 
differentiate between an inadequate inhibition of ADSS by hadacidin and adequate inhibition in the 
absence of flux through this pathway during ischemia. Dose-response curves were performed and no 
response was observed at higher doses despite demonstrating that hadacidin was detectable in mouse 
hearts after 12 minutes of warm ischaemia (Figure 43). The initial step converting aspartate to 
adenylosuccinate in the PNC requires energy in the form of GTP. In the ischaemic environment of the cell 
low concentrations of GTP would make this unfavourable and could explain the failure of hadaciding to 
change tissue concentrations of succinate in these data.  
 






Figure 42: Effect of hadacidin administration on ischaemic metabolism in the mouse heart 
Donor animals (n = 4) received various metabolic inhibitors (2 mM aminooxyacetate (AOA), 3.2 mg 
dimethyl malonate (DMM), 1 mM diazoxide (DZX), 2 mM hadacidin (HAD), or 60 µM rotenone (ROT)) 
as bolus injections in St Thomas’ cardioplegia via a central vein immediately prior to rapid excision and 
storage in warm ischaemic conditions (12 minutes). Relative metabolite abundance was compared to 
control hearts that were treated with cardioplegia alone and stored in warm ischaemic conditions for 
12 minutes (n = 8). One-way ANOVA with Bonferroni multiple comparison testing. * P < 0.05, ** P < 



































































































Figure 43 (a and b): The efficacy of hadacidin administration by bolus injection and the impact on PNC 
intermediate metabolites during warm ischaemia.  
Donor animals (n = 1-4) received the metabolic inhibitor Hadacidin at variable concentrations (20 µM, 
200 µM, 2 mM , 20 mM, 50 mM) as a bolus injections in St Thomas’ cardioplegia via a central vein 
immediately prior to rapid excision and storage in warm ischaemic conditions (12 minutes). Hadacidin 
abundance was detected in hearts by LC-MS. Relative metabolite abundance was compared to control 
hearts that were treated with cardioplegia alone and stored in warm ischaemic conditions for 12 
minutes (n = 4). One-way ANOVA with Bonferroni multiple comparison testing. Mean baseline control 

















































































































4.6 Thenoyltrifluoroacetone (TTFA) and Diazoxide (DZX) 
In addition to competitive inhibition at the dicarboxylate binding site, complex II can also be inhibited at 
the ubiquinone binding site (Q-site). TTFA is a non-competitive inhibitor of complex II. When bound to the 
Q-site it prevents the transfer of electrons from the dicarboxylate binding site of complex II (168, 169). 
Preliminary dose-response studies demonstrated low solubility and tissue delivery at concentrations 
above 100 µM in cardioplegic solution alone. In order to increase delivery to concentrations that had 
previously demonstrated a metabolic effect it was necessary to increase solubility. This was achieved with 
dimethyl sulfoxide (DMSO). When TTFA was administered with 5% DMSO w/v in cardioplegic solution a 
metabolic effect on succinate accumulation was observed with concentrations of 1 mM TTFA (Figure 44). 
Succinate accumulation during ischaemia was significantly ameliorated at 12 minutes of warm ischaemia 
(one-way ANOVA and Bonferroni multiple comparison testing, p = 0.001). This was not however, 
associated with a significant change in fumarate or other CAC and MAS intermediate compared to control 
(Figure 37 and Figure 40).  
DZX has been shown to effect cardiac metabolism through two pathways. DZX is a selective opener of the 
ATP sensitive-potassium channel that has been shown to have cardioprotective properties and improve 
preservation of hearts stored in cold storage (170). More recently, however, DZX has also been shown to 
directly inhibit complex II (171, 172). In contrast to TTFA, DZX administration demonstrated no significant 
amelioration of succinate accumulation during warm ischaemia, although there was a significant 
reduction in fumarate abundance. Interestingly, changes in tissue fumarate were not observed with TTFA 
(Figure 37 and Figure 40). Whilst there were trends towards a reduction in tissue malate with the 
administration of DZX and TTFA, these were not statistically significant (one-way ANOVA with Bonferroni 
multiple comparison testing) (Figure 37).  
 






Figure 44: TTFA solubility and delivery to the heart following IVC bolus injection with cardioplegia. 
Donor animals (n = 1-4) received the metabolic inhibitor TTFA at variable concentrations (10 µM, 100 
µM, 1 mM , 1 mM, 10 mM) as a bolus injections in St Thomas’ cardioplegia via a central vein 
immediately prior to rapid excision and storage in warm ischaemic conditions (12 minutes). Relative 
metabolite abundance was compared to control hearts that were treated with cardioplegia alone and 
stored in warm ischaemic conditions for 12 minutes (n = 4). Significant changes by one-way ANOVA 





















































Rotenone is a potent, irreversible inhibitor of complex I. In these experiments, it did not have any effect 
on succinate, fumarate or other metabolites during ischaemia. While this may be due to inadequate 
delivery in vivo, it would equally be consistent with low activity of complex I during ischaemia (Figure 37, 
Figure 38 and Figure 40)(173). The lack of changes in CAC metabolites would be consistent with the rapid 
cessation of oxidative phosphorylation at the onset of ischaemia and complex I inhibition would 
potentially be hypothesised to have a greater impact on reperfusion. Complex I is fundamental to the 
burst of mtROS on reperfusion and therefore, effectively delivering an agent that could inhibit this 
process in vivo could be invaluable to investigating IR injury. The poor solubility of rotenone in vivo 
however makes this very challenging. Moreover, the central role of complex I to oxidative 
phosphorylation makes complex I inhibitors highly toxic to the cell and the irreversible nature of complex I 
inhibition with rotenone will make identifying a therapeutic window in vivo difficult. It would nevertheless 
be interesting to examine the early metabolic changes in the first few minutes following reperfusion in a 
transplanted heart treated with rotenone however, the toxicity may confound longer term follow up and 
the interpretation of reperfusion injury and its impact on organ dysfunction. An alternative approach 
could be to investigate the efficacy of less potent complex I inhibitors such as the biguanide, metformin.  
 






The comparative metabolomics from chapter 3 identified a rapid accumulation of succinate during warm 
ischaemia that was significantly abrogated by cold storage of organs. The rapid accumulation of succinate 
and the mechanisms through which it accumulates have previously been explored in an ex vivo global 
ischaemia model(53). In this chapter, I further examined the metabolic processes involved in succinate 
accumulation during warm ischaemia. Focussing on complex I and II, the PNC and the MAS, I examined 
the early period of warm ischaemia (12 minutes) when a marked divergence in the metabolomic profiles 
was apparent between organs preserved in cold and warm storage. Moreover, the untargeted LC-MS 
approach enabled analysis of multiple metabolic intermediates and pathways in myocardial tissue during 
ischaemia. To examine the accumulation of succinate during warm ischaemia I used metabolic inhibitors 
of the PNC, the MAS and 3 different inhibitors of complex II.  
4.8.1 Efficacy of metabolic inhibitors in organ storage 
Three of these inhibitors, TTFA, DMM and AOA, had a significant effect on succinate accumulation during 
ischaemia. The Q site inhibitor of complex II, TTFA, reduced the accumulation of succinate during 
ischaemia. This was not, however, associated with a significant change in fumarate. Fumarate is reduced 
to succinate in the presence of a highly reduced Q-pool during ischaemia. Inhibition of SDH could 
potentially produce reciprocal changes in other CAC intermediates. There was a non-significant decrease 
in tissue fumarate observed with TTFA. Succinate is required for co-transport of malate at the 
dicarboxylate carrier (DIC) into the mitochondria. The malate exchanged into the mitochondria is 
converted into fumarate by fumarate hydratase and therefore the decrease in available mitochondrial 
malate would be consistent with the changes in fumarate concentrations observed with TTFA 
administration in this study (54). DZX also inhibits complex II. Unlike TTFA however, administration of DZX 
was not associated with a change in tissue succinate. There was however, a significant decrease in tissue 
fumarate associated with DZX. Whether the failure to ameliorate succinate accumulation was due to 
inadequate delivery to the mitochondrial matrix, inadequate concentrations at the onset of ischaemia or 
a consequence of an off-target effect was not identified. In other studies, the inhibitory effect of DZX was 
observed to be less efficient than TTFA and malonate (169, 172).  
Competitive inhibition of the dicarboxylate binding site of complex II with malonate also demonstrated a 
significant amelioration of succinate accumulation during ischaemia with no change in fumarate. 
Interestingly, there was a significant decrease in malate with DMM administration. There was a general 
trend towards a more rapid decrease in malate with all complex II inhibitors and AOA, but only reached 
statistical significance in hearts treated with DMM and AOA.  
AOA is a competitive inhibitor of aspartate aminotransferase and was also shown to significantly reduce 
succinate accumulation during warm ischaemia in this model. In addition, administration of AOA was 
associated with a significant increase in tissue aspartate and a decrease in tissue fumarate compared to 
the untreated control. The non-specific nature of transaminase inhibition by AOA was highlighted by the 
 





significant reduction in the rise in tissue alanine that was observed during ischaemia. In addition, this 
further supports flux through a pathway involving alanine during ischaemia. The marked accumulation of 
alanine during cardiac ischaemia has previously been observed (151). It was observed to increase 
stoichiometrically to the rate of aspartate degradation. Succinate accumulation in this study was minor in 
comparison and it was thus proposed that alanine accumulated in ischaemic myocardium through a series 
of anapleurotic reactions utilising aspartate and CAC intermediates (151). The metabolic changes 
observed in this study would support flux through a process involving alanine but in contrast to this being 
isolated from succinate accumulation, it would appear to be intricately involved. It could be proposed that 
the transamination of pyruvate and glutamate to alanine regenerates a-ketoglutarate in the process 
enabling the further generation of oxaloacetate. This process would require continued production of 
pyruvate through glycolysis. Alanine tissue concentrations are observed to increase rapidly during the first 
12 minutes of warm ischaemia before remaining constant. This would be consistent with such a 
mechanism. 
4.8.2 Activity of PNC during ischaemia  
The PNC has previously been proposed as a source of fumarate during ischaemia. Hadacidin is a specific 
inhibitor of ADSS which is necessary for the generation of fumarate and AMP from adenylosuccinate. 
There was no change in succinate associated with ADSS administration. Furthermore, there was no 
change in any of the downstream metabolites after ADSS. These findings could either be interpreted as a 
failure in adequate delivery and inhibition of ADSS or as a lack of flux through the PNC during ischaemia in 
this model. It is interesting that the initial step involving the generation of adenylosuccinate from 
aspartate and IMP is a GTP-dependent process which is likely to be scarce during ischaemia. 
The heart is highly metabolically active and myocardial oxygen reserves are rapidly exhausted following 
complete cessation of coronary flow. During aerobic respiration myocardium derives energy in the form 
of ATP primarily from ß-oxidation of fatty acids and the oxidation of glucose (34). In the absence of 
oxygen, these processes cease and the heart is reliant on glycolysis as the principal source of energy. The 
heart can demonstrate versatility, however, switching between these different metabolic processes 
depending on a variety of other conditions including substrate availability and myocardial energy status 
(34, 36, 174). This has the potential to influence the effects of metabolic inhibitors in vivo when 
investigating their impact on ischaemic metabolism. The technique employed in this model sought to 
minimise the metabolic effect of administering inhibitors during normoxia by delivering the metabolic 
inhibitor at the onset of ischaemia without any prior ischaemic insult. The animal was oxygenated 
throughout anaesthesia prior to the administration of cardioplegia and the metabolic inhibitor being 
examined. The rapid induction of diastolic asystole was visually confirmed by the cessation of an apex 
beat and subsequent rapid excision of the heart prevented spontaneous return of contraction. 
In examining the effect of a metabolic inhibitor, it is necessary to ensure adequate delivery of the 
inhibitor at adequate concentrations to its target. All metabolic inhibitors were administered by IVC bolus 
 





injection with cardioplegia. Rapid intracellular or extracellular hydrolysis of the precursor DMM to 
malonate was confirmed by the presence of significantly elevated tissue malonate and the absence of a 
DMM LC-MS signal after 12 minutes of ischaemia. The inner mitochondrial membrane is highly 
impermeable to charged molecules and therefore, transport of intermediates into mitochondria is highly 
regulated requiring specific transporters. Although malonate has previously been shown to be taken up 
into mitochondria, direct competitive inhibition could nevertheless not be definitively confirmed. The 
other metabolic inhibitors used in this study did not undergo modification after administration and, 
therefore, similar inferences could not be made. LC-MS signals were detectable in tissues after 12 minutes 
ischaemia following IVC bolus injection. The exact intracellular or extracellular location of these can only 
be assumed, however significant alterations in the metabolic profile of hearts was observed using some of 
these which provides a useful surrogate.  
Another potential problem in analysing the impact metabolic inhibitors of mitochondrial processes in vivo 
is that the LC-MS analysis cannot differentiate between the exact location of intermediates. The cytosolic 
compartment constitutes, by volume, a greater proportion of cell mass than the mitochondrial matrix. 
Small but biologically significant changes in mitochondrial metabolic intermediates could thus not be 
detected as significant changes in overall tissue concentrations of metabolites in our analysis. Similarly, 
stoichiometric changes between compartments were also not appreciated using this technique.  
4.8.3 Summary 
In summary, the amelioration of succinate accumulation by DMM and TTFA supports the hypothesis that 
succinate accumulation during ischaemia occurs through reduction of fumarate at complex II. The effect 
of AOA inhibition on aspartate aminotransferase and the reduction in succinate accumulation further 
supports aspartate as a source of fumarate used to generate this succinate. The observation that AOA 
inhibition also significantly alters alanine concentrations suggests a possible additional role for alanine in 
this process.  
It has previously been proposed that the PNC is a source of fumarate during ischaemia. The results from 
these data do not support this. No change in any of the measured PNC metabolites were identified. 
Adequate intracellular and or mitochondrial delivery of metabolic inhibitors remains a potential concern, 
however, since the PNC is an energy dependent process requiring GTP. In the energy depleted 
environment of ischaemic myocardium, although previous data has suggested to the contrary, it would 
seem paradoxical for it to be activated and therefore, one explanation for these findings is that PNC is 
inactive during ischaemia.  
In addition to providing important additional insights to the existing literature on the mechanism of 
succinate accumulation during ischaemia, this work also highlights the potential of DMM as a therapeutic 
agent in the amelioration of IR injury associated with organ preservation and provided a rationale to 
investigate the efficacy of DMM in a small animal model of IR injury in organ transplantation.  
 






Chapter 5:  Moderating IR injury in a model of solid organ 
transplantation 
 





5.1 Moderating IR injury in a model of solid organ transplantation 
5.1.1 Introduction 
The murine heterotopic heart transplant is a vascularised model of solid organ transplantation developed 
by Corry et al(135). It has previously been modified to study the role of ischaemia reperfusion injury in 
organ transplantation. In this adapted model, a standard (30 minute) or prolonged (240 minute) period of 
cold ischaemia was used to induce mild or severe ischaemic injury before transplantation(138). The 
metabolomic data described in chapter 3 identified warm ischaemia as the predominant factor in the 
accumulation of succinate in a mouse heart model of organ storage. Succinate accumulation has been 
shown to be a key factor in driving IR injury and a recent clinical study has identified warm ischaemia as a 
key determinant of graft survival in solid organ transplantation(175). This provided the rationale for the 
development of a novel model of IR injury within the setting of solid organ transplantation that examined 
the effect of warm ischaemia in exacerbating IR injury and organ dysfunction. 
Outcome markers related to both mitochondrial and organ dysfunction were examined. Mitochondrial 
dysfunction was assessed by measuring mitochondrial DNA damage. This was done by measuring the 
relative amplification by PCR of short and long sequences of mitochondrial DNA. Mitochondrial damage 
interrupts the amplification of the long sequence and is therefore inversely proportional to relative 
mitochondrial damage. Organ dysfunction was assessed by measuring the recipient serum troponin at 24 
hours after transplantation. 
5.1.2 Developing a novel and reproducible model of IR injury in 
organ transplantation 
To replicate a DCD scenario, a period of warm ischaemia was introduced by exsanguinating the animal 
under anaesthesia. A standoff period was observed with the thorax closed to mimic the clinical scenario. 
During this period the animals core temperature was maintained at 37°C using a heating pad and relayed 
rectal temperature probe. Initially, hearts were retrieved after a stand-off period of 6 and 12 minutes and 
compared to hearts retrieved immediately with minimal exposure to additional warm ischaemia. 
After a 6-minute delay before proceeding with the standard retrieval all hearts would beat spontaneously 
on reperfusion. When hearts retrieved with an additional 6 minutes of warm ischaemia were compared to 
those retrieved immediately with minimal additional warm ischaemia, there was marked variability 
observed within the warm ischaemia group and no significant difference in serum troponin (control vs 6 
mins WI, 12.3 ± 5.3 (n=3) vs 6.9 ± 1.2 (n=7)). (Figure 45). Furthermore, there was no significant difference 
in mitochondrial dysfunction between groups (Figure 45(a)). 
Metabolomic analysis demonstrated that there was a continued rise in succinate accumulation beyond 12 
minutes. Since all hearts were observed to contract spontaneously on reperfusion after 6 minutes of 
additional warm ischaemia, the warm ischaemic period was extended to 12 minutes. Increasing additional 
warm ischaemia to 12 minutes resulted in a non-significant increase in the mean serum troponin rise at 
 





24 hours when compared to 6 minutes of primary warm ischaemia (16.9 ± 6.4 (n=4) vs 12.3 ± 5.3 (n=3) p = 
0.62). As observed with 6 minutes additional warm ischaemia, there was marked variability in organ 
dysfunction following the reperfusion of hearts exposed to 12 minutes of additional warm ischaemia 
which led to a failure to demonstrate a difference in either, mitochondrial DNA damage or organ 
dysfunction between hearts transplanted with and without the additional 12 minutes of primary warm 
ischaemia (relative amplification of mtDNA (0.41 ± 0.07 (n=4) vs 0.31 ± 0.05, (n = 7) p = 0.35); recipient 
serum troponin at 24 hours (16.9 ± 6.4 (n = 4) vs 12.3 ± 5.3 (n = 7) p = 0.07) (Figure 46). 
 
Figure 45: Effect of 6 minutes of warm ischaemia on IR injury following heterotopic heart 
transplantation in the mouse. 
Donor animals (n = 3 - 7) were anaesthetised and exsanguinated by division of the IVC and aorta. A 
standoff period of 6 minutes was observed with the donor animals core temperature maintained at 
37°C. Hearts were heterotopically transplanted after minimal additional cold ischaemia and the 
























































Figure 46: Effect of 12 minutes of warm ischaemia on IR injury following heterotopic heart 
transplantation in the mouse. 
Donor animals (n = 4 - 7) were anaesthetised and exsanguinated by division of the IVC and aorta. A 
standoff period of 12 minutes was observed with the donor animals core temperature maintained at 
37°C. Hearts were heterotopically transplanted after minimal additional cold ischaemia and the 
reperfusion injury compared to those of a standard transplant without additional warm ischaemia.  
 
During the donor retrieval operation, topical ice-cold saline was regularly applied to the heart. There is 
inherent variability in the efficacy of myocardial cooling using this technique which is likely to be amplified 
by the cardioplegic effects of hypothermia and the associated effects on metabolism. To minimise the 
effects of variable cardiac contraction during warm ischaemia and the retrieval operation a new protocol 
with administration of cardioplegia to the donor animal at the time of organ harvest was developed. 
Cardioplegia has been used in human clinical practice in a variety of situations during cardiac surgery for a 
number of decades (44). It can be administered directly to the heart as an antegrade or retrograde 
infusion. Direct cardiac infusion was precluded in this model due to limited access to microsurgical 
positive pressure ventilation in our institution. Intubation and ventilation would have been necessary if a 
sternotomy were to be performed allowing access to the mediastinum for appropriate preparation and 
cannulation of vessels. Systemic, central venous administration via the abdominal IVC provided a reliable 
alternative approach inducing cardiac arrest within 5 seconds of a bolus injection of 500 µL cardioplegic 
solution (Cardioplegic Solution, Harefield Hospital Formulation, Terumo BCT Ltd, UK). There was an 
apparent passive diffusion of cardioplegia following bolus administration that was aided by respiratory 
effort, evidenced by a return of cardiac contraction within approximately 60 seconds following bolus 
administration of cardioplegia if there was no additional intervention. By proceeding immediately to 
retrieval however, a sufficient extracellular potassium concentration was maintained and the heart 
remained in diastole. The donor heart could then be subjected to an additional period of warm ischaemia 




















































5.1.3 Additional primary warm ischaemia following retrieval with 
cardioplegia 
To examine whether cardioplegia impacted IR injury in this model recipient serum troponin at 24 hours 
post reperfusion was compared in hearts retrieved with and without cardioplegia. Hearts were retrieved 
either following donor administration of cardioplegia or without cardioplegia and transplanted 
heterotopically into recipient animals. Recipient serum troponin at 24 hours post reperfusion was 
significantly reduced when cardioplegia was administered to the donor animal arresting cardiac 
contraction (Figure 47(a)). In addition to significantly reducing the mean tissue injury there was also a 
reduction in variability when cardioplegia was administered prior to retrieval (1.96 ± 0.13 (n=6) vs 6.90 ± 
1.17 (n=7), p = 0.0007) (Figure 47). The difference observed in IR injury with the presence or absence of 
cardiac contraction during retrieval was not observed when hearts were exposed to an additional 12-
minute period of warm ischaemia. There was no significant difference in IR injury between hearts exposed 
to an additional 12 minutes of warm ischaemia following the administration of cardioplegia or when 
retrieved after exsanguination and a 12-minute standoff time. There was however, a reduction in the 
variability in serum troponin following the administration of cardioplegia (8.6 ± 1.9 (n = 6) vs 16.8 ± 6.4 (n 
= 4), p = 0.18). These findings suggested that the administration of cardioplegia to the donor heart during 
retrieval reduced IR injury but also reduced the variability in IR injury when compared to hearts that 
continued to contract during the retrieval operation. Importantly, when hearts were retrieved after 
administration of cardioplegia and subjected to an additional period of warm ischaemia and were 
compared to hearts transplanted without additional warm ischaemia there was a significant increase in IR 
injury (1.0 ± 0.13 (n=6) vs 8.6 ± 1.9 (n=6) p = 0.003) (Figure 47(b)). In Section 5.1.2 I demonstrated that 
mouse hearts could be successfully transplanted following IR injury that resulted in a troponin rise at 24 
hours post reperfusion of up to 33 ng/ml (Figure 46(a)). This troponin rise was greater than that observed 
in any transplant performed when cardioplegia was administered to donor hearts. The greatest serum 
troponin rise observed in recipients of donor hearts retrieved after cardioplegia administration and 
exposed to 12 minutes of additional warm ischaemia was 17 ng/ml (Figure 47(b)). The duration of primary 
warm ischaemia in donor hearts retrieved after cardioplegia administration could theoretically be 
increased further without compromising successful transplantation. However, the use of 12 minutes of 
warm ischaemia enabled comparison with metabolomic data and was shown to significantly increase IR 
injury in this model. Therefore, extending primary warm ischaemia beyond 12 minutes was not explored.  
 







Figure 47: Effect of cardioplegia and 12 minutes of warm ischaemia on reperfusion injury in the 
heterotopic heart transplant. 
(a) Hearts (n = 6-7) were retrieved from anaesthetised donors following IVC administration with 
cardioplegia or retrieved after standard exsanguination and division of the IVC and aorta. Hearts were 
heterotopically transplanted after minimal additional cold ischaemia and recipient serum troponin 
measured at 24 hours. (b) Hearts (n = 6) were retrieved from anaesthetised donors immediately 
following IVC administration of cardioplegic solution. Hearts were either heterotopically transplanted 
with no additional warm ischaemia or stored for 12 minutes of warm ischaemia in the carcass of the 




In summary, I have established a reproducible mouse model of ischaemia reperfusion injury in heart 
transplantation with the ischaemic component comprising an additional 12 minutes of warm ischaemia. 
There was a reduction in the extent and variability of reperfusion injury observed in all hearts when 
cardioplegia was administered during the retrieval procedure. This model was then used to investigate 



















































5.2 Therapeutic efficacy of agents in ameliorating IR injury in organ 
transplantation 
The metabolomic data presented in chapter 3 demonstrated that succinate accumulates in the mouse 
heart during organ storage to a greater extent during warm ischaemia. In other models of IR injury, the 
accumulation of succinate during ischaemia was shown to be responsible for driving ROS production and 
organ dysfunction upon reperfusion. Succinate accumulation during ischaemia has also been shown to be 
attenuated with inhibitors of various steps in this pathway providing not only a testable hypothesis but 
also therapeutic potential in this setting.  
During organ transplantation, there are multiple opportunities during which therapeutic agents could 
potentially be administered to the donor organ or recipient. Chouchani et al demonstrated a 
cardioprotective effect of DMM in the in situ LAD occlusion model. In this model, DMM (4 mgKg-1min-1, 
total dose 3.2 mg) was administered as a continuous infusion 10 minutes prior to the onset of ischaemia 
and continued throughout the proceeding 30 minutes of ischaemia. In a solid organ transplant model, 
continuous infusion during the ischaemic phase is not feasible in a small animal model. An equivalent 
dose of DMM was therefore infused into the donor animal 10 minutes prior to retrieval.  
The efficacy of DMM in ameliorating reperfusion injury was examined following a donor DMM infusion for 
10 minutes (0.32 mgmin-1) immediately prior to ischaemia. Donor hearts were subjected to an additional 
12 minutes of warm ischaemia after retrieval. All hearts contracted spontaneously following reperfusion 
and were beating at 24 hours. Reperfusion injury, denoted by recipient serum troponin concentration at 
24 hours, was significantly decreased in hearts from donors that received the DMM infusion immediately 
prior to retrieval (Figure 48).  
 






Figure 48: DMM ameliorates IR injury in a mouse heart transplant model. 
Anaesthetised donors were either treated with an infusion of DMM (n =5) or saline control (n=6) 10 
minutes prior to retrieval. Donor hearts were retrieved following IVC administration of cardioplegia 
and exposed to either 12 minutes of warm ischaemia or no additional warm ischaemia. Donor hearts 
were then transplanted heterotopically in to recipient animals and compared to control transplants (n 
= 6). Control hearts were retrieved from donor animals after administration of cardioplegia and were 
not exposed to any additional warm ischaemia. Following retrieval hearts were heterotopically 
transplanted after minimal additional cold ischaemia and recipient serum troponin measured at 24 
hours. One-way ANOVA with Bonferroni’s multiple comparison testing. * p < 0.05, ** p < 0.01. 
 
In chapter 4, I demonstrated that the same total dose of DMM used in this experiment administered as a 
bolus with cardioplegia significantly reduced tissue succinate concentrations after 12 minutes of warm 
ischaemia. These findings were consistent with previous reports (53). In this model, DMM administered as 
an infusion during normoxia prior to the onset of ischaemia did not ameliorate succinate accumulation 


































Figure 49: The effect of DMM infusion on tissue malonate and succinate concentrations. 
Anaesthetised donor animals (n = 5 per group) received an infusion of DMM at increasing 
concentrations (total DMM infusion 0.8 mg, 1.6 mg or 3.2 mg) or a saline control for 10 minutes prior 
to retrieval. Hearts were retrieved following exsanguination and exposed to an additional 6 minutes 
warm ischaemia prior to clamp freezing and metabolomic analysis by LC-MS. One-way ANOVA with 
Bonferroni’s multiple comparison testing. **** p < 0.0001 
 
There was a discrepancy between the metabolic effect on succinate accumulation of DMM administered 
at subtly different stages of organ retrieval and the observed amelioration of IR injury with DMM. When 
DMM was administered as an infusion prior to retrieval there was a significant reduction in serum 
troponin. In contrast, when DMM was administered as a bolus with cardioplegic solution the significant 
reduction in serum troponin was no longer observed (Figure 50). The limited study period and resources 
precluded further examination of this disparity however, one explanation could be insufficient numbers 
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Figure 50: DMM administered as a bolus did not significantly ameliorate IR injury in a mouse heart 
transplant model. 
Anaesthetised donors were retrieved immediately after a receiving a bolus of DMM (3.2 mg) in 
cardioplegic solution (n = 3) or cardioplegia alone (n= 6). Hearts were exposed to either 12 minutes of 
warm ischaemia. Donor hearts were transplanted heterotopically in to recipient animals and 
compared to control transplants that were not exposed to any additional warm ischaemia (n = 6). 
Allograft dysfunction was assessed by recipient serum troponin measured at 24 hours. One-way 
ANOVA with Bonferroni’s multiple comparison testing. ** p < 0.01. 
 
5.2.1 Modifying succinate accumulation and exacerbating IR injury 
in the mouse heart during organ transplantation 
Chouchani et al. demonstrated exacerbation of IR injury following the administration of dimethyl 
succinate (DMS) (53). To investigate whether exogenous succinate could be delivered to myocardial tissue 
in this model I examined whether a bolus administration of DMS with cardioplegia would significantly 
elevate tissue concentrations of succinate. Tissue concentrations of DMS, succinate and fumarate were 
measured by LC-MS after 12 minutes of warm ischaemia.  
In contrast to DMM, there was a detectable DMS signal after 12 minutes of warm ischaemia suggesting 
hydrolysis of the precursor, DMS, to succinate was less rapid than DMM in vivo (Figure 51(a)). 
Furthermore, there was no significant increase in tissue succinate (p = 0.25) nor significant decrease in 
tissue fumarate (p = 0.07) following administration of DMS to donor hearts. This failure to demonstrate a 
metabolic effect with DMS translated into a failure of DMS to exacerbate injury; a DMS (0.64 mgmin-1) 
infusion administered over 10 minutes prior to retrieval failed to exacerbate IR injury when compared to a 

































Figure 51: DMS delivery following IV bolus with cardioplegia and the associated metabolomic effect. 
Donor animals (n = 4) received DMM (3.2 mg) or DMS (6.4 mg) as bolus injections in St Thomas’ 
cardioplegia via a central vein immediately prior to rapid excision and storage in warm ischaemic 
conditions (12 minutes). Relative metabolite abundance was compared to control hearts that were 
treated with cardioplegia alone and stored in warm ischaemic conditions for 12 minutes (n = 8). One-
way ANOVA with Bonferroni’s multiple comparison testing. ** p < 0.01. 
 
 
Figure 52: DMS, AMS (in 5% w/v DMSO) or 5% DMSO administered to donor hearts prior to ischaemia 
did not significantly exacerbate reperfusion injury in a mouse heart transplant model. 
Anaesthetised donors received an infusion of DMS (6.4 mg) (n = 5), acetoxymethyl succinate (AMS) in 
5% w/v DMSO (n = 3), 5% DMSO (n = 3), or a saline control (n = 6) 10 minutes prior to retrieval. 
Cardioplegia was administered immediately prior to retrieval. Donor hearts were transplanted 
heterotopically into recipient animals. Allograft dysfunction was assessed by recipient serum troponin 
measured at 24 hours. 
 
The presence of DMS in donor hearts after 12 minutes of ischaemia (Figure 51(a)), and the failure to 
exacerbate tissue injury could be explained by inadequate hydrolysis of the DMS in vivo in this model. To 
improve delivery of succinate to tissues alternative compounds were examined. Acetoxymethyl succinate 
is rapidly hydrolysed in vitro (176). It is poorly soluble in saline and 5% w/v DMSO was used to increase 
solubility. 5% w/v DMSO was not demonstrated to be detrimental when administered to donor hearts 















































































52). Unfortunately, due to limited availability of the compound I was unable to examine the effect of 
acetoxymethyl succinate on tissue succinate concentrations during ischaemia. It will be important to 
examine this in the future.  
 






In this chapter, a novel, vascularised, small animal model of IR injury in solid organ transplantation was 
developed. Previous metabolomic data identified warm ischaemia as the predominant driver of succinate 
accumulation in organ storage. To investigate the effect of succinate accumulation on reperfusion injury 
in organ transplantation it was necessary to develop a small animal model of solid organ transplantation 
in which the additional ischaemic injury was a period of warm ischaemia. This was in contrast to previous 
models that used prolonged cold ischaemia to introduce a severe ischaemic component. The addition of a 
period of warm ischaemia has clinical relevance in the UK where the use of DCD organs is increasing and 
recent evidence from registry data has identified increased primary warm ischaemia to be associated with 
worse graft outcomes(175). 
When primary warm ischaemia was introduced in this model by means of a standoff period similar to that 
used in DCD donors marked variability in the extent of IR injury was observed. To reduce the variability of 
the ischaemic injury, cardioplegia was administered to donor animals. With the introduction of 
cardioplegia the variability in the model was reduced. A reproducible ischaemic insult of 12 minutes of 
primary warm ischaemia translated into significant exacerbation of organ dysfunction as measured by 
recipient serum troponin at 24 hours post reperfusion when compared to organ dysfunction following 
transplantation without any additional warm ischaemia.  
Having developed a novel model of IR injury in organ transplantation, the therapeutic efficacy of 
metabolic inhibitors and compounds in modifying tissue succinate was examined. The relatively 
controlled onset of ischaemia and reperfusion in organ transplantation makes it appealing for the 
development of therapeutic interventions. In the model used in these experiments there are a number of 
potential opportunities to administer therapies. Chouchani et al demonstrated efficacy of DMM in a non-
recovery LAD occlusion mouse model. In this model DMM was administered as an infusion 10 minutes 
prior to the onset of ischaemia and then continued throughout the subsequent 30 minutes of 
ischaemia(53).  
When a similar approach was used to deliver DMM in the organ transplant model, an infusion of DMM 
prior to the onset of ischaemia significantly reduced reperfusion injury. Further studies confirmed 
adequate delivery of malonate to tissues was achieved with this DMM regime however, a significant 
reduction in succinate accumulation was not observed. When DMM was administered as a bolus with 
cardioplegia, adequate delivery of malonate was again observed. In contrast to DMM administration as an 
infusion, this also translated into a significant reduction in tissue succinate. This did not however, 
translate into a significant reduction in organ dysfunction on reperfusion as observed when DMM was 
administered as an infusion. These differences in the metabolic effects following subtly different 
techniques of DMM administration could be explained by the direction in which the CAC is operating at 
the time of DMM administration. The absence or presence of oxygen is a critical determinant of the 
direction of the CAC. During administration of DMM as an infusion the CAC will be operating in a forward 
 





direction and rapid oxidation of succinate may explain the failure of it to significantly change tissue 
concentrations of succinate. Malonate has been shown to be protective against reperfusion injury when 
administered both before or during hypoxia (53, 161). In the organ transplant model, DMM was shown to 
protect against reperfusion injury when administered as an infusion and whilst DMM administration was 
not shown to be protective when administered as a bolus with cardioplegia at the onset of ischaemia, the 
numbers in this group (n = 3) may have been insufficiently powered to demonstrated significance.  
To test the hypothesis that succinate accumulation drives reperfusion injury, I sought to examine the 
effect of increasing tissue succinate concentrations. DMS was administered as a bolus with cardioplegia. 
DMS remained detectable after 12 minutes of ischaemia and did not significantly increase tissue succinate 
concentrations. The detection of DMS but not DMM in mouse hearts after minutes of organ storage is 
consistent with a reduced rate of hydrolysis of DMS in vivo compared to DMM and could explain the 
failure of DMS to increase tissue succinate concentrations. Acetoxymethyl succinate (AMS) is more rapidly 
hydrolysed in vitro and has previously been shown to have therapeutic efficacy in modifying 
mitochondrial complex II function (176). There was a limited supply of AMS during the period of these 
studies preventing analysis of the metabolic effects during ischaemia in this model. The effect of 
administration of AMS to donor hearts on organ dysfunction following reperfusion was however 
examined. Both AMS and DMS failed to exacerbate organ dysfunction when administered to donors as an 
infusion during normoxia prior to the onset of ischaemia.  
In summary, this chapter has demonstrated therapeutic efficacy of DMM in ameliorating reperfusion 
injury during organ transplantation in a novel small animal model but there were inconsistencies between 
data relating to levels of injury and succinate accumulation across the models. The development of a 
reproducible model provides a foundation for future work to further examine the therapeutic efficacy of 
metabolic inhibitors and the mechanisms through which reperfusion injury is ameliorated. 
  
 





Chapter 6:  Examining the role of IR injury in a model of 
chronic rejection 
 





6.1 The role of ischaemia reperfusion injury in chronic allograft 
vasculopathy 
6.1.1 Introduction 
Despite improvements in short-term outcomes, most transplanted organs suffer an insidious decline in 
function. This process involves progressive allograft vasculopathy that leads to gradual fibrosis of graft 
parenchyma and eventual graft failure. This ‘chronic rejection’ or chronic graft dysfunction remains a 
major problem and is observed in a significant proportion of allografts within 5 years following 
transplantation. The aetiology of chronic rejection is likely multifactorial with contributions from, the 
alloimmune response, IR injury, toxicity from immunosuppressive agents, and recurrence of the 
underlying disease (116, 177).  
A better understanding of the role of IR injury and its contribution to chronic rejection is fundamental if 
therapies or protective strategies are to be developed to ameliorate this process. To investigate this 
further I examined whether increasing IR injury augments the alloimmune response, exacerbates allograft 
vasculopathy and reduces allograft survival in a model of chronic rejection that has been well 
characterised in our laboratory (131). 
 





6.2 Prolonged cold ischaemia and chronic rejection of the allograft 
The Bm12.Kd.IE strain was developed in house by Dr Jason Ali (Department of Surgery, Cambridge, UK) 
and kindly gifted for this work. The strain was created through two crosses. First, Bm12 mice were crossed 
with B6.Kd. Offspring expressing I-ABm12 and H-2Kd but not I-Ab were selected using PCR. These Bm12.Kd 
mice were then crossed with ABOIE animals (gifted by Prof C Benoist (Joslin Diabetes Center, Boston, 
MA)). Flow cytometry was used to confirm the presence of H-2Kd and I-E on peripheral blood 
mononuclear leukocytes. When Bm12.Kd.IE hearts were heterotopically transplanted into a C57BL/6J 
recipient they are chronically rejected with a median survival time of > 100 days. The mechanism of 
rejection has been well characterised and is the result of an alloimmune response directed against both 
MHC class I and II, and an autoimmune response (131). An additional mismatch can be achieved in this 
model by transplanting hearts from donors into a recipient of the opposite sex. This results in the indirect 
allorecognition of minor H-Y antigens. There is literature to suggest a gender difference in tolerance to 
ischaemia and therefore only female donor-recipient pairs were used in these experiments. Hearts from 
female Bm12.Kd.IE donors were transplanted heterotopically into female C57BL/6 recipients after either a 
standard (30 minutes) or a prolonged (240 minutes) period of cold static storage. The alloimmune 
response to the allograft was assessed by serum anti-H-2Kd alloantibody production and allograft survival 
assessed by weekly abdominal palpation. Histological assessment of chronic allograft vasculopathy (CAV) 
was performed at 100 days by quantifying the mean luminal stenosis of intra-myocardial vessels in the 
donor heart (Figure 53).  
 
 






Figure 53 (a – c): Chronic rejection of the bm12.Kd.IE cardiac allograft following transplantation into a 
C57BL/6 recipient after standard or prolonged cold static storage. 
Female Bm12.Kd.IE donor hearts were flushed with 0.5 mL Soltran and then subjected to 30 minutes of 
cold static storage (n = 6) or 240 minutes (n = 6) of cold static storage before being transplanted into 
female C57BL/6 recipients; (a) Rejection kinetics of transplanted allografts was assessed by weekly 
abdominal palpation (n = 6 per group), p = 0.32 by Log-rank (Mantel-Cox) test. (b) Recipient anti-H-2Kd 
alloantibody production in weekly serum samples assessed by ELISA (n = 6 per group), p = 0.98 by two-
way ANOVA. (c) Allograft vasculopathy as assessed on elastin van Gieson stained paraffin sections (n = 
2-3*) p = 0.53 by unpaired t-test. *Some allografts were lost during processing.  
 
Consistent with previous reports, an alloimmune response with evidence of chronic allograft vasculopathy 
and graft loss was demonstrated in this model. There was, however, no difference in the allograft survival, 
CAV or the recipient alloimmune response against donor hearts that were exposed to prolonged cold 
storage when compared to hearts transplanted using a standard technique. The vasculopathy observed in 
this model has been shown to be the result of both an alloimmune and autoimmune response. 
Assessment of the autoantibody production was not performed due to a lack of available serum. 
It is noteworthy that the alloimmune response and allograft vasculopathy observed in both groups was 
lower than that previously reported by Ali et al (131). This global reduction in the immune response and 
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observed. This difference in chronic rejection could be explained by both the flushing of the donor heart 
and the use of female donor allografts. Flushing of the donor allograft more closely replicates practice in 
clinical transplantation and also provides a unique opportunity to administer therapeutic agents to 
isolated organs during transplantation. However, donor CD4 T cells are responsible for the generation of 
both the alloimmune and autoimmune response in this model and flushing of the donor allograft has 
been shown to remove a modest proportion of donor leucocytes (Dr J Ali, personal communication). By 
removing the CD4 T cells, flushing of the allograft could result in the abrogation of the alloimmune 
response and CAV. Another potential mechanism for the reduction in the rate of chronic rejection is the 
absence of indirect allorecognition of minor H-Y antigen due to the transplantation of female rather than 
male allografts into female recipients. There is literature to suggest that there is a gender difference in 
tolerance to IR injury and in these studies female donors and recipients were used throughout to remove 
this potential confounder (178, 179). The absence of minor H-Y antigen could however, also explain the 
amelioration of allograft vasculopathy observed in these data. 
Modifying the period of cold storage has previously been shown to be a reproducible method of 
introducing a modifiable ischaemic injury to hearts during murine heterotopic heart transplantation. Dare 
et al demonstrated that a prolonged period of cold ischaemia increased mitochondrial dysfunction and IR 
injury in a syngeneic model and that this translated into measurable differences in outcome markers of 
myocardial tissue damage at 3 and 24 hours post reperfusion (138). The same model of ischaemic injury 
was used in this experiment but the difference in ischaemic injury did not translate to an increase in 
chronic rejection. When compared to the heterotopic heart transplantation technique described by Corrie 
et al, the operation used in this experiment requires additional steps to ligate branches of the aorta to 
enable allograft flushing. These result in the heart being exposed to an additional period (approximately 
50% of the operative time) of moderate warm ischaemia. Hearts were topically cooled, intermittently 
during this period however their core temperature cycled between 10°C and approximately ambient 
room temperature (Figure 6). The accumulation of succinate in mouse hearts was shown in chapter 3 
(Figure 25 and Figure 26) to have a linear relationship with temperature and to plateau at a threshold 
concentration. In the mouse heart this peak succinate accumulation occurs after approximately 12 
minutes of (37 degree) warm ischaemia (Figure 19). One explanation for the failure of additional, 
prolonged cold ischaemia to impact organ dysfunction and as a result chronic rejection is that even in the 
standard transplant, succinate accumulation was significantly elevated and the relative difference 
introduced by the additional period of warm ischaemia was insufficient to translate into a difference in 
chronic rejection. 
In order to reduce the initial inherent injury to the heart and examine whether flushing was responsible 
for a reduction in chronic allograft rejection I examined the effect of prolonged cold ischaemia on chronic 
rejection in a heterotopic heart transplant without flushing of the donor heart. 
 





6.3 Flushing of the donor heart and chronic rejection of the 
allograft 
Mouse hearts were transplanted heterotopically after retrieval without flushing. The alloimmune 
response, CAV and allograft rejection of standard transplants exposed to minimal cold ischaemia was 
compared to that of allografts exposed to prolonged cold ischaemia (240 mins). Assessment of the 
autoantibody production was again not performed in this experiment due to a lack of available serum. 
 
Figure 54 (a - c): Chronic rejection of the bm12.Kd.IE cardiac allograft prepared without flushing of the 
allograft during retrieval and transplanted into a C57BL/6 recipient after standard or prolonged cold 
static storage. 
Female Bm12.Kd.IE donor hearts were retrieved without flushing of the allograft and subjected to 30 
minutes (n = 5) of cold static storage or 240 minutes (n = 6) of cold static storage before 
transplantation into female C57BL/6 recipients. (a) Rejection kinetics of transplanted allografts was 
assessed by weekly abdominal palpation, p > 0.99 by Log-rank (Mantel-Cox) test. (b) Recipient anti-H-
2Kd alloantibody production in weekly serum samples assessed by ELISA, p = 0.75 by two-way ANOVA. 
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There was again no significant difference in any measures of chronic rejection when hearts were retrieved 
without flushing and stored for standard or prolonged periods of cold static storage. Furthermore, 
allograft vasculopathy was similar to that reported when hearts were flushed and lower than that 
observed in historical analyses. These findings do not support the hypothesis that flushing of the heart 
during the retrieval process significantly abrogates the alloimmune response to the allograft. In addition, 
although there was a reduction in allograft vasculopathy compared to historical controls these 
experiments did not examine the cause for this nor the role of indirect allorecognition of minor H-Y 
antigen in amplifying the alloimmune and autoimmune response in this model.  
Interestingly, reduction in the ischaemic injury inherent to the retrieval operation again failed to translate 
into differences in acute or chronic allograft survival previously observed using additional periods of cold 
ischaemia. No allografts were rejected in this experiment and the lack of overt rejection limits the 
potential for any treatment condition to have a significant effect on outcome markers.  
 





6.4 Warm ischaemia and chronic rejection of the allograft 
During the course of these experiments, the metabolic profile of succinate accumulation during warm and 
cold ischaemia was better characterised. The difference in the profile of succinate accumulation during 
warm and cold ischaemia together with the potential for manipulation of succinate accumulation by small 
molecule inhibitors of SDH supported the development of a model of chronic rejection that introduced an 
additional warm ischaemic insult during retrieval of the donor heart rather than using prolonged cold 
static storage. Such a model also has clinical relevance to DCD donors which form a significant proportion 
of donors used in UK clinical transplantation. 
Donor animals were exsanguinated and then left for a standoff period of 6 minutes before proceeding to 
retrieval. Allografts were not flushed during the retrieval operation and were heterotopically transplanted 
into the abdomen of the recipient animal.  
 
Figure 55 (a – d): Chronic rejection of the bm12.Kd.IE cardiac allograft prepared without flushing of the 
allograft during retrieval and transplanted into a C57BL/6 recipient following a standard retrieval or 
with an additional 6 minutes of warm ischaemia. 
Female Bm12.Kd.IE donor animals were exsanguinated and the hearts left in the carcass of donor 
animal for 6 minutes (donor animal maintained at 37 degrees with a heat mat) and then retrieved 
without flushing of the allograft (n = 7). Control donor hearts underwent standard retrieval (n = 6). (a) 
Rejection kinetics of transplanted allografts was assessed by weekly abdominal palpation, p = 0.08 by 
Log-rank (Mantel-Cox) test. (b) Recipient anti-H-2Kd alloantibody production in weekly serum samples 
assessed by ELISA, p = 0.21 by two-way ANOVA. (c) Allograft vasculopathy as assessed on elastin van 
Gieson stained paraffin sections, p = 0.11 by unpaired t-test. (d) Recipient autoantibody production at 
early (5 weeks) and late (15 weeks) time points assessed by HEp-2 indirect immunofluorescence, p = 




































































































The introduction of an additional period of warm ischaemia to the transplant procedure did not 
significantly impact the recipient alloimmune response, autoantibody production or chronic rejection of 
the allograft when compared to the standard heart transplant (Figure 55). Allograft vasculopathy was 
again abrogated when compared to historical data however, a non-significantly increased rate of clinical 
rejection was observed in the warm ischaemic group. This again supports a possible role of the indirect 
allorecognition of minor H-Y antigen in mediating allograft rejection in this model. The alloimmune 
response appears to be stronger in both the control and treatment groups when compared to other 
experiments (Figure 53 and Figure 54) but this did not translate to a difference in CAV. An alternative 
explanation for the observed difference in the alloimmune response could be experimental variation in 
the standard pooled hyperimmune sera. Alloantibody was calculated as a relative change compared to a 
standard pooled hyperimmune sera and variation in the concentration or affinity of this could impact the 
relative observed change in serum alloantibody. Recipient production of autoantibody was assessed at 
late and early time points by HEp-2 indirect immunofluorescence. This confirmed the generation of 
autoantibody against the allografts in recipients at both early and late time points. There was no 
difference in the levels of autoantibody between groups at either early or late time points.  
 





6.5 Increased IR injury and its impact on chronic rejection 
Further characterisation of the metabolic profile of murine heart tissue and in particular succinate during 
warm and cold ischaemia highlighted the rapidity and sensitivity to temperature of these pathways. To 
translate this to the mouse heart transplant model it was clear that further refinement of the retrieval 
process would be required to reduce variability in the ischaemic insult.  
To minimise variability and enable therapies to be administered to the allograft at the time of retrieval, 
cardioplegia was administered to the recipient to prevent continued contraction during the retrieval 
operation and the warm ischaemic period. Following administration of cardioplegia it was necessary to 
immediately proceed to retrieval rather than leave the animal for a stand-off period. Whilst this does not 
directly replicate the clinical scenario, a stand-off period risked passive diffusion of cardioplegia from the 
heart, aided by changes in intrathoracic pressure, that would result in a spontaneous restoration of 
cardiac contraction. It was therefore necessary to immediately perform the retrieval operation and then 
introduce an additional warm ischaemic period to the treatment group. In previous experiments, flushing 
of the donor heart was not demonstrated to have a significant impact on chronic rejection and therefore 
allografts were flushed with a view to future administration of mitochondria-targeted therapies. 
  
 







Figure 56 (a - d): Chronic rejection of the bm12.Kd.IE cardiac allograft following either no additional 
warm ischaemia or 12 minutes warm ischaemia prior to transplantation into a C57BL/6 recipient. 
Female Bm12.Kd.IE donor hearts were retrieved after systemic administration of St Thomas’ 
cardioplegia to the donor and flushed with 0.5 mL Soltran. Donor hearts were then exposed to an 
additional 12 minutes warm ischaemia or no additional warm ischaemia and transplanted using the 
standard technique. (a) Rejection kinetics of transplanted allografts was assessed by weekly abdominal 
palpation, p = 0.32 Log-rank (Mantel-Cox) (b) Recipient anti-H-2Kd alloantibody production in weekly 
serum samples assessed by ELISA, p = 0.64 by two-way ANOVA. (c) Allograft vasculopathy as assessed 
on elastin van Gieson stained paraffin sections p = 0.08 by unpaired t-test. (d) Recipient autoantibody 
production in serum samples at intervals following transplant assessed by HEp-2 indirect 
immunofluorescence, p = 0.97 by two-way ANOVA. 
 
Chronic rejection of the allografts was observed in both groups. This occurred in the presence of a 
demonstrable recipient alloimmune and autoimmune antibody production, and chronic allograft 
vasculopathy. There was no significant difference in the rejection of allografts exposed to an additional 
period of warm ischaemia when compared to a standard transplant (Figure 56). The relative alloantibody 
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In this chapter, the impact of a defined period of additional ischaemic injury on the chronic rejection of a 
vascularised allograft was examined. The impact of additional warm ischaemia and prolonged cold 
ischaemia were both examined in these experiments. No significant difference in chronic rejection was 
observed between the standard and severe ischaemia groups as assessed by; alloantibody, autoantibody 
allograft vasculopathy or rate of chronic rejection of the allografts. The work presented in this chapter 
therefore does not demonstrate that IR injury exacerbates chronic graft dysfunction. 
These data have demonstrated some of the challenges of working with this model of chronic rejection. I 
have been able to demonstrate evidence of chronic allograft rejection in the Bm12.Kd.IE to C57BL/6J 
heterotopic heart transplant model and demonstrated that production of both alloantibody and 
autoantobody but it was not possible to introduce a reproducible, modifiable difference in the rate of this 
chronic rejection. 
A recipient alloimmune response against class I alloantigen and an autoimmune response were both 
demonstrated in these studies with the corresponding development of CAV and rejection. The absence of 
indirect allorecognition of minor H-Y antigen due to the use of female donors and recipients may have 
had an impact on the observed vasculopathy and chronic rejection. Chronic allograft vasculopathy and 
rejection was abrogated when compared to historical analyses, but these observations were not 
definitively investigated and could be explained by other factors such as genetic drift in strains. In these 
data, flushing of the allografts did not have any significant impact on chronic rejection. 
Chronic rejection remains a major clinical problem and improvements in rates and the treatment of acute 
allograft rejection have not been replicated in longer-term allograft survival. The alloimmune and 
autoimmune response appear integral to the process of chronic rejection and an immune-mediated 
response is necessary for hearts to be chronically rejected in the murine heterotopic heart transplant 
model (131). IR injury itself is a short-lived phenomenon but these early events in the transplant process 
are frequently hypothesised to set in motion a series of events either through increased tissue damage 
and the generation of a heightened inflammatory milieu, or through direct immunomodulatory effects on 
specific immune components associated with the alloimmune or autoimmune response. A role for IR 
injury negatively impacting longer-term outcome in solid organ transplantation is supported by clinical 
data from registries and case series (79-81, 86). Nevertheless, the underlying pathophysiology that links IR 
injury to late outcomes and chronic rejection is very poorly understood and lacks definitive experimental 
evidence to support these observed associations. How best to answer these questions however, remains 
to be seen. 
To definitively investigate these mechanisms robust models are required. The multifactorial aetiology of 
chronic rejection makes the development of such animal models very challenging. The model used in 
these experiments was designed to overcome some of the recognised problems of other models by 
 





creating a more clinically relevant immune mediated chronic rejection. The immune response in this 
model has been well characterised but inherent shortfalls remain. It is important to remember that there 
are significant differences between the development, activation, and response to challenge of the murine 
and human immune systems. Whilst the immune response is likely integral to the process of chronic 
rejection there are other aetiologies that have also been implicated and these are not examined by this 
model.  
One problem observed in these experiments was the difficulty in generating a reproducible, measurable, 
significant difference in the ischaemic insults between the control (standard transplant) and treatment 
(severe ischaemia) groups. There is inherent, operator variability associated with technically demanding 
procedures such as heterotopic heart transplantation and this is associated with a long learning curve 
(approximately 300 transplants). Minimising background IR injury and the variability associated with the 
procedure itself is essential if additional warm or cold ischaemic insults are to impact outcome. 
Refinements of the technique such as the introduction of cardioplegia had a significant effect in reducing 
the variability and minimising background ischaemic injury (Figure 48). Other measures to objectively 
assess the IR injury such as recipient serum troponin 24 hours after transplantation could enable better 
correlation between IR injury and long-term outcome. In addition, whilst allograft rejection remains the 
clinically relevant outcome measure, a biochemical measure of rejection and allograft failure such as brain 
natriuretic peptide (BNP) might provide a more sensitive tool for allograft assessment however, this has 
not been characterised in this model.  
An alternative, more targeted approach to examining the role of IR injury in chronic rejection could build 
on evidence that donor CD4 T cells augment both the alloimmune and autoimmune response. This 
provides a potential mechanism through which IR injury could upregulate immune mediated chronic 
rejection. One approach would involve a model of chronic rejection in which CD4 T cell deplete allografts 
were transplanted into recipients who were reconstituted on the day of transplantation with donor CD4 T 
cells. These donor CD4 T cells could be exposed in vitro to variable periods of ischaemia. Exposing cells in 
vitro to true anoxia is notoriously difficult however and may limit this approach. Moreover, an 
understanding of how ischaemia upregulates donor CD4 T cell antigen recognition or activation and a 
mechanism to demonstrate cell viability following exposure to ischaemia would be required to interpret 
any results. Future research into chronic rejection  
Basic scientific research into chronic solid organ rejection remains paramount. Nevertheless, this work has 
highlighted some of the potential difficulties in studying the role of IR injury in chronic rejection. In the 
first instance developing a robust, reproducible model that can be used to explore the mechanisms 
underpinning chronic rejection remains the principal problem preventing progress in this area. The 
models that have formed the mainstay of in vivo transplant immunological research in the past have not 
routinely employed immunosuppression. This is contrary to clinical practice and it is important to 
recognise this limitation if findings from these studies are to be extrapolated into clinical transplantation. 
 





An alternative approach would be to use a fully mismatched model (eg. Balb/c to C57BL/6J) with recipient 
animals receiving immunosuppression. The chronic rejection associated with these models will still be 
inherently variable and therefore, increased numbers in each group may be required to demonstrated 
sufficient power within groups. Furthermore, this approach does not address the inherent  significant 
differences between murine and human immune system development, activation and response challenge 
with antigen (180). 
Basic research into the pathophysiology and mechanism through which IR injury exacerbates chronic 
rejection may conversely be better directed towards ameliorating acute graft dysfunction rather than 
focusing directly on chronic rejection. It would seem counterintuitive that any IR injury therapy would fail 
to demonstrate efficacy in ameliorating acute graft dysfunction yet improve long-term outcomes. 
Therefore, actively pursuing the translation of agents with therapeutic efficacy in ameliorating IR injury 
and acute graft dysfunction to well-designed clinical trials that enable the concurrent examination of 
short and long-term outcomes might be a more rewarding longer-term approach in answering the 
question of whether IR injury exacerbates chronic rejection in human solid organ transplantation. This 
approach would avoid potential problems associated with extrapolating findings from small animal 
chronic rejection models to clinical practice however, it is only relevant to IR injury where the 
pathophysiology is a short-lived phenomenon. Ongoing research into the allo- and autoimmune response 
would likely complement and provide avenues for further research in the future and remains 















7.1 General discussion 
Mitigating the effects of the inevitable period of organ ischaemia is fundamental to the success of solid 
organ transplantation. Over the past seven decades, a number of approaches have been explored in order 
to better preserve organs during storage. Cold storage has been central to this for much of the history of 
organ transplantation but organs are inevitably exposed to variable periods of both warm and cold 
ischaemia during organ retrieval. Whilst some of the metabolic changes during organ storage have been 
explored in a range of species, significant gaps in our understanding remain. 
7.1.1 Metabolic profile of ischaemia  
In this work, models were designed to mimic transplantation and used to assess the metabolic changes in 
mice, pig and human hearts. To investigate these metabolic changes, it was important to have a reliable 
baseline, normoxic control value to which metabolic changes could be compared. Following the onset of 
hypoxia, the switch to ischaemic metabolism is rapid in mammalian metabolism, occurring within a few 
seconds. Rapid organ retrieval and freezing of tissue specimens were therefore paramount and initial 
results demonstrated an increased variability during the retrieval process due to operator factors. This 
variability was reduced following multiple, incremental, refinements in the retrieval technique. These 
included; changes to the induction of anaesthesia, the introduction of intra-operative rectal temperature 
monitoring, the use of cardioplegia, and changes to aspects of the operation to improve economy of 
movement and reduce operative times without impacting outcome. In addition, variability in the 
processing of specimens was further reduced with the use of more efficient tissue homogenising 
techniques.   
For efficient translation of clinical therapies, it is essential to ensure metabolic pathways are conserved 
across species from the experimental model to the patient at the outset. The difficulties in replicating 
metabolism and hypoxia both in vitro and ex vivo means research is, at present, reliant on in vivo models. 
Mouse models are well established in basic science research, have formed the backbone of transplant 
immunology research, and provided a versatile model to initially investigate the hypotheses in this work. 
The rate of organ cooling and therefore the kinetics of warm and cold ischaemia is however, critically 
affected by the size of organs. Corroborating findings from the small animal model in organs that were a 
similar size to human organs provided a foundation for the development of the pig model. This 
methodological approach, designed to enable concurrent investigation of hypotheses across both small 
and large animal models simultaneously, is different from the more traditional stepwise approach of drug 
development and has the potential to identify problems in the translation of therapies earlier and to 
stream line the process. 
There are a number of factors that must be taken into consideration when drawing conclusions from this 
data. The models used to understand ischaemic metabolism in organs storage did not directly reflect the 
clinical scenario of organ transplantation.  The complexity of clinical organ transplantation introduces 







simplify the process and examine warm and cold ischaemia in isolation. This approach was carried 
through to the pig and human models. To enable direct comparison of metabolomic analyses of the 
mouse, pig and human data I looked to replicate the model as far as technically feasible. Due to the size 
and cost of large animal models, it was not possible to use multiple hearts for each time point. To resolve 
this issue, the initial apical section served as a control for all remaining time points. However, any 
variability in the sampling of the baseline control specimen had the potential to influence all remaining 
time points to a greater extent than in the mouse experiments where the normoxic control was calculated 
from the mean of replicates. Further differences between the small and large animal models were the 
result of differences in the available animal facilities. The pig experiments were performed on a separate 
site under a different animal license and this study plan precluded entering the thorax or mediastinum of 
the animal prior to death. In addition, the pigs were anaesthetised with a different anaesthetic regime to 
the mouse. The human model used a similar approach to the pig model with each heart providing 
multiple time points due to the reasons discussed above. In contrast to the pig model however, the 
human organ donation routinely permitted access to the thorax and thus to the heart at the time of 
retrieval. Finally, in contrast to the human donors, the animals in the mouse and pig model were not 
exposed to brainstem injury. Brain death results in a large catecholamine release and changes in the 
donor’s haemodynamic status. This has the potential to affect the procured organs and human donors 
receive a variety of medications to manage this and optimise the haemodynamic status of the donor prior 
to organ procurement. Other groups have used models that introduce significant brain injury, but these 
were not available in our facilities. In general, despite the variation in the techniques and the potential 
confounders described above the metabolomic data demonstrated a conserved process across the 
species examined.  
Energy stores in these models were shown to be better preserved by cold ischaemia when compared to 
warm ischaemia. The principal means of sustaining energy stores in the absence of oxidative 
phosphorylation is through glycolysis. Interestingly, there were differences in the apparent rate limiting 
components of glycolysis in warm and cold ischaemia. During cold ischaemia exhaustion of glycogen 
stores limited glycolysis however, during warm ischaemia the elevated NADH/NAD+ ratio was the limiting 
factor (Chapter 3). A comparative metabolomic approach was then used to examine metabolic changes in 
this heart tissue during warm and cold ischaemia (Chapter 3). Succinate accumulation during ischaemia 
has been shown to be integral to reperfusion injury and mitochondrial dysfunction (53). In this analysis, 
the accumulation of succinate during organ storage was also present. Furthermore, it was shown to be 
conserved across species and was more rapid during warm compared to cold ischaemia. The 
accumulation of succinate has been hypothesised to be due to reversal of SDH(54). Whilst succinate 
accumulation was a conserved finding in this analysis it was interesting to observe that tissue 
concentrations of the other CAC intermediates fumarate and malate demonstrated disparate changes 
during ischaemia between the mouse, and the pig and human data. Fumarate and malate demonstrated 







hearts, Wistar rat hearts in an isolated ex vivo organ perfusion model have also been reported to 
demonstrate metabolic changes during ischaemia that were similar to the profiles from pig and human 
tissue in these analyses (162). The selective accumulation of succinate over other CAC metabolites during 
ischaemia may be a consequence of multiple metabolic reactions converging on succinate which, in 
contrast to other CAC metabolites, cannot be metabolised further. The disparities in the accumulation of 
fumarate and malate during ischaemia between species is difficult to interpret and may be a consequence 
of these multiple converging pathways. Nevertheless, the conserved nature of succinate accumulation 
across species remains reassuring for the translation of future therapeutic interventions targeting 
succinate accumulation and reperfusion injury.  
The protective effects of cold organ storage are generally attributed to a reduction in global metabolic 
rate. In this analysis, a linear relationship with temperature was observed in the accumulation of a range 
of metabolites in the mouse heart, including succinate, supporting this theory. Accumulation of succinate 
was however, observed to be a rapid phenomenon with significant increases in succinate relative to 
baseline tissue concentrations still occurring after 12 minutes of organ storage at 16°C. In comparison to 
the mouse heart, human organs cool more slowly even with the use of cold perfusion techniques (181). 
These findings therefore suggest; the accumulation of succinate is likely to feature in both DBD and DCD 
transplantation, the reliance on cold storage to abrogate succinate accumulation is unlikely to be 
effective, and there is therapeutic potential for additional clinical therapies that target this process. 
The comparative metabolomic approach was then used to explore the source of succinate accumulation 
in this model. Metabolic inhibitors were administered in a bolus of cardioplegia prior to organ retrieval 
and 12 minutes of warm ischaemic storage. This technique delivered the inhibitor to tissues at the onset 
of ischaemia in an organ that, until this time, had been perfused in normoxic conditions in vivo. This is in 
contrast to other ex vivo organ perfusion models that frequently require a stabilisation period. The 
perfusate used during a period of stabilisation can itself result in changes to the metabolism of these 
organs and this can potentially affect subsequent ischaemic metabolism (34, 36, 174). Adequate 
intracellular and mitochondrial delivery of metabolic inhibitors using intravenous administration with 
cardioplegia was a concern however, LC/MS analysis enabled simultaneous assessment of both metabolic 
intermediates and tissue concentrations of metabolic inhibitors (AOA, DMM, HAD and TTFA). 
Furthermore, in the case of DMM where hydrolysis of the precursor to malonate was required the 
kinetics of this reaction could also be assessed. Amelioration of succinate accumulation was observed 
with inhibitors of both SDH and transamination. The corresponding changes in other CAC intermediates 
were more variable and further experiments would be required to elucidate the underlying 
pathophysiology. The non-specific inhibition of transaminases by AOA not only prevents transamination 
of aspartate to oxaloacetate but also the transamination of pyruvate to alanine. There is evidence 
that some marine animals (eg Mytilus edulis) undergo periods of facultative anaerobic respiration and 
generate energy through the transamination of pyruvate to alanine and that this process is coupled 







preliminary data, AOA administration demonstrated an increase in aspartate, a reduction in alanine and a 
reduction of succinate tissue accumulation that was consistent with actions on both pathways. These 
preliminary data require future work to examine the role of these pathways in the accumulation of 
succinate during warm and cold ischaemia and IR injury. Previous data has suggested the PNC may 
contribute to succinate accumulation during ischaemia (53). In these data administration of the PNC 
inhibitor, ADSS, failed to result in any changes to tissue metabolite concentrations including succinate 
accumulation. Hadacidin was detected in tissue after 12 minutes of warm ischaemia supporting adequate 
delivery however, the failure to change tissue metabolite concentrations does not confirm the absence of 
flux through this pathway. These data do not definitively identify the source of succinate however, they 
demonstrate this model to be effective in delivering inhibitors and manipulating metabolism during organ 
storage. Further experiments with compounds to increase tissue concentrations of metabolites would 
provide a greater understanding of some of these pathways. In addition, understanding the changes in 
both mitochondrial and cytoplasmic metabolite concentrations would also aid the elucidation of 
pathways in the future.  
7.1.2 Examining IR injury in vivo in organ transplantation 
The identification of rapid succinate accumulation in donor organs during warm ischaemia and the 
adequate delivery of metabolic inhibitors at the time of organ harvest provided the background for the 
development of a novel small animal model of solid organ transplantation to investigate the effect of 
reperfusion injury in organ transplantation.  The heterotopic heart transplant model has previously been 
invaluable in exploring a range of different questions within the context of solid organ transplantation and 
transplant immunology. A well validated small animal transplant reperfusion model with robust markers 
of acute organ dysfunction would expand the potential applications considerably into the field of 
transplant IR injury and explore areas that have not been investigated in the current models. In this work, 
troponin was used a surrogate of organ dysfunction. Although a specific marker of myocardial injury it 
provides limited information on the upstream pathophysiology or organ function. This could in the future 
be addressed through the use of assays examining the actual burst of mtROS, or downstream sequelae of 
the ROS production that support the role of mitochondrial dysfunction in IR injury such as; isoprostanes, 
protein carbonyl formation, or mtDNA damage. Furthermore, pressure-volume loops could also be used 
to characterise the effect of reperfusion injury on cardiac function.  
In Chapter 5 a transplant model was developed with a reproducible warm ischaemic insult and the 
therapeutic efficacy of DMM in ameliorating reperfusion injury was examined. When DMM was 
administered to the donor as an infusion immediately prior to hypoxia, DMM ameliorated reperfusion 
injury. Interestingly, when DMM was administered with cardioplegia, at the onset of hypoxia, there was 
only a non-significant trend towards a reduction in reperfusion injury. Furthermore, the different 
methods of administering DMM had differing effects on succinate accumulation on donor hearts during 
ischaemia with an infusion of DMM having no effect on succinate accumulation and bolus administration 







to insufficiently powered experiments. An alternative explanation is the differing effect of exogenous 
malonate on the CAC in the presence and absence of oxygen. When malonate was administered as an 
infusion in the presence of oxygen the CAC would have been cycling in the standard direction and might 
not affect tissue succinate concentrations until the heart was retrieved. When DMM was administered as 
a bolus at the onset of hypoxia malonate would have been delivered to the CAC cycling in reverse, 
potentially inhibiting succinate accumulation.  
Malonate is hypothesised to inhibit the pathological oxidation of succinate to fumarate upon reperfusion 
(53). Despite the differing effects of malonate administration described above, a reduction in reperfusion 
injury could theoretically be achieved either, by reducing the initial succinate concentration, or by 
sufficiently elevating tissue malonate concentrations relative to tissue succinate concentrations at the 
time of reperfusion. This interpretation provides an explanation for the apparently contrasting data 
described above and is supported by data demonstrating the efficacy of malonate in reducing reperfusion 
injury when administered at the time of reperfusion (161). 
7.1.3 Examining IR injury and chronic organ rejection  
In Chapter 6, the novel model of reperfusion injury in organ transplantation developed in Chapter 5 was 
used to examine whether reperfusion injury would translate to measurable differences in the rate of 
allograft rejection in a well-established model of chronic allograft vasculopathy. No difference was 
observed in the immune response or the long-term outcome of allografts when donor hearts were 
exposed to additional ischaemic insults. Chronic rejection remains a major problem in organ 
transplantation and there is clinical data supporting a detrimental effect of reperfusion injury on long 
term outcome (80, 81, 86). A better understanding of the pathophysiological process would enable 
development of specific therapies however, the multifactorial nature of chronic rejection makes research 
challenging. Reproducible small animal models are yet to be developed for this precise purpose and their 
translational potential given the known limitations of some of these models should be taken into 
consideration (180). The Bm12KdIE to BL/6 model of chronic rejection has been well validated and 
provided an opportunity to examine the key pathways in chronic rejection; the direct alloimmune 
response, the indirect alloimmune response, and the autoimmune response. Nevertheless, the approach 
was reliant on creating a modifiable reproducible IR injury. The steep learning curve associated with the 
technique, the incremental refinements that had to be made, and the long duration of follow up were all 
potential confounders and could explain the failure of these data to demonstrate the exacerbation of 
chronic rejection reported in clinical data.  
An alternative approach to the translation of basic research to clinical practice in the management of 
chronic rejection in organ transplantation focusing on the longer-term outcomes of trials whose primary 
outcomes were designed to examine the efficacy of treatments ameliorating reperfusion injury and acute 







The metabolic changes during organ storage have been demonstrated in this work to be amenable to 
therapeutic intervention and have the potential to ameliorate ischaemia reperfusion. This approach, using 
a model that is directly relevant and translatable to the clinical environment has provided a wealth of 
data that could provide the foundation of future work. Reperfusion injury is inherent to organ 
transplantation and a better understanding of the pathophysiological processes will enable the develop of 
future therapies and potentially improve both short and long-term transplant outcomes.  
In summary, this thesis examined the mechanism of IR injury in organ transplantation and the relationship 
between IR injury and early and late organ dysfunction. This work has examined the metabolic profile of 
myocardial tissue during warm and cold organ storage in mice, pigs, and humans and demonstrated that 
succinate accumulation was a conserved process during ischaemia across species. Moreover, this work 
has demonstrated the potential to moderate this process during organ storage. To investigate whether 
the amelioration of succinate accumulation during organ storage would translate to a reduction in 
reperfusion injury, a small animal model of IR injury in organ transplantation was developed. The efficacy 
of DMM, a small molecule inhibitor of SDH, in ameliorating reperfusion injury following organ 
transplantation was then confirmed. Finally, the effect of IR injury on chronic rejection was examined in a 
well characterised model of chronic rejection. In this model, an increase in IR injury failed to translate into 








7.2 Future directions 
Mitochondrial research has rapidly expanded over the course of the last two decades. This has 
transformed our understanding of their role within the cell from simple, powerhouses to their now well 
recognised role in an ever-increasing number of central, cellular functions and disease processes including 
IR injury. Until recently it had been assumed that the mechanisms underlying IR were imprecise with 
multiple sources resulting in non-specific cellular and organ dysregulation (54). The identification of a 
specific, common pathway has provided an opportunity to better understand the process and develop 
potential therapies. I would propose that future work should focus on two key areas; the pathophysiology 
of succinate accumulation during ischaemia, and the development of therapies to ameliorate reperfusion 
injury in organ transplantation.  
The source of the succinate that has been shown in this work to accumulate during ischaemia is yet to be 
conclusively described. In these data there was disparity in the changes in the CAC metabolites, fumarate 
and malate, in mice and other species during ischaemia despite a conserved accumulation of succinate. It 
will be important to investigate this further and in the first instance, the ischaemic metabolic changes in 
rat hearts and other wildtype mouse strains could be examined in vivo to enable a direct comparison. The 
preliminary data presented in this work examining the potential source of succinate demonstrated the 
efficacy of the technique and adequate delivery of metabolic inhibitors. This technique examined 
ischaemia in a model that directly reflected normal ischaemic metabolism. This may be more readily 
translatable to the clinical scenario than other ex vivo perfusion models. Further work is required to 
explore why some metabolic inhibitors failed to have an effect on metabolism and whether this reflects a 
lack of uptake in the ischaemic environment following bolus injection or is due to a lack of flux through 
pathways during ischaemia. Previous work demonstrated an exacerbation of reperfusion injury by 
elevating tissue succinate concentrations (54). DMS was not hydrolysed sufficiently to elevate tissue 
succinate however, more rapidly hydrolysed versions have been developed by our collaborators and 
could provide a new approach to exploring this area. Complex I is fundamental to the generation of 
mtROS. Inhibition in vivo is challenging but would also be an important area to explore in the future. 
Finally, the comparative metabolic analysis highlighted other metabolites such as alanine that had 
different profiles in warm and cold ischaemia that have not been explored. Understanding the 
pathophysiology of these processes would provide another interesting area of research. 
In moderating succinate accumulation or the rate of succinate oxidation at the time of reperfusion the 
environment into which metabolic inhibitors are delivered appears to be critical. The relatively controlled 
onset of ischaemia and subsequent reperfusion provides a wealth of potential opportunities to administer 
therapies in organ transplantation. Reperfusion injury could be abrogated in transplantation by treating a 
combination of the donor, the organ, or the recipient. The work presented here suggests moderating 
metabolism in this setting is critically dependent on the timing of administration and the presence or 







inhibitors that have been designed to be more rapidly delivered to the cell in vivo or selectively targeted 
to mitochondria using strategies such as by conjugation to lipophilic cations such as 
triphenylphosphonium. This work has demonstrated that the heterotopic heart transplant mouse model 
can be used to examine IR injury within the context of transplantation. Further work should look to 
expand the repertoire of outcome markers used to examine IR injury. Examining ROS, mitochondrial and 
organ dysfunction at different times during the evolution of reperfusion would improve the under. 
Markers characterising the severity of the IR injury without the need to sacrifice the animal would enable 
correlations between early mitochondrial dysfunction and later organ dysfunction and explore the 
downstream pathways in more details in vivo. 
In conclusion, since the recognition of IR injury as a pathophysiological process there have been 
numerous therapeutic avenues that have been explored. The initial optimism with some of these has 
unfortunately failed to translate to an improvement in clinical outcomes. With the recognition of a 
specific metabolic pathway underpinning this process there is renewed optimism that rational therapeutic 
strategies may have greater success in treating IR injury. Collaboration will continue to be instrumental in 
delivering this success as an increasing number of ever more complex techniques and new in vivo or ex 
vivo models may be required to further examine the pathophysiological process. Chronic rejection 
remains a major clinical problem but with the benefit of hindsight, I do not believe the approach I pursued 
in this work was the most efficient method of exploring the problem of chronic rejection and its 
relationship with IR injury. With finite resources, I would suggest that we invest time into better 
understanding the pathophysiology of IR injury. This would focus and expedite the development of 
therapies to ameliorate IR injury. With well-designed clinical trials, the efficacy of these therapies in 
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Chapter 9:  Appendix 
 
LC-MS raw data of tissue abundance of analysed metabolites in the mouse, pig and human heart during 


















Appendix 1: Mouse LC-MS data





Control - 1 5.92E+07 136787579.7 83039266.6 2.05E+07 NF
Control - 2 6.11E+07 137173546.6 47580746.17 NF NF
Control - 3 5.89E+07 174586983.9 24333483.07 NF NF
Control - 4 5.96E+07 179048227.2 32659346.08 2.78E+06 NF
Control - 5 6.25E+07 166135707 50690052.51 NF NF
Control - 6 5.96E+07 175343454 59482257.41 1.63E+07 NF
6WI - 1 5.23E+07 143932150.1 36997397.78 NF NF
6WI - 2 5.38E+07 100897988.7 38596206.59 NF NF
6WI - 3 4.77E+07 113610544.7 62898893.27 2.20E+05 NF
6WI - 4 4.86E+07 130203847.4 33983848.01 NF NF
6WI - 5 4.96E+07 108452986.7 36478424.22 NF NF
12WI - 1 4.07E+07 116411979.3 40789181.89 NF NF
12WI - 2 4.32E+07 125464359.2 42093209.89 NF NF
12WI - 3 3.45E+07 102500513.2 53640643.3 NF NF
12WI - 4 3.93E+07 132403698.5 44170399.64 NF NF
12WI - 5 4.25E+07 163373616.5 44610861 NF NF
30WI - 1 4.97E+07 97752940.36 71045310.46 NF 6.59E+07
30WI - 2 3.45E+07 110221210.5 52709117.08 NF 4.79E+07
30WI - 3 3.92E+07 75924801.04 36060703.96 NF NF
30WI - 4 3.46E+07 117925161.7 68624626.34 NF 4.19E+07
30WI - 5 3.42E+07 148188511.1 81986244.17 NF 3.84E+07
6CI - 1 5.45E+07 135518060.4 34223542.01 NF NF
6CI - 2 5.50E+07 114577037.1 12538898.5 3.80E+06 NF
6CI - 3 5.36E+07 164530155.2 17746287.15 7.81E+06 NF
6CI - 4 5.55E+07 152014692 35072228.41 NF NF
6CI - 5 5.50E+07 235130287.7 49601459.94 3.14E+07 NF
12CI - 1 5.59E+07 151377869.9 31972709.54 5.47E+06 NF
12CI - 2 6.02E+07 181515996.7 22126740.77 3.42E+06 NF
12CI - 3 5.26E+07 166259683.5 22478733.33 3.66E+06 NF
12CI - 4 5.62E+07 126905826.8 21643221.43 1.53E+06 NF
12CI - 5 5.57E+07 168159274.2 25706804.97 1.14E+07 NF
30CI - 1 5.33E+07 149467954.8 28850033.97 1.18E+06 NF
30CI - 2 5.24E+07 150507575.3 17389760.47 2.97E+06 NF
30CI - 3 5.54E+07 125507618.1 14378191.61 NF NF
30CI - 4 5.22E+07 176662034.3 21784281.85 1.83E+06 NF
30CI - 5 5.18E+07 167427024.5 22223348.8 2.30E+07 NF
240CI - 1 4.98E+07 153909786.7 23626489.57 7.15E+05 NF
240CI - 2 4.55E+07 130250962.2 17484437.96 NF 2.13E+07
240CI - 3 4.38E+07 143430319.5 23389936.15 NF NF
240CI - 4 4.84E+07 105683117.3 18967379.51 NF NF
240CI - 5 4.81E+07 138038093.7 25829576.82 NF NF
480CI - 1 5.04E+07 121473948.4 31896595.03 8.13E+05 NF
480CI - 2 4.45E+07 189136086 35110132.72 NF NF
480CI - 3 4.50E+07 183759905 24174782.22 NF NF
Control 31671657 160797137 22152241 0 0
Control 30767346 232557663 30165304 0 0
Control 33800942 186093130 16519256 0 0
Control 20437761 217786878 26380142 0 0
Control 31515492 228451998 36179504 0 0
240WI 22580676 178418374 41902221 0 0
240WI 24304349 141025503 42879845 0 0
240WI 31015529 163049513 38281227 0 0









Appendix 1: Mouse LC-MS data
condition acetoacetate acetyl 
carnitine
acetylcarnitine acetylcholine aconitate
Control - 1 1.96E+07 1.85E+10 4159136147 644540563.8 187183732.6
Control - 2 2.61E+07 1.70E+10 5606607555 410830954.5 263031214.3
Control - 3 9.91E+06 3.15E+10 6332678113 829890884.2 206297422.3
Control - 4 3.54E+06 2.43E+10 2936587513 869261608.9 233425033.4
Control - 5 1.05E+07 3.13E+10 3947587791 692692560.4 229539500.3
Control - 6 8.90E+06 2.90E+10 4295616560 1179878047 144156841.6
6WI - 1 NF 2.87E+10 2640167156 1228236629 56378354.99
6WI - 2 4.74E+06 2.99E+10 7635101026 804257878.5 101931406.8
6WI - 3 4.41E+06 3.14E+10 8009034688 678329459.9 82454093.29
6WI - 4 2.08E+06 3.19E+10 7597391352 843356887.3 55692026.58
6WI - 5 1.78E+06 3.19E+10 6459470401 833208756.3 54202881.99
12WI - 1 1.45E+06 2.96E+10 8106330380 798944595.3 52232281
12WI - 2 NF 2.30E+10 5528450126 686941984.2 48648312.32
12WI - 3 NF 2.54E+10 4282278803 804212515.9 14889828.72
12WI - 4 NF 2.71E+10 2898949369 805120203.1 31279913.24
12WI - 5 NF 2.95E+10 3196346802 1022183065 38478914.43
30WI - 1 NF 1.20E+10 1725897939 739120681.6 56267276.98
30WI - 2 NF 1.38E+10 3879519304 755319438.6 26614570.35
30WI - 3 NF 8.95E+09 1401539911 829545470.2 14467875.35
30WI - 4 NF 1.30E+10 1634650852 699102477.2 11889348.73
30WI - 5 NF 9.65E+09 1347228034 1772631162 15825739.43
6CI - 1 9.55E+06 1.42E+10 2266606102 734255991 171910214
6CI - 2 7.76E+06 1.50E+10 4807970689 603607387.4 222661100.4
6CI - 3 5.04E+06 1.37E+10 2228072765 838856484.3 191808605.4
6CI - 4 NF 2.29E+10 3488125602 856248854.2 207366470
6CI - 5 1.70E+07 1.98E+10 5979439234 1471761059 179495086.9
12CI - 1 1.60E+07 1.74E+10 5126665459 931105095.4 256819938.2
12CI - 2 1.80E+07 1.68E+10 5187299441 1076913547 315942934.9
12CI - 3 1.00E+07 1.92E+10 5134095177 751006282.2 171949583.9
12CI - 4 1.32E+07 1.52E+10 4444866491 777138657.2 216399023.7
12CI - 5 6.29E+06 2.65E+10 3547611437 878657163.3 83622048.62
30CI - 1 4.75E+06 3.45E+10 6119245083 710219208.6 132600164.7
30CI - 2 NF 2.20E+10 3652079962 988924999.2 188067918.9
30CI - 3 4.01E+06 2.84E+10 7335436892 1148684730 250338274.4
30CI - 4 NF 2.44E+10 4447641388 892919276.5 141582878.2
30CI - 5 5.30E+06 2.67E+10 6228702418 893301289 152057034.5
240CI - 1 3.51E+06 2.93E+10 7719517136 683320807 93045726.28
240CI - 2 4.39E+06 3.39E+10 5894083565 910218962.8 77264428.25
240CI - 3 2.17E+06 2.75E+10 6916070319 611298161.8 90442407.43
240CI - 4 3.19E+06 2.52E+10 7414551500 649886541.3 98291642.05
240CI - 5 9.21E+05 2.95E+10 4101896342 693479070.8 41284352.32
480CI - 1 3.58E+06 1.42E+10 2038398598 645241012.8 54168433.21
480CI - 2 NF 2.69E+10 5162818517 1784763830 45976690.91
480CI - 3 NF 2.37E+10 3489605139 974133725.8 34561975.24
Control 11975511 18636465019 748932538 474632479
Control 6896390 35512706268 775400701 532155591
Control 5759903 21702923844 827948406 445545720
Control 4737146 15043627003 857264988 530890958
Control 5400932 23970209111 892006193 486524603
240WI 0 783108060 936458904 14956287
240WI 0 0 986864214 10845848
240WI 0 754523142 608034869 9394300









Appendix 1: Mouse LC-MS data
condition adenine adenosine adenylo-
succinate
ADP agmatine
Control - 1 3158655.099 61353448.76 NF 6.65E+07 6.96E+04
Control - 2 2369884.749 12128047.6 NF 1.09E+07 1.22E+05
Control - 3 9063740.728 15154714.95 NF 1.45E+07 1.16E+05
Control - 4 30419575.51 94973306.28 NF 5.17E+07 7.53E+04
Control - 5 21997675.7 93292054.43 NF 2.72E+07 9.04E+04
Control - 6 15957001.14 10291678.6 NF 6.24E+07 5.72E+04
6WI - 1 238530896.2 2192314844 1.41E+05 8.71E+07 1.53E+05
6WI - 2 88594079.92 2550156451 NF 6.37E+07 3.00E+04
6WI - 3 109458369.6 2953751000 NF 1.09E+08 5.08E+04
6WI - 4 137336297.1 2797462365 NF 1.03E+08 1.80E+05
6WI - 5 167145196.2 2893416627 5.35E+04 1.30E+08 1.07E+05
12WI - 1 256232037.7 6362769234 NF 8.83E+07 1.62E+05
12WI - 2 265068594.8 7051592776 NF 7.42E+07 1.16E+05
12WI - 3 492397101 14756932725 NF 4.83E+07 1.62E+05
12WI - 4 565901076.5 7947433930 NF 1.02E+08 1.53E+05
12WI - 5 571656361.1 8753728493 8.07E+04 1.48E+08 1.58E+05
30WI - 1 1549504483 9593395682 NF 8.54E+06 1.33E+05
30WI - 2 749322989.7 12383871700 NF 3.87E+06 1.11E+05
30WI - 3 1760568810 11869490175 NF 7.45E+06 1.02E+05
30WI - 4 1565020798 13648945791 NF 3.69E+06 2.35E+05
30WI - 5 1858438811 13672000533 8.46E+03 1.16E+07 7.48E+04
6CI - 1 31524263.01 2397840806 3.07E+04 5.69E+07 8.72E+04
6CI - 2 11502047.75 2734996127 NF 8.70E+07 NF
6CI - 3 47177596.49 3292484626 3.17E+04 1.19E+08 1.70E+05
6CI - 4 42739626.88 1203018852 NF 1.01E+08 1.67E+05
6CI - 5 15098177.74 1392493425 2.44E+06 3.51E+08 8.37E+04
12CI - 1 15352398.57 4040256937 1.57E+05 1.46E+08 1.23E+05
12CI - 2 13568151.98 1036836296 1.74E+04 6.11E+07 7.22E+04
12CI - 3 19937848.89 2374495635 6.95E+04 1.64E+08 1.33E+05
12CI - 4 17062413.39 1322431212 8.85E+04 8.66E+07 8.06E+04
12CI - 5 56214097 3583142494 2.15E+06 2.95E+08 1.23E+05
30CI - 1 43451431.82 2315638884 2.17E+05 1.87E+08 1.12E+05
30CI - 2 55271305.66 3181145412 3.86E+04 1.40E+08 8.20E+04
30CI - 3 38643014.76 2701675813 7.65E+03 1.19E+08 6.49E+04
30CI - 4 95100057.37 4212347380 5.61E+05 1.92E+08 1.42E+05
30CI - 5 28966023.35 1340586602 4.28E+06 3.91E+08 8.46E+04
240CI - 1 164937866.1 9431852397 2.11E+05 9.36E+07 1.23E+05
240CI - 2 226986699 5274387646 2.08E+05 9.09E+07 6.76E+04
240CI - 3 160109856.9 9172571689 1.26E+06 7.44E+07 2.06E+04
240CI - 4 158080018.1 12303490774 2.69E+06 5.55E+07 3.11E+04
240CI - 5 211022393.8 7264747608 4.23E+05 6.86E+07 8.90E+04
480CI - 1 380471016.2 13745246985 2.19E+06 2.36E+07 4.40E+04
480CI - 2 461504322 5770814114 7.36E+05 1.20E+07 1.96E+05
480CI - 3 396461515.6 7065562041 4.06E+05 1.18E+07 6.16E+04
Control 11407628 3291699 0 32582409 0
Control 21793333 3181979 0 41348257 0
Control 14420957 26460539 0 42036859 0
Control 16129244 10788021 0 23304635 0
Control 11413569 8807937 0 31561961 11159
240WI 782446881 255631633 0 1169750 410363
240WI 753591832 244967030 0 1999663 216315
240WI 1253605628 327516484 0 1192677 19025









Appendix 1: Mouse LC-MS data
condition aKG alanine allantoin AMP arginine ascorbic 
acid
Control - 1 4.30E+07 5184824142 266965860.2 1.26E+08 846607604.7 362672.2
Control - 2 1.38E+07 5251209286 235370948.6 4.80E+07 1362019776 439557.74
Control - 3 1.49E+07 5733682918 220527989.6 2.36E+07 1172558285 1053001.5
Control - 4 1.62E+07 7562331407 272125295 1.93E+08 1108825081 2306877.9
Control - 5 1.73E+07 6326076099 218251307.1 8.11E+07 1033079421 5776302.8
Control - 6 9.80E+06 5457960774 179128634.4 3.66E+07 782585889.5 40189795
6WI - 1 3.35E+06 8270047794 166220710 9.12E+08 1242120554 7913959.4
6WI - 2 1.21E+06 6563988122 137907248.7 7.29E+08 776672816 10513556
6WI - 3 3.01E+06 6710438618 149690072.9 5.70E+08 1006164631 409289.93
6WI - 4 1.38E+06 7405923980 191305099.1 4.42E+08 1594532713 41151358
6WI - 5 NF 8787357512 203076965.1 7.51E+08 1131524661 53502199
12WI - 1 NF 9935955069 201121359.3 1.11E+09 1934831350 150684475
12WI - 2 NF 9988851269 192910762.6 1.15E+09 1566130962 156371429
12WI - 3 NF 7552660628 167068325.1 1.84E+09 1416558290 107498069
12WI - 4 NF 11918391993 207022043.7 8.89E+08 2037490064 76084099
12WI - 5 NF 13329620413 240008148.1 1.50E+09 1739125790 147264647
30WI - 1 NF 9962173588 260616116.5 1.19E+09 1489964461 40280165
30WI - 2 NF 10681946458 159162028.2 1.79E+09 1580958839 218046648
30WI - 3 NF 9363505049 182070312.6 1.34E+09 1763359737 75780797
30WI - 4 NF 12599863443 185786197.5 1.78E+09 1800968681 130854391
30WI - 5 NF 11226786296 190052898.3 1.82E+09 1470250605 97927244
6CI - 1 NF 5721276371 204834590.9 2.20E+08 1160181509 36335801
6CI - 2 8.51E+05 5465687902 179651152.9 3.60E+08 894084258.6 88119623
6CI - 3 NF 7602512071 221164350.3 4.61E+08 1633951464 22592238
6CI - 4 NF 6481042770 229042078.6 3.38E+08 1040533990 54705637
6CI - 5 3.23E+06 5421132990 188546755.7 1.31E+09 839748792.3 157014128
12CI - 1 NF 5583487459 181544657.6 9.19E+08 1209180136 146922617
12CI - 2 2.04E+06 4395014293 159201780.6 1.24E+08 1053413900 101584723
12CI - 3 NF 6235723289 185642900.3 7.22E+08 1383940176 129625416
12CI - 4 NF 6197125796 221922587.6 1.56E+08 1057487495 92808861
12CI - 5 NF 8254760332 202179159.8 1.67E+09 1029931392 130499941
30CI - 1 NF 6257266684 178366629.2 8.70E+08 1170112776 104985750
30CI - 2 NF 6052649639 193453325.9 4.52E+08 1005957992 32702205
30CI - 3 NF 4231533263 111026350.2 6.56E+08 1256143193 192756199
30CI - 4 NF 5871788158 165368647.9 6.69E+08 1494909513 53742114
30CI - 5 NF 7178468173 177433256.8 1.86E+09 831960155 135942664
240CI - 1 NF 5227764081 164103437.3 4.27E+08 971550671.7 87279839
240CI - 2 NF 5882222985 221603832 4.05E+08 1291908788 51625003
240CI - 3 NF 5044521614 146485222.5 5.39E+08 952954023.8 189035839
240CI - 4 NF 4954887731 150831236.4 5.63E+08 797874413.1 234414368
240CI - 5 NF 5777455101 182159230 4.22E+08 1126711154 90207026
480CI - 1 NF 4927278849 91080077.17 8.59E+08 689433420.3 155548402
480CI - 2 NF 7197448908 122091193 9.43E+08 1428190992 148542627
480CI - 3 NF 6415008608 173843137.6 8.47E+08 1479656844 185302558
Control 65958357 3669173071 43690253 45352750 712741071 0
Control 50492833 4188273240 86136337 54147483 732887539 262428
Control 41991782 3443310820 70307252 61507099 648829433 3874887
Control 22296264 3822697569 68740142 35644525 619322242 1357452
Control 26988002 2911057340 41437590 41838827 619100105 13697200
240WI 0 8582527167 62034773 64474179 4517491075 26578548
240WI 0 7134772950 55981973 143955563 3494937847 13189076
240WI 0 8217546686 77657651 110102753 1507474143 0









Appendix 1: Mouse LC-MS data
condition asparagine aspartate ATP betaine butyrylcarnitine
Control - 1 230450645.1 5274482080 7.39E+07 816909129 1.11E+08
Control - 2 240482304.3 2467075818 3.79E+06 888647215 4.29E+07
Control - 3 270964322.4 4058233597 2.58E+07 453545044 5.88E+07
Control - 4 309706865.4 2768734857 2.71E+07 2091698414 2.70E+07
Control - 5 270803503.6 3504289104 2.58E+07 1566407325 4.19E+07
Control - 6 383809246.7 3650660977 1.54E+08 775850933 1.36E+08
6WI - 1 363696726.8 2043719123 7.87E+06 1876595636 1.10E+09
6WI - 2 226554184.8 3882569737 1.56E+06 612299349 1.50E+09
6WI - 3 210641870.8 1281118563 1.82E+07 634009932 2.12E+09
6WI - 4 283246558.8 1175393746 8.60E+06 701293915 1.97E+09
6WI - 5 277155176.8 3521743422 1.48E+07 925216216 1.36E+09
12WI - 1 248722897 1541973396 2.10E+06 809380616 2.10E+09
12WI - 2 269594006.9 825468238.2 8.90E+05 584884987 2.10E+09
12WI - 3 284811894.7 990555150.5 1.17E+06 998136959 2.45E+09
12WI - 4 423370408.3 1489130239 3.94E+06 2563939050 1.99E+09
12WI - 5 456279748.2 2534294066 1.00E+07 1837814166 2.06E+09
30WI - 1 312502654.2 3839270578 7.00E+04 2808837987 1.41E+09
30WI - 2 177910691 974493854.1 NF 933276495 1.50E+09
30WI - 3 285330201.3 773264867.7 NF 3211297561 8.14E+08
30WI - 4 430203667.2 1765878173 9.81E+04 1896798115 1.09E+09
30WI - 5 474538300.4 717162137 NF 3500767973 1.28E+09
6CI - 1 187301810.3 6869223677 1.99E+07 1285139149 8.64E+07
6CI - 2 131446578.9 2616549333 4.25E+07 459184757 5.06E+07
6CI - 3 275919250.7 5336644963 3.43E+07 2032051332 6.21E+07
6CI - 4 300750537 4320335454 2.08E+07 2473844993 4.43E+07
6CI - 5 265872019.3 5724569710 7.85E+07 629696827 1.40E+08
12CI - 1 142204999 3228677994 4.42E+07 808369475 4.33E+07
12CI - 2 229938333.1 3768745240 4.79E+07 541907399 8.96E+07
12CI - 3 279916972.4 4015619396 4.37E+07 793364959 3.91E+07
12CI - 4 217404048.1 7031608529 5.24E+07 824866547 5.07E+07
12CI - 5 240760643.3 3725133710 4.37E+07 2271227740 1.53E+08
30CI - 1 201041597.5 4722751026 3.90E+07 1264344147 2.27E+08
30CI - 2 177212494.6 4182653464 4.61E+07 2298128889 4.45E+07
30CI - 3 203783129.1 2861178317 1.56E+07 575144940 1.23E+08
30CI - 4 222821232.5 4830234458 4.91E+07 2531909779 7.45E+07
30CI - 5 204081894.3 5244117983 5.37E+07 762779977 1.57E+08
240CI - 1 97599420.88 2426261034 3.15E+07 1012510642 2.17E+09
240CI - 2 158975393.4 5070963311 1.32E+07 2695698201 2.17E+09
240CI - 3 105667277.3 2902634844 1.10E+07 855800578 1.71E+09
240CI - 4 65948741.57 3971002229 1.59E+07 835860253 1.27E+09
240CI - 5 131275501.6 3205387146 9.28E+06 1842311806 1.85E+09
480CI - 1 75185655.95 3335913197 7.09E+06 2032403648 1.29E+09
480CI - 2 214025019.1 4263877584 1.41E+06 2436346024 2.39E+09
480CI - 3 125982028.4 4707553260 6.30E+05 2419670883 1.60E+09
Control 126235298 1246306702 25763417 0 31108134
Control 110421456 1356251634 28358930 0 27520992
Control 88835140 1778404111 28208927 0 22303057
Control 88099863 2604030442 12580829 0 15349480
Control 121619062 1896224712 33696777 0 39303180
240WI 474115509 1875564842 0 0 18927089
240WI 267634774 1479553441 0 0 33044293
240WI 108430507 967200442 0 330757388 11228053









Appendix 1: Mouse LC-MS data
condition carbamoyl-
phosphate
carnitine CDP choline citrate
Control - 1 1.95E+08 4.78E+10 4.25E+04 1777689505 1.22E+09
Control - 2 2.09E+08 5.22E+10 NF 1850474945 8.21E+08
Control - 3 2.53E+08 5.80E+10 NF 1718503511 9.95E+08
Control - 4 2.56E+08 5.81E+10 1.34E+04 2779530236 1.08E+09
Control - 5 2.37E+08 5.37E+10 1.17E+04 2030059436 1.03E+09
Control - 6 2.39E+08 6.21E+10 1.41E+05 3106914600 1.48E+09
6WI - 1 2.47E+08 5.55E+10 2.05E+04 3032694100 3.68E+08
6WI - 2 2.10E+08 4.31E+10 NF 2546549684 3.78E+08
6WI - 3 1.83E+08 5.04E+10 NF 2251777783 3.83E+08
6WI - 4 2.53E+08 5.59E+10 NF 2026431128 3.56E+08
6WI - 5 2.54E+08 5.44E+10 1.33E+04 2325265627 2.98E+08
12WI - 1 2.41E+08 5.26E+10 NF 2110055063 1.98E+08
12WI - 2 2.43E+08 5.30E+10 NF 2338708283 2.07E+08
12WI - 3 2.37E+08 6.18E+10 NF 2619639818 2.75E+08
12WI - 4 2.57E+08 5.07E+10 NF 2622011539 2.61E+08
12WI - 5 2.58E+08 5.13E+10 NF 2989096063 3.16E+08
30WI - 1 2.46E+08 6.24E+10 NF 4736618364 4.47E+08
30WI - 2 2.65E+08 6.57E+10 1.22E+04 2541102364 1.45E+08
30WI - 3 2.47E+08 7.25E+10 NF 4241220580 1.09E+08
30WI - 4 2.70E+08 6.54E+10 NF 2823906161 2.14E+08
30WI - 5 2.57E+08 6.69E+10 NF 4620531721 2.19E+08
6CI - 1 2.58E+08 6.09E+10 NF 2033054224 9.27E+08
6CI - 2 1.83E+08 6.30E+10 1.61E+05 1676862156 9.58E+08
6CI - 3 2.91E+08 6.74E+10 2.64E+05 2251711762 9.36E+08
6CI - 4 2.89E+08 6.67E+10 8.19E+04 1761828349 9.59E+08
6CI - 5 2.61E+08 7.13E+10 1.98E+06 3049046268 1.48E+09
12CI - 1 3.07E+08 6.56E+10 7.10E+05 2205501600 1.13E+09
12CI - 2 2.74E+08 6.53E+10 6.30E+04 2967224556 1.07E+09
12CI - 3 2.93E+08 6.07E+10 6.40E+05 2316860544 9.02E+08
12CI - 4 2.85E+08 6.88E+10 1.61E+05 2143187037 9.60E+08
12CI - 5 3.00E+08 5.32E+10 1.52E+06 2362565166 1.38E+09
30CI - 1 3.12E+08 6.04E+10 5.21E+05 2197218931 1.15E+09
30CI - 2 2.88E+08 6.40E+10 2.58E+05 2998831898 9.22E+08
30CI - 3 2.94E+08 6.59E+10 1.71E+05 2916795127 9.21E+08
30CI - 4 3.02E+08 5.83E+10 5.85E+05 2390075219 8.10E+08
30CI - 5 3.00E+08 5.98E+10 2.68E+06 2129212252 1.39E+09
240CI - 1 3.41E+08 4.64E+10 5.21E+04 2372568949 5.10E+08
240CI - 2 3.27E+08 6.09E+10 4.42E+04 2671345830 4.92E+08
240CI - 3 3.23E+08 4.57E+10 4.27E+04 2375153239 5.05E+08
240CI - 4 3.28E+08 4.41E+10 7.53E+04 2702741371 5.47E+08
240CI - 5 3.14E+08 4.61E+10 5.68E+04 2474095277 3.49E+08
480CI - 1 3.47E+08 4.14E+10 NF 2427041544 7.71E+08
480CI - 2 3.56E+08 6.07E+10 NF 3914864683 4.77E+08
480CI - 3 3.48E+08 5.78E+10 NF 3170157291 4.49E+08
Control 239598634 44567841091 0 2406487636 458971349
Control 239225815 39021973204 0 1711562381 570522555
Control 239114169 52735458956 0 2089418239 527643320
Control 186902413 33809665914 0 1821644463 356363034
Control 231888151 49268916234 0 2201550616 543936989
240WI 228985974 53389513726 0 8145498738 17499343
240WI 200467355 44600391071 0 4997399917 18340405
240WI 250777573 58278993561 0 4726276168 14696069









Appendix 1: Mouse LC-MS data
condition citrulline creatine cytidine dihydro-
thymine
ethanolamine
Control - 1 843487411.5 8.41E+10 2.12E+07 64923748.38 6.19E+07
Control - 2 898978502.9 9.03E+10 1.82E+07 77083211.17 7.41E+07
Control - 3 1068611767 1.08E+11 1.70E+07 93963472.66 8.74E+07
Control - 4 1182708727 1.10E+11 9.53E+06 96061310.48 7.57E+07
Control - 5 903623934 9.72E+10 1.98E+07 80289163.15 6.36E+07
Control - 6 1193915258 1.00E+11 4.28E+07 96349174.93 2.22E+08
6WI - 1 1059928746 1.03E+11 2.53E+08 101053246.5 1.68E+08
6WI - 2 735531373.7 9.09E+10 2.07E+08 65017560.39 1.25E+08
6WI - 3 1081709300 1.05E+11 2.56E+08 67597743.64 8.02E+07
6WI - 4 1418826094 1.13E+11 3.67E+08 100144452 9.84E+07
6WI - 5 993290098.5 1.12E+11 2.63E+08 90604019.23 1.12E+08
12WI - 1 1145064128 1.04E+11 1.73E+08 80685177.68 1.03E+08
12WI - 2 1017027171 1.08E+11 2.43E+08 73099508.06 1.08E+08
12WI - 3 1078278833 1.10E+11 3.73E+08 96908406.36 1.07E+08
12WI - 4 1322333378 1.08E+11 2.42E+08 106052234.9 9.72E+07
12WI - 5 1544529386 1.08E+11 2.71E+08 110027650.3 1.09E+08
30WI - 1 1102966357 1.01E+11 3.11E+08 77618655.15 2.47E+08
30WI - 2 1132642767 1.04E+11 2.52E+08 73224817 1.75E+08
30WI - 3 1375516221 1.10E+11 2.63E+08 107225796.4 1.98E+08
30WI - 4 1207674484 1.13E+11 2.27E+08 96209572.69 1.26E+08
30WI - 5 1659249885 1.05E+11 2.75E+08 131447560.7 2.65E+08
6CI - 1 1019108459 1.02E+11 1.12E+07 58170973.72 7.99E+07
6CI - 2 1052959682 9.53E+10 1.02E+07 62190449.98 6.50E+07
6CI - 3 1117102148 1.07E+11 7.00E+06 70430641.5 8.53E+07
6CI - 4 1238035296 1.18E+11 1.30E+07 82797724.42 7.16E+07
6CI - 5 1657700912 1.08E+11 2.63E+07 79865688.13 1.46E+08
12CI - 1 1007492983 1.16E+11 1.53E+07 50567336.3 9.08E+07
12CI - 2 1499274879 1.09E+11 1.05E+07 85164202.58 1.28E+08
12CI - 3 954471045.9 1.13E+11 1.39E+07 71930092.66 7.06E+07
12CI - 4 1068185092 1.09E+11 1.02E+07 68754629.98 8.04E+07
12CI - 5 1203456390 1.07E+11 1.55E+07 55401346.38 9.15E+07
30CI - 1 1152500571 1.17E+11 8.45E+06 64799172.45 5.18E+07
30CI - 2 1161206138 1.11E+11 4.75E+06 67491970.09 7.48E+07
30CI - 3 1529770032 1.08E+11 1.56E+07 76885163.51 1.35E+08
30CI - 4 1278173849 1.05E+11 3.13E+07 66884639.16 5.42E+07
30CI - 5 1122856185 1.12E+11 2.07E+07 58016467.94 7.33E+07
240CI - 1 923716312.8 1.04E+11 5.97E+06 23853956.71 5.00E+07
240CI - 2 1366206638 1.11E+11 7.36E+06 56597832.49 7.77E+07
240CI - 3 851831960.6 9.70E+10 2.00E+07 24291814.7 5.53E+07
240CI - 4 781266733.1 8.77E+10 2.26E+07 18157609.51 5.41E+07
240CI - 5 1025782947 1.02E+11 1.29E+07 32424219.7 5.36E+07
480CI - 1 654033244.8 7.80E+10 6.45E+07 11830439.05 5.88E+07
480CI - 2 1477164340 1.02E+11 9.36E+07 74180517.26 1.33E+08
480CI - 3 1458794792 1.07E+11 7.36E+07 42266448.75 1.02E+08
Control 769544269 52283444176 5113277 37092104 50901651
Control 891733412 57786467646 4409194 33503980 39434340
Control 834714579 56004605038 4343821 34516903 46463797
Control 823078413 52614718389 3228456 33063551 30094125
Control 815264852 55521084788 6698623 35778056 47540303
240WI 802108585 59062408034 231205792 40755966 519584713
240WI 860063843 51944447912 151083770 26219688 303070108
240WI 1066620151 65853152899 126088154 38623237 256515470















Control - 1 2.94E+07 NF 659389579.1 7.83E+04 11722515.25
Control - 2 2.18E+07 NF 293183228.6 NF 4719989.892
Control - 3 2.53E+07 NF 552107934.6 NF 9763754.894
Control - 4 2.27E+07 NF 501565627.8 NF 17421767.95
Control - 5 3.64E+07 NF 543416216.9 NF 16378011.07
Control - 6 3.96E+07 1.02E+06 593147756.8 1.06E+05 13933928.45
6WI - 1 1.85E+07 NF 197811031.5 NF 13096051.27
6WI - 2 8.12E+06 NF 154886890 NF 5963305.996
6WI - 3 8.77E+06 NF 111084713.1 2.25E+05 5999463.264
6WI - 4 1.51E+07 NF 131844320.6 NF 9598563.569
6WI - 5 1.97E+07 NF 201314746.1 NF 9321617.758
12WI - 1 1.67E+07 NF 70574274.7 NF 5959788.414
12WI - 2 9.34E+06 NF 63545324.36 NF 4516782.466
12WI - 3 1.45E+06 NF 71191824.08 NF 9232522.86
12WI - 4 1.24E+07 NF 79823648.64 NF 13626852.07
12WI - 5 7.28E+06 NF 221330565.3 7.95E+04 14537321.17
30WI - 1 4.09E+06 NF 54287692.06 NF 14667898.89
30WI - 2 4.72E+06 NF 18300750.17 NF 4747487.666
30WI - 3 3.31E+06 NF 46666503.47 NF 13194638.13
30WI - 4 4.44E+06 NF 15593025.82 NF 11506371.1
30WI - 5 2.67E+06 NF 179638848.7 1.84E+04 13088979.79
6CI - 1 2.04E+07 NF 644935930.6 NF 7501325.781
6CI - 2 5.62E+06 NF 217412226.6 3.00E+05 6768937.325
6CI - 3 9.50E+06 NF 797158598.1 NF 10245000.14
6CI - 4 1.47E+07 NF 485507879.3 NF 16332860.34
6CI - 5 5.76E+06 NF 728890444.4 1.74E+06 8655826.103
12CI - 1 1.05E+07 NF 361057599 6.88E+05 6624075.129
12CI - 2 1.41E+07 NF 501057524.4 3.11E+04 6579234.254
12CI - 3 1.28E+07 NF 338621654.8 3.19E+05 9649742.31
12CI - 4 1.03E+07 NF 500193518.8 3.32E+04 6800007.878
12CI - 5 8.57E+06 1.41E+06 592159896.6 2.34E+06 10262664.11
30CI - 1 1.91E+07 NF 377449697.8 6.50E+05 8695314.322
30CI - 2 1.65E+07 NF 417927902.7 2.42E+05 9275186.25
30CI - 3 1.74E+07 NF 188710860.2 NF 5054561.22
30CI - 4 1.84E+07 NF 397825538.1 4.51E+05 12386164.99
30CI - 5 8.23E+06 4.93E+06 570993543.9 3.47E+06 9651891.089
240CI - 1 3.65E+07 NF 161786403.2 4.45E+05 2665280.199
240CI - 2 2.89E+07 NF 208723526.5 NF 9099564.84
240CI - 3 1.11E+07 NF 190551312.8 6.92E+04 2298024.142
240CI - 4 8.38E+06 NF 166543554 2.40E+05 1320233.208
240CI - 5 8.11E+06 NF 146988678 8.25E+04 3585527.048
480CI - 1 7.17E+06 NF 119356450.1 1.96E+05 201739.7181
480CI - 2 3.96E+06 NF 103857836.2 NF 9914549.427
480CI - 3 3.42E+06 NF 95267119.78 NF 6704780.747
Control 22039710 0 3.29E+08 25063 13721296
Control 24230457 0 3.14E+08 16707 14523350
Control 24992046 0 2.49E+08 0 13443772
Control 20724612 0 3.53E+08 0 14496347
Control 29518677 0 3.20E+08 12279 15707634
240WI 3295968 0 5.65E+07 0 18453075
240WI 1614542 0 4.17E+07 0 13370612
240WI 3610457 0 6.29E+07 0 14374506









Appendix 1: Mouse LC-MS data




Control - 1 7436035541 3.00E+07 23483977571 23623370956 8.32E+06
Control - 2 6341026079 2.62E+07 14452395811 26396680797 6.26E+06
Control - 3 3219522130 3.17E+07 22901065008 36325263267 3.46E+06
Control - 4 4746523371 2.46E+07 24907048675 35977403639 1.37E+07
Control - 5 6668157935 4.59E+07 25345596674 29246597042 5.66E+06
Control - 6 4286429034 3.96E+07 23563643890 37255247789 5.61E+06
6WI - 1 971629320.7 2.17E+07 18596679256 37900813486 8.34E+06
6WI - 2 1563068182 1.01E+07 15143446934 27382649086 8.81E+06
6WI - 3 1383536262 1.13E+07 15033614021 27912490448 1.22E+07
6WI - 4 682663180.4 1.69E+07 18708536961 35989650996 1.02E+07
6WI - 5 672128231.7 2.37E+07 17147926304 33333785228 2.01E+07
12WI - 1 523397124.7 1.72E+07 15334255953 33044488581 2.04E+07
12WI - 2 323753789.5 1.07E+07 12532333723 32318544770 9.45E+06
12WI - 3 312283878.7 1.73E+06 16346800284 35036274507 6.24E+06
12WI - 4 239698027.7 1.50E+07 18943399694 39997093154 1.26E+07
12WI - 5 228848863.9 8.42E+06 21035008946 44576487765 8.30E+06
30WI - 1 1444103969 3.78E+06 22205770113 29195621961 9.07E+06
30WI - 2 257066941.7 4.32E+06 12892605770 32250334364 3.67E+06
30WI - 3 268439566.1 3.02E+06 17249373731 38679932724 8.34E+06
30WI - 4 200784415.1 5.05E+06 17170546973 36751926445 4.03E+06
30WI - 5 369781065.4 2.43E+06 16073754882 54168113559 3.06E+06
6CI - 1 4863960398 2.28E+07 18508659372 28767690469 7.05E+06
6CI - 2 1975458152 6.92E+06 17282331828 27886822518 7.09E+06
6CI - 3 4377588951 1.06E+07 18696955962 37238719242 1.05E+07
6CI - 4 3678845646 1.74E+07 26002291104 35718785049 8.47E+06
6CI - 5 4333641475 5.30E+06 20095668296 40111201684 6.34E+06
12CI - 1 3877895261 1.27E+07 19639077331 28992429864 8.05E+06
12CI - 2 4598137291 1.56E+07 16152607309 37958266251 6.65E+06
12CI - 3 2804926922 1.61E+07 20779868172 33198320568 1.28E+07
12CI - 4 3160774269 1.18E+07 18005010062 30659132751 4.93E+06
12CI - 5 3448018513 8.89E+06 20979659681 30603723201 6.91E+06
30CI - 1 1681111583 2.48E+07 20758047174 30777930819 1.05E+07
30CI - 2 2891225397 2.05E+07 15665447350 37911478391 7.84E+06
30CI - 3 971287453.5 2.19E+07 17243989491 36482764307 6.54E+06
30CI - 4 3367988559 2.16E+07 20624962703 37481967783 9.05E+06
30CI - 5 1606196787 7.96E+06 23093687469 29163081052 1.04E+07
240CI - 1 965287718.5 3.90E+07 12332753558 20425211724 1.80E+06
240CI - 2 591607120.2 3.53E+07 16695832404 33132474780 1.17E+06
240CI - 3 625462009.6 1.20E+07 12795353513 20909383870 NF
240CI - 4 805875850.7 1.00E+07 10819917339 18119654533 6.54E+05
240CI - 5 699312615.1 9.39E+06 15151469323 24853002393 NF
480CI - 1 585377559.1 6.37E+06 8548783965 13834658806 7.61E+05
480CI - 2 360370638.5 4.60E+06 20484061304 49117943369 NF
480CI - 3 731633099.4 3.09E+06 16641533665 31301221245 1.84E+05
Control 1923826093 20836537 14237424523 15969187876 827826
Control 1300152503 24016827 22565391819 18120048135 3846668
Control 1421020793 20900337 19703380979 18395517087 3535606
Control 1944366837 13963308 21509925100 16896452767 4003452
Control 2077647613 24706940 16966494163 12991379638 361543
240WI 1465296699 4542863 20280688904 15824141071 2468979
240WI 257126385 2641481 15557995601 12250242936 423426
240WI 1101887282 3323872 22762901863 20495056824 3643942









Appendix 1: Mouse LC-MS data





Control - 1 NF 9.38E+06 86310403.95 1.66E+07 972617286.8
Control - 2 NF 6.63E+06 211645568.7 1.61E+07 671444241.9
Control - 3 NF 7.07E+06 57202353.24 1.53E+07 826630486.7
Control - 4 NF 4.62E+06 203737319.1 1.56E+07 1127342821
Control - 5 NF 8.77E+06 177279198 1.55E+07 977416437.2
Control - 6 NF 6.38E+06 76614902.23 1.58E+07 1053369149
6WI - 1 NF 2.79E+07 162135390.1 1.30E+07 1053143496
6WI - 2 NF 3.12E+07 398922204.4 2.68E+07 851998927.8
6WI - 3 NF 2.15E+07 411975996.4 1.41E+07 910804654.4
6WI - 4 NF 2.11E+07 55587580.84 1.80E+07 850628454.6
6WI - 5 NF 2.07E+07 50887065.8 1.22E+07 814693050.7
12WI - 1 NF 4.34E+07 364004800.8 1.33E+07 998682601
12WI - 2 NF 4.13E+07 323701928.9 1.16E+07 830748638.2
12WI - 3 NF 4.06E+07 69487025.26 1.48E+07 910096101
12WI - 4 NF 4.35E+07 175897541.3 1.36E+07 1072438969
12WI - 5 NF 4.43E+07 139713676.1 1.71E+07 1609842890
30WI - 1 NF 1.19E+08 134162853.5 1.40E+07 1590884349
30WI - 2 NF 9.98E+07 394184704.8 1.32E+07 826674835.2
30WI - 3 NF 1.23E+08 125582490.6 1.01E+07 1144985891
30WI - 4 NF 9.54E+07 95611970.6 1.53E+07 1048692785
30WI - 5 NF 1.10E+08 90665640.92 8.64E+06 1527050164
6CI - 1 NF 6.65E+06 136050748.9 1.45E+07 1003306880
6CI - 2 NF 2.81E+06 199879264 1.86E+07 774833191.5
6CI - 3 NF 2.59E+06 187719488.2 9.98E+06 1093426528
6CI - 4 NF 3.68E+06 312506758.9 1.64E+07 1150889217
6CI - 5 NF 3.65E+06 353642088.4 1.27E+07 979663839.8
12CI - 1 NF 6.18E+06 630549552.9 1.32E+07 754491870
12CI - 2 NF 4.13E+06 342062986.8 9.75E+06 769800495.1
12CI - 3 NF 3.04E+06 61484262.22 1.67E+07 825869426.3
12CI - 4 NF 5.88E+06 61220952.67 1.23E+07 753882068
12CI - 5 NF 7.25E+06 127707070.1 1.63E+07 1233435661
30CI - 1 NF 4.01E+06 81226396.3 1.35E+07 829356207.7
30CI - 2 NF 5.00E+06 213888685.6 1.29E+07 1054317925
30CI - 3 NF 4.29E+06 496777773.2 1.33E+07 818158957
30CI - 4 NF 2.95E+06 254206286.8 1.25E+07 940834207.7
30CI - 5 NF 5.53E+06 452189094.6 1.55E+07 963285493.9
240CI - 1 NF 7.28E+06 419543775.2 1.10E+07 644549595
240CI - 2 NF 1.04E+07 212866788.8 1.32E+07 991718418.5
240CI - 3 NF 6.91E+06 443780766.9 8.69E+06 593788707.8
240CI - 4 NF 6.21E+06 456419909.4 8.67E+06 583019848.7
240CI - 5 NF 5.34E+06 93177318.18 1.08E+07 732655159.6
480CI - 1 NF 2.00E+07 45942571.51 5.58E+06 611018914.3
480CI - 2 NF 3.61E+07 66450063.8 2.87E+06 1045878015
480CI - 3 NF 2.01E+07 50916327.56 5.18E+06 915282431.1
Control 0 7691981 157910723 16946975 644919850
Control 0 7480448 209201629 15773976 708960408
Control 0 7869356 172250283 13006787 651107255
Control 304892 0 196607201 7041923 601224320
Control 0 11535263 206913007 15604236 558280791
240WI 5818743 5.76E+08 160234886 29694796 1927288134
240WI 4596650 4.54E+08 120393309 15753343 1265752063
240WI 532385 5.01E+08 137715325 22891983 1462926863









Appendix 1: Mouse LC-MS data
condition GMP GSH GSH GSSG GSSG guanine
Control - 1 NF 9.48E+08 2461276420 2.88E+07 14918523.95 1.61E+06
Control - 2 NF 8.55E+08 2621352339 1.81E+07 3151964.595 2.28E+05
Control - 3 NF 1.15E+09 3998048932 1.34E+07 5521309.982 6.46E+05
Control - 4 NF 1.14E+09 3098007585 1.25E+07 9437712.332 5.81E+05
Control - 5 NF 1.21E+09 3178158640 9.86E+06 6858274.586 1.18E+06
Control - 6 NF 9.85E+08 3633031576 2.58E+07 8655822.118 1.48E+06
6WI - 1 1420106.293 9.52E+08 2579494973 7.03E+06 7978153.419 6.09E+06
6WI - 2 25941080.31 8.65E+08 2815930124 5.59E+06 3082335.145 9.04E+06
6WI - 3 15225968.65 9.91E+08 3068721807 4.24E+06 3588321.771 6.93E+06
6WI - 4 8646800.416 1.07E+09 3469187100 1.01E+07 9054362.37 5.45E+06
6WI - 5 8097129.675 1.19E+09 3720288148 4.94E+06 7698623.369 6.49E+06
12WI - 1 27134059.28 1.16E+09 3925172229 4.55E+06 6844221.912 1.30E+07
12WI - 2 29455717.17 1.01E+09 3469327866 6.27E+06 5813166.592 9.26E+06
12WI - 3 9473007.139 1.00E+09 3279094517 5.34E+06 6333530.946 1.29E+07
12WI - 4 1279150.631 1.10E+09 3272307244 5.24E+06 7189457.006 1.25E+07
12WI - 5 754516.1423 1.16E+09 3095398120 9.86E+06 23640877.27 1.63E+07
30WI - 1 696799.997 8.53E+08 2287607140 2.19E+07 7990515.487 2.24E+07
30WI - 2 35589069.63 9.97E+08 3590026082 4.59E+06 6813166.599 1.26E+07
30WI - 3 3432640.236 1.02E+09 2286988764 2.56E+06 10395586.06 2.07E+07
30WI - 4 831840.2946 1.12E+09 2927801872 7.54E+06 12097245.88 2.46E+07
30WI - 5 2994773.276 9.26E+08 2962191895 1.06E+07 11527666.02 2.32E+07
6CI - 1 NF 1.14E+09 2725608430 1.29E+07 10244550.49 4.46E+05
6CI - 2 3306976.265 9.95E+08 3406185270 7.38E+06 7627581.162 8.04E+05
6CI - 3 NF 1.19E+09 1624720753 1.27E+07 37570655.05 3.08E+05
6CI - 4 NF 1.25E+09 3042531052 1.03E+07 13476294.48 4.23E+05
6CI - 5 16950221.5 1.13E+09 4439835920 1.45E+07 6246479.871 7.46E+05
12CI - 1 10141069.68 9.09E+08 3530973323 4.22E+07 23342137.48 9.50E+05
12CI - 2 6202826.085 1.06E+09 3815408868 7.97E+06 8356012.581 2.85E+05
12CI - 3 4257077.913 1.33E+09 3924979277 9.84E+06 18734949.55 4.83E+05
12CI - 4 2154111.892 1.21E+09 3706608433 9.16E+06 11400822.24 8.50E+04
12CI - 5 NF 1.07E+09 4134425024 2.88E+07 12691367.73 5.49E+05
30CI - 1 2294863.786 1.05E+09 3494874096 2.93E+07 13387688.23 1.98E+05
30CI - 2 NF 1.24E+09 2409978915 1.09E+07 19697068.72 2.53E+05
30CI - 3 9478182.293 1.09E+09 3966052922 1.12E+07 8560349.927 3.80E+05
30CI - 4 NF 1.35E+09 2780798095 9.29E+06 23607380.77 1.34E+06
30CI - 5 27432302.84 1.09E+09 4248795098 2.80E+07 12153465.85 5.33E+05
240CI - 1 7263710.707 9.29E+08 3452656745 4.45E+07 29454181.54 7.01E+05
240CI - 2 305276.4762 1.22E+09 2917590679 1.94E+07 26161848.41 9.58E+05
240CI - 3 25444707.08 1.11E+09 3633296457 2.71E+07 21509884.03 1.10E+06
240CI - 4 31278214.99 1.07E+09 3405690292 3.72E+07 35759181.21 4.36E+05
240CI - 5 NF 1.12E+09 3175084541 1.80E+07 17347946.03 8.38E+05
480CI - 1 5278378.302 9.38E+08 3063846052 4.84E+07 14213117.92 4.70E+06
480CI - 2 37883217.35 1.23E+09 3290207735 1.21E+07 25158319.74 3.72E+06
480CI - 3 23405474.72 1.27E+09 3015305845 1.75E+07 24508839.37 4.35E+06
Control 0 2.481E+09 1943275 109262
Control 0 1.842E+09 11089520 0
Control 0 2.454E+09 3637616 526491
Control 0 2.647E+09 1338654 0
Control 0 2.169E+09 3382792 0
240WI 0 1.091E+09 3954217 15772113
240WI 0 1.26E+09 852095 29119747
240WI 0 1.057E+09 17898527 1879470









Appendix 1: Mouse LC-MS data
condition guanosine histamine histidine hypotaurine hypoxanthine inosine
Control - 1 NF 48235271.89 277922377 36433482.39 2092995.803 289235.264
Control - 2 NF 19012021.17 318572242.9 44085326.3 1208274.325 NF
Control - 3 NF 7063231.966 214477385.5 46298786.47 NF NF
Control - 4 NF 21496648.96 399184379.6 31361452.9 1957043.595 NF
Control - 5 NF 39581860.72 314581772.2 30201744.82 3568594.281 218238.323
Control - 6 NF 8665005.007 377634657 94382017.42 NF NF
6WI - 1 41208081.1 38395408.94 480369426.4 92540544.9 1689709891 990440065
6WI - 2 42241702 69133642.14 332138895.7 84395240.97 1620292345 785113775
6WI - 3 49660441.9 23273555.45 359901489 38704503.52 1606267714 764030211
6WI - 4 44799005.1 13715092.1 326375702.2 43429957.17 1693896146 794424955
6WI - 5 48055720.5 17311384.48 227873330.7 37049458.16 1670148369 743769045
12WI - 1 116729570 59127200.37 477883675.3 37165376.65 2487837860 2149634762
12WI - 2 107806802 42519234.12 387130729.5 36914680.87 2263918350 1663832481
12WI - 3 176839550 37141290.41 157177845.1 33637808.03 2536315573 1743321914
12WI - 4 136982295 13914409.81 474531233.1 31117076.85 3130763126 2080184192
12WI - 5 148920198 6011323.313 481480215.9 37810624.53 4487863900 2174964530
30WI - 1 198845340 113348537.8 307629410.6 38620675.12 9334178612 5699905080
30WI - 2 188466478 6548968.37 434331831 40352072.62 5807521859 5386369510
30WI - 3 241399194 38203597.8 421029408 40375322.56 8405051415 6814413668
30WI - 4 206212753 3872607.537 187100385.1 32120621.65 5898352261 5472220384
30WI - 5 267734353 18670758.14 634529988.9 79885962.79 9108503732 6799883218
6CI - 1 NF 85850056.39 282885739.7 35853779.56 53296934.74 24455053
6CI - 2 NF 104695450.9 299592712.4 38730475.17 67030092.34 41141291.1
6CI - 3 NF 74885846.92 381963674.1 27911341.87 90844997.62 28923468.4
6CI - 4 NF 13180240.61 420944846.8 31530031.62 49222555.06 22650691.1
6CI - 5 NF 24577853.94 507650450.3 102818157.7 127081155.7 67685599.7
12CI - 1 NF 43573015.96 430594641.3 26945261.16 64603014.55 35076480.9
12CI - 2 198056.086 47868812.93 478862089.5 64179858.92 48825704.81 46530044.2
12CI - 3 NF 51994416.39 287457342.4 29383224.4 104060066.6 65763666
12CI - 4 NF 23615776.05 324048887.8 32739858 56091006.4 44082797.7
12CI - 5 216576.752 27662740.43 373429551.3 23160592.3 283096142.2 133494453
30CI - 1 202007.844 17338201.29 202526051.6 26914890.15 210206932.4 179879030
30CI - 2 NF 31951027.33 349114069.4 31133260.71 190289689.7 181317362
30CI - 3 642725.665 42781909.18 545453278.2 98028618.9 176863507.9 273529031
30CI - 4 3951146.97 43138362.85 397091116.4 27184283.12 325101659.4 283355102
30CI - 5 NF 17707083.25 398903218 30378036.31 364403923.5 278635385
240CI - 1 3578039.88 77810864.06 339213134.2 17617959.02 1116934334 1466029540
240CI - 2 4315952.51 45113244.99 420142766.6 32792893.06 861669374.9 1410647155
240CI - 3 2914136.31 69523236.81 317501794.8 15592869.42 667093342.2 1255633648
240CI - 4 764555.945 59009401.09 274456548.1 13815537.24 670077968.5 1255363766
240CI - 5 4698222.75 20607357.6 258099130 20691027.58 820391794.6 1378610308
480CI - 1 28727460.2 53295179.44 157250288.2 7776965.672 2442468422 2778787553
480CI - 2 28165273.9 19631368.97 707975351.4 68852025.66 1983028931 2593929086
480CI - 3 22802954.9 44658043.64 391508029 27314597.3 1984859875 2527922327
Control 0 25773761 81405034 51394621 0.00E+00 0
Control 0 5143927 109429059 48115215 0.00E+00 0
Control 0 23005019 95999125 44816041 0.00E+00 0
Control 0 0 84347524 42556248 0.00E+00 0
Control 0 11004578 116229353 54306759 0.00E+00 0
240WI 61323961 25609223 310455585 52035999 1.14E+10 4306104693
240WI 45712405 20079997 189663606 40589598 9.42E+09 4349612706
240WI 22926984 1193424 145191819 54628081 1.28E+10 6242586442









Appendix 1: Mouse LC-MS data
condition Isovalerylcarnitin
e
lactate leucine / 
isoleucine
linoleic acid lysine
Control - 1 2.02E+07 2273803741 8576259358 6.81E+07 1363039325
Control - 2 3.49E+07 1794776936 9077869773 7.95E+07 1791712299
Control - 3 3.03E+07 1753599326 4297163343 3.83E+07 1829698157
Control - 4 9.99E+06 2250792304 5974523828 9.16E+07 2023160231
Control - 5 2.59E+07 2602148558 9217477467 7.17E+07 1818863367
Control - 6 2.00E+07 1306140377 4948383227 1.39E+07 1104479497
6WI - 1 1.01E+08 8686868487 6484167514 4.36E+07 1664156733
6WI - 2 1.07E+08 6530130328 5661580040 5.82E+07 947360819.1
6WI - 3 1.15E+08 7547794555 7311490051 3.86E+07 1227819701
6WI - 4 1.15E+08 7301704394 5934092416 1.14E+07 2106580761
6WI - 5 1.28E+08 8623959972 7319179864 9.66E+06 1793999293
12WI - 1 3.37E+08 12542441154 7765929157 8.13E+06 2530155242
12WI - 2 3.73E+08 11792324851 6262967962 8.58E+06 2371545745
12WI - 3 2.51E+08 8809490001 7116195159 1.11E+07 1995434529
12WI - 4 4.19E+08 13395052574 8275080757 1.46E+06 3016699805
12WI - 5 3.40E+08 14213876375 8008510409 1.80E+07 2430486761
30WI - 1 2.87E+08 11066746903 12843911132 1.04E+08 2078592758
30WI - 2 8.44E+08 13312023799 10725663863 3.11E+07 1871930008
30WI - 3 3.23E+08 11998523083 8488867041 6.35E+07 2391019044
30WI - 4 5.95E+08 12677656037 8540216409 2.64E+07 2758846050
30WI - 5 4.00E+08 14067563647 10396631208 7.44E+07 1887528101
6CI - 1 1.74E+07 2945100317 4841454549 4.58E+07 1761453188
6CI - 2 1.43E+07 2831452337 4460057964 5.10E+07 1274066340
6CI - 3 1.77E+07 4203374006 4790379895 1.89E+07 2800223894
6CI - 4 1.99E+07 3646127439 5509856944 5.48E+07 1811023208
6CI - 5 2.60E+07 2965952444 4940010076 9.77E+06 986419830.6
12CI - 1 1.84E+07 3525364519 9069470219 3.31E+07 1803349960
12CI - 2 2.68E+07 3055274375 5164694037 1.94E+07 1384427775
12CI - 3 1.65E+07 4495229578 5801615172 1.36E+07 2213324979
12CI - 4 2.01E+07 3310658480 6165697692 1.59E+07 1654985818
12CI - 5 1.61E+07 6205958551 6590344700 3.58E+07 1675357759
30CI - 1 1.92E+07 6198188637 5837891668 2.11E+07 1742812416
30CI - 2 1.02E+07 6586495546 5116632889 9.11E+06 1654505280
30CI - 3 1.31E+07 4974024566 3176078113 1.12E+07 1165531232
30CI - 4 1.58E+07 7674629098 5809542155 1.29E+07 2144581920
30CI - 5 1.48E+07 6376111861 5841063523 1.71E+07 1344526324
240CI - 1 7.02E+07 10009273663 5946934022 3.19E+08 1171824735
240CI - 2 7.45E+07 11602256043 6063568695 5.87E+06 1945535605
240CI - 3 6.34E+07 8025438141 4863796612 1.34E+07 1348849818
240CI - 4 5.01E+07 7103443918 4753374890 5.00E+07 1197145844
240CI - 5 6.52E+07 10375489599 5500336465 2.26E+06 1592837422
480CI - 1 8.35E+07 6558610702 5020628617 7.88E+07 1038881623
480CI - 2 1.19E+08 9318910993 4825811100 4.78E+07 1716074554
480CI - 3 7.77E+07 7538409475 5592539358 3.49E+07 2209710706
Control 9879908 1557169687 1953620445 49737418 1379481518
Control 13408532 1529521430 2964326400 113915737 1139481880
Control 12681762 1115095901 1890983128 88718274 1190448489
Control 9810203 1013777467 2115918408 43684391 956264556
Control 20384607 1012494181 1964283893 63886979 1031827872
240WI 16942314 9589859763 32701995619 1.267E+09 5241154577
240WI 16044986 7211457593 29273259006 1.628E+09 4113344243
240WI 11501354 8776805099 8434382967 728976803 2082313542









Appendix 1: Mouse LC-MS data





Control - 1 1.59E+09 112159925.6 NF 1268521050 1.30E+07 1.69E+07
Control - 2 1.31E+09 73706695.02 NF 1751318986 9.25E+06 4.28E+06
Control - 3 1.81E+09 70527405.72 NF 1047749880 8.80E+06 1.31E+07
Control - 4 1.32E+09 197591015.4 NF 702849575.6 7.87E+06 4.31E+06
Control - 5 1.72E+09 140547464.6 NF 888867114.2 5.65E+06 4.72E+06
Control - 6 1.56E+09 101071636.4 NF 927003230.4 6.31E+06 2.95E+07
6WI - 1 8.34E+08 111966543.7 NF 697600575.7 7.97E+06 1.48E+07
6WI - 2 8.14E+08 71698951.37 NF 1405393366 1.16E+07 3.84E+07
6WI - 3 5.80E+08 74065471.3 NF 1167315927 1.19E+07 2.62E+07
6WI - 4 5.69E+08 82070035.45 NF 1324698448 8.23E+06 3.33E+07
6WI - 5 9.66E+08 72538975.29 NF 1103095440 6.51E+06 2.56E+07
12WI - 1 4.62E+08 56656274.51 NF 2059810926 8.89E+06 9.73E+06
12WI - 2 4.31E+08 55600865.78 NF 1717663360 7.99E+06 5.50E+06
12WI - 3 3.45E+08 50487484.21 NF 1086724632 9.56E+06 2.74E+07
12WI - 4 4.20E+08 117627268.4 NF 1055774928 4.83E+06 3.87E+06
12WI - 5 6.22E+08 166307290 NF 1154457594 4.80E+06 1.43E+07
30WI - 1 2.97E+08 173923109.9 NF 846613127.2 1.74E+07 1.37E+07
30WI - 2 1.06E+08 53644259.4 NF 1581746304 7.87E+06 3.71E+06
30WI - 3 2.32E+08 119795770.9 NF 636979815.1 8.97E+06 1.23E+07
30WI - 4 1.02E+08 82073918.65 NF 1626802275 9.48E+06 1.82E+06
30WI - 5 3.27E+08 135648289.2 NF 674821110.2 1.06E+07 8.44E+06
6CI - 1 1.97E+09 118856416.4 NF 946472907.4 1.40E+07 4.34E+07
6CI - 2 9.39E+08 75792602.51 NF 1312996519 1.12E+07 1.02E+07
6CI - 3 1.90E+09 221363224.8 NF 869083728.4 9.68E+06 9.92E+06
6CI - 4 1.53E+09 163927605.6 NF 684381961.3 9.61E+06 1.26E+07
6CI - 5 1.88E+09 85415092.79 NF 1599510519 3.21E+06 5.38E+07
12CI - 1 1.29E+09 67588186.94 NF 1557134592 1.04E+07 6.78E+06
12CI - 2 1.74E+09 76620771.92 NF 1241631981 9.42E+06 2.05E+07
12CI - 3 1.16E+09 73964678.81 NF 1908543219 1.03E+07 7.27E+06
12CI - 4 1.97E+09 74208607.3 NF 1421480176 1.06E+07 1.46E+07
12CI - 5 1.91E+09 127374494.2 NF 1084041656 7.20E+06 4.54E+07
30CI - 1 1.43E+09 79753605.51 NF 1269393988 6.94E+06 1.99E+07
30CI - 2 1.21E+09 187184967.9 NF 532806439.1 6.29E+06 5.23E+06
30CI - 3 7.89E+08 47156106.34 NF 1127402492 1.19E+07 1.55E+07
30CI - 4 1.28E+09 189810579.3 NF 793902569.9 6.91E+06 1.15E+07
30CI - 5 1.56E+09 100350442.3 NF 1321792393 7.07E+06 5.70E+07
240CI - 1 7.40E+08 63112044.53 NF 1475353362 3.08E+07 5.11E+07
240CI - 2 9.03E+08 165728220.6 NF 744137909.7 8.69E+06 4.85E+07
240CI - 3 8.48E+08 51094231.98 NF 1470807956 1.14E+07 5.07E+07
240CI - 4 8.19E+08 48506590.71 NF 1280398601 1.11E+07 7.85E+07
240CI - 5 7.75E+08 75464505.7 NF 1277294604 7.97E+06 4.79E+07
480CI - 1 6.96E+08 62564947.05 NF 906452462.2 1.24E+07 2.96E+07
480CI - 2 5.39E+08 120220341.5 NF 980975625.7 1.14E+07 3.26E+07
480CI - 3 5.88E+08 124806331.8 NF 876899123.9 1.10E+07 2.58E+07
Control 1.41E+09 0.00E+00 612869 688351125 7119454 4324109
Control 1.33E+09 7.95E+05 632685 773273321 8917159 1552742
Control 1.31E+09 0.00E+00 3107433 531200990 11640953 3535927
Control 1.16E+09 0.00E+00 1171927 520260093 4965874 3537578
Control 1.57E+09 0.00E+00 2240267 528529056 9708799 7024659
240WI 68995212 1.13E+07 21686674 4872978102 28249638 0
240WI 24953516 4.10E+06 4421469 4109035248 56587823 723338
240WI 14751717 2.90E+06 13619569 1364932667 20350816 0









Appendix 1: Mouse LC-MS data
condition n-acetyl 
aspartate
NAD NADH nicotinamide octanoylcarnitine
Control - 1 359705037.9 2.13E+07 NF 2828477605 5.06E+06
Control - 2 73528051.42 2.24E+07 NF 1986877679 1.38E+06
Control - 3 94996110.16 3.25E+07 1.33E+06 1435256181 2.35E+06
Control - 4 144152733 3.20E+07 7.06E+05 2747655471 7.95E+05
Control - 5 285003344.9 2.54E+07 1.56E+06 1264741013 5.99E+05
Control - 6 166009172 3.12E+07 5.78E+06 1926342068 7.49E+06
6WI - 1 134267352.3 2.33E+07 9.58E+06 2880646777 1.20E+07
6WI - 2 285593193.8 1.59E+07 5.44E+06 1627562860 1.76E+07
6WI - 3 92077642.28 2.33E+07 1.19E+07 1426351156 1.79E+07
6WI - 4 69987959.71 2.29E+07 1.46E+07 1049508819 1.44E+07
6WI - 5 79544736.31 2.46E+07 1.33E+07 1543230914 1.75E+07
12WI - 1 96541586.32 1.66E+07 1.06E+07 1499226344 2.01E+07
12WI - 2 82691632.2 1.89E+07 1.14E+07 1612697037 2.54E+07
12WI - 3 98017286.79 1.96E+07 1.80E+07 1157186565 2.67E+07
12WI - 4 115268181.5 1.91E+07 1.68E+07 1272338157 1.44E+07
12WI - 5 176461289.2 2.99E+07 8.64E+06 3507236697 2.65E+07
30WI - 1 602827373.3 9.95E+06 1.72E+07 1348957098 2.28E+07
30WI - 2 88442885.31 1.45E+07 1.92E+07 1611846320 1.74E+07
30WI - 3 133736714.5 1.10E+07 2.72E+07 1231563528 9.75E+06
30WI - 4 106011445.5 1.08E+07 2.20E+07 943680474.4 8.13E+06
30WI - 5 235780395.8 1.96E+07 1.89E+07 3175587423 3.14E+07
6CI - 1 349930538.4 2.21E+07 3.17E+06 1868743477 9.16E+06
6CI - 2 163915386.3 2.28E+07 7.09E+06 2112047964 1.68E+06
6CI - 3 168488804.9 2.61E+07 2.07E+06 3530994694 7.38E+06
6CI - 4 125081681 2.47E+07 1.01E+07 1841798145 2.48E+06
6CI - 5 172764494.8 2.53E+07 2.69E+06 4672977925 1.37E+07
12CI - 1 99783841.71 2.59E+07 7.33E+06 3109860437 1.46E+06
12CI - 2 124952034.4 2.85E+07 1.10E+07 1253168828 2.92E+06
12CI - 3 95103271.55 2.64E+07 7.03E+06 2885359445 2.38E+06
12CI - 4 93868656.17 2.56E+07 1.19E+07 775107205 2.42E+06
12CI - 5 273749724 2.42E+07 4.42E+06 4053282554 7.96E+06
30CI - 1 102899872.3 2.51E+07 1.33E+07 2346152366 2.22E+06
30CI - 2 158131699.2 2.54E+07 9.25E+06 1789433706 5.92E+05
30CI - 3 107015472.7 2.50E+07 1.51E+07 1771764829 1.65E+06
30CI - 4 162570497.9 2.72E+07 1.39E+07 2369389340 3.25E+06
30CI - 5 130486619.5 2.41E+07 6.85E+06 4848853632 8.15E+06
240CI - 1 106449946.1 2.38E+07 5.30E+06 1288438985 4.37E+06
240CI - 2 180097419 2.74E+07 1.38E+07 1062472005 4.48E+06
240CI - 3 180702793.4 2.15E+07 1.04E+07 915499038.6 4.78E+06
240CI - 4 477199052.7 1.95E+07 9.00E+06 741244489.9 5.68E+06
240CI - 5 122223318.7 2.13E+07 1.17E+07 667029724.6 4.87E+06
480CI - 1 619952190.2 1.41E+07 1.25E+07 464553328.4 6.21E+06
480CI - 2 190904510.3 1.74E+07 3.01E+07 499982173.1 8.00E+06
480CI - 3 225880727.2 1.66E+07 2.91E+07 623870290.9 3.46E+06
Control 128903242 2.3E+07 3954239 76821054 724651
Control 101848275 2.3E+07 8364852 117211363 203776
Control 123844736 3.1E+07 9396270 141714897 261045
Control 87416805 1.5E+07 3468843 98118210 345896
Control 106163706 2.6E+07 6748266 129413050 1197708
240WI 131342218 209315 3215798 1317258319 0
240WI 174609347 349530 4065605 1037900565 0
240WI 124119376 657710 2626142 2003503411 92931









Appendix 1: Mouse LC-MS data
condition oleic acid oleyl 
carnitine




Control - 1 5.96E+07 7.81E+07 170335182.1 1325659.108 1.62E+08 1.22E+07
Control - 2 5.95E+07 3.97E+07 284923987.9 590154.0182 1.38E+08 7.70E+06
Control - 3 3.02E+07 4.70E+07 133515878.2 570728.2054 1.17E+08 3.43E+06
Control - 4 4.25E+07 6.95E+07 166517522.3 566416.9508 1.31E+08 3.84E+06
Control - 5 4.65E+07 2.72E+07 179251676.2 426089.8324 1.16E+08 5.60E+06
Control - 6 1.74E+07 5.95E+07 77688340.88 335580.0529 9.01E+07 1.83E+06
6WI - 1 2.86E+07 3.19E+07 159887756.6 1541291.293 1.06E+08 2.22E+06
6WI - 2 6.52E+07 7.31E+07 183967441.6 698534.6603 1.39E+08 1.19E+07
6WI - 3 4.77E+07 7.69E+07 126320932.6 681118.1906 1.23E+08 5.92E+06
6WI - 4 1.40E+07 8.34E+07 89019731.54 648094.5553 1.19E+08 9.90E+05
6WI - 5 1.10E+07 4.16E+07 99142968.67 552372.8879 9.30E+07 NF
12WI - 1 1.10E+07 3.10E+07 207162357 1259685.801 9.38E+07 1.49E+06
12WI - 2 1.11E+07 2.38E+07 154249061.5 873002.0692 9.75E+07 1.91E+06
12WI - 3 1.50E+07 8.06E+07 94133694.68 413029.0435 1.22E+08 2.33E+06
12WI - 4 4.76E+06 1.43E+07 178793939.3 1015102.728 6.95E+07 NF
12WI - 5 1.23E+07 3.95E+07 170103530.7 1406107.872 7.06E+07 NF
30WI - 1 9.44E+07 1.13E+08 248878096.9 1910046.074 2.18E+08 1.75E+07
30WI - 2 2.56E+07 2.69E+07 161663401 853568.1569 1.13E+08 3.79E+05
30WI - 3 5.70E+07 6.63E+07 94697614.65 719728.1226 1.39E+08 3.65E+06
30WI - 4 2.09E+07 2.22E+07 212949077.3 2136693.198 1.30E+08 9.15E+05
30WI - 5 4.72E+07 6.41E+07 141939250.7 2209915.361 1.56E+08 6.42E+06
6CI - 1 4.84E+07 1.27E+08 81349228.51 629987.4299 1.76E+08 6.92E+06
6CI - 2 5.07E+07 5.64E+07 101989666.7 137894.0992 1.38E+08 6.73E+06
6CI - 3 1.11E+07 4.07E+07 101758648.3 951752.7111 1.22E+08 NF
6CI - 4 3.03E+07 5.37E+07 85136980.07 535844.385 1.34E+08 5.55E+06
6CI - 5 7.96E+06 1.06E+08 101278103.6 244291.7225 7.14E+07 4.09E+05
12CI - 1 2.03E+07 8.23E+07 145965221.4 400398.2844 1.33E+08 9.23E+05
12CI - 2 1.29E+07 7.02E+07 108835651.9 649897.2068 1.25E+08 2.28E+06
12CI - 3 1.42E+07 4.03E+07 128173284.9 481637.109 1.04E+08 NF
12CI - 4 7.47E+06 4.12E+07 96021398.67 382216.6968 1.13E+08 NF
12CI - 5 2.27E+07 2.18E+08 109841289.7 285814.9695 1.00E+08 2.20E+06
30CI - 1 1.39E+07 2.09E+08 99559567.53 772860.7976 1.14E+08 1.15E+06
30CI - 2 8.58E+06 3.56E+07 90722624.61 398226.1584 1.15E+08 NF
30CI - 3 8.09E+06 8.42E+07 100390501.3 293573.6246 1.17E+08 1.62E+05
30CI - 4 1.18E+07 6.85E+07 113606556.6 645621.1261 1.03E+08 NF
30CI - 5 1.41E+07 1.44E+08 76481547.34 891770.5518 1.04E+08 1.99E+05
240CI - 1 3.42E+08 3.37E+08 103413424.9 979755.5172 3.37E+08 6.47E+07
240CI - 2 8.31E+06 2.70E+08 86358896 1415064.981 1.19E+08 NF
240CI - 3 1.81E+07 2.57E+08 84350449.92 834212.1824 1.18E+08 1.71E+06
240CI - 4 6.94E+07 4.76E+08 82414383.94 1257486.077 1.22E+08 1.37E+07
240CI - 5 2.89E+06 2.41E+08 78750289.54 1342850.659 9.11E+07 NF
480CI - 1 8.78E+07 1.89E+08 109575671.2 1549721.509 1.68E+08 1.80E+07
480CI - 2 2.99E+07 1.70E+08 133619756.1 5610666.593 1.14E+08 1.99E+06
480CI - 3 2.59E+07 1.24E+08 78245101.17 2288882.787 1.42E+08 1.19E+06
Control 37118126 16747882 48973348 51064 1.22E+08 4808499
Control 78339085 7900238 57099994 260090 1.5E+08 10053364
Control 53484333 12004873 34749159 87653 1.46E+08 12523579
Control 26390807 12755628 26165663 267105 79932651 5662729
Control 40323554 24605915 29804950 112648 1.31E+08 8609245
240WI 600980789 5043125 757025535 588007 7.92E+08 52302883
240WI 798813453 4932195 1011011215 2738730 1.01E+09 111593978
240WI 412630602 11312485 143358468 150453 6.31E+08 38453180



















Control - 1 77864802.59 457283932.2 1507503785 8.62E+05 1746308401
Control - 2 44450143.49 460268488.8 1880858657 NF 1977990791
Control - 3 56788629.93 536834111.6 1123636102 NF 1956123653
Control - 4 52479203.47 1068821847 1326362917 NF 2339464018
Control - 5 32323088.08 570879971.4 1435422280 NF 2253553696
Control - 6 78584219.86 611802233.8 1272531771 6.76E+05 1590679935
6WI - 1 47444034.4 969307299.3 2104241013 NF 2535781845
6WI - 2 83910764.29 644878669.6 1664695167 NF 1977364378
6WI - 3 64288726.03 777516309.5 1482477279 NF 1782433452
6WI - 4 66986953.65 870506514.3 1159475117 NF 1845390646
6WI - 5 49275960.43 892757883.8 1313409205 1.27E+05 1697917343
12WI - 1 38466450.1 846687411.9 1673609839 NF 2905856549
12WI - 2 29594948.79 781078411.3 1542645287 NF 2581969033
12WI - 3 74343412.54 1016600817 1500867996 NF 1761124099
12WI - 4 25568043.52 1161207627 1960093446 NF 3270601050
12WI - 5 49582143.75 1629396663 2043455591 NF 3724847614
30WI - 1 94500397.62 1077902736 2570607558 NF 3411318962
30WI - 2 25281192.6 870110323.9 2158648633 NF 2846931270
30WI - 3 58726557.94 1322086476 1975132212 NF 2755815102
30WI - 4 17907152.5 1044670375 1904823310 NF 3844425721
30WI - 5 57278874.45 2285805847 3634919176 NF 3560848629
6CI - 1 156921004.4 663564424.1 996375281.2 NF 1450330712
6CI - 2 53234773.27 513055344.2 991984783.7 4.44E+05 2006136809
6CI - 3 52622452.19 959842922.1 1399454946 4.05E+05 1914213512
6CI - 4 72472951.78 838013548.7 1208547026 1.95E+05 1890854542
6CI - 5 137703442.5 660058740.7 1547065766 4.71E+06 1875383553
12CI - 1 71286362.96 687373041.4 1404966617 2.19E+05 2075826578
12CI - 2 94385672.02 678678794 1471817075 NF 1435856083
12CI - 3 48182177.03 632878594.3 1361121743 3.14E+05 2214056252
12CI - 4 72189735.72 652548487.1 1262148260 NF 1457074509
12CI - 5 157971516.8 829818526.2 1174224078 1.49E+06 3053105731
30CI - 1 201094443 772581299 1074749205 NF 1570945598
30CI - 2 59715100.94 771023548 1167831992 NF 1693885643
30CI - 3 110821689 720229992.4 1391078385 NF 1423369116
30CI - 4 100507410.7 905077551.5 1532026407 NF 1914459571
30CI - 5 130522680.8 636414439.5 1089974335 3.72E+06 1911661111
240CI - 1 295166699.1 713503215.7 1093841022 1.66E+05 2526889998
240CI - 2 283495792.3 1470427821 1357442915 NF 1634405024
240CI - 3 242311413.6 555695372.8 931048969.4 NF 1579354869
240CI - 4 393100564.3 548209933.8 873976527.4 NF 1709611321
240CI - 5 246731158.8 765989997.7 1079437273 NF 1732908272
480CI - 1 173680762.3 493232544.7 791734793.9 NF 2501547789
480CI - 2 210019636 1306661922 2118111645 NF 2923504223
480CI - 3 179781731.9 1128674613 999462334.2 NF 1815096813
Control 36510680 321895420 444755002 0 798204529
Control 14640784 484504059 694963852 0 1090095428
Control 19614028 416248744 525163365 0 746963009
Control 23837390 372210436 593160931 0 632674636
Control 44275319 342759657 539098465 0 549678407
240WI 10936209 1178314666 11635046168 0 8878266669
240WI 6325104 754178126 10771710731 0 4516293297
240WI 11772007 1338636880 2565708504 0 2742885314









Appendix 1: Mouse LC-MS data
condition propionyl-
carnitine




Control - 1 139604361 170765315 3.78E+07 NF 6.91E+04
Control - 2 67716882.62 109388045.7 2.86E+07 NF 6.49E+04
Control - 3 92858286.62 186334169.7 9.74E+06 NF 1.29E+05
Control - 4 94050646.51 312928549.8 8.47E+06 NF 1.90E+05
Control - 5 127871710.6 201619759.8 9.12E+06 NF 1.59E+05
Control - 6 149474157.5 226383842.3 7.45E+06 NF 2.17E+05
6WI - 1 1074548459 360177359.8 4.33E+06 1.68E+07 1.05E+05
6WI - 2 883321555.1 160357160.1 2.19E+06 1.26E+07 3.46E+04
6WI - 3 914044266.5 171053178.3 4.33E+06 1.91E+07 4.22E+04
6WI - 4 1012314592 225303414.1 2.51E+06 2.03E+07 7.96E+04
6WI - 5 1263414158 253709350.7 NF 1.95E+07 8.18E+04
12WI - 1 2008233435 172756169.7 NF 3.29E+07 4.75E+04
12WI - 2 1883679036 153527166.6 NF 2.35E+07 7.42E+04
12WI - 3 1400995657 290142193.4 NF 3.10E+07 2.50E+04
12WI - 4 2350547704 341125319 NF 3.33E+07 9.46E+04
12WI - 5 1940277347 457603215.6 3.13E+06 3.58E+07 1.29E+05
30WI - 1 978954563.1 393385954.6 NF 6.32E+07 4.28E+04
30WI - 2 2406494637 205647856 NF 6.77E+07 2.11E+04
30WI - 3 943951804.5 501688830.6 NF 7.78E+07 3.74E+04
30WI - 4 1660135642 408654628.9 4.46E+06 7.29E+07 6.80E+04
30WI - 5 1101133066 720837078.3 6.57E+06 8.61E+07 5.15E+05
6CI - 1 152112041.8 275293029.8 2.74E+06 4.23E+05 4.82E+04
6CI - 2 94277234.53 228553797.2 4.36E+06 1.57E+05 3.73E+04
6CI - 3 130274409.1 448502269.2 4.60E+06 NF 1.87E+05
6CI - 4 125322346 372711654.9 3.81E+06 1.48E+05 9.33E+04
6CI - 5 245521972.4 215528146 9.74E+06 2.88E+06 3.97E+05
12CI - 1 143606298.1 188404376.8 3.66E+06 NF 1.15E+05
12CI - 2 323732168.1 180487167.4 2.60E+06 3.53E+05 1.62E+05
12CI - 3 137718153.7 268731783.8 2.80E+06 3.36E+05 1.53E+05
12CI - 4 132890277.5 193127995.6 NF NF 1.67E+05
12CI - 5 198844282.5 319929867.5 4.57E+06 1.77E+06 1.46E+05
30CI - 1 230084708.1 298039033.9 NF NF 1.10E+05
30CI - 2 166236021.5 481728686.1 1.78E+06 7.39E+05 1.16E+05
30CI - 3 224593570.3 223194707.2 1.72E+06 NF 1.42E+05
30CI - 4 222132260.6 580984772.3 NF 1.05E+06 1.94E+05
30CI - 5 173049936.2 216112564.6 7.75E+06 3.56E+06 1.93E+05
240CI - 1 810415752.6 325008128 2.32E+06 2.82E+06 5.27E+04
240CI - 2 883583609.9 783037131.1 NF 5.34E+06 8.39E+04
240CI - 3 716766365 338141115.8 NF 2.50E+06 9.27E+04
240CI - 4 604393397.9 410376362.3 NF 1.86E+06 5.31E+04
240CI - 5 741879393.8 506171223.7 NF 3.15E+06 5.08E+04
480CI - 1 471716409.9 478767116.8 2.18E+06 1.76E+07 6.83E+04
480CI - 2 558664666.2 920565739.3 NF 2.09E+07 1.10E+05
480CI - 3 373403250.2 671144065.4 NF 2.16E+07 7.67E+04
Control 51640569 51337973 31136587 344511 31507
Control 56173280 105202849 10119083 174376 0
Control 51795355 110440259 5850605 0 0
Control 73076155 99404961 3778805 0 0
Control 75117739 42429022 8139521 0 34398
240WI 38368818 548330618 9650758 64682971 36746
240WI 45264917 270620073 0 56750955 11841
240WI 45171471 514631751 0 69919172 19757
















serine serotonin stearic 
acid
Control - 1 7.66E+05 4.30E+07 NF 763786372.4 2.13E+07 1.23E+08
Control - 2 1.45E+05 5.46E+07 NF 889536887.6 2.20E+07 1.05E+08
Control - 3 NF 6.06E+07 NF 776503964 1.24E+07 9.65E+07
Control - 4 NF 4.52E+07 NF 1297847349 1.14E+07 1.14E+08
Control - 5 2.82E+05 4.84E+07 NF 906569978.1 1.04E+07 8.40E+07
Control - 6 2.05E+05 3.04E+07 NF 939954049.1 8.28E+06 5.55E+07
6WI - 1 5.54E+06 2.63E+07 NF 940182621.4 5.81E+06 7.65E+07
6WI - 2 1.52E+07 2.62E+07 NF 683992781.8 1.48E+07 1.13E+08
6WI - 3 5.59E+06 2.27E+07 NF 913780017.1 9.01E+06 1.18E+08
6WI - 4 7.19E+06 2.69E+07 NF 865608711.9 7.01E+06 1.19E+08
6WI - 5 1.12E+07 2.49E+07 NF 806021019.8 4.86E+06 9.77E+07
12WI - 1 8.38E+06 2.78E+07 NF 1090267288 5.42E+06 9.31E+07
12WI - 2 1.31E+07 2.96E+07 NF 1220302565 5.28E+06 1.27E+08
12WI - 3 1.07E+07 2.35E+07 NF 1024114347 6.40E+06 1.26E+08
12WI - 4 8.49E+06 2.68E+07 NF 1659003952 5.19E+06 8.07E+07
12WI - 5 1.16E+07 2.31E+07 NF 1694830835 5.40E+06 6.06E+07
30WI - 1 6.95E+07 2.30E+07 NF 1093128421 2.00E+07 1.82E+08
30WI - 2 2.63E+07 2.76E+07 NF 852846951.2 4.22E+06 1.05E+08
30WI - 3 3.55E+07 2.52E+07 NF 994765889 4.29E+06 1.14E+08
30WI - 4 5.65E+07 3.14E+07 NF 1739221779 3.55E+06 1.29E+08
30WI - 5 3.72E+07 2.00E+07 NF 1560531440 3.91E+06 8.89E+07
6CI - 1 1.66E+06 2.80E+07 NF 922040912.2 8.70E+06 1.33E+08
6CI - 2 8.44E+05 1.88E+07 NF 613587989.7 7.34E+06 1.25E+08
6CI - 3 3.41E+06 2.50E+07 NF 1316048878 4.91E+06 1.07E+08
6CI - 4 2.36E+06 3.42E+07 NF 1473890106 4.39E+06 1.44E+08
6CI - 5 1.30E+06 1.64E+07 NF 782353994.1 2.94E+06 4.48E+07
12CI - 1 2.28E+06 1.53E+07 NF 724884877.1 5.13E+06 1.42E+08
12CI - 2 7.44E+05 2.51E+07 NF 662827930.1 4.64E+06 1.01E+08
12CI - 3 4.42E+06 2.27E+07 NF 1227492596 6.25E+06 1.04E+08
12CI - 4 1.52E+06 2.67E+07 NF 871473281 4.07E+06 9.86E+07
12CI - 5 5.51E+06 1.24E+07 NF 1173992621 6.36E+06 4.92E+07
30CI - 1 4.00E+06 2.27E+07 NF 1077741400 5.92E+06 1.15E+08
30CI - 2 3.21E+06 2.05E+07 NF 1029425207 5.94E+06 9.90E+07
30CI - 3 9.75E+05 2.51E+07 NF 767992752 4.36E+06 1.08E+08
30CI - 4 7.38E+06 2.25E+07 NF 1402419231 8.42E+06 1.09E+08
30CI - 5 3.39E+06 1.41E+07 NF 1030478889 4.36E+06 7.02E+07
240CI - 1 5.51E+06 1.29E+07 NF 909450230.2 1.36E+07 1.55E+08
240CI - 2 8.14E+06 2.04E+07 NF 1094568600 6.11E+06 1.30E+08
240CI - 3 6.60E+06 1.78E+07 NF 873645827.3 8.89E+06 1.17E+08
240CI - 4 6.49E+06 1.42E+07 NF 544348116.9 1.13E+07 9.43E+07
240CI - 5 6.41E+06 1.90E+07 NF 1184470104 6.68E+06 9.87E+07
480CI - 1 1.63E+07 1.17E+07 NF 617534738.3 1.84E+07 9.55E+07
480CI - 2 8.39E+06 2.13E+07 NF 1207855896 3.47E+06 8.48E+07
480CI - 3 9.71E+06 2.32E+07 NF 1215828540 6.64E+06 1.08E+08
Control 19622 71695526 0 649442734 12352236 83576114
Control 103916 65989237 0 946871631 7982069 87739549
Control 21864 59519452 0 555456969 4318761 88421766
Control 18273 51270906 0 786069731 3499146 59717151
Control 75001 64356221 0 721805699 7309712 92047333
240WI 91268701 15914816 5307393 1878799460 11945023 4.17E+08
240WI 67732595 12406727 3748479 1402388967 7851626 4.52E+08
240WI 91487640 22222239 5595237 1063748051 3386210 3.33E+08









Appendix 1: Mouse LC-MS data
condition stearoyl 
carnitine





Control - 1 1.85E+07 410970884.1 4.06E+07 NF 11751224674
Control - 2 8.00E+06 453836246.6 4.59E+07 NF 11654139567
Control - 3 1.33E+07 991867872.8 2.14E+07 NF 11850115686
Control - 4 8.62E+06 654649481 2.52E+07 NF 12786911579
Control - 5 6.68E+06 819340334.5 4.10E+07 NF 12060076506
Control - 6 2.79E+07 808025866.7 2.56E+07 NF 11801600582
6WI - 1 1.84E+07 7035155042 3.08E+06 1.09E+06 12427683909
6WI - 2 3.17E+07 5082346889 NF 1.79E+06 11093423090
6WI - 3 3.87E+07 5346196474 NF 3.28E+05 11889921639
6WI - 4 3.72E+07 6437135668 NF 4.06E+05 11747089979
6WI - 5 2.15E+07 7513795713 NF 1.88E+06 11959361843
12WI - 1 1.68E+07 7193485969 NF 2.81E+06 12041594301
12WI - 2 1.45E+07 6554397401 NF 1.53E+06 11847556637
12WI - 3 6.21E+07 6813385311 NF 1.31E+06 11719461090
12WI - 4 1.18E+07 10158118460 NF 3.20E+06 12673864148
12WI - 5 2.35E+07 9787014635 NF 4.16E+06 12623714372
30WI - 1 1.44E+08 8408268472 NF 6.32E+06 12655088865
30WI - 2 5.87E+07 8504302623 NF 7.25E+06 11890362104
30WI - 3 1.20E+08 7855248346 NF 2.04E+06 13242753228
30WI - 4 6.90E+07 9338957473 NF 8.62E+06 11760153023
30WI - 5 1.44E+08 9117132897 NF 3.49E+06 13476008252
6CI - 1 3.54E+07 1586665848 3.03E+07 1.31E+05 12204258091
6CI - 2 1.64E+07 1119460197 NF NF 11464915406
6CI - 3 1.68E+07 1668083430 2.05E+07 7.88E+04 12903551121
6CI - 4 9.12E+06 1895801115 1.98E+07 NF 12937547035
6CI - 5 4.47E+07 1299001720 2.93E+07 1.64E+05 11977857609
12CI - 1 2.37E+07 1402616867 2.67E+07 NF 11459780612
12CI - 2 2.13E+07 1553286559 2.86E+07 3.08E+04 11917632535
12CI - 3 1.90E+07 1646323704 1.70E+07 NF 11647263793
12CI - 4 2.07E+07 1705169290 2.07E+07 NF 11754360214
12CI - 5 4.10E+07 2106063995 1.86E+07 3.09E+05 11792761217
30CI - 1 3.83E+07 2656934572 8.71E+06 5.42E+04 11296735280
30CI - 2 1.84E+07 2281210043 1.41E+07 6.19E+04 12726909577
30CI - 3 3.26E+07 1938720377 NF NF 11911183195
30CI - 4 3.22E+07 3052857864 1.98E+07 NF 12918365545
30CI - 5 5.13E+07 2063943075 NF 8.28E+04 11616919512
240CI - 1 1.50E+08 3840365375 4.11E+06 9.98E+04 10756776560
240CI - 2 1.51E+08 5775581653 NF 8.03E+04 12855923983
240CI - 3 1.64E+08 3711134205 NF 1.75E+05 10488074019
240CI - 4 1.73E+08 3576547147 2.16E+06 1.36E+05 10507462154
240CI - 5 1.63E+08 4891583976 NF 1.32E+05 11383007366
480CI - 1 1.32E+08 4259730053 NF 3.61E+06 10094755731
480CI - 2 2.04E+08 6796970173 NF 1.31E+06 12628748437
480CI - 3 1.54E+08 6070019696 NF 1.26E+06 12389559846
Control 6596751 6.95E+08 92229251 21162 6668389858
Control 2426032 8.12E+08 75690946 0 6676378196
Control 2743035 6.65E+08 111800020 0 7090772563
Control 2981503 7.63E+08 73594407 0 6909448031
Control 5338695 7.08E+08 106711239 0 7052123875
240WI 22472552 8.21E+09 113692829 3975374 7073029469
240WI 16723584 6.79E+09 89440671 2288357 6703981795
240WI 27743185 8.02E+09 144583151 921859 7169503745









Appendix 1: Mouse LC-MS data
condition threonine thymine tryptophan tyrosine uracil uric acid
Control - 1 2213628318 5071165.228 650813215.3 329733982 NF 6339944.8
Control - 2 2393257094 6214353.301 566794966 522786306 NF 3277654.5
Control - 3 2006930993 7783316.033 352378898.6 345723521 NF 1512396.5
Control - 4 2400832469 8935030.073 374945424.1 539388746 185292.847 1083020.5
Control - 5 2191684320 7653387.05 511902849 786676672 NF 1972227.9
Control - 6 1600643231 7242438.109 428478196.9 475813537 NF 3658427.7
6WI - 1 1696506757 10451869.62 547848026.6 1093086987 62083772.9 35247633
6WI - 2 1749298091 5738522.317 458053168.8 390062831 25196377.7 42314820
6WI - 3 1874294774 4890617.377 342982455.3 302506376 46741021.1 27827099
6WI - 4 2266368307 8584063.519 388646651.6 315871652 50138764.7 22516230
6WI - 5 2237192350 7631597.664 443677353.1 380557542 39648137.3 20234475
12WI - 1 2566082085 5808080.199 362543717.9 401565153 61812621.3 15678803
12WI - 2 2654219016 5180849.199 339315644.3 368066501 59503761.8 23178883
12WI - 3 2183661056 9066374.273 337673815.7 385032058 66916799.7 23003526
12WI - 4 2858589924 9727231.836 443807487.2 940237200 88599897.3 12799793
12WI - 5 2509140311 10029118.04 489582739.3 798460838 129600277 33515684
30WI - 1 2722468542 7307243.027 584543965.5 984134842 241799448 55724856
30WI - 2 1787506219 5504224.969 517938167.5 520424723 139930653 4712516.3
30WI - 3 2035966001 10323182.35 447845241 767465947 246876525 24625560
30WI - 4 2602280788 8376584.292 504875848.3 883084272 158244298 3485794.7
30WI - 5 1923188107 13805825.22 550762302.9 1139045542 313710464 21978873
6CI - 1 1819145561 3775192.734 378750345.1 483182656 NF 5764927.2
6CI - 2 1540056044 4486948.117 243374625.6 269100520 NF 1569431
6CI - 3 2553440034 5445671.348 442990104.2 839643369 1053284.97 3058447
6CI - 4 2096198641 6476086.411 351924626.5 782292157 936651.063 1903768
6CI - 5 1663108586 6242422.799 483298521.3 591414913 NF 8023867.5
12CI - 1 1796690117 2877489.722 399028279.7 557452929 NF 3149335.9
12CI - 2 1732493197 7721732.267 406320422.5 517014442 NF 5903857.8
12CI - 3 2453459615 5574050.088 402158732 455504423 NF 1742323
12CI - 4 2150022114 4580578.274 359793847.1 336996563 NF 596142.16
12CI - 5 2268904509 4695756.639 354637244.2 709216780 NF 5926889.8
30CI - 1 1841790054 4792257.628 335713070.5 499209608 353084.018 2136492.3
30CI - 2 1614146486 4696403.809 283930196.4 795632802 424977.445 1985799.4
30CI - 3 1475729233 6284809.041 372459978.9 493503702 NF 2478549.4
30CI - 4 2074124153 4765883.077 440188891.8 1063676241 457429.508 5337272.1
30CI - 5 2199869398 4021461.711 325965856.6 386226313 NF 4489742.8
240CI - 1 1266819068 606314.9574 262485409.4 407178224 NF 732318.41
240CI - 2 1671573087 4010456.053 288095835.9 807790884 NF 442524.91
240CI - 3 1383938014 NF 218770543 293481101 NF 210327.29
240CI - 4 1178601621 NF 207788041.3 242844869 NF 299614.78
240CI - 5 1647560808 1086492.108 266514184.1 482309467 NF NF
480CI - 1 997911103 162431.8818 189658999.6 510127074 9877296.32 698074.66
480CI - 2 1533700891 4856175.706 373504091.5 908556412 34090684.5 957654.65
480CI - 3 1884758018 2088874.027 247884001.8 478761690 38713382.8 163039.46
Control 1235476691 3426497 149198236 262087112 540422 1713747
Control 1544525221 2978677 262330985 418627085 734782 140860
Control 1281211910 2431144 191401717 318388636 434075 180122
Control 1381764786 2661700 175713484 286502712 0 1465709
Control 1098835498 3176817 193681019 245802022 215937 1283741
240WI 4495181484 4122365 1785478901 2936928880 374445418 4257577
240WI 3446839077 2410344 1526553111 3115596276 380133418 2057382
240WI 2254360561 3536323 444413290 1047615872 293428756 5863161









Appendix 1: Mouse LC-MS data
condition uridine valine xanthine
Control - 1 3069343.265 2208768577 223484.8142
Control - 2 2565130.313 2697964226 200027.6451
Control - 3 2098846.009 1837209331 NF
Control - 4 3223497.793 2357676098 NF
Control - 5 919441.8517 1815754042 349183.9913
Control - 6 2193351.537 3331026862 NF
6WI - 1 1398091.592 2862983018 330511904
6WI - 2 NF 2847742382 346250206.9
6WI - 3 2137532.142 1995222469 330827734.2
6WI - 4 2528084.968 1882731907 320497376.2
6WI - 5 1744044.601 1998770691 276433603.9
12WI - 1 2219313.003 1682429477 630760630
12WI - 2 1423536.504 1887271473 635160338
12WI - 3 2187222.342 1778116732 621582523.4
12WI - 4 2727654.95 2278382806 806477880.1
12WI - 5 5074014.278 2100330276 824440487.1
30WI - 1 3391964.755 2502297440 1622034511
30WI - 2 2523536.087 1833078233 1382669660
30WI - 3 2670241.02 1970523988 1671209727
30WI - 4 541009.4691 2663718734 1124240765
30WI - 5 3972539.382 3631715484 1668334744
6CI - 1 2255679.319 1779321191 605286.7038
6CI - 2 404194.0351 3340555657 1105917.298
6CI - 3 946835.2377 1847517749 327493.3775
6CI - 4 4154192.008 2110893799 202828.4281
6CI - 5 1554188.462 3197219906 1944252.118
12CI - 1 2331331.767 2045556880 1726138.122
12CI - 2 1744161.218 2523935483 778272.7422
12CI - 3 544876.2587 1720643717 1579232.874
12CI - 4 1809291.356 1665789127 372479.4913
12CI - 5 981955.9122 1778996350 1709834.837
30CI - 1 915720.5198 2067594254 926226.0918
30CI - 2 1743786.83 2259441739 6833377.692
30CI - 3 NF 3004613663 9851042.442
30CI - 4 1336844.741 2144050500 16376797.39
30CI - 5 3015148.249 1906397842 15934833.01
240CI - 1 NF 3612150843 27882924.96
240CI - 2 497645.7606 2296374690 16883856.14
240CI - 3 NF 2060173662 16952657.16
240CI - 4 NF 1922641204 9874521.383
240CI - 5 412845.7745 2287681944 16476359.32
480CI - 1 206542.5218 1749918942 28403881.85
480CI - 2 196447.3435 2999934950 22912110.9
480CI - 3 NF 1922758373 18200149.6
Control 0 1750843745 0.00E+00
Control 738132 2156582264 0.00E+00
Control 0 1785438989 0.00E+00
Control 658759 2118360817 0.00E+00
Control 0 1887341410 0.00E+00
240WI 56604906 12406756055 3.93E+09
240WI 63955508 10121225874 3.21E+09
240WI 31535408 5970244752 4.79E+09

















Appendix 2: Pig LC-MS data
peak area (a.u.)
HEPES succinyl-acetone fumarate succinate 3-hydroxy-butyrate lactate
Control 17024381 0 51978896 853649949 20402397 4222260800
6WI 11031072 0 94777230 2107847153 22985089 11087629645
12WI 7530629 0 99020675 2213128974 22206310 12119207471
30WI 15021385 0 36606086 1238096859 17800731 6189381325
60WI 14746700 0 117401818 8524662632 78989478 29707457631
240WI 18904728 0 88938531 5878564521 54538810 33408326284
6CI 15670751 0 39119989 1022674566 20781822 4657149420
12CI 13341629 0 30816206 959101798 19282361 3246651953
30CI 12943227 0 101823767 5014465295 44283696 22301730415
60 CI 15726817 0 34234860 1285921019 18140657 7599598621
240CI 15500735 0 40825427 906497812 14491491 8696817765
480CI 14862883 0 33028965 1024807137 15218861 10879267127
Control 28195319 14949705 61460273 1169318830 43197588 6749835418
6WI 25763237 12544606 150574580 3362413936 37695386 24974264958
12WI 21082135 10315738 147631258 3961265313 43324446 25737152061
30WI 21799613 12395341 163222779 4719613998 56390682 26920209342
60WI 20061743 9892238 189050043 5269662105 53683283 30218835579
240WI 20399389 13284747 90879982 3247150913 60927074 26671329313
6CI 22889294 10541737 49228681 1279206489 26109175 5822367133
12CI 23730417 12836153 40958160 976588123 20377036 5464117765
30CI 22773729 11900224 49786688 1536363885 26635727 11202378173
60 CI 15873261 12174396 48048783 1116775452 18915093 6734127567
240CI 21565238 9442834 68110672 1812311708 26394220 17341682675
480CI 18619856 12769268 28769599 452702744 10022063 6238845388
Control 18120936 12688939 54465098 514198600 25931438 2320761251
6WI 2309744 1675939 37105556 992085193 12194373 5575413091
12WI 20777765 12557964 103856235 3401814445 34082571 20886509359
30WI 18631192 9886638 139176769 7985253979 72445403 31993636424
60WI 17979821 14552763 93477444 7991588898 78133820 29090762305
240WI 19890872 9616728 35877890 7077280739 58782538 23135217812
6CI 21418111 10407938 40050223 785403612 19660273 3066171866
12CI 25595507 11185611 57719026 1417193558 29008766 5607263257
30CI 23484705 9189748 47570319 1347652165 19490223 6028942116
60 CI 20774473 13574268 39647408 882293771 13388462 5438846733
240CI 29355460 11340065 71619766 2048096407 23880616 15634768169
480CI 19014582 5974279 30741923 1082444264 23666387 11507294391
Control 16897147 7270420 57361409 824124858 24901185 2817590368
6WI 21016048 6424131 170991165 4254252751 36199750 20570496295
12WI 22675729 7784716 209193991 5179605197 32980050 26998184420
30WI 21571864 8438180 218940207 7496668437 57656248 28966012320
60WI 19910818 6902031 194222678 6305731745 51485012 30013347553
240WI 27869323 7041527 53974397 6900673516 50882074 25435531092
6CI 27402128 6645910 61710572 1625068778 26281810 6243941745
12CI 24039779 7845752 38307294 789843003 19343050 3240345692
30CI 16628783 6796844 54178122 1602847532 22656714 6363560793
60 CI 20858262 6645530 63837940 2033539115 22630085 9596526066
240CI 20656793 8680061 67777003 1656331689 16585610 12243442959
480CI 24956054 9366126 57672214 2014698223 22913179 21787355681
Control 25587254 6015529 56796842 676047298 29419214 3995704000
6WI 18489884 5942846 138242937 3984239685 31856210 19834735543
12WI 20622569 8718781 216242880 4847811725 43839829 26391511848
30WI 21975775 6927421 174867972 6005062059 64151074 30385682152
60WI 22051213 15811173 167256908 8031018735 89064684 32289555901
240WI 19655465 9670544 154652996 5752662355 60524588 32890011413
6CI 23745240 9996600 48421288 883588527 19583732 5600927741
12CI 22080994 9730034 60484853 1293106355 25863508 8612600522
30CI 22714476 7603654 41421018 1234138874 18828130 6640042235
60 CI 21599434 8553719 43009315 1100778045 16337967 6634020784
240CI 25040598 13653741 52284985 635193690 16829593 6897118896





























Control 282297632 187724774 65756485 231083172 14373791 6757712
6WI 276862621 241470410 25063093 180879473 15805127 12777484
12WI 157003214 96800718 0 130677415 10603046 14707186
30WI 198000312 126965550 0 318598488 10250258 7717163
60WI 251288519 44362461 0 325356847 27444906 16428572
240WI 249643275 13389607 4646877 898933767 38172946 14296820
6CI 245390900 158078326 17532392 366384500 20907694 4673153
12CI 272750488 126469866 20478698 322282930 14347263 8366245
30CI 202457200 56525365 0 245940221 22391195 17564098
60 CI 280169999 128479761 5360749 324249568 18551778 6770909
240CI 163122655 37035539 0 659645768 22972357 6024681
480CI 142134118 14134932 0 475794900 18538272 6170659
Control 980362086 226783044 24798501 199551670 15405786 22068765
6WI 623518983 109428503 3033999 271968125 21737190 25300126
12WI 598162325 37518822 0 240646977 25013598 27348030
30WI 559047817 73649884 0 299028764 31879175 25822841
60WI 551650978 58876569 3324945 314390291 32955340 21952716
240WI 612786248 13877935 0 612922735 27466193 25406291
6CI 593110466 160117692 13077537 406861224 9179441 18358713
12CI 562047061 131659674 7630363 610879227 10649316 6162832
30CI 793950293 157377958 7816219 473259270 20682117 18549700
60 CI 485628340 121143966 0 413687441 10400471 7901122
240CI 585214836 67336150 5178243 468951820 18272952 22343593
480CI 134295370 9718712 0 805645483 17216636 9256478
Control 370888139 185718742 83421971 115995352 10787891 14761505
6WI 69868603 48603722 0 29074899 4990790 4224973
12WI 258349026 54627223 0 111644505 35334475 18998761
30WI 516606353 100736593 0 117190118 36296176 24114020
60WI 323494855 60970448 0 157349076 40668919 18240963
240WI 249200494 7232897 0 203109726 25367322 16190927
6CI 381394870 122469341 14663662 268184237 20605114 9581689
12CI 504804053 219555362 28315651 336091656 38373117 12488344
30CI 384006186 159049885 16328363 277907266 24803315 18426871
60 CI 229779542 115794669 6026674 573097484 20259634 11972923
240CI 271846912 102575102 0 790728575 33498346 16744148
480CI 142564998 16395132 0 502671115 24647708 11261973
Control 380598054 169760211 35950703 65345701 14858694 11061018
6WI 458232256 327200976 30890712 159048701 17066647 15755391
12WI 393515458 125731638 21492193 267558012 22273212 20904630
30WI 454617125 88987324 7177536 242649503 30525102 18687781
60WI 395574292 39190097 29053307 186565263 36519764 11560144
240WI 279855042 3711143 0 379230967 24121560 18736876
6CI 427010388 203511329 18495036 253004076 10731506 16550028
12CI 300580635 140230706 10230192 433600157 7982387 11555935
30CI 408074073 190509936 9693541 241190750 12803476 8882792
60 CI 388195401 234300686 7187092 485194782 15832636 8039308
240CI 258334015 77081438 4091525 607567879 22078061 11075069
480CI 400075819 21371307 3806902 553234534 27309600 14004016
Control 533762555 150869621 55374549 169324680 16976628 22199078
6WI 506464064 283296763 20285149 121309384 19339149 24230656
12WI 561708043 102964241 9771562 156897510 30195623 27852197
30WI 516170766 73817321 6475444 144762381 32651404 29186180
60WI 539088427 48101350 9184060 188965891 34197478 30861088
240WI 463292223 18423811 0 494688823 43415582 29307780
6CI 396328336 105842424 10956675 284326703 13506812 12334196
12CI 504164259 158758829 14048336 363116424 29576531 12095197
30CI 447724915 139289082 10351749 516302061 18908429 4709426
60 CI 317713096 118366984 0 574317312 16155958 14032923
240CI 118899312 49122067 0 709242224 20095265 16065995
























Appendix 2: Pig LC-MS data
uracil malate 2-HG xanthine nicotinamide hypoxanthine
Control 0 616993692 747384061 9121054 192792358 494375502
6WI 4881205 1011330502 491164019 10184457 812838455 1139781149
12WI 6330613 1050608592 490330348 3992677 980217350 1422670969
30WI 0 488006273 495452387 7561755 618886611 742901327
60WI 97907040 1350171588 736235593 28964091 2916170471 8807578374
240WI 245211731 1684390636 657347358 52823188 7933008485 20349627022
6CI 0 473758340 556912262 11590449 302764341 493563857
12CI 0 356002584 536098428 12185933 303607962 421964261
30CI 30635393 1066604745 582293321 5182856 1667246544 4614584820
60 CI 0 452901459 510646191 11281927 913030351 820987314
240CI 0 673137697 336826152 4434460 807648056 1300222604
480CI 2836395 358878374 361762138 5882576 984353474 2396489378
Control 5115575 672758502 353967562 11863483 444626839 668184877
6WI 20066114 0 284508958 8333894 4791215277 2671788028
12WI 44711879 1654192615 263291062 6729388 6196782338 5812876906
30WI 64567675 2108111585 359706813 13922287 3434869172 8585178339
60WI 95874719 2429662826 353610933 5285041 5619743664 11708882892
240WI 216681384 1403370336 262721667 9368047 9550531055 21808333096
6CI 1816081 401798420 257807271 4828523 400974578 480651891
12CI 2354365 299515814 221857265 2800887 767062966 534009735
30CI 4888035 480329221 222426408 7212443 1748763289 995253692
60 CI 0 329369114 193023488 1487521 782507425 640434740
240CI 5226127 813750158 243088454 9103399 852475763 1366127048
480CI 0 175655877 76039830 0 399362806 1102650307
Control 0 527561798 739305296 13009765 132738685 655078069
6WI 571283 278248965 135811497 419552 537532531 529293249
12WI 15865838 1277882699 467218566 7460204 2157193135 3412821502
30WI 51525586 1974255109 711350773 23577669 2938843132 7098114325
60WI 76040913 1173418356 644030022 16976441 2632351356 8905113756
240WI 80721955 214760010 564493078 7673118 3223691020 11958163562
6CI 0 306253292 653666311 13043781 367185223 967562100
12CI 0 560255548 915197916 11246865 802212548 1431796693
30CI 0 557385821 900454859 18150699 800727052 1328449869
60 CI 0 371963240 393318171 9193361 872859025 2281468475
240CI 890704 960912653 672207249 11830614 1895544158 4200565974
480CI 0 201423555 347623175 5719666 969330413 3708303959
Control 0 595844961 669280413 5143042 153738279 591868163
6WI 8971232 2061919949 803545271 8144362 2211627640 2509166073
12WI 23968440 2381161387 761986216 5009791 3259194750 4536367419
30WI 63991504 2830774998 738450640 8051452 2785574254 8661522213
60WI 67680425 2488070279 719210579 4030662 4065486091 9768875040
240WI 110179987 587526998 749689060 5258248 5205398594 13658286465
6CI 0 607495669 834807275 7004218 343158888 739856945
12CI 162004 342990032 495666427 1481410 334456840 515149347
30CI 0 538868978 745004863 3208455 550747512 851075536
60 CI 537308 749048218 581506909 4526232 990187648 992146049
240CI 0 996822918 525024419 405381 896547887 1610642295
480CI 3184870 617399220 466463533 3791965 1209870212 3119616127
Control 0 532034596 801483784 4613394 344747898 680808540
6WI 8898085 1694461392 728215354 3661858 1802645129 2385258106
12WI 33387804 2878088169 638749665 7790044 4078118970 5190640066
30WI 58351776 2116685347 750307590 6607334 3606720893 7623556287
60WI 98498216 2148661730 714008363 5273299 4649438078 12190773288
240WI 202791040 2501850149 800333680 4977356 7450117718 20389189627
6CI 0 456290463 539447398 4256868 587069181 796577107
12CI 0 688456605 739974526 6110772 1127871220 1177623514
30CI 0 374887940 503644311 5224988 914945312 1254381146
60 CI 593333 435327257 367366558 4633528 1067641493 1669128516
240CI 827079 508269282 198285992 4672321 776153585 2658499060
























Appendix 2: Pig LC-MS data
orotate succinyl-adenosine urea allopurinol / inosine ascorbic acid uridine
Control 0 0 2834632873 100802485 134947491 5054840
6WI 0 0 2313438921 814385239 336479169 4345385
12WI 0 948115 1671834405 1499407193 272087616 2535330
30WI 0 0 1529756897 671092692 61351729 3675541
60WI 0 9874384 2610845772 5468394944 509112115 7269353
240WI 0 11931066 2609651505 6729528770 357604939 12293748
6CI 0 0 2236037980 229429209 232543032 3409721
12CI 0 0 1766278604 375644656 475972540 4147862
30CI 0 2170161 2055401491 3859607603 318269058 5178456
60 CI 0 0 1859880102 894644713 213198987 4833586
240CI 0 0 417381661 2253154072 520985 1667465
480CI 0 535885 376925162 4230625408 51413724 511014
Control 1012726 0 5516672280 119820208 151892 27073498
6WI 0 1202060 3909874057 2625603193 0 20324084
12WI 0 2778763 3351036846 5357627949 3338630 17771826
30WI 0 2352808 4065611042 4798569305 326977508 21656912
60WI 0 8751213 3257497054 6524088223 48856036 19112466
240WI 0 2745647 2748974303 5161041897 186723479 19524653
6CI 671422 0 3196933564 231163865 25441266 14678094
12CI 264663 0 2794837042 602235816 2770039 12603820
30CI 529799 0 2967868056 1359993493 17454683 15754812
60 CI 88414 0 1164603555 1216708798 170856411 7202166
240CI 378525 265255 2266215886 1822833348 33081565 11116487
480CI 0 0 262470940 2273048854 4563363 913084
Control 0 0 4195881191 80028099 0 11844370
6WI 0 0 792463052 476930985 19526899 913749
12WI 0 1463406 2165614944 2776895500 9010850 7143147
30WI 0 10107307 3633757359 5450303593 449338895 12630046
60WI 0 6246009 2573740691 5304990805 274534014 9467236
240WI 0 2272471 1424942652 4135512281 30447349 5359217
6CI 352148 0 3744553405 293202077 130478404 11918327
12CI 994621 0 4038553755 482828554 305512815 12159420
30CI 740780 0 3483870937 914816321 262458483 12021017
60 CI 3897792 0 576260553 2014499276 106070265 2823292
240CI 4302190 0 834732801 4602464016 0 5712154
480CI 5103966 0 237264056 4648248586 2183382 1507819
Control 0 0 2356512528 86498218 0 9268196
6WI 0 1749040 2618621475 1948098482 259399906 10396980
12WI 0 6837240 2337380200 3915444022 143724927 10074259
30WI 0 9182741 2297568227 5669124541 356453914 10260910
60WI 0 9913782 1668159949 5724950813 501896405 7498337
240WI 0 5222045 1163657013 5606034227 71416258 6665106
6CI 0 0 2454479686 306019034 255580493 10168640
12CI 0 0 1245356952 342008871 4817510 6203769
30CI 0 0 1767941722 643862187 152822178 7800541
60 CI 0 0 1551663431 1106191292 338077884 6280071
240CI 0 0 776750102 2290495520 758377 3589598
480CI 0 841744 887717629 4755132110 166146116 4659632
Control 129581 0 4943616650 164961199 3625947 12024480
6WI 0 779529 3948485210 1807648886 480784007 11057874
12WI 0 6798628 4034809827 4065819860 399435156 9555797
30WI 0 9173410 3697199155 5859857857 675917556 9977880
60WI 0 11247104 3384033042 6773199782 355737311 9693009
240WI 126142 14646429 3201121974 6138419989 605777551 12528702
6CI 183794 0 3113003378 517075561 157935629 7677077
12CI 200612 0 3425056438 894698866 249321151 8936378
30CI 279533 0 2803140904 1093278089 21939575 7277077
60 CI 468090 0 1309069345 1892662707 11527000 4607197
240CI 1725184 0 376379563 4334097622 0 615758
























Appendix 2: Pig LC-MS data
uric acid guanosine tryptophan adenosine methionine allantoin
Control 5236944 13498055 111897387 531572546 336226032 22030113
6WI 4977515 43325280 94878657 2305364574 352540050 18922031
12WI 2571769 74477037 72772871 3001303656 242631177 11803194
30WI 2592041 19860075 81906700 6560674913 282782381 13913169
60WI 6738503 278474284 163265674 1699289325 353782949 18462011
240WI 8631321 622740537 262705597 210095470 410575013 23207266
6CI 2302940 10826672 73917312 9517662204 349023134 12593572
12CI 3629967 7249578 74866259 7411652360 295993987 11471854
30CI 3896362 186159949 111731414 1484992544 248373361 17386619
60 CI 5640453 13924886 84848055 5965311240 348832449 13839771
240CI 1255492 15695406 54768381 16898926196 172396385 1594135
480CI 2874518 36905241 56392688 7792427133 201076939 5642462
Control 5529480 27051542 253694281 644355958 672792859 31223544
6WI 5888509 177428815 185746739 7335829986 453738577 21389176
12WI 5606804 307940248 179021632 6072746479 400483594 19594193
30WI 10669299 359868560 249228225 2222163492 393237643 26155262
60WI 3369658 387572886 219535074 748813474 372072092 17533709
240WI 3670845 685980983 306925757 156974917 466630771 16609347
6CI 3203483 15910430 139342239 8857999564 383843548 13644440
12CI 1900131 12406679 114165461 16178535527 335316924 12205642
30CI 3729324 23619062 149677257 9557732341 377153131 15320775
60 CI 784817 8785032 101283771 10515376558 378380605 5576875
240CI 2773983 22746947 132911863 8427403441 447623315 12327468
480CI 0 7540111 28686433 23188371892 92467567 0
Control 1914714 12908996 144026971 156523671 196492977 47351971
6WI 244168 20538528 23724815 1865332169 65750975 6312867
12WI 761676 154550552 98359818 4733544615 135776142 27749973
30WI 3731251 307026963 146127724 3274202473 162619968 33027049
60WI 1299029 288517151 144146633 1363805426 149199098 26658970
240WI 436975 320956063 168308743 388202742 270537718 19169497
6CI 1677118 15543188 119092094 5811485813 224085438 37206029
12CI 1550499 18965343 132730601 8459249783 257804239 36352785
30CI 2114129 15354535 125707176 5729495566 222260711 36549354
60 CI 218723 6184435 64352148 15777824392 117548467 9151059
240CI 1276085 18766955 105351312 16008772147 192541574 15065794
480CI 629538 23695942 54677770 13307673388 91128254 5254548
Control 1385878 14791727 136084959 397367116 260200565 31813390
6WI 1520077 116954133 129048532 6568944001 359794408 31239258
12WI 522901 225146349 134554281 7807915862 291788286 34010840
30WI 1097104 289737988 154204250 1996128277 297854084 33839170
60WI 641785 300488771 157075240 651732872 302108673 22602072
240WI 712753 411368486 210331232 371895127 347949652 19988818
6CI 1031891 19458244 112123191 4456224302 335667323 33238177
12CI 144291 11459601 68321976 12677922980 253757441 13921604
30CI 446112 16591012 91243155 6060905589 349007301 20574069
60 CI 875045 18107483 96408238 12210464841 349899322 20070458
240CI 0 15711902 70222371 13813322180 228251787 11697169
480CI 619144 47739482 102565166 7461965292 301416023 17426119
Control 750966 19102148 236520251 1119328120 328693182 37861883
6WI 228014 128015611 174626311 6231933724 363126832 20629144
12WI 812500 272800664 186405775 6567816853 309293345 25757917
30WI 476952 327992930 204687568 2495082895 327047768 24104846
60WI 489778 463030093 246216538 763184248 326526937 25613278
240WI 264779 614112551 326135412 624300714 420223025 21461281
6CI 268807 24311113 136463731 7169402045 202221025 21437297
12CI 617277 29837770 165696788 9813413160 262673742 21698332
30CI 289020 12387958 144451287 11133437386 289726057 19582686
60 CI 0 9491142 100473288 15975755499 210284834 8799722
240CI 0 10530276 43255397 20530386118 111201907 526969
























Appendix 2: Pig LC-MS data
glucose leucine and isoleucine
propionyl 
carnitine GABA guanine homocysteine
Control 2291881741 3366808653 99310594 117830186 13684056 37834165
6WI 1872730805 3201781846 148419521 96696946 14988199 32316951
12WI 1506767676 2050098556 160811330 52668211 11662575 21254396
30WI 1417105917 2480330871 72844715 39594368 8901963 25192645
60WI 524698928 5297013765 818568773 48918479 45622259 37011451
240WI 1252167179 7326634165 176160416 33001096 185319066 27863912
6CI 1306657636 2724309004 79247662 39947306 7490317 31326341
12CI 1142241320 2391431085 54046306 38767590 6686790 25458118
30CI 1093020844 3243355622 432890839 52617058 32186769 26674841
60 CI 668982847 2872977289 62200010 52161812 9223422 24957287
240CI 458685715 1488866638 64025515 8741707 1622763 8705645
480CI 887292281 1433762453 41886590 10527616 3950242 9029759
Control 3712148960 7923287912 231303962 214406833 36536030 49983334
6WI 3197295977 6290311210 537423326 144709782 30890527 28787793
12WI 3871473665 5826747586 481459589 113335824 44781181 18176989
30WI 3745144695 7178002699 522481465 101860900 65392440 21811320
60WI 1153238249 6875939714 951673099 75039658 73030675 19708882
240WI 1215515168 8351710247 211045234 48904814 318156169 25737408
6CI 2127267840 4658573803 141422806 63916746 13619329 27985586
12CI 1383164969 4295563290 114280472 38625800 7171541 23664992
30CI 2382480005 4768883159 186246741 53195801 13880183 31674962
60 CI 410254646 3121794635 104326222 42407691 6105317 13781656
240CI 936266350 4538184034 165303190 45303117 13299417 18513621
480CI 223377305 865753154 57322463 3152704 0 2234374
Control 3552588377 4504249244 62679809 180923207 14721043 43272811
6WI 700472612 937716338 79090091 39788832 4202368 7257316
12WI 1930219891 3204008100 352607394 67813800 25571390 9799222
30WI 1330928744 5248977429 1062397280 94239697 44791540 29237828
60WI 509177799 4731186668 1060298322 63198471 48848944 16204418
240WI 2540235462 4741141145 79093461 43222453 88960839 10268916
6CI 1964965951 4313057508 59321158 88817681 12807529 35357943
12CI 1852294289 4761498531 107007354 82902396 12585005 48650719
30CI 1467636180 4350933045 74140661 75356124 14497486 37726769
60 CI 127382530 1754778227 56673241 17133598 1269293 12166983
240CI 443256132 2741200016 80310200 16681820 3763797 17423967
480CI 611863569 1402176090 38442648 5948600 1631361 6928680
Control 3636676842 3743879825 77416246 155223435 13183809 39090606
6WI 2584245331 4513581553 355835979 132582106 20874514 43046494
12WI 2408033415 4772583207 445821462 110964744 32705616 35493641
30WI 1190591445 5245229812 775609096 85424983 43422181 31387947
60WI 2192728110 4423483489 616021204 60938357 45933782 23663298
240WI 2690906194 5816193244 89430974 50088791 92137087 13908537
6CI 2118490505 3943486421 97884961 110533442 13501141 39858860
12CI 891698631 2216008950 60964443 38582060 4869853 21590192
30CI 1490246313 3096968944 79914602 72123097 9287647 30996552
60 CI 633060383 3347484713 103773885 43199980 6351104 32159164
240CI 372432824 2060708752 72195112 18287538 4792324 17737343
480CI 1194329883 2795091726 54633932 22967199 7287725 25979806
Control 3711645125 5342609852 124215465 180443655 15997288 38960526
6WI 1914666975 4936072224 403262342 158275839 24262067 47344267
12WI 2358492410 5257575572 565669448 127625933 34049194 43753782
30WI 1064682800 5633808845 760749252 117561804 42693245 41701417
60WI 1253751964 6917779889 787596089 112861657 84254731 28920189
240WI 1270768935 8187266705 209313927 62887519 199916042 32938728
6CI 2283085082 3318337468 107125084 62654678 9566764 35440004
12CI 2998196459 4056751386 155429705 60444836 11897831 41724323
30CI 743245686 3818225241 76087957 44596465 7079923 37231068
60 CI 228771049 2190993266 54187283 18859682 3625776 18886216
240CI 324094776 1054011745 49707625 4540787 373337 6277492
























Appendix 2: Pig LC-MS data
GSH acetylcarnitine tyrosine AMP GMP palmitoyl carnitine
Control 4142746120 3530212134 231282644 188710826 349993 26761556
6WI 3484776325 5262614553 210216797 314240323 2998285 35693179
12WI 2114665336 4018282681 153688933 177385291 1900379 13985404
30WI 2540843866 4490153082 146330551 302536443 3137786 42422162
60WI 4383887144 5449474158 381727359 761693381 12392115 46636896
240WI 3311453854 4011841165 521401195 506845144 8358656 50091407
6CI 2710861949 4598133941 134238115 65105767 0 33637246
12CI 2565100032 4076887692 132469613 175552605 0 60769582
30CI 3033246720 4657668548 257442062 287836740 7110375 22901339
60 CI 3050211127 4769767298 168138665 492280019 2617187 67658817
240CI 1648256006 2988165413 60630428 252587555 0 28820386
480CI 1607723970 2683300781 69424163 670227909 3310246 15121636
Control 7965388293 8224879144 670282084 520171279 1118830 79162548
6WI 5621873026 7658088815 527846826 982035273 10981690 37575736
12WI 4508304735 5297152397 464326231 870259778 20218476 36243534
30WI 4276575751 5020755368 520979664 298399707 3221367 39524068
60WI 4275071346 4698596339 552186859 740701371 14477447 41900027
240WI 1772477154 3566602121 488860416 210520667 6671397 45274758
6CI 4094834094 7173214165 320457086 191884028 882470 78290875
12CI 2912007551 5331047434 225453265 197893629 421926 65131973
30CI 3739375067 7463356694 320978282 624430097 3671221 52323180
60 CI 2504221369 5569457915 151229339 289790677 1210833 22295660
240CI 3568889515 7765642662 274675695 450193007 582788 15041367
480CI 881607841 1418071652 41568503 210935901 0 5554801
Control 4875784946 3092620287 277048278 64065876 0 19381780
6WI 977694124 2091693715 53296414 174940854 1169084 881827
12WI 2774648897 3178965113 116489562 821047648 9649438 11685661
30WI 4976360724 6397007419 313532273 749921082 9148314 17747290
60WI 4153572500 3615717401 293671235 792280698 10518746 31314938
240WI 2647084330 1894896797 204163118 657167979 8570248 25779854
6CI 4480619161 3885808415 215495582 130263165 0 12472414
12CI 4692658126 5467630398 221675383 157651350 0 28749584
30CI 4821700322 5055647706 223148836 298979270 1233570 45677034
60 CI 2020807608 3504355217 59494032 317988620 0 5496863
240CI 3204904102 5873071205 109307542 531810995 409112 19926722
480CI 1891001439 2675918155 56960968 461758495 866457 9121114
Control 4745695430 4537987073 270188605 66031869 0 124994623
6WI 5979018945 9061764223 336184014 591207138 4797372 109708193
12WI 5076064854 7545376052 329509169 530437726 8700881 96027858
30WI 5249354634 6624746819 370573683 433564696 5114745 52154890
60WI 3847594996 5429076705 292858116 846100860 14717276 52224084
240WI 3357698689 2801989737 307579442 674446663 11717058 44759328
6CI 5353836579 6595652938 261452920 114988815 421673 214247153
12CI 2879056333 5022161902 110023596 82575263 0 90479066
30CI 3867707039 6366186175 187053071 217435187 938839 175056661
60 CI 3809293488 7200085241 160441065 278713896 0 198262090
240CI 2704386630 5375235597 106143874 256665897 305238 110705847
480CI 3456164736 6222907359 149401328 711561255 2608607 83874043
Control 4741431731 3288287104 361345088 294827276 352989 10791416
6WI 4725969588 7782920381 337423020 493868577 6738357 7882509
12WI 4659645145 6886131465 401643186 704797763 14019668 6901235
30WI 4366451597 6567237211 397071406 493302820 9529399 10950347
60WI 4150847441 4302128033 462557620 777997069 18259502 22729399
240WI 3191344939 3868995510 564629448 462599045 6504062 28575581
6CI 3069759146 3626452491 216231788 260425334 782472 1394082
12CI 3193516287 4903053064 239216146 339504312 1115130 1874759
30CI 3662387150 5737351911 208419922 390891067 1551562 10493406
60 CI 2702136644 4490895570 117819985 353590905 1089935 2397600
240CI 1756982183 2184629437 46858851 467678039 0 3346370
























Appendix 2: Pig LC-MS data
proline taurine 2-succinyl cysteine cysteine
alanine and 
sarcosine glutamate
Control 2112435387 4529228859 472703 9920507 1797572315 13840563840
6WI 2255794954 3017373708 0 13604669 2499253051 10888093361
12WI 1282060963 3508220232 307952 4446306 2290551525 5614157266
30WI 1519455487 2195797077 0 23487584 1601483578 8206651446
60WI 2722232517 3747555584 304949 87152753 6634048135 5868070630
240WI 3402056507 3283399065 0 474618097 7533140183 4347889515
6CI 2010365096 1425984483 0 29757420 1624588123 9851843765
12CI 1576119054 1587445147 0 11484446 1439143562 8792676385
30CI 1900892835 3539566886 0 36658711 4006086199 5837246450
60 CI 1800886582 2035556157 0 40693740 1760842505 10322066517
240CI 750806149 262417462 0 19460532 1057561767 3823570471
480CI 755717280 358786571 0 30240629 1130766122 3685786329
Control 4662108391 5909638734 2032394 58007696 2077853229 31555454357
6WI 3608358757 4769883082 2387963 54724858 3446641486 21540295709
12WI 3307059175 4072142699 2783227 54414097 3581277692 16767699970
30WI 3520141067 5471820222 1130194 171811823 4359054097 15650091769
60WI 3495452633 4529345248 1402728 179139410 5586299794 10545630997
240WI 3635169184 3446416381 1010954 1067664700 5722957201 7063112043
6CI 2679690646 2942275290 735746 29249383 1782184407 17583537602
12CI 2201099733 1233121981 371295 19765218 1509567069 14657950894
30CI 2607670393 1936383993 0 37601527 2050493796 16393797779
60 CI 1442528278 1119900396 347835 24174188 1294390261 10999862620
240CI 2213179719 2841615497 1694963 11958416 2307821206 15224758053
480CI 572994816 130311182 0 5363619 642703815 2360856606
Control 3198779835 6887239923 494799 4239649 2350251149 22858884532
6WI 821528120 2175132774 0 2722249 1113903659 4058106597
12WI 2525407484 3583419028 489347 19625018 3562103099 9833984074
30WI 3403605146 5288717687 781217 199296124 6822683819 12905234228
60WI 3208499108 4425365682 0 91597027 6852153870 8503813428
240WI 2622172424 3831680797 0 295082687 5890118152 5241896796
6CI 3234151359 4779129395 1379268 1714090 2428805459 19751639634
12CI 3535138267 3079397611 245916 50009901 3023420634 20214721213
30CI 3279935256 4355618022 0 18887169 2949531888 18614622147
60 CI 993800041 449158572 311086 38334688 1218471053 6679256676
240CI 1582735591 674517074 0 52815483 2723466252 9122417134
480CI 786525452 433898128 0 51325371 1421675980 4385137436
Control 1913328371 6284042377 0 4073713 2020101688 18433979860
6WI 2818246695 4751704273 0 42422028 4614278335 18783608166
12WI 2719637370 5101737773 0 6611795 5317479267 16726059950
30WI 2772599097 4689004556 677684 113418828 7172864757 12221035514
60WI 2317240388 3478770886 0 253915404 5938269753 8507970600
240WI 2427399002 3392402604 0 166395252 6551417980 6889134307
6CI 2466953680 4578729502 582199 7954022 2786978546 20218194794
12CI 1505224614 1226077063 0 4186901 1386054488 11171702519
30CI 1836019890 2925454749 0 29664814 2321083126 15055105375
60 CI 1880049786 1694778359 445534 31396795 2650757754 13730445704
240CI 1153005629 1080943751 0 10736002 2101843351 7754180745
480CI 1517321013 1385694877 0 30969303 2661262899 10360480120
Control 2997378224 6338055203 676504 11134932 2614202952 25523130303
6WI 2964547727 5258210985 0 45012385 4482745790 22290044732
12WI 3052717641 5268567745 393314 118288351 5388491261 18640948107
30WI 2921887311 5091404689 606701 107633793 5927415648 16882184215
60WI 3084493387 5262276269 391408 238232976 7476665565 14918581993
240WI 3339782809 5348673821 0 470022889 7793963180 8625807509
6CI 1991680702 3517953290 0 19748359 2089425116 15038425703
12CI 2093997588 2999265530 0 86179275 2534268021 16185563227
30CI 2191948350 2317262754 352062 17982660 2215793175 16876397956
60 CI 1244774805 1253193585 0 20270310 1548112271 9788705599
240CI 620722949 195661502 0 12788229 958642417 4634806523
























Appendix 2: Pig LC-MS data
glutamine phenylalanine aspartate threonine acetylcholine butyryl carnitine
Control 39902486863 671200814 171346639 325789792 2960442893 44431739
6WI 31257433426 595049328 206652353 365912581 2525152795 374272742
12WI 27038065396 434667646 198467633 240336252 2021424070 380683590
30WI 27299208734 490688269 158461874 244941072 2170995253 148206966
60WI 40205657509 1233860409 263744816 504802132 2969289049 1447376072
240WI 38123119247 1939491291 885678331 584984462 2995951524 1093977734
6CI 31945626510 545363367 177572347 255159183 2694836283 68721352
12CI 27351216899 477709858 198351583 231752101 2285427418 101123719
30CI 34198748449 696216075 207153532 338892471 2563900343 894176963
60 CI 30584716639 584587229 199248975 301541731 2397559291 151735143
240CI 13609529217 251053620 230032874 115752506 1100399897 246455022
480CI 14670027332 247725510 245355485 117245898 1156988659 377941390
Control 42098941953 2246140349 217795474 1147493261 5297027155 404200834
6WI 34572134846 1749059432 486524081 896724062 4173660671 813847663
12WI 32085198068 1613171229 549273772 842049001 3728043714 973170583
30WI 29254529287 2008056615 674005458 809432933 4081955371 1230144921
60WI 30735993994 1936026077 1567113633 892433251 3649920063 1016496945
240WI 24209240202 2267391212 2294980320 865983172 3056783897 1082168866
6CI 29760809103 1265356268 246058207 668474171 3657361737 290904485
12CI 25077839476 1110345885 188338849 539486529 3342807941 112528988
30CI 28135878024 1345241090 266818431 667010759 3570360943 250676467
60 CI 19144335510 721352830 192892096 395284610 2473101575 134613466
240CI 24070640363 1113532745 394069237 585198771 3206131542 480199522
480CI 5391974197 173671684 203817000 101531039 673783532 220831539
Control 25654550943 873503517 401464353 471515390 3760215346 25158778
6WI 6495108833 153401504 103863260 127514798 1066228811 126046075
12WI 15875797275 664416326 386058560 343726850 2404841877 693127889
30WI 24597279493 1041765305 301424198 482953642 3948358725 1563959221
60WI 20286696608 1049960624 452421050 467441068 3279113861 1339258822
240WI 15801880181 1160358809 101924509 423167471 2770189467 548070712
6CI 24721185603 796944233 354976853 473219539 3922015045 24062816
12CI 26659361190 910057062 350476145 484652417 4408406534 46399999
30CI 23301363877 848938593 387758077 474194610 3843121121 76193557
60 CI 8975861727 288420209 179203731 145399302 1530715462 60598094
240CI 13338078115 508024794 264333333 232968390 2260030283 635164452
480CI 6782946912 240723844 137533988 113695183 995982071 578560333
Control 31469074746 824926413 406340934 381369851 3814135856 115338269
6WI 33668929113 1075610508 173966373 480250443 3974980592 1145480035
12WI 32720280380 1084642878 225620899 464672374 3734594425 1337862192
30WI 29285012153 1210677901 415294795 474157008 3798934362 1531636211
60WI 24230063158 1022405617 423158037 410167737 3551419443 1275000268
240WI 22684457239 1604761101 249002608 470363966 2750478346 816017949
6CI 31791986516 872474721 315327079 414547460 3976476933 313194543
12CI 21480003395 506543517 266515332 231720728 2812260471 127434453
30CI 26575403402 689585227 274376181 322915001 3542328916 392672215
60 CI 26095961002 712635720 308102063 295825979 3426727576 372767301
240CI 16708997423 439830541 291279455 165977362 2211980595 495631641
480CI 19102335626 615261766 353198116 220535881 2544771453 1001288871
Control 30031595801 1345744839 364766768 839543420 4505310145 31443560
6WI 27977011880 1158175712 275446680 807484944 4379317809 621960732
12WI 27112836821 1342332330 546839360 847715251 4114833693 847422874
30WI 26104771857 1391093364 533589103 816432147 4032537347 1092979107
60WI 24627944597 1591736642 487593722 843295158 4055371256 1003593502
240WI 22876780832 2186611340 1260059104 846472133 3563410031 792740160
6CI 18940082519 797030259 382715307 512814425 3317313262 26420977
12CI 20998322328 961885186 379966844 569550230 4068579300 48208673
30CI 21041948236 866312458 257158176 532244041 3366574970 80429717
60 CI 14328079681 532104583 176884423 284359959 2164278124 69685593
240CI 6255748083 176211927 139765325 131102337 895421097 218272624
























Appendix 2: Pig LC-MS data
dihydrothymine glyceryl phosphorylcholine CMP asparagine serine
Control 117682557 907919697 529970 76653036 375123446
6WI 105473594 837579250 0 96007984 490817668
12WI 96345467 435586320 391880 50442606 267982139
30WI 60352677 625316037 0 41160321 267426032
60WI 127582782 990189565 1076424 109647637 581223470
240WI 119126095 1197853956 1077494 127980889 718771103
6CI 60497308 761742996 0 58853248 408311502
12CI 55738068 733115053 0 43551289 295041042
30CI 114902388 642417178 717675 71673452 343413357
60 CI 62108906 822214379 0 55478700 366440641
240CI 20234052 434577959 337906 18677705 148483516
480CI 23168650 430264433 0 17992640 147924771
Control 99372880 3869845902 622811 266169735 732299001
6WI 91760711 2862101235 236506 223170899 637817031
12WI 91067607 2858701203 411268 206067488 589607965
30WI 82282660 2431342160 697343 174812568 582812975
60WI 90819955 2802202790 284631 207381774 663045223
240WI 71783132 2307956369 658343 201789162 740357377
6CI 51501568 2768373186 897502 118414374 475757315
12CI 35712545 2167002565 0 85218269 358608226
30CI 47128467 2620633241 1349645 107165006 414209772
60 CI 35069538 2093507467 0 78811632 272747342
240CI 35468258 2550239959 254997 85099503 377034175
480CI 5033749 705709258 0 16489205 85048897
Control 74372120 1201132426 0 76111811 498309423
6WI 28432243 298813021 0 24421365 128629680
12WI 52002568 920577995 4940054 63161197 405782219
30WI 77188451 1328879478 1510050 79489328 475861625
60WI 67803226 1190085000 1436861 79762500 510537643
240WI 60147015 1252482469 1693044 81254481 512606538
6CI 44655544 1546747333 272662 52340183 445772825
12CI 47464497 1483805876 0 57468448 464770597
30CI 42352059 1224537900 646846 49495384 412250413
60 CI 12295771 702551253 190277 13560991 137007633
240CI 13642985 874105922 1079528 16868271 223889133
480CI 6382531 471069956 346972 6344248 96317469
Control 93038826 876690949 610844 94971642 323090106
6WI 89560350 1571654356 0 102152676 424507830
12WI 91403919 1350591498 576564 92067787 401646161
30WI 85199572 1553306936 722683 91110755 431914198
60WI 75351209 1148278866 0 89646647 369814788
240WI 76121926 1356800387 1541029 96371318 471553537
6CI 69014934 1398778216 514825 71649041 350098327
12CI 36401369 913955562 0 39320106 230606836
30CI 56402433 1226468977 0 60631476 294325926
60 CI 42043325 1220902117 600436 45970241 269725251
240CI 24341282 735114305 542420 22520307 157459601
480CI 24399550 1059917097 1183219 27787683 201404572
Control 78340572 1527059645 302366 123163849 524573374
6WI 72973898 1200504657 257987 128469518 562059491
12WI 72749174 1283590092 746208 131170808 584964055
30WI 73574369 1197292876 536631 127735319 583189885
60WI 75567851 1144252316 1496576 148394879 634012251
240WI 74969490 1142646239 408963 136395675 627859297
6CI 36794282 929240554 0 52980031 289544768
12CI 41902147 1112952357 407785 62547079 316154538
30CI 27703454 1085502151 0 50026984 370945288
60 CI 17525232 564688893 396786 25347626 202380536
240CI 4516040 347416437 462476 9489013 104282352
























Appendix 2: Pig LC-MS data
sarcosine adenine glycine GSSG carnitine citrulline
Control 38650421 1.42E+07 1171805047 749520 6828471704 426250164
6WI 38994617 1.76E+07 640795274 1262438 4519266680 527516135
12WI 27547921 2.16E+07 450744871 3550648 3500044317 206080374
30WI 30555657 1.58E+07 432887375 6674293 5313964230 321099071
60WI 78956532 4.32E+07 817639247 2013171 5506387283 545145022
240WI 88470532 1.76E+07 1149672168 670188 7014075371 704707249
6CI 31876861 5.99E+06 512810304 18382449 7408991059 490279456
12CI 29859271 1.33E+07 451844441 22073443 6198336197 361679976
30CI 34298058 2.97E+07 653120741 1159946 4249336433 308996911
60 CI 33123015 1.49E+07 538295560 7113469 6158731717 438570054
240CI 18958513 3.85E+07 226571259 30622522 3482715030 202772159
480CI 20741245 2.97E+07 218552192 9690662 3960421943 235730622
Control 124383686 2.06E+07 1154572075 2897526 9713972394 2262569134
6WI 90533183 5.94E+07 971122653 1909164 6817636978 1632818522
12WI 99139159 7.81E+07 950093019 754735 6731907198 1539319848
30WI 133089314 1.76E+07 1187803757 2801031 6410829314 1044367515
60WI 101288217 3.92E+07 1026333245 527594 7030438140 1384817270
240WI 80714153 4.02E+06 1590772139 0 7086849695 1257530566
6CI 77604904 1.32E+07 661631422 22962037 7676444605 1163358266
12CI 72537038 2.35E+07 569667330 49637072 8170002684 914701480
30CI 81705001 3.23E+07 717013107 24508977 7121240348 1191458350
60 CI 57912881 1.70E+07 373780761 28953376 6587615509 797318454
240CI 93300956 3.37E+07 548370513 27839626 7016108673 1086173875
480CI 24440602 5.86E+07 144369498 119225216 2317301733 243925887
Control 91718351 9.30E+06 969066256 2236416 8499234161 1164844786
6WI 16946708 2.12E+07 198950381 119131 1609541172 234046914
12WI 65431517 8.41E+07 713186385 2973133 4415022945 833827828
30WI 99980129 7.00E+07 1048227466 684527 6398236138 1306997052
60WI 113300159 4.19E+07 873851718 697753 5879563369 1130811026
240WI 86671667 1.99E+07 696602538 126929 7279417225 864128541
6CI 76821672 2.28E+08 802184983 18403004 8753221984 1159579830
12CI 92125497 4.25E+08 909990486 22668776 10286823920 1308926492
30CI 81340265 3.65E+08 823221811 12838969 8295633435 1152077978
60 CI 40547020 1.45E+09 322557515 34482345 3959851101 414315724
240CI 73392231 1.54E+09 486738399 34867408 4181254057 674893071
480CI 44979259 1.75E+09 314158223 28448121 2209604340 267319700
Control 67728594 1.64E+06 912434450 5165422 8238983470 648423639
6WI 60860264 4.24E+07 996005199 7899031 6102086663 1082486953
12WI 60199892 7.05E+07 983360982 32021986 5706946180 807551668
30WI 74022666 3.11E+07 1127772419 3199758 6173418794 978043080
60WI 54640687 3.37E+07 896424744 369022 7577336431 826152852
240WI 51565601 2.31E+07 854732974 199821 6678475103 795544412
6CI 57787071 9.40E+06 855066305 18809466 7907493160 945604335
12CI 38398218 1.17E+07 491391181 56171484 7020529772 498527710
30CI 41040828 7.89E+06 658882726 17971769 7717028697 783155707
60 CI 51986212 1.45E+07 642987973 34422845 7598858094 781141585
240CI 38337859 3.24E+07 387057910 41676047 4933400444 410594206
480CI 51804304 2.94E+07 588897695 28800912 5549214978 648093385
Control 74990061 2.01E+07 1251639456 3878057 8832854626 1022049372
6WI 68634793 4.65E+07 1038529436 827928 7235270428 1032096430
12WI 74366603 8.27E+07 1183003985 1741581 6907415527 1001181029
30WI 66623942 4.22E+07 1139785463 1257353 7094472461 979513208
60WI 101043054 4.19E+07 1189511173 183739 8272103275 987721892
240WI 79851720 1.06E+07 1349876088 241698 8414427304 807327515
6CI 54985630 2.17E+08 792267684 17404653 6987970536 526333322
12CI 84157195 2.94E+08 887856268 23862045 8646670746 573999808
30CI 54520772 3.75E+08 702907974 32860876 7813789586 826703563
60 CI 46200954 6.52E+08 433232120 52284975 5353141108 409161911
240CI 18061941 1.24E+09 274518072 62490832 2539528030 232549074
























Appendix 2: Pig LC-MS data
creatinine choline aminolevulinic acid phosphorylcholine argininosuccinate
Control 2861170379 2819204961 606381168 13938070 0
6WI 1362854281 4364154209 675419370 14028941 0
12WI 824973574 4157165140 356319247 8792728 0
30WI 1301943649 2581215668 409445167 10197956 0
60WI 1252512327 6199825793 680094174 17752749 819470
240WI 2035662115 8287184271 780278409 17781681 560543
6CI 2430840926 2747326434 512100721 13746753 0
12CI 2164760436 2411172618 411376777 12917248 0
30CI 1010997204 5424570364 487985292 11786279 0
60 CI 1244532886 2886034481 506681784 11883518 0
240CI 487649273 1612709163 175230758 5251895 0
480CI 409264468 1425346975 189252671 5370627 0
Control 3053578028 6165411254 889006997 21765488 0
6WI 1832310375 8292307994 665972798 13754051 0
12WI 1598903147 8018196530 589581221 11381978 426161
30WI 1836749001 9971595897 629697236 10300985 0
60WI 1606364229 8860370823 571686569 12131915 866943
240WI 1678073659 11186728739 516405713 17875798 0
6CI 2343376436 3707460891 459806411 13900600 0
12CI 1686918569 3636906645 346053910 11459375 0
30CI 1536449293 4933815858 455472985 13724957 0
60 CI 962047964 2918097379 237828954 10235083 0
240CI 1288433264 5071438080 378727012 11586168 0
480CI 273742412 1580616131 75229989 2177124 0
Control 5859098700 3054132622 860465516 18913338 0
6WI 372601540 875266668 209743485 3160374 0
12WI 1273165107 3788308250 650747208 8276179 0
30WI 2133941797 5447135525 893723469 20411980 0
60WI 1630618626 4108542157 750631495 13762293 0
240WI 1314256745 4566160774 591587035 11234841 0
6CI 6010254880 2728685857 854683000 16341982 0
12CI 4199849063 3160733827 922883634 22039261 0
30CI 3376743921 2912940881 847369720 17057853 0
60 CI 760971739 1407295906 224182894 7692930 0
240CI 920777531 2691339315 363036960 10421098 0
480CI 421049311 1784874039 167351177 5156950 0
Control 3688240696 3205631368 742885914 13484606 0
6WI 1768923461 7338536304 1048738453 18053934 0
12WI 1681191943 7555017032 973429032 15658659 382593
30WI 1700385363 7095541686 976362723 16480836 1435692
60WI 1570816765 7251864389 781403319 13860015 758997
240WI 1450571847 5894694651 672524783 10305135 0
6CI 3123790529 3655185882 928195099 17015754 0
12CI 2072578191 2390651570 469492191 11736413 0
30CI 1787469941 3259209153 692033907 14027048 0
60 CI 1397027639 2997325183 612494297 15927631 0
240CI 814614110 2758761226 343332680 8855399 0
480CI 901453692 3113043425 512945286 11148102 0
Control 4372341781 4380818087 727665020 17809626 0
6WI 1673344598 5882202146 673761252 22325611 0
12WI 1761920966 6616602279 719433471 22452652 658105
30WI 1743021277 5749714623 665078282 18723564 511441
60WI 1680965385 6875495136 635728805 19225178 710232
240WI 1988267635 7848453434 577106093 18042561 833355
6CI 1973077775 3201980697 452857950 11577523 0
12CI 1887567394 4507922677 462191460 13606691 0
30CI 2271713992 3116093997 486211481 13230948 0
60 CI 1210697101 2126487888 250298140 8858079 0
240CI 330747475 1447569590 116144838 3466762 0
























Appendix 2: Pig LC-MS data
histidine hypotaurine lysine ornithine arginine histamine
Control 84514856 78484713 259337513 106297495 445871135 17952041
6WI 68402519 63056177 243647291 84728499 381985753 231282533
12WI 61165079 84599239 175009207 54550995 304963178 3420394
30WI 65374912 45822878 217932345 67012938 392454113 8388577
60WI 124872621 57918773 474917865 108089353 679753288 9922891
240WI 144397656 50083892 660160691 172976155 953149064 26753111
6CI 73704246 31541886 218212075 82303032 382899880 10359084
12CI 58789798 24903759 191806196 61503378 332094940 140240305
30CI 92021368 71050009 297923123 81779705 520759258 8142816
60 CI 77789351 39108790 249215799 76471611 447687936 75291219
240CI 30901039 6221287 120148063 42607330 228757994 7520007
480CI 31820225 5703150 117354208 36091240 206635212 31705774
Control 286340823 27055923 928579520 97180002 995542173 69189418
6WI 199719132 20062031 732405856 73411808 786183314 15821186
12WI 178483547 17552209 670203402 63204959 732620206 38664580
30WI 177808625 32507158 723459849 66184220 776506407 493014369
60WI 191451892 20568025 764433014 71870865 829806551 20035708
240WI 197663131 15037571 887440343 99234379 1087420599 141687035
6CI 158774842 16562181 529451320 74923453 566203265 10996311
12CI 144379534 4488866 456072867 40171132 527438793 75789000
30CI 145910281 8779992 513709965 53714345 589281720 225361034
60 CI 93448264 4708018 306458323 25208466 354614190 47000104
240CI 134737695 9619461 474265970 39354296 549404639 65215192
480CI 20536107 0 89086578 9462784 102235091 13636243
Control 64016982 59721598 241994811 70659171 480143649 25181811
6WI 9353822 21384464 46864985 10805707 83977331 4978245
12WI 39787028 24546132 193279493 52087637 360182351 63758719
30WI 63467362 29041670 301824355 76318407 583514928 50411623
60WI 58251822 30338678 297579184 56396085 530916873 18801562
240WI 53478879 28192756 324690755 55356973 469990500 15498912
6CI 48696635 30684253 210133236 62561544 445412239 19368847
12CI 70506813 22374083 241303636 67915492 533822479 50698465
30CI 49507349 29364945 216670657 57645943 440120300 12973029
60 CI 15453720 1861207 87372153 24647304 194256938 155478022
240CI 29879227 4590685 141732444 44993504 306144150 15703393
480CI 17387032 3308228 80139998 19616064 154888979 10387696
Control 124341361 72139153 377867211 69159321 711869696 222698467
6WI 136002299 35931031 463257482 95312378 853800884 42253475
12WI 129596666 39131237 462244946 85600863 888021194 29827473
30WI 117809120 30810521 509103030 86794459 962746852 693945236
60WI 114816680 23033613 411946050 75689763 768880099 462650763
240WI 93899882 27355341 505040163 86848933 779791417 81275324
6CI 113834283 36985489 387159013 78046691 738972588 30940587
12CI 70694466 11553333 219600861 51703054 436576678 32265869
30CI 105464138 23786075 308194535 59053673 637279778 126403712
60 CI 89772320 16692665 312494471 69406368 634857938 28715516
240CI 57313840 8865110 207980807 45051490 417173920 31894266
480CI 67523463 13188845 252071327 58076548 552252024 389855342
Control 155303791 60564606 451399852 91399541 903110277 797706483
6WI 156722501 47742674 407979987 64370242 803678896 300974521
12WI 139206384 44780442 450634799 84710171 831311892 633530482
30WI 142462521 49260964 446952067 69187314 797352238 286536966
60WI 161358288 50130325 544532888 75430501 945855147 263907361
240WI 181587476 55172619 691554549 99601082 1072972503 406899667
6CI 92393356 33518305 266076783 53247011 570001164 753964107
12CI 120775564 33819603 339180207 64626543 725751867 859715642
30CI 93944855 17955672 288698016 55821357 602600464 333309740
60 CI 60829439 11904969 173044379 34180692 359027586 261216393
240CI 21664624 636969 86357284 20886118 160311936 190030825
























Appendix 2: Pig LC-MS data
cytosine putrescine ammonium and isovalerate spermidine cytidine
Control 1547296 44184261 9475531 50122937 13520694.47
6WI 0 29369193 9032391 1918113 38199575.1
12WI 0 19986176 4206573 3085916 35419529.89
30WI 563718 30704087 7316019 31241468 18722814.43
60WI 2509887 49559518 3324163 20157335 66223544.15
240WI 2855681 59218189 2798149 53975916 136984054.3
6CI 0 41567430 8993644 4131921 12641391.19
12CI 1220925 23835960 8813143 0 8212604.456
30CI 957686 34227605 8070217 26267562 50433732.33
60 CI 976711 33726544 9691760 0 17642849.63
240CI 0 18147266 9188821 0 12988715.13
480CI 0 15196201 11429771 0 17836864.39
Control 5707703 74916169 17691352 21695549 37697064.16
6WI 4469364 57195180 11924196 53209693 125196597
12WI 5592859 48946139 8680038 6385733 118926675.3
30WI 6261514 55865205 4455274 114064378 130269872.8
60WI 5693677 58584995 7783496 11094848 98021057.14
240WI 5351345 47381175 6281131 4140763 218379494.2
6CI 3916647 46097025 9553263 2727397 19693974.95
12CI 1787178 42884117 13235268 28320550 18488421.92
30CI 3599575 46599410 13877242 16671542 51165298.43
60 CI 945779 26739033 19525433 0 13350706.57
240CI 2304452 34777787 12980140 1037790 40519341.92
480CI 0 7673886 10368066 0 8295967.831
Control 3685747 55472935 10009106 20479406 10740131.03
6WI 0 5829437 1276629 0 14581998.2
12WI 1759296 27581666 6499958 0 58602266.66
30WI 5405699 70905961 24298622 3596545 101996490.8
60WI 3514457 39855991 6200988 0 57633873.73
240WI 2394655 45959374 7064671 2194115 55620178.78
6CI 3478638 35673085 6948697 1332309 9988298.853
12CI 3566653 44534557 12520944 0 13449156.3
30CI 3686961 41810352 7352442 538370 11282338.37
60 CI 446046 22277617 7097406 1529477 5371108.312
240CI 924328 40799383 14859887 24442007 16352740.36
480CI 911493 19718448 13030175 599043 16370070.5
Control 2413346 27741351 10009955 0 11894839.88
6WI 3645915 38119623 9841896 0 95465184.76
12WI 4242401 35476272 5950426 2227066 91767332.58
30WI 5104904 37679755 6039984 8324757 84015020.14
60WI 2635549 37197699 8220217 0 63454922.21
240WI 3597421 27879257 4845242 79787844 74819888.82
6CI 3290493 26393278 11909693 15171155 15129948.63
12CI 1216529 24084601 12714548 0 6509233.113
30CI 1369661 24665953 14242564 0 14038828.47
60 CI 2033256 36818724 12835998 0 13485558.47
240CI 1160948 21802775 15769625 15852032 11509051.35
480CI 1829601 23274901 15728982 24750750 32345824.52
Control 2922634 30401186 8768067 19836652 22262712.58
6WI 2053070 37878926 10622574 3503833 95501185.97
12WI 1330423 37560106 15367971 0 105682591.3
30WI 2180319 37027792 4913788 3849817 89590561.26
60WI 3701897 41490746 5487996 0 90785660.52
240WI 3119924 40249966 2860870 0 144471330
6CI 2105912 26939398 4497103 15552792 22482152.94
12CI 1888494 34450284 8149774 0 35300224.93
30CI 1881960 24979666 12528978 24230136 12378041.84
60 CI 980244 18424950 11705236 626413 8302635.734
240CI 0 9951978 13888863 5394113 13903090.1







































Control 1.73E+07 155015235 578505528 51730945 186759892
6WI 1.84E+07 332693387 5338385773 52726737 132219482
12WI 1.44E+07 222707768 6278955683 31238932 122805413
30WI 1.93E+07 100220942 6047224501 0 101115679
60WI 1.97E+07 129179374 7458784535 15473002 136897242
240WI 1.30E+07 152094152 3311469243 0 98313491
6CI 1.58E+07 151275941 807778019 25858547 80947522
12CI 2.21E+07 165609426 3296900454 31228466 116902510
30CI 1.85E+07 149073572 2070397842 32446962 101807382
60 CI 1.60E+07 198507900 4084705609 38159897 93130482
240CI 2.28E+07 261337200 3479570187 22218726 91914367
480CI 2.00E+07 130396114 4203880803 10765369 77635794
Control 1.65E+07 1.31E+08 9.18E+08 9.65E+06 1.51E+08
6WI 1.33E+07 4.05E+08 6.83E+09 6.34E+06 1.01E+08
12WI 1.51E+07 4.47E+08 8.84E+09 8.45E+06 1.30E+08
30WI 1.37E+07 3.14E+08 1.19E+10 8.55E+06 1.60E+08
60WI 1.67E+07 3.42E+08 1.72E+10 1.17E+07 2.48E+08
240WI 1.11E+07 8.71E+08 7.86E+09 9.61E+06 2.13E+08
6CI 1.90E+07 1.10E+08 1.32E+09 9.69E+06 1.02E+08
12CI 1.21E+07 9.26E+07 1.30E+09 1.00E+07 8.48E+07
30CI 1.69E+07 7.14E+07 1.06E+09 1.04E+07 5.04E+07
60 CI 1.79E+07 1.21E+08 1.53E+09 1.32E+07 4.97E+07
240CI 1.34E+07 1.02E+08 2.34E+09 7.41E+06 5.35E+07
480CI 1.10E+07 5.27E+07 2.20E+09 8.33E+06 3.17E+07
1440CI 1.43E+07 3.71E+07 3.79E+09 8.89E+06 4.00E+07
Control 22448769 26260651 171153411 1129318816.29 23771193 84498705
6WI 39910347 46979229 279946230 5663938666 63516221 134408354
12WI 26933665 33560337 357240409 7265330979 35829041 135129159
30WI 29421041 27949554 302721184 4930891909 25058376 131769724
60WI 27548100 18807833 165624526 9743020952 24991670 188085244
240WI 26473177 31972371 287037618 7222249222 35906790 152256500
6CI 25224272 24640736 156530288 2258807319 29202430 85306716
12CI 28677878 37391442 144782706 2670836762 35693813 93737459
30CI 26169780 40984145 122472628 2317381880 34678945 75140335
60 CI 24121420 29002105 91674148 2864732513 30582323 77112564
240CI 22860044 30268034 95761696 2501792307 31027020 60905039
480CI 24054976 36715536 101200772 3155632003 37608867 63951899
1440CI 23819160 23935437 36307800 4222482193 29824415 42702912
Control 1.98E+07 1.62E+07 4.72E+08 2.01E+09 3.53E+07 1.08E+08
6WI 1.89E+07 2.18E+07 8.45E+08 7.74E+09 4.96E+07 8.69E+07
12WI 2.38E+07 5.45E+07 8.01E+08 1.00E+10 6.00E+07 1.34E+08
30WI 1.71E+07 2.30E+07 7.55E+08 9.67E+09 4.21E+07 1.50E+08
60WI 1.43E+07 2.87E+07 3.90E+08 8.28E+09 4.60E+07 1.64E+08
240WI 1.52E+07 2.09E+07 4.64E+08 8.47E+09 4.30E+07 2.05E+08
6CI 1.64E+07 2.92E+07 4.08E+08 3.98E+09 5.00E+07 1.01E+08
12CI 1.71E+07 3.34E+07 3.50E+08 4.02E+09 4.90E+07 8.00E+07
30CI 1.56E+07 2.03E+07 1.95E+08 2.77E+09 4.16E+07 5.38E+07
60 CI 1.53E+07 3.68E+07 2.75E+08 3.73E+09 4.17E+07 6.60E+07
240CI 1.62E+07 4.62E+07 3.47E+08 4.13E+09 6.22E+07 9.30E+07
480CI 1.30E+07 3.15E+07 1.61E+08 2.45E+09 5.43E+07 2.82E+07































Control 2795236299 73240796 332718987 57326409 56354953 1.28E+07
6WI 15397837660 64738999 388540927 107528621 27914145 1.77E+07
12WI 14469865183 52219829 209397540 123934965 26111088 1.65E+07
30WI 13538968979 44917615 23360441 104621890 24882340 2.23E+07
60WI 20267157520 63884505 105736779 268602088 36237867 1.79E+07
240WI 18912461383 48240767 19622674 355887684 24637925 1.59E+07
6CI 3536536278 41947568 165905278 315458757 11021612 1.46E+07
12CI 10724276318 69310303 236271507 486791215 37350834 2.34E+07
30CI 7958152283 59899180 226484492 349872149 26938919 1.75E+07
60 CI 16462106866 57383408 266361920 398191080 29622729 2.29E+07
240CI 18899098733 79858809 180432438 630469483 36061482 2.08E+07
480CI 15342250779 63938584 101095113 589174787 27781942 1.75E+07
Control 3.69E+09 1.27E+08 1.53E+08 8.38E+07 0.00E+00
6WI 2.30E+10 7.05E+07 2.55E+08 5.82E+07 0.00E+00
12WI 3.12E+10 9.55E+07 1.78E+08 9.42E+07 0.00E+00
30WI 3.46E+10 1.20E+08 2.67E+08 7.46E+07 0.00E+00
60WI 5.70E+10 1.16E+08 8.39E+07 1.57E+08 2.36E+07
240WI 5.67E+10 8.50E+07 7.23E+07 2.50E+08 6.16E+07
6CI 4.52E+09 1.06E+08 1.60E+08 1.70E+08 0.00E+00
12CI 4.30E+09 9.21E+07 1.52E+08 8.78E+07 0.00E+00
30CI 3.33E+09 7.29E+07 1.22E+08 2.74E+08 0.00E+00
60 CI 7.68E+09 1.02E+08 1.20E+08 4.68E+08 0.00E+00
240CI 1.92E+10 8.25E+07 3.88E+07 1.94E+08 0.00E+00
480CI 1.12E+10 6.72E+07 1.47E+07 3.05E+08 0.00E+00
1440CI 1.71E+10 7.48E+07 6.71E+06 5.30E+08 0.00E+00
Control 4190603106 149162783 175889021 184438459
6WI 26949157173 176240612 222052651 552175545
12WI 32781661379 140721338 104925355 244250374
30WI 33301102965 137547416 26196201 244098877
60WI 43472817780 111793664 24752477 390193517
240WI 46655755841 140467314 5001659 736557402
6CI 7603626112 147985638 306162739 268979256
12CI 9351770945 147093401 250092893 275432189
30CI 9685143896 185327503 299532785 265529750
60 CI 11719407955 139702731 252525413 277604062
240CI 16843936939 114944491 72405121 266219489
480CI 14955068100 191293615 43740677 391285731
1440CI 17928422168 115048026 26916017 469079098
Control 6.17E+09 7.32E+07 1.76E+08 2.24E+08
6WI 2.29E+10 7.32E+07 1.34E+08 1.62E+08
12WI 2.62E+10 7.95E+07 9.67E+07 2.80E+08
30WI 2.99E+10 8.60E+07 1.02E+08 2.31E+08
60WI 1.85E+10 9.19E+07 6.51E+07 3.23E+08
240WI 2.30E+10 1.76E+08 1.13E+08 1.90E+09
6CI 1.09E+10 6.70E+07 2.06E+08 2.32E+08
12CI 1.00E+10 8.31E+07 1.53E+08 2.45E+08
30CI 1.24E+10 6.37E+07 1.19E+08 2.47E+08
60 CI 9.70E+09 7.45E+07 1.76E+08 2.64E+08
240CI 1.47E+10 7.00E+07 6.84E+07 3.21E+08
480CI 7.74E+09 5.78E+07 2.90E+07 4.31E+08

























Appendix 3: Human LC-MS data
sample uracil xanthine nicotinaminde hypoxanthine orotate
succinyl-
adenosine
Control 0 370176 94645688 25984379 0
6WI 228378 3708296 1513257111 1561784513 0
12WI 21102202 10118062 2055069160 4310013090 6055297
30WI 43811208 22228406 1598964510 6418562259 7982359
60WI 61629399 58664415 2376941974 9296441461 12913501
240WI 201402012 216981377 6356232855 22862090385 15517997
6CI 0 782321 179525099 87782962 0
12CI 11257537 14417373 912981223 2781728373 2795615
30CI 223448 1110739 668636995 282167586 0
60 CI 51648948 64016957 2388944477 8055616065 3431044
240CI 10977251 21787247 1638528842 3208332491 1373064
480CI 6329435 9367145 1127047580 2913432333 1571776
Control 0.00E+00 5.31E+05 2.05E+08 1.25E+08 1.62E+06 0.00E+00
6WI 0.00E+00 6.36E+05 1.58E+09 9.40E+08 1.09E+06 1.40E+05
12WI 0.00E+00 3.93E+06 2.56E+09 1.96E+09 1.10E+06 1.19E+06
30WI 0.00E+00 1.49E+07 1.91E+09 2.58E+09 1.21E+06 3.52E+06
60WI 3.23E+06 2.17E+07 3.36E+09 4.87E+09 7.77E+05 1.65E+07
240WI 2.50E+07 1.07E+08 6.44E+09 9.24E+09 4.27E+05 3.98E+07
6CI 0.00E+00 6.20E+05 2.49E+08 1.17E+08 1.27E+06 0.00E+00
12CI 0.00E+00 5.62E+05 2.28E+08 2.33E+08 1.91E+06 0.00E+00
30CI 0.00E+00 0.00E+00 2.15E+08 1.05E+08 6.81E+05 0.00E+00
60 CI 0.00E+00 0.00E+00 4.83E+08 2.82E+08 7.63E+05 0.00E+00
240CI 0.00E+00 0.00E+00 1.13E+09 4.74E+08 9.55E+05 0.00E+00
480CI 0.00E+00 1.67E+05 3.01E+08 3.05E+08 3.17E+05 0.00E+00
1440CI 0.00E+00 1.47E+06 3.08E+08 1.20E+09 1.51E+05 0.00E+00
Control 2379816 1282553 209838881 75683031 3705582 NF
6WI 51698458 12650141 2171878838 1553465575 3015194 1068169
12WI 105196999 16863466 3806522083 2695714733 1537240 4414912
30WI 94936518 59815196 4786952123 5054869994 1721497 11072043
60WI 117765573 72603235 3526323701 6191922407 1073781 19915958
240WI 130215210 491343204 6893066975 10787803015 2051185 30999863
6CI 4448024 2127861 190300131 90816700 2456435 NF
12CI 5021484 6458622 264991800 263528167 2336416 NF
30CI 6509824 1903715 299189552 151214443 2716997 NF
60 CI 6254316 2157721 343457540 201974893 2022555 NF
240CI 11750727 2470312 815838214 436128419 976309 NF
480CI 2628748 1254657 339985925 443019043 399250 NF
1440CI 639192 1259917 320754076 1163204523 162534 NF
Control 7.75E+05 4.50E+06 4.92E+08 7.57E+08 3.60E+05 NF
6WI 1.97E+05 3.63E+06 3.12E+09 3.24E+09 2.15E+05 1.33E+06
12WI 8.72E+06 1.97E+07 5.15E+09 5.81E+09 2.20E+05 1.29E+07
30WI 1.21E+07 3.64E+07 5.69E+09 8.62E+09 NF 2.46E+07
60WI 6.42E+07 1.16E+08 4.55E+09 1.47E+10 1.02E+05 2.14E+07
240WI 3.18E+08 5.15E+08 9.96E+09 4.47E+10 2.99E+05 5.03E+07
6CI NF 1.84E+05 4.61E+08 2.58E+08 8.64E+04 NF
12CI NF 1.74E+06 6.74E+08 3.65E+08 2.96E+05 NF
30CI NF 1.56E+06 1.12E+09 5.41E+08 9.70E+04 NF
60 CI NF 6.57E+05 3.67E+08 3.46E+08 9.54E+04 NF
240CI 2.07E+05 3.38E+06 1.60E+09 1.42E+09 1.06E+05 1.68E+05
480CI NF 7.38E+05 6.90E+08 1.36E+09 NF 1.91E+05

























Appendix 3: Human LC-MS data
sample urea allopurinol inosine
ascorbic 
acid uridine uric acid
Control 3818975038 9486888 0 5121299 109547016
6WI 3724911902 1003327323 0 3473853 118208422
12WI 3251572215 1873083468 0 2941879 89122558
30WI 1705245026 2765336859 31770483 575559 65163667
60WI 2844312026 3960562673 0 2224789 94550380
240WI 2447958878 3946415478 0 5213001 72221585
6CI 1919804529 90816040 0 949326 55612611
12CI 2773451510 1263099338 3049378 1238537 80359676
30CI 2466642340 485414372 0 1395882 90428406
60 CI 2254069335 2167075913 13243889 2135204 84638311
240CI 2047970244 2303646273 0 2516961 86344160
480CI 1623852775 2807815475 7365667 1304225 61741627
Control 5.84E+09 8.03E+07 1.34E+08 5.23E+06 3.08E+06 8.91E+07
6WI 4.32E+09 6.73E+08 1.09E+09 5.21E+07 6.03E+07 5.37E+07
12WI 4.68E+09 1.39E+09 2.20E+09 3.87E+07 1.17E+08 7.47E+07
30WI 3.68E+09 1.92E+09 3.21E+09 4.05E+07 9.37E+07 3.83E+07
60WI 5.04E+09 3.38E+09 5.40E+09 9.04E+07 1.69E+08 6.47E+07
240WI 3.86E+09 4.21E+09 6.84E+09 1.05E+08 2.14E+08 4.51E+07
6CI 4.43E+09 1.51E+08 2.17E+08 0.00E+00 4.54E+06 7.15E+07
12CI 4.28E+09 1.75E+08 2.59E+08 9.93E+07 4.50E+06 4.13E+07
30CI 2.45E+09 2.08E+08 3.26E+08 0.00E+00 1.52E+06 4.16E+07
60 CI 1.67E+09 5.55E+08 9.12E+08 0.00E+00 3.38E+06 3.84E+07
240CI 1.48E+09 1.10E+09 1.72E+09 0.00E+00 1.19E+07 2.61E+07
480CI 2.37E+08 1.08E+09 1.67E+09 0.00E+00 2.56E+06 9.00E+06
1440CI 1.43E+08 3.10E+09 5.01E+09 0.00E+00 2.99E+06 1.68E+07
Control 3598190893 232965746 211878839 7800502 1648321 73623132
6WI 4681898850 2401412679 2152552094 292527879 3648300 114527114
12WI 4490293925 3390863634 3064511574 276258425 2483197 110425730
30WI 3659278805 6829125115 5679924873 61050209 3114761 88505924
60WI 3634852539 6771240472 6096906815 506760607 3518550 97437424
240WI 3715772844 8718282348 7504643010 167395723 5865319 77943872
6CI 2978660133 282657362 244335240 186162469 1679700 61537526
12CI 3381646317 353288750 306248988 328837873 1815676 77408998
30CI 2836389979 666831764 575557999 242772518 1846718 68214125
60 CI 2940562581 726216517 651418726 68376159 1782010 67864151
240CI 1613677093 1804860397 1670757418 5952137 1299289 51445903
480CI 488012367 2256803626 2110466433 122290993 NF 29553951
1440CI 282687889 4512916157 4016585784 8702568 NF 24886315
Control 5.92E+09 3.45E+08 8.59E+06 1.63E+08
6WI 4.09E+09 3.24E+09 3.70E+06 9.48E+07
12WI 4.61E+09 5.74E+09 6.08E+06 1.17E+08
30WI 3.76E+09 8.83E+09 4.27E+06 9.62E+07
60WI 3.99E+09 7.85E+09 6.48E+06 1.31E+08
240WI 5.15E+09 9.59E+09 1.80E+07 1.55E+08
6CI 3.49E+09 5.93E+08 3.30E+06 9.35E+07
12CI 3.85E+09 9.56E+08 4.50E+06 1.06E+08
30CI 3.04E+09 1.75E+09 2.43E+06 8.17E+07
60 CI 2.95E+09 9.32E+08 3.70E+06 8.56E+07
240CI 1.55E+09 4.33E+09 2.22E+06 5.93E+07
480CI 3.04E+08 6.34E+09 NF 2.72E+07

























Appendix 3: Human LC-MS data
sample guanosine tryptophan adenosine methionine glucose
leucine and 
isoleucine
Control 642307 50460096 7.13E+07 320108833 4909373615 981866010
6WI 76799985 47873636 2495198480 315387403 682049734 1211760821
12WI 122371383 44757461 3923075315 275778240 142971190 1281152762
30WI 178819028 78419536 1021968436 225205634 118535321 1879653360
60WI 293766627 102935696 3028725176 363527638 328109294 2482725871
240WI 373596122 261566742 207363873 500522315 138912570 5971450684
6CI 675512 22034165 8623271968 219697632 1128255250 478318408
12CI 66258269 50464961 12035354445 288922309 1017127711 1167679408
30CI 14069473 39135731 9800845266 234393528 771507927 715879266
60 CI 140070660 83221928 6218563600 308810391 801469654 2152740971
240CI 88424324 54041681 11745842883 312133094 594814273 1204054056
480CI 74751029 35727155 9700420675 220739991 308105358 862209936
Control 6.71E+06 5.72E+07 1.74E+09 3.64E+08 4.51E+09 2.06E+09
6WI 5.91E+07 5.58E+07 1.95E+09 2.78E+08 1.45E+09 1.48E+09
12WI 1.10E+08 7.04E+07 1.88E+09 3.10E+08 1.22E+09 2.02E+09
30WI 1.84E+08 7.80E+07 2.10E+09 2.67E+08 1.68E+09 2.19E+09
60WI 3.77E+08 1.68E+08 2.20E+09 4.10E+08 1.16E+09 4.19E+09
240WI 4.99E+08 1.01E+09 1.03E+09 1.94E+09 6.33E+09 1.88E+10
6CI 8.98E+06 5.99E+07 7.36E+09 2.46E+08 1.84E+09 1.38E+09
12CI 1.15E+07 4.81E+07 3.64E+09 3.46E+08 1.76E+09 1.53E+09
30CI 4.52E+06 2.99E+07 1.19E+10 2.30E+08 6.15E+08 9.39E+08
60 CI 1.21E+07 3.34E+07 2.06E+10 2.11E+08 2.29E+08 9.64E+08
240CI 2.15E+07 2.76E+07 8.16E+09 1.65E+08 2.27E+08 8.51E+08
480CI 1.86E+07 1.33E+07 1.38E+10 6.30E+07 8.47E+07 4.00E+08
1440CI 3.06E+07 2.05E+07 1.05E+10 4.48E+07 1.86E+08 5.32E+08
Control 6905743 215524572 1.59E+09 535453908 888433838 1518673816
6WI 110397156 298135159 6411281237 844850210 924342071 4032448252
12WI 184953279 298769854 3887089321 693223245 678347902 2779647803
30WI 304112931 400023256 3458136991 920167736 675291047 5335266548
60WI 457775544 425505280 2736212805 811288684 396726398 5720413208
240WI 568330737 2006579585 696178584 4097528953 1505616896 32349999558
6CI 8957350 168951940 9870170539 456976202 465397512 1349850608
12CI 13575543 205211119 6783666246 612833990 898208903 2489678385
30CI 19860661 176183496 13724662553 478545698 462962267 1313639825
60 CI 19142041 169190189 10119017795 532023725 596563217 1401143921
240CI 54613723 124866219 11559185217 302320781 349971086 954215717
480CI 23424728 111143282 18797145722 212690869 257081340 1004243721
1440CI 21885344 83065092 13574903442 109109351 194632733 819814760
Control 1.33E+07 6.39E+07 1.12E+09 4.37E+08 4.31E+09 2.14E+09
6WI 1.17E+08 5.07E+07 2.99E+09 2.98E+08 1.15E+09 1.64E+09
12WI 2.65E+08 8.55E+07 4.45E+09 3.44E+08 7.64E+08 2.61E+09
30WI 4.15E+08 1.22E+08 2.29E+09 4.02E+08 4.86E+08 3.37E+09
60WI 4.79E+08 1.58E+08 1.30E+09 3.51E+08 1.10E+08 3.71E+09
240WI 7.84E+08 5.49E+08 8.91E+08 9.92E+08 1.81E+08 1.01E+10
6CI 1.63E+07 3.56E+07 8.11E+09 2.66E+08 7.10E+08 1.45E+09
12CI 2.55E+07 3.54E+07 8.44E+09 2.87E+08 7.16E+08 1.24E+09
30CI 4.43E+07 2.60E+07 8.56E+09 3.01E+08 9.64E+08 8.59E+08
60 CI 1.53E+07 4.32E+07 9.02E+09 3.22E+08 9.38E+08 1.36E+09
240CI 9.37E+07 3.92E+07 1.42E+10 2.74E+08 3.31E+08 1.33E+09
480CI 7.29E+07 2.08E+07 1.85E+10 1.28E+08 2.32E+08 5.56E+08
































semialdehyde guanine homocysteine GSH
Control 160051543 0 949421 5331505666
6WI 124632665 10212390 2239068 5630484224
12WI 92721491 28943818 3167353 6101380540
30WI 78312373 38930862 0 3519110232
60WI 69823664 59557514 3777090 3639339293
240WI 46435307 222673619 5106325 3374388207
6CI 46213551 0 3129109 2289786879
12CI 53315979 7196524 3260188 2652377764
30CI 62478198 0 3367982 3928351769
60 CI 56871169 41014252 3505962 2961190231
240CI 64103735 8934143 3628894 3211545717
480CI 37395845 5122363 1775032 2063828869
Control 4.63E+08 2.45E+08 2.15E+07 0.00E+00 2.52E+06 3.81E+09
6WI 1.47E+09 2.01E+08 1.45E+07 3.71E+06 9.96E+05 4.54E+09
12WI 3.20E+09 2.03E+08 1.98E+07 0.00E+00 8.27E+05 4.22E+09
30WI 4.09E+09 1.82E+08 1.57E+07 8.58E+06 9.67E+05 3.23E+09
60WI 4.18E+09 1.60E+08 1.95E+07 2.62E+07 2.10E+06 4.54E+09
240WI 7.73E+08 1.18E+08 3.30E+07 6.77E+07 2.01E+06 3.08E+09
6CI 3.52E+08 2.15E+08 1.87E+07 0.00E+00 1.99E+06 4.43E+09
12CI 3.12E+08 2.70E+08 1.96E+07 0.00E+00 2.11E+06 4.44E+09
30CI 2.51E+08 1.76E+08 1.47E+07 0.00E+00 1.59E+06 3.04E+09
60 CI 3.32E+08 1.10E+08 1.15E+07 0.00E+00 1.60E+06 2.85E+09
240CI 2.46E+08 1.74E+08 1.02E+07 0.00E+00 8.78E+05 2.33E+09
480CI 3.91E+08 5.86E+07 0.00E+00 0.00E+00 0.00E+00 1.37E+09
1440CI 5.59E+08 5.79E+07 0.00E+00 5.53E+06 0.00E+00 1.62E+09
Control 912191251 219984494 57499175 164568 2113601 6053398495
6WI 2387449795 244297310 71666462 11480390 3075783 6958986350
12WI 3959910312 216791938 52350190 20981991 1415346 7691678678
30WI 3459567841 161808274 41991813 26198485 1737960 5621281326
60WI 5262117805 149020713 24473882 40218362 2392472 6305754418
240WI 927686817 177560719 115555873 26240169 4373094 4927738424
6CI 497559966 217595256 31862026 701156 1212623 6041034764
12CI 561482896 241631416 59722320 235857 1134517 6281039071
30CI 531487353 231580971 31695893 451231 1357340 6533946969
60 CI 436596702 220650967 39459634 NF 700784 6121986684
240CI 497435338 204055644 21481760 381480 1142762 5116121754
480CI 919422586 127134540 16955055 NF NF 4753082286
1440CI 1677081962 122994119 13413116 179011 865121 4051508733
Control 4.97E+08 1.65E+08 1.68E+06 3.30E+06 7.29E+09
6WI 1.08E+09 1.56E+08 1.50E+07 5.88E+06 6.11E+09
12WI 1.63E+09 1.42E+08 3.28E+07 3.19E+06 6.73E+09
30WI 2.03E+09 1.22E+08 4.02E+07 5.84E+06 6.21E+09
60WI 6.09E+08 1.33E+08 1.28E+08 6.19E+06 4.90E+09
240WI 3.14E+08 1.60E+08 5.61E+08 1.33E+07 5.62E+09
6CI 3.40E+08 1.30E+08 NF 3.90E+06 4.75E+09
12CI 2.66E+08 1.71E+08 NF 4.08E+06 5.59E+09
30CI 1.66E+08 1.72E+08 2.58E+05 2.98E+06 4.59E+09
60 CI 2.35E+08 1.57E+08 NF 3.94E+06 5.48E+09
240CI 3.44E+08 9.69E+07 8.05E+05 2.13E+06 3.44E+09
480CI 4.69E+08 4.80E+07 NF NF 2.09E+09


























Appendix 3: Human LC-MS data
sample
acetyl 
carnitine tyrosine AMP GMP
palmitoyl 
carnitine proline
Control 6192275081 237208854 68475839 119872646 1063431290
6WI 8312815506 298839257 878461592 202759251 1490322081
12WI 7562926471 273669930 1473800930 264422644 1868521681
30WI 2944564515 144609089 1517338237 103724512 1682024857
60WI 5485297736 397117834 1160864753 94755801 2436836574
240WI 3299875719 702767342 324931758 93183016 2945107622
6CI 6035898682 119785990 272922921 176732730 1148954655
12CI 7178180968 208600993 567027941 207418257 1695096784
30CI 7109839155 188754571 676148517 261014015 1115222828
60 CI 8711100017 285730009 359855798 239138525 1638590962
240CI 10970994282 194995115 251508733 454086835 1387798343
480CI 8632393819 150045294 679987129 233816619 1283225430
Control 3.51E+09 2.15E+08 1.66E+08 0.00E+00 1.25E+07 2.21E+09
6WI 1.23E+10 2.58E+08 1.07E+09 5.29E+06 7.79E+07 1.37E+09
12WI 1.08E+10 1.86E+08 1.49E+09 1.89E+07 4.43E+07 1.85E+09
30WI 1.46E+10 2.28E+08 9.94E+08 1.09E+07 3.99E+07 1.35E+09
60WI 1.16E+10 3.55E+08 2.52E+09 9.72E+06 1.21E+08 2.34E+09
240WI 5.61E+09 1.05E+09 5.55E+08 1.46E+06 8.39E+07 2.81E+09
6CI 6.13E+09 2.85E+08 2.16E+08 2.90E+05 1.40E+07 1.33E+09
12CI 7.83E+09 2.34E+08 1.71E+08 0.00E+00 2.87E+07 1.44E+09
30CI 8.18E+09 1.50E+08 2.75E+08 4.66E+05 5.33E+07 1.11E+09
60 CI 9.53E+09 1.31E+08 4.61E+08 2.89E+06 8.58E+07 9.85E+08
240CI 8.45E+09 1.06E+08 1.10E+09 6.35E+06 1.55E+08 7.91E+08
480CI 6.79E+09 4.41E+07 1.03E+08 4.64E+05 2.94E+08 4.48E+08
1440CI 5.31E+09 6.15E+07 2.70E+08 2.44E+06 1.94E+08 5.02E+08
Control 12402239732 673563019 456851340 1.11E+06 46538958 450075032
6WI 19376633722 1020214808 1174902882 14659105 117587284 871927729
12WI 18262237382 880780160 1645039105 24383050 78109018 860903200
30WI 12379098552 949533575 1338299928 28228409 61037013 1093908739
60WI 12605812287 967673200 2290385138 17976586 83709855 1257818225
240WI 8683857002 3184847996 1088290861 6792624 36591887 3948403990
6CI 14775824032 589810362 498319407 2032084 77169630 479046717
12CI 16875390114 673799287 413522168 1439503 77706097 585324639
30CI 14194344395 628411064 455974031 2750704 88692953 500316726
60 CI 15597318768 612513592 272670384 1043934 92569607 456127946
240CI 12162768844 483571490 389155554 2912043 137436010 334625221
480CI 12824676826 361341142 163123031 394952 199854644 452270638
1440CI 9652842894 275835117 479738765 8181507 239708893 258044788
Control 1.19E+10 4.54E+08 1.34E+08 NF 1.22E+08 1.49E+09
6WI 1.56E+10 4.22E+08 1.00E+09 1.90E+06 8.74E+07 1.36E+09
12WI 1.43E+10 5.50E+08 1.85E+09 7.52E+06 1.03E+08 1.61E+09
30WI 1.18E+10 5.76E+08 1.34E+09 1.63E+06 1.03E+08 1.71E+09
60WI 7.03E+09 6.55E+08 1.31E+09 7.84E+06 1.40E+08 2.18E+09
240WI 1.03E+10 1.47E+09 8.45E+08 NF 2.35E+08 5.53E+09
6CI 1.65E+10 3.06E+08 5.07E+08 NF 8.48E+07 1.06E+09
12CI 1.58E+10 3.41E+08 3.63E+08 NF 8.63E+07 1.09E+09
30CI 1.00E+10 2.50E+08 3.34E+08 NF 1.57E+08 8.24E+08
60 CI 1.36E+10 3.30E+08 5.13E+07 NF 1.29E+08 1.15E+09
240CI 1.33E+10 1.91E+08 1.53E+09 7.46E+06 1.54E+08 6.87E+08
480CI 5.45E+09 8.12E+07 6.46E+08 8.96E+05 1.59E+08 3.32E+08






























Control 5546554430 18984656 6072289809 22749509750 3535504887
6WI 4849283935 79314937 9416443676 20385974455 3698546169
12WI 4421409950 92561730 9730686748 14339099080 4379746850
30WI 4561271343 177235264 7804397779 11138780471 3224794123
60WI 3000506529 224058715 11006580817 13075009793 3362472743
240WI 3945342538 679941112 10636111058 7733193982 2898893246
6CI 1200154707 14092118 4399495681 10531015954 2152556209
12CI 1540866109 2985132 7581203520 14664285455 2400887365
30CI 2381410129 43353520 5986442621 15654402702 2377320295
60 CI 2152197651 28880356 8190510281 12987202802 2543324158
240CI 1589570012 31316491 7734558501 17041145380 2544809761
480CI 1311573698 17777298 6633105496 10314410792 2245138327
Control 7.17E+09 1.16E+06 4.02E+09 2.44E+10 2.00E+10
6WI 7.93E+09 2.56E+07 5.72E+09 1.93E+10 1.73E+10
12WI 6.56E+09 1.53E+07 7.50E+09 2.21E+10 1.98E+10
30WI 5.91E+09 3.22E+07 6.98E+09 1.30E+10 1.58E+10
60WI 6.98E+09 8.98E+07 1.18E+10 1.35E+10 2.17E+10
240WI 7.39E+09 2.02E+08 1.33E+10 8.31E+09 1.67E+10
6CI 8.90E+09 1.62E+07 4.29E+09 2.37E+10 1.73E+10
12CI 7.22E+09 1.05E+07 3.56E+09 2.38E+10 2.02E+10
30CI 5.83E+09 4.73E+06 2.55E+09 2.14E+10 1.58E+10
60 CI 4.85E+09 8.34E+06 2.26E+09 1.64E+10 1.24E+10
240CI 4.49E+09 1.73E+07 2.42E+09 1.50E+10 1.24E+10
480CI 2.26E+09 9.88E+06 1.06E+09 6.59E+09 5.07E+09
1440CI 2.81E+09 1.25E+07 2.22E+09 7.44E+09 5.90E+09
Control 7806155160 257803 2724695117 14881162663 22910869648
6WI 7086698526 3566612 5293606061 14174543433 30992550708
12WI 7586067529 12563939 6344474899 13292976037 27091127823
30WI 5928773580 13836985 5953818134 10043296882 23936525961
60WI 6443931324 26375356 7883823506 9459735225 26501854071
240WI 6421782173 121850723 10864212587 9585723343 23716264875
6CI 8130903885 3250238 3042416675 15332914382 20738907909
12CI 8046370871 2453545 3447198832 15362569632 21622690312
30CI 7863726741 2028113 3035362584 18498494200 19126739844
60 CI 7287037607 5037991 3062386653 15885342027 22455269615
240CI 6379429392 1821369 2561804192 15382120952 16873555415
480CI 4813449726 1541719 2421398793 12132118471 10803946269
1440CI 3853411234 844402 2906753023 9919168894 12190073903
Control 1.07E+10 NF 7.61E+09 2.34E+10 3.66E+10
6WI 9.96E+09 3.07E+07 9.97E+09 2.22E+10 2.85E+10
12WI 1.01E+10 9.56E+07 1.17E+10 2.15E+10 3.23E+10
30WI 9.54E+09 1.26E+08 1.27E+10 1.71E+10 2.92E+10
60WI 9.55E+09 2.49E+08 1.09E+10 1.57E+10 2.63E+10
240WI 1.15E+10 1.15E+09 1.87E+10 1.92E+10 3.55E+10
6CI 7.96E+09 9.31E+06 7.58E+09 1.65E+10 2.83E+10
12CI 9.06E+09 2.74E+07 7.22E+09 2.40E+10 3.28E+10
30CI 7.35E+09 2.33E+07 4.47E+09 2.09E+10 2.92E+10
60 CI 8.68E+09 7.77E+06 7.28E+09 2.13E+10 2.89E+10
240CI 5.77E+09 1.37E+07 5.89E+09 1.28E+10 2.05E+10
480CI 2.69E+09 1.48E+07 2.16E+09 7.69E+09 8.53E+09

























Appendix 3: Human LC-MS data





Control 1548653913 2197358104 472717942 1140775668 557285324 54807720
6WI 1849054064 1338218183 498962605 1079817756 1266162236 55058697
12WI 1852918731 589043725 463595727 853192941 1532925657 67140687
30WI 1611906441 384472676 466581208 666168639 1323506223 48466071
60WI 2303414339 1184077173 573645340 955635888 2588019693 48501910
240WI 3300071817 2248552781 903683498 798532469 290275209 42066085
6CI 982257473 716995686 287610856 552232288 327706382 31104457
12CI 1726379617 1027406308 504848079 898343807 1104178737 34978649
30CI 1389501945 1146326231 537770441 876311496 443912820 34741674
60 CI 1861490695 1223668145 545872378 914049035 994215057 35981646
240CI 1667868066 830372356 500011761 906448184 1206462552 36500498
480CI 1217375449 587826669 337841942 694383435 1446663462 31793187
Control 1.03E+09 1.10E+09 4.96E+08 2.23E+09 2.86E+08 6.13E+07
6WI 8.82E+08 7.08E+08 4.51E+08 1.95E+09 1.01E+09 6.56E+07
12WI 1.03E+09 6.65E+08 4.38E+08 2.22E+09 1.87E+09 5.38E+07
30WI 9.60E+08 6.60E+08 3.44E+08 2.55E+09 4.05E+09 7.78E+07
60WI 1.76E+09 1.65E+09 6.21E+08 2.74E+09 5.32E+09 7.25E+07
240WI 6.47E+09 2.05E+08 9.74E+08 2.17E+09 1.10E+09 7.18E+07
6CI 9.00E+08 1.53E+09 4.79E+08 1.99E+09 2.03E+08 4.19E+07
12CI 9.18E+08 1.13E+09 4.33E+08 2.60E+09 3.06E+08 6.98E+07
30CI 6.13E+08 8.52E+08 3.50E+08 1.70E+09 2.28E+08 2.38E+07
60 CI 6.24E+08 5.52E+08 2.70E+08 1.38E+09 3.44E+08 7.55E+06
240CI 5.13E+08 5.36E+08 2.36E+08 1.52E+09 4.48E+08 3.42E+07
480CI 2.27E+08 1.37E+08 8.85E+07 6.78E+08 7.43E+08 9.19E+06
1440CI 3.38E+08 1.30E+08 1.39E+08 6.82E+08 5.90E+08 4.71E+06
Control 1246069161 2000678483 468017070 1454763529 506537237 86612268
6WI 2056710079 969502449 706539426 1438462582 2574682427 101849055
12WI 1769051660 892677368 608320164 1536502197 3339920553 93470753
30WI 2633334315 1211159546 620556519 1299247930 2053890469 83459139
60WI 2715448105 1050348261 666196893 1510977544 4816654226 81441491
240WI 12257057942 208429668 1360331061 1406249973 2158036010 72165881
6CI 1126518404 1178613393 467736984 1433586741 599985827 68440689
12CI 1487308948 1495881846 497453990 1388543853 774629123 80552361
30CI 1113011371 1356393524 471534662 1426143159 599320891 51347438
60 CI 1242100935 1155599683 481357366 1508473782 907401458 81609550
240CI 923058396 721802035 374818048 1248211694 1314490828 59674030
480CI 610329591 562317006 240081145 972532545 2931884807 16583874
1440CI 613706149 215972337 265258266 1041277163 2971041631 20074900
Control 1.66E+09 8.39E+09 1.15E+09 1.19E+09 5.44E+08 9.58E+07
6WI 1.32E+09 3.19E+09 1.11E+09 1.09E+09 1.07E+09 7.62E+07
12WI 1.79E+09 3.83E+09 1.24E+09 1.11E+09 1.66E+09 8.41E+07
30WI 2.03E+09 3.60E+09 1.24E+09 1.12E+09 1.85E+09 8.10E+07
60WI 2.19E+09 1.88E+09 1.12E+09 9.39E+08 9.02E+08 8.95E+07
240WI 5.79E+09 4.16E+09 1.97E+09 1.22E+09 5.81E+08 1.08E+08
6CI 1.08E+09 4.22E+09 9.57E+08 9.63E+08 5.19E+08 8.01E+07
12CI 1.18E+09 5.95E+09 1.15E+09 1.05E+09 7.93E+08 7.61E+07
30CI 9.29E+08 4.37E+09 8.59E+08 9.76E+08 4.32E+08 7.68E+07
60 CI 1.08E+09 4.11E+09 1.06E+09 9.96E+08 4.61E+08 7.49E+07
240CI 7.51E+08 2.59E+09 6.55E+08 6.95E+08 1.56E+09 4.91E+07
480CI 3.42E+08 1.45E+09 2.31E+08 3.64E+08 1.05E+09 1.00E+07

























Appendix 3: Human LC-MS data
sample
glyceryl 
phosphorylcholine CMP asparagine serine adenine glycine
Control 1362466489 236984042 1383621171 1041623 653891050
6WI 1330162281 242969790 1501799845 125611211 756633860
12WI 1426026271 233461288 1414542096 252593983 967012736
30WI 1110418554 208514663 1187852051 401762839 820626152
60WI 1329195909 241327886 1551409618 380128078 1051023089
240WI 919809940 253748187 1540264462 87069590 1052078214
6CI 858284773 127503119 861256019 25573651 444198113
12CI 1394939421 164496955 1183563049 134724536 705818159
30CI 1245200155 148090351 935322106 59161744 530357106
60 CI 1146068592 176908423 1193061286 130949854 680801401
240CI 1323478642 162976268 1103308347 129124878 596491067
480CI 1098746740 131448627 910172695 207645677 539013502
Control 2.26E+09 0.00E+00 1.56E+08 5.75E+08 1.41E+07 4.17E+08
6WI 1.88E+09 4.21E+06 1.38E+08 4.34E+08 9.68E+07 3.32E+08
12WI 2.34E+09 4.12E+06 1.47E+08 6.20E+08 1.59E+08 4.05E+08
30WI 2.26E+09 2.00E+06 1.51E+08 4.50E+08 2.10E+08 3.32E+08
60WI 2.53E+09 4.86E+05 1.45E+08 6.31E+08 3.30E+08 4.90E+08
240WI 1.96E+09 1.08E+06 1.91E+08 9.20E+08 1.58E+08 6.33E+08
6CI 2.20E+09 6.12E+05 8.88E+07 3.70E+08 2.43E+07 2.93E+08
12CI 2.46E+09 2.67E+05 1.40E+08 4.32E+08 1.69E+07 2.74E+08
30CI 1.74E+09 0.00E+00 4.50E+07 2.55E+08 4.55E+07 1.71E+08
60 CI 1.72E+09 2.52E+05 1.65E+07 1.57E+08 1.11E+08 1.38E+08
240CI 1.60E+09 2.00E+06 4.49E+07 2.32E+08 1.44E+08 1.46E+08
480CI 1.14E+09 0.00E+00 7.57E+06 6.24E+07 3.50E+08 6.42E+07
1440CI 1.04E+09 4.04E+05 7.38E+06 9.08E+07 3.52E+08 9.56E+07
Control 4526940268 5370719 218832375 694142319 248438822
6WI 5823236702 11418459 213879747 1011448356 404058273
12WI 5204830988 12056877 231736694 860051052 368500246
30WI 4576251374 9401726 244044151 929870343 394046375
60WI 4974754274 8381024 232543218 1005483457 464397169
240WI 5485593359 2602731 324851496 1773536132 840979488
6CI 4859626174 4053012 120312129 513710278 197333730
12CI 4926359456 4085209 185401544 691413447 256203023
30CI 5391864806 2828426 98518348 476269332 201853351
60 CI 4936872011 2324932 145926725 530024022 191643091
240CI 4362039730 2463595 92036663 371352913 148667620
480CI 4616820882 1752502 29746291 200460565 127110962
1440CI 4791303687 1898622 29587916 194137272 90130665
Control 4.15E+09 1.97E+06 3.03E+08 9.00E+08 1.46E+07 5.89E+08
6WI 3.36E+09 4.26E+06 2.46E+08 7.02E+08 1.78E+08 4.97E+08
12WI 3.57E+09 3.45E+06 2.75E+08 8.21E+08 3.24E+08 6.02E+08
30WI 3.38E+09 2.61E+06 2.56E+08 7.97E+08 3.07E+08 6.29E+08
60WI 1.90E+09 1.81E+06 3.08E+08 8.54E+08 2.92E+08 7.56E+08
240WI 2.78E+09 3.66E+05 4.74E+08 1.53E+09 2.09E+08 1.89E+09
6CI 2.88E+09 1.04E+06 1.76E+08 5.46E+08 3.73E+07 3.58E+08
12CI 3.53E+09 1.39E+06 1.88E+08 5.96E+08 5.39E+07 3.99E+08
30CI 2.87E+09 7.91E+05 1.68E+08 4.97E+08 7.36E+07 2.97E+08
60 CI 3.18E+09 4.17E+05 1.82E+08 5.66E+08 5.80E+07 3.73E+08
240CI 2.47E+09 2.39E+06 8.29E+07 3.15E+08 1.80E+08 2.39E+08
480CI 1.84E+09 NF 1.61E+07 1.37E+08 1.73E+08 1.08E+08


























Appendix 3: Human LC-MS data
sample GSSG carnitine citrulline creatinine choline cytidine
Control 1556387 15011529074 49070268 2098671169 795490570
6WI 0 12238048193 52785719 853258292 5238061530
12WI 2791496 10590461574 46139005 788856363 4392604560
30WI 0 10805783106 29338660 545454706 4549537746
60WI 40102588 13403477324 53567423 724907121 5927475169
240WI 0 13055850297 37034497 803656320 14589068689
6CI 18999382 9632101676 25643861 532529171 1166933715
12CI 64298238 13215542832 37592742 731910470 3473459070
30CI 18145426 12889800452 29286626 700915872 1448705167
60 CI 50142452 11982519684 40442860 613581261 6278169357
240CI 63623340 12120609386 39843022 596321992 3791633348
480CI 53197626 9874037725 32898001 450286402 3033473143
Control 2.26E+07 2.89E+10 6.18E+07 1.08E+10 2.38E+09 0.00E+00
6WI 1.30E+06 2.03E+10 3.13E+07 1.79E+09 5.08E+09 2.85E+07
12WI 5.71E+05 2.12E+10 5.61E+07 1.66E+09 5.52E+09 4.06E+07
30WI 4.32E+06 2.40E+10 3.76E+07 1.48E+09 5.47E+09 3.02E+07
60WI 5.23E+06 2.63E+10 5.46E+07 1.91E+09 6.57E+09 1.96E+07
240WI 2.59E+06 2.68E+10 2.54E+07 1.62E+09 6.70E+09 1.78E+07
6CI 2.04E+07 2.53E+10 2.08E+07 7.42E+09 2.61E+09 5.79E+05
12CI 7.82E+06 3.17E+10 4.81E+07 8.09E+09 1.99E+09 0.00E+00
30CI 1.91E+07 2.07E+10 3.74E+07 4.49E+09 1.51E+09 0.00E+00
60 CI 2.46E+07 1.86E+10 3.09E+07 3.06E+09 2.18E+09 7.87E+05
240CI 8.31E+06 1.98E+10 2.70E+07 1.11E+09 2.06E+09 4.66E+06
480CI 2.73E+07 1.19E+10 9.43E+06 9.96E+08 1.48E+09 3.38E+06
1440CI 3.21E+07 8.71E+09 7.03E+06 6.05E+08 1.26E+09 3.43E+05
Control 121631627 28292644750 34013552 1991817029 3765936971 2095404
6WI 192947514 28388328571 79329875 1689864041 8308363135 38508148
12WI 101805666 25668927818 42124873 1370753927 8957608937 55838330
30WI 60594214 28121863740 40707294 1191135426 9782036132 15781463
60WI 75763130 27779264706 45263272 1374672090 7694042487 17025364
240WI 38040384 33856648050 41567991 1853243691 10737214734 28795353
6CI 89879898 22802689435 28347038 1753051868 2590004811 4006691
12CI 87986809 27247521981 51332308 2650206687 2885082624 3583842
30CI 97187607 24305280077 26584851 2113247320 2476995166 5414015
60 CI 62527442 24787898143 33970093 3452493528 3178383305 5395532
240CI 62480754 19936427465 20356566 1395322766 2702757547 9538657
480CI 79391891 14704511173 9462113 1879875127 2087147771 2106182
1440CI 66082976 13436781907 17106305 1245785649 2287321860 1062545
Control 5.04E+07 2.61E+10 1.14E+08 2.93E+09 2.40E+09 5.70E+05
6WI 4.52E+06 1.93E+10 4.82E+07 1.09E+09 5.95E+09 2.00E+07
12WI 1.07E+07 2.07E+10 5.96E+07 1.25E+09 8.90E+09 2.75E+07
30WI 4.22E+05 2.07E+10 3.79E+07 1.19E+09 1.03E+10 1.18E+07
60WI 1.07E+06 1.91E+10 5.58E+07 9.12E+08 2.37E+10 1.98E+07
240WI 3.64E+06 2.32E+10 1.09E+08 1.58E+09 4.28E+10 1.39E+07
6CI 1.21E+07 1.84E+10 4.19E+07 1.02E+09 1.11E+09 5.95E+06
12CI 1.16E+07 2.06E+10 6.40E+07 1.78E+09 1.14E+09 2.47E+06
30CI 6.17E+06 2.27E+10 7.17E+07 1.64E+09 1.35E+09 2.43E+06
60 CI 1.34E+07 2.04E+10 2.93E+07 4.02E+09 9.22E+08 1.23E+06
240CI 8.29E+06 1.53E+10 3.54E+07 7.34E+08 3.26E+09 8.06E+06
480CI 1.18E+07 1.33E+10 2.52E+07 4.01E+08 1.93E+09 4.60E+06




































Control 239428197 3972978 2167019016 186197442
6WI 296605342 5034074 2472925088 199055973
12WI 315563309 2599218 2321772655 160558641
30WI 237202783 1346749 1348386221 134533689
60WI 285006117 4697166 3004799391 213478576
240WI 221543524 4256969 3259374363 220066553
6CI 151979812 2028842 2124212893 103180030
12CI 239058344 2623372 3188480142 155176400
30CI 203305389 4937908 2672523751 126356069
60 CI 199347089 4536466 2973648688 166131811
240CI 210160114 4677193 2771218727 157500820
480CI 182616984 2307649 2641265660 126221897
Control 5.33E+08 9.83E+06 2.40E+09 1.85E+07 2.49E+05 2.36E+08
6WI 4.29E+08 7.13E+06 1.85E+09 7.53E+05 9.12E+04 1.90E+08
12WI 5.23E+08 6.40E+06 2.36E+09 0.00E+00 8.33E+05 2.50E+08
30WI 3.83E+08 1.35E+07 2.89E+09 1.99E+06 1.34E+06 2.25E+08
60WI 5.67E+08 1.29E+07 2.89E+09 0.00E+00 1.44E+06 3.29E+08
240WI 4.20E+08 1.13E+07 5.26E+09 3.27E+06 8.14E+06 3.86E+08
6CI 4.77E+08 8.74E+06 2.05E+09 4.14E+06 2.60E+05 1.59E+08
12CI 4.67E+08 8.93E+06 2.47E+09 2.82E+06 3.80E+05 2.34E+08
30CI 3.53E+08 2.49E+06 1.82E+09 0.00E+00 1.21E+05 1.43E+08
60 CI 3.08E+08 2.94E+06 1.94E+09 1.16E+06 1.46E+05 1.36E+08
240CI 2.61E+08 2.83E+06 1.83E+09 2.96E+05 1.28E+05 1.27E+08
480CI 1.17E+08 7.27E+05 2.20E+09 5.66E+05 3.44E+05 5.80E+07
1440CI 1.37E+08 0.00E+00 2.07E+09 0.00E+00 1.11E+05 5.50E+07
Control 44449827 29396612 1177792831 237999 3062432 408008824
6WI 52227903 36792215 1606184736 5138325 4697019 584696967
12WI 52972187 36835358 1000958914 3730061 5695303 521960328
30WI 40358973 30651597 1651321781 8186367 6260869 538512649
60WI 52392154 34086793 1734331187 7810935 6405880 588948092
240WI 39962764 32168822 6597234006 68477782 17923078 1054969994
6CI 54391893 21388571 927679866 1527352 3481320 295457606
12CI 47208357 26451785 1217767017 6334924 3141629 376758595
30CI 58137350 20113587 977295570 512714 3063287 283574761
60 CI 58150150 24356248 969525680 3159136 3328264 375516540
240CI 46205982 19205029 910414441 1636166 2415867 239744601
480CI 37455491 15268243 694472789 127463 3015448 157747438
1440CI 30803601 10949074 791171219 1257564 2874036 173597258
Control 2.03E+08 8.55E+08 3.54E+06 2.65E+06 2.74E+08
6WI 1.81E+08 5.98E+08 1.53E+06 1.75E+06 1.61E+08
12WI 1.90E+08 1.30E+09 2.42E+06 2.98E+06 1.94E+08
30WI 1.85E+08 1.85E+09 2.98E+06 4.04E+06 1.54E+08
60WI 1.48E+08 1.73E+09 1.48E+07 2.74E+06 1.78E+08
240WI 2.17E+08 4.10E+09 8.63E+07 1.48E+07 3.00E+08
6CI 1.56E+08 7.23E+08 2.06E+06 1.52E+06 1.34E+08
12CI 1.65E+08 5.63E+08 2.77E+06 8.73E+05 1.71E+08
30CI 1.45E+08 4.48E+08 5.72E+05 8.79E+05 1.49E+08
60 CI 1.68E+08 6.76E+08 6.30E+05 1.14E+06 1.45E+08
240CI 1.01E+08 4.11E+08 1.23E+06 8.82E+05 9.47E+07
480CI 4.53E+07 9.83E+08 4.67E+05 1.19E+05 4.40E+07


























Appendix 3: Human LC-MS data
sample hypotaurine lysine ornithine arginine histamine thymine
Control 15911248 406560635 175505432 246764958 269907042 3583784
6WI 10232432 491893838 190249635 322685350 251583000 2915852
12WI 13656571 444965315 197229301 327279565 313706062 3473158
30WI 20479584 359400047 156183568 307887368 226271848 3162354
60WI 3358650 589604858 189703387 503273052 336617702 2355973
240WI 9090677 986662496 171710678 1026392553 255837184 1532170
6CI 2549070 238497036 148252231 156718992 161128101 839205
12CI 2975978 382726300 167410729 283152454 303414526 1389499
30CI 8716195 309041598 170793181 213532258 274577338 738720
60 CI 4435111 444238770 177839772 358307348 222973897 1453171
240CI 2170504 420459448 185325131 319146855 279971927 2014583
480CI 2428133 294510673 159596347 226324495 287261220 972344
Control 2.55E+07 5.61E+08 1.22E+08 4.57E+08 3.25E+08 3.92E+06
6WI 3.74E+07 4.31E+08 8.16E+07 3.87E+08 3.41E+08 3.26E+06
12WI 2.24E+07 5.48E+08 1.04E+08 4.91E+08 3.04E+08 1.96E+06
30WI 2.46E+07 4.83E+08 8.58E+07 4.78E+08 2.26E+08 4.39E+06
60WI 2.89E+07 8.44E+08 1.32E+08 8.76E+08 3.40E+08 3.89E+06
240WI 3.94E+07 1.56E+09 9.27E+07 2.10E+09 4.04E+08 4.22E+06
6CI 4.63E+07 4.05E+08 7.77E+07 3.88E+08 2.90E+08 1.53E+06
12CI 2.80E+07 4.87E+08 9.88E+07 4.30E+08 2.22E+08 3.99E+06
30CI 2.75E+07 3.43E+08 7.56E+07 3.62E+08 1.87E+08 5.69E+05
60 CI 2.60E+07 3.81E+08 8.04E+07 4.16E+08 2.71E+08 0.00E+00
240CI 2.04E+07 2.88E+08 5.50E+07 2.90E+08 2.38E+08 1.04E+06
480CI 1.42E+07 1.46E+08 3.13E+07 1.53E+08 1.88E+08 0.00E+00
1440CI 1.77E+07 1.48E+08 3.32E+07 1.97E+08 3.00E+08 0.00E+00
Control 3511500 1016101673 171370272 1132215498 416042598 7016033.793
6WI 2078610 1660332284 236422187 2012499358 648387410 7698672.572
12WI 2396480 1398281072 211055248 1709076237 665192513 5610407.019
30WI 2122224 1535668198 182598885 2268084899 536216189 5580629.125
60WI 4659467 1696519091 209530978 2412560831 629073377 5100844.893
240WI 2316889 4263849085 223447807 6607057637 590857833 4511132.27
6CI 9377066 966071330 169865017 1200373762 481417156 4350952.094
12CI 5441605 1138010565 178385921 1381217014 459050656 5990036.865
30CI 8593019 899213815 144281369 1125426054 606275806 3090051.985
60 CI 6991803 1102293314 166466659 1391641508 494011707 5042155.068
240CI 12444521 804065770 122042277 1075859894 465695026 4103795.794
480CI 17372855 574896226 84999217.6 768698732 614937107 171217.2608
1440CI 9627826 637608175 86257458.4 900776133 474145530 204108.6418
Control 6.18E+07 1.14E+09 2.97E+08 7.04E+08 2.39E+08 4.68E+06
6WI 7.32E+07 8.44E+08 2.22E+08 5.41E+08 2.00E+08 3.27E+06
12WI 7.08E+07 1.11E+09 2.70E+08 7.83E+08 2.33E+08 3.92E+06
30WI 7.81E+07 1.01E+09 2.12E+08 8.00E+08 2.38E+08 3.50E+06
60WI 6.67E+07 1.12E+09 2.27E+08 9.76E+08 2.83E+08 4.99E+06
240WI 7.12E+07 2.61E+09 3.79E+08 2.63E+09 3.63E+08 5.88E+06
6CI 5.80E+07 7.63E+08 2.09E+08 4.83E+08 2.01E+08 2.09E+06
12CI 6.22E+07 8.61E+08 2.15E+08 5.73E+08 3.45E+08 2.77E+06
30CI 4.70E+07 7.84E+08 2.01E+08 4.86E+08 2.48E+08 3.02E+06
60 CI 7.86E+07 7.66E+08 2.01E+08 5.08E+08 2.94E+08 3.32E+06
240CI 4.90E+07 5.78E+08 1.54E+08 4.00E+08 2.57E+08 1.85E+06
480CI 2.65E+07 3.12E+08 8.40E+07 2.16E+08 2.43E+08 NF

























Appendix 3: Human LC-MS data
sample betaine putrescine
ammonium and 
isovalerate spermidine pantothenic acid
Control 6780155 25020854 0
6WI 6597757 26186702 0
12WI 17186980 25977719 7930126
30WI 12789377 26797484 4239142
60WI 10109623 26488961 729224
240WI 7670426 51666965 0
6CI 3381827 27830496 8496384
12CI 7666326 29315557 83685020
30CI 8998706 24881420 0
60 CI 1485259 44407001 65118622
240CI 4475128 33027755 3421371
480CI 4940618 33060355 27448356
Control 0.00E+00 5.38E+06 0.00E+00 9.43E+07
6WI 1.83E+06 6.97E+06 0.00E+00 1.14E+08
12WI 0.00E+00 1.04E+07 0.00E+00 1.35E+08
30WI 0.00E+00 1.36E+07 0.00E+00 1.78E+08
60WI 1.56E+06 1.06E+07 0.00E+00 2.43E+08
240WI 2.77E+06 5.52E+06 4.82E+06 3.00E+08
6CI 2.24E+06 5.90E+06 0.00E+00 1.03E+08
12CI 4.43E+05 5.67E+06 2.36E+06 1.22E+08
30CI 0.00E+00 6.69E+06 0.00E+00 7.24E+07
60 CI 0.00E+00 7.35E+06 0.00E+00 7.89E+07
240CI 0.00E+00 7.67E+06 0.00E+00 6.92E+07
480CI 0.00E+00 1.01E+07 0.00E+00 3.81E+07
1440CI 0.00E+00 4.99E+06 0.00E+00 3.42E+07
Control 2003178894 1282918 7619877 94877657
6WI 1759582977 3109877 8355680 146902520
12WI 2052944013 12473007 5233221 144567481
30WI 1554443110 4270209 5225312 114581671
60WI 2032104424 7598447 5350518 165447176
240WI 1494761582 4292569 2774036 400341832
6CI 2578729750 6706298 3453560 79326196
12CI 1956858213 1890340 3638483 101627431
30CI 2460402786 4409466 2801482 90495357
60 CI 2605688366 3629452 4814751 103991160
240CI 2733262028 4016346 2915588 77304442
480CI 2413509976 896296 2401507 63754870
1440CI 2596175691 537265 2450089 64962508
Control 2.26E+06 2.53E+07 1.99E+08
6WI 5.38E+05 1.50E+07 1.69E+08
12WI 1.73E+06 3.46E+07 2.37E+08
30WI 1.60E+06 NF 2.19E+08
60WI 3.84E+06 NF 2.86E+08
240WI 7.75E+06 1.47E+05 1.04E+09
6CI 7.68E+05 NF 1.25E+08
12CI 5.55E+05 4.08E+06 1.57E+08
30CI 1.26E+06 5.30E+05 1.27E+08
60 CI 7.76E+05 7.25E+05 1.38E+08
240CI 7.74E+05 2.36E+07 1.06E+08
480CI 2.21E+06 NF 5.38E+07































Control 0 132267400 1.16E+09
6WI 7505289 146929476 2.50E+09
12WI 22981288 158963137 2.14E+09
30WI 6065123 98166017 7.08E+08
60WI 3232887 148211541 1.52E+09
240WI 1491982 56257068 1.74E+09
6CI 657626 88374959 8.58E+08
12CI 623368 150481857 2.11E+09
30CI 1312228 108895812 1.80E+09
60 CI 1457525 111623464 2.28E+09
240CI 1298461 146715643 3.52E+09



























Control 1.42E+06 NF 1.42E+08 9.91E+05
6WI 8.53E+06 NF 1.05E+08 6.05E+05
12WI 8.99E+06 NF 1.05E+08 4.28E+05
30WI 3.27E+06 NF 1.06E+08 9.70E+05
60WI 4.34E+06 4.81E+05 6.66E+07 NF
240WI 1.23E+06 5.49E+06 8.03E+07 4.78E+06
6CI 1.76E+06 NF 1.21E+08 6.81E+05
12CI 3.98E+05 NF 1.11E+08 7.81E+05
30CI 7.90E+05 NF 1.06E+08 3.48E+05
60 CI 7.72E+05 NF 1.15E+08 7.97E+05
240CI 2.70E+06 NF 7.30E+07 3.04E+05
480CI 9.09E+05 NF 3.58E+07 2.15E+05
1440CI 9.01E+05 NF 3.18E+07 2.20E+05
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